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ABSTRACT
Optimal conditions for hydrolysis of urinary oestrogen
conjugates in the human have been sought, A |3-glucuronidase-
sulphatase mixture (H, plmatia) is shown to be effective in
cleaving the sulphate and glucosiduronate forms of some eight
metabolites, A bacterial (E, coli) /^-glucuronidase preparation
is particularly active in hydrolysing both oestrogen and 17-
ketosteroid glucosiduronates. Using these techniques and other
improved methodology, levels of seven or eight oestrogen
metabolites have been measured in normal and diabetic pregnancy
(human). Apparent abnormalities are seen in the diabetic state
and tentative conclusions are drawn regarding sites of produc¬
tion of certain oestrogens during pregnancy.
Metabolism of some free oestrogens have been studied in the
human in vivo and in vitro and in certain other species in vitro.
Oestriol and 16-epioestriol are shown to be not necessarily 'end
products' of metabolism but to be variably metabolized by laying
hen liver, erythrocytes of certain species and by the human in
vivo. The 2-methoxylation of oestrone has been studied in rat
liver fractions and the metabolism of the clinically useful
synthetic compound 17o(-ethynyloestradiol-17/3-3-cyclopentyl ether
has been delineated in the human.
The conjugation patterns of urinary oestrogen metabolites in
the pregnant and non-pregnant human are shown to be similar by a
differential hydrolytic technique. The quantitative importance
of oestrone in the sulphate fraction has been established as well
as that of 16<x-hydroxyoestrone and 16-ketooestradiol-17^3 in the
sulphoglucosiduronate fraction.
It has been shown that tissues from the laying hen are more
active, with respect to aulphurylation, towards phenolic steroids
than to dehydroisoandrostarone. Also, liver from the same
species directly interconverts the 3~sulphates of oestrone and
17^-oestradiol. The ability of a rat liver preparation to
sulphurylate the 3 position of phenolic steroids appears to be
related to the constituents of ring D of the steroid.
The glucosiduronates and sulphates of oestrone and 11(3~
oestradiol have been successfully separated chromatographically
and the procedure has been employed to prove that the human
conjugates 17/3-oestradiol to yield both its 3- and 17-monoglu-
cosiduronates. The fates of the latter two conjugates differ in
vivo in that the former is subjected mainly to 17-dehydrogenation
and little deconjugation, whereas the latter undergoes an
enterohepatic type of metabolism with considerable deconjugation
and reconjugation. The metabolism of the monoglucosides of
17/3-oestradiol in the human has been studied. The 3-glucoside
residue is rapidly removed with the release, and extensive
metabolism, of 17/3-oestradiol. The 17-glucoside residua is much
less readily removed and the metabolism of the 17-glucosides of
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GENERAL INTRODUCTION
This thesis incorporates studies performed over the
approximate period 1958-1971. In the late fifties and early
sixties, due largely to the isolation of many new oestrogen
metabolites by Marrian et al. (1-4) and others (5-8), one of
the main questions concerned the manner in which so many metabo¬
lites arose from the secreted hormone (now considered to be
mainly 17/3 -oestradiol*) in the human. This necessitated several
lines of study, involving (a) methodology (including means of
conjugate hydrolysis) for the measurement of oestrogen metabo¬
lites other than oestrone, oestradiol and oestriol, the latter
having been so ably pioneered by Brown (9) and Bauld (10)}
(b) the mode of interconversion and formation of the newer
metabolites in their free, unconjugated form; (c) methodology
for the direct separation of steroid conjugates so as not to
rely too heavily on direct hydrolysis of crude mixtures of these
compounds as a means of identification; (d) the possibility of
metabolism of oestrogen conjugates such as glucosiduronates and
sulphates.
The greater part of the work here submitted involves
various aspects of methodology and metabolism, almost wholly of
the oestrogens, as they concern the human subject. In addition,
however, studies on certain small animal species are included.
These latter, mostly performed in vitro, have been particularly
Hereafter referred to as oestradiol except where distinction
from 17<* -oestradiol is necessary.
helpful in the biosynthesis of certain conjugated steroids
required for human studies.
In the author's laboratory, studies on conditions for
enzymatic and acid hydrolysis of steroid conjugates, along with
other methodology (Section A), produced for the first time a
quantitatively meaningful pattern of several oestrogens besides
oestrone, oestradiol and oestriol in human pregnancy urine
(Section B). Besides this, patterns of oestrogens in diabetic
pregnancy urine were established (Section B). These above data
were, however, obtained without regard to the specific type of
conjugation of the urinary steroids and did not, therefore,
elucidate the conjugation pattern.
In addition to the above, considerable information was
obtained, both in vivo and in vitro with human and other species,
regarding the interrelationships of various phenolic steroids,
particularly the 16-oxygenated compounds, in their unconjugated
forms (Section C).
Further studies, involving more or less specific means of
hydrolysis, e.g., ^3-glucuronidase incubation and solvolysis,
to split glucosiduronates and sulphates, respectively, shed
some light, mostly indirect, on patterns of oestrogen conjugate
metabolites in both pregnant and non-pregnant individuals
(Section D). This study also resulted in establishing without
question that oestrone-3-sulphate can be quantitatively, in
some humans, a most Important urinary metabolite.
The formation and metabolism of oestrogen sulphates, in
vitro and in vivo, has been explored to some degree in species
other than the human (Section E). Particularly useful informa¬
tion has been obtained in this respect using as a test species
the laying hen (Gallus domesticus) since conjugation of
oestrogens in this species in vivo appears to be confined to
sulphurylation (10a).
The necessity for methodology which would more directly
allow of the study of steroid conjugate patterns and metabolism,
e.g., the direct separation of intact conjugates, became obvious.
The original studies of Hahnel (11,12) utilizing DEAE-Sephadex
chromatography to achieve this in a partial fashion, presented
a basic procedure which was modified in the author's laboratory
to successfully separate several conjugates of oestrone and
oestradiol (Section F). This technique was then employed to
describe, for the first time, the interconversions and bio¬
synthesis of various conjugates, notably the glucosiduronates
of oestrone and oestradiol in the human subject (Section G).
Information was then obtained for the metabolism of the 3- and
17-glucoside conjugates of 17/3 -oestradiol and the 17-glucoside
of 17<X -oestradiol in the human in vivo (Section H). This
latter -was performed in order to compare the behaviour of
charged and relatively uncharged conjugates of otherwise very
similar structure.
SECTION A
ASPECTS OF CONJUGATE HYDROLYSIS AND STEROID METHODOLOGY
INTRODUCTION
A great deal of work in the last decade has centred around
the measurement of oestrogens, particularly oestriol, in
diabetic, and other compromised pregnancies, in view of the
high intrauterine death rate and the possibility that oestrogens
may be usefully monitored with a view to more effective control
and treatment of pregnancy (13-19). A necessary step in all
earlier, and many current methods, was hot acid hydrolysis to
release the steroids from conjugation. Brown and Blair (20),
in an attempt to establish optimum conditions for this step,
mentioned an apparent destructive effect of glucose, in the
presence of hot acid, on the oestrogens. These same studies
established conditions for the enzymatic hydrolysis of urinary
oestrone, oestradiol and oestriol conjugates using a preparation
from the common limpet (Patella vulgata) which contained both
ft-glucuronidase and phenolsulphatase(s). These early data,
together with the isolation of many new oestrogen metabolites
(1-8) necessitated enquiry into suitable procedures for hydro-
lyzing the conjugated forms of these (besides those of the three
'classical* oestrogens and of the urinary 17-ketosteroids) prior
to successfully measuring the steroids released.
The methods of Brown (9) and Bauld (10) were the first
capable of measuring with some reliability the levels of the
three 'classical' oestrogens, oestrone, oestradiol and oestriol,
in the urine of the non-pregnant human. Unfortunately, these
techniques came to be frequently used in situations where their
sensitivities were not adequate. Thus data were seen which
fell below the useful working range of the procedures. Also,
the method of Bauld appeared to yield certain values which were
higher than expected (21) and it therefore became necessary to
evaluate this latter procedure in several modified forms.
Discussion of Published Work (Appendix - Section A)
The apparent destructive effect of glucose on classical
oestrogen conjugates during hot acid hydrolysis, and the manner
in which this can be overcome, either by prior high dilution of
the urine or by enzymatic means, has been published (Hobkirk,
Alfheim and Bugge, J Clin Bndocr 19: 1352, 1959). This infor¬
mation has proved most useful to the author and others in the
measurement of urinary oestrogens in pregnancy (19, 22-24).
A comparison of the relative abilities of several enzyme
preparations to hydrolyze the conjugated forms of some six
urinary oestrogen metabolites in pregnancy urine led to the
establishment of suitable conditions for incubation (Bugge,
Nilsen, Metcalfe-Gibson and Hobkirk, Can J Biochem Physiol 39:
1501, 1951). The enzyme preparations employed were; a highly
purified beef liver fi -glucuronidase (Ketodase), a bacterial
^3-glucuronidase preparation (£. coli), a crude mixture of
enzymes, including ^-glucuronidase and sulphatase(s), from the
edible snail (Helix pomatia), and a similar mixture from the
common limpet. The snail preparation appeared to be the one of
choice where overall hydrolysis of urinary oestrogen conjugates
was desired. The bacterial preparation was most efficient for
glucosiduronate hydrolysis. Thus for the first time conditions
were established for the optimum hydrolysis of oestrogen
conjugates other than those of the classical three. Particularly
important in this respect was the successful hydrolysis of the
conjugates of the rather unstable 16(X -hydroxyoestrone and 16-
ketooestradiol-17(3* with apparently minimal destruction. This
information has been used by other investigators (24-26), and by
the author (Hobkirk and Nilsen, J Clin Endocr 22s pp 134 and
142, 1962; see Section B) in the elucidation of the pattern of
some seven steroids in pregnancy urine which at the time of
study was not at all known.
A somewhat similar enzymatic study was performed with
respect to urinary 17-ketosteroid conjugates in the human (Hobkirk
and Cohen, Can J Biochem Physiol 38s 769, I960). An interesting
stereochemical effect was apparent. Over the incubation periods
studied (12-96 hr) the 5(3 steroids (aetiocholane series,
including aetiocholanolone and its 11(3 -hydroxy and 11-keto
forms) were released from conjugation relatively readily and to
similar extents by the four enzyme preparations. The 5oc
steroids (androstane series, including androsterone and its
11 (3 -hydroxy form) on the other hand, were released efficiently
by the bacterial preparation but less so by the other enzymes,
Referred to hereafter as 16-ketooestradiol.
notably the beef liver (3 -glucuronidase. Indeed, the latter
enzyme preparation, at concentrations which released maximum
amounts of the 5(3 steroids, released only a fraction of the 5«
steroids liberated by the bacterial preparation. However, at
very high concentrations of the liver enzyme liberation of
androsterone approached that seen with the bacterial preparation.
It seemed likely, therefore, that hydrolysis with the liver
preparation could lead to very erroneous results for the urinary
levels of the steroids and might well suggest the presence
of 'unknown' conjugates rather than indicate a structural effect
(see reference 27). These data demonstrate the need for care
in the choice of enzymes and in the interpretation of results.
They have been adequately borne out by Beale et al. in studies
reported in 1959 (27a).
The requirement for increased sensitivity and specificity
in the measurement of oestrone, ©estradiol and oestriol by
Bauld's method led to an investigation of a modified technique
(Hobkirk and Nilsen, Steroids 3: 453, 1964). The incorporation
of the Ittrich fluorimetric procedure unquestionably influenced
results for the better and a combined procedure adapted from
the methods of Bauld (10) and Givner et al. (28) produced data
for males and post-menopausal females which compared well with
those of other authors using mainly the Brown technique or
modifications of it. Spectrophotometry and fluorirnetry yielded
similar values in the modified method. The study resulted in a
good technique for later use in the author's laboratory.
-8-
Attempts to accurately quantitate ring D o<-ketol phenolic
steroids at this stage yielded results of doubtful validity.
Unpublished Data Related to the Above1*
It appears that a bacterial ^-glucuronidase preparation is
exceptionally active in hydrolyzing both urinary oestrogen and
17-ketosteroid conjugates (presumably glucosiduronates)• The
data in Table 1 (obtained by the method of Bauld) show that as
little as 2 units of activity per ml of urine were as active as
20 units per ml in liberating the three classical oestrogens
from conjugation in non-pregnancy urine within 24 hours. The
bacterial preparation gave rather similar results to, although
somewhat better than, those obtained by hot acid, liver enzyme
and limpet enzyme hydrolysis. It is to be expected, however,
that in urines containing considerable oestrogen sulphates (see
Section B) the molluscan preparations would be of great value.
The lower results obtained with the snail preparation may have
been due to particularly troublesome emulsions formed on
extraction at the high enzyme-protein concentrations employed.
The amounts of enzymes used were based on optimal or excess
requirements reported by other investigators. The reason for
the particularly high activity of the bacterial preparation was
sought.
♦
This material has actually appeared in book form as part of
the proceedings of a United States N.I.H. Workshop on Estrogen
Methodology held in 1963.
Reference: Estrogen Assays in Clinical Medicine, ed. C. A.
Paulsen, Univ. of Washington Press, 1965, pp. 10-18.
TABLS 1
Measurement of Oestrone, ©estradiol and Oestriol after
Hydrolysis by Various Methods in Pooled Luteal Phase
Urine from 5 Women without Medication.
Oestrogen Levels (uq per 1/5 urine pool
Hydrolytic conditions* Oestriol Oestrone Oestradiol Total
Boiling with 15 vol %
HC1, 1 hr 21.0 8.0 4.9 33.9
2 Units bacterial enzyme/
ml, pH 6.5, 24 hr 23.3 8.4 4.8 36.5
20 Units bacterial enzyme
as above 21.9 10.2 4.0 36.1
300 Units liver enzyme/
ml, pH 5.0, 120 hr 20.1 8.5 4.2 32.8
1000 Units limpet enzyme/
ml, pH 4.6, 96 hr 20.5 7.6 3.9 32.0
1500 Units snail enzyme/
ml, pH 5.2, 24 hr 15.0 7.1 3.7 25.8
*
Incubations were at 37°C. The unit of activity is based on
the ability of ea.ch preparation to hydrolyze phenolphthalein
glucuronide at the respective pH values shown; i.e., it
approximates a Fishman unit and is, therefore, only a measure
of^3-glucuronidase content.
Table 2 shows relative activities of the various enzyme
preparations towards oestriol glucosiduronate (isolated from
human pregnancy urine and presumably mainly oestriol-16-
glucosiduronate) as substrate. Although the bacterial prepara¬
tion displays maximum activity near neutral pH, relatively small
amounts (cf. other preparations) were still active at pH 5.0,
Also, the inhibitory effect of urine was much more marked at
pH 5.0 than at 6.5 for the bacterial enzyme and it was very high
for the other preparations at pH 4.5 - 5.2. In addition it was
noted (Fig. 1) that inhibition of the bacterial^3-glucuronidase
with boiled saccharate solutions was extremely difficult at pH
6.5 compared with the picture for the other enzymes at their
best pH values. This was also true of the endogenous inhibitors
present in urine (Fig. 1). Even at pH 5.0 inhibition of the
bacterial enzyme by boiled saccharate was less than for the
other enzymes at pH 4.5 ~ 5.2, although the presence of urine
caused marked lowering of the activity of enzymes from all
sources at around pH 5. Supporting data are shown for
phenolphthalein glucuronide as substrate in Table 3. For all
enzyme preparations much larger concentrations of inhibitor were
required at pH 6.5 than at 4.5 - 5.2 to yield comparable
inhibition. This is presumably due to the greater stability of
the active inhibitor, saccharo-1, 4-lactone at the lower pH
values (29). Endogenous urinary inhibitors of this type would
probably behave similarly during enzymatic hydrolysis. Thus
the value of bacterial ^3-glucuronidase may reside partly in the
INHIBITIONOF^-GLUCURONIDASEHYDROLYSISEST IOL GLUCURONIDE(4-45x105M)BYSAC HARATOL TION
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TABLE 2
Approximate Amounts of ft-Glucuronidase Preparations
Required to Yield Equal Degrees of Hydrolysis of
Oestriol Glucosiduronate (4,45 x 10""*M) in 16 hr at
37°C.
Enzyme Units of ft-Glucuronidase per ml
preparation pH Pure Substrate Substrate + Urine
Bacterial 6.5 15 17, 19
Bacterial o•in 30 120, 50
Liver 5.0 600-700 1600-1700
Limpet in• 50-60 400-500
Snail 5.2 80-90 250-350
• Urine (0.5 ml) accounted for one-half of total reaction
volume.
# Two urines were used for the bacterial preparation; one
for the others.
TABLE 3
Effect of pH on the Inhibition of /3-Glucuronidase
Activity by Boiled Saccharate Solutions
(Phenolphthalein Glucuronide used as Substrate)
Enzyme* Molarity of Molarity of Saccharate
preparation Substrate pH giving 50% inhibition
Bacterial 2 X
—4
10 * o•tn 5.2 X 10~2
fl n 6.5 1 X Mo
1H
Liver 1 X 10~3 5.0 3.6 X 10~4
rt It 6.5 CM•in X 10""2
Limpet 1 X 10~3 4.5 1 X 10~4
ft tt 6.5 1.3 X 10~2
Snail 1 X 10~3 5.2 1.9 X 10~3
tt 6.5 1 X 10-1
*
Fifty units of /3-glucuronidase activity were used in all
incubations at each pH value.
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position of its optimum pH arid partly in its * basic resistance*
to inhibition. Moreover, its apparently low specificity towards
the stereochemistry of the A/B ring fusion in its substrates
(Hobkirk and Cohen, Can J Biochem Physiol 38: 769, 1960)
further commends it as a means of hydrolyzing steroid glucosi-
duronates. It should be noted that Jayle et al. in 1959 (30)
had claimed that the snail enzyme preparation was better than
bacterial ^-glucuronidase or hot acid hydrolysis in releasing
urinary oestrone, oestradiol and oestriol from conjugation. In
1962 Kirk et al. (25) showed that the bacterial preparation was
superior to the mammalian liver ^3-glucuronidase for release of
17-ketosteroids and oestrogens.
Recent work by Roy and Slaunwhite (31), and also unpublished
observations in the author's laboratory, showed that a steroid
17fi -hydroxy dehydrogenase could be present in some batches of
bacterial fi -glucuronidase. In none of the studies reported in
this thesis was such material utilized. In later work in which
oestrone and oestradiol conjugates were purified in the intact
form (see Section G) the highly purified liver /3-glucuronidase
was generally employed in hydrolysis. It should be noted that
claims have bean made (32, 32a) that certain ^S-glucuronidase-
containing preparations, including that of bacterial origin, may




URINARY OESTROGEN LEVELS IN PREGNANCY WITHOUT REGARD
TO SPECIFIC MODES OF CONJUGATION
INTRODUCTION
Although urinary oestriol in pregnancy had been measurable
for some time it was not until the advent of the Brown (9) and
Bauld (10) methods that it and its companion compounds,
oestrone and oestradiol, could be quantitated with some
certainty. Brown established the pattern of these steroids in
normal pregnancy in 1956 (33) but left unresolved the picture
for diabetic pregnancy, a condition associated with a high
intrauterine death rate. The isolation of many more oestrogen
metabolites (1-7, 34) required that the pattern of at least
some of these be established as well. The availability of
information on the hydrolysis of the conjugates of several of
these oestrogens (see Section A, above) was the first step
towards an understanding of the problem, and a modification of
the procedure of Givner et al. (28), made in the author's
laboratory, allowed the measurement of the three classical
oestrogens together with 2-methoxyoestrone, 16-epioestriol and
the ring D-ketols (mainly 16oc-hydroxyoestrone and 16-
ketooestradiol) to be made. These studies were designed to
yield information on overall patterns without specific relation
to conjugation but, hopefully, by the use of methods where
optimal hydrolysis was achieved.
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Discussion of Published Work (Appendix - Section B)
By laboratory procedures which were reliable, data were
obtained which suggested that, although oestrone and oestradiol
levels were within normal range in most diabetic pregnancies,
oestriol was, on the average, low (Hobkirk, Blahey, Alfheim,
Raeside and Joron, J Clin Sndocr 20: 805, 1960). With the
exception of one early publication (35) dealing with a very
few subjects, this appears to be the first published study,
using modern techniques, on urinary oestrogens in diabetic
pregnancy. The above-mentioned work of Rubin et al. (35) con¬
cluded that oestrogens may be low in diabetic subjects with
pre-eclamptic toxemia but normal in diabetes without associated
toxemia. It became known over the period 1962-63, after much
study (14, 15, 18, 19), that urinary oestriol levels may be
closely related to foetal condition and it is likely, indeed
probable, that, in our original paper, lowest oestriol levels
were associated with foetal distress. More specifically
clinical aspects of such studies were published by Joron,
Hobkirk, Blahey, Routledge and Fowler (Diabetes II, 514, 1962)
which showed that the behaviour of urinary oestriol was indica¬
tive of foetal viability.
In 1962 two publications (Hobkirk and Nilsen, J Clin
Sndocr 22: pp. 134 and 142, 1962) established the pattern of
several of the newer oestrogen metabolites, together with the
classical compounds, in both normal and diabetic pregnancy.
The normal values were to prove remarkably similar to those
—13—
quoted by Breuer in 1965 (36), using mainly paper chromatog¬
raphy, although the latter investigator did not show data for
the likely variation between individuals. He did, however, give
data for a large number of metabolites besides those measured
by this author. Others who have reported procedures for
measurement of urinary oestrogens in addition to the classical
three are Wotiz and Chattoraj in 1964 (37), and Eechaute et al.
in 1967 (38), both of whom reported values similar to the
author's although their data were more limited in number. The
former investigators (37) utilized gas-liquid chromatography,
the latter (38), silica gel chromatography and fluorimetry for
analysis. The most recent data available have been published
by Adlercreutz and Luukkainen in 1970 (39) in which a large
number of oestrogens and metabolites were measured, and
identified, in various biological fluids in pregnancy by gas-
liquid chromatography combined with mass spectrometry. The
urinary values are quite comparable with those of eight years
standing published by the present author. In the papers of
Hobkirk et al. it was noted that the ring D oc -ketols were
quantitatively Important metabolites and appeared to be higher
in diabetic than in normal pregnancy. Also, in some Individuals
urinary oestrone was markedly elevated in diabetic pregnancy
(see also Hobkirk et al., J Clin Endocr 20: 805, 1960). In
addition, 2-methoxyoestrone appeared to show a trend in
excretion during the second half of pregnancy which was dif¬
ferent from the other metabolites and was frequently,
-14-
apparently, absent even In late pregnancy. This point was
studied in more depth using a modified, and more sensitive
procedure (Hobkirk and Nilsen, J Clin Endocr 231 21A, 1963).
It was confirmed that 2-rcethoxyoestrone frequently did not
behave as did total oestrogens during the last 25 weeks, or so,
of pregnancy, being more or less immeasurable in some and
relatively hiyh (up to 1 mg/24 hrs, corrected for losses) in
others. Wotiz and Chattoraj in 1964 (37) and Adlercreuts and
Luukkainen in 1970 (39) have arrived at substantially the same
conclusion. It was suggested in the present author's publica¬
tion, based on limited data, that the behaviour of 2-methoxy-
oestrone might be due to a variable degree of demethylation
in vivo as shown for the 3-methyl ether of oestrogens by Brown
(40) and, as published in 1964, for the 2-methoxy group, under
different experimental conditions, by Breuer et al. (41).
More recent work by Yoshizawa and Fishman (42), using radio-
actively labelled 2-methoxyoestrone (entirely unavailable to
the present author in the early sixties) strongly suggests that
no demethylation occurs. There can, however, be little
question of the data for endogenous 2-methoxyoestrone patterns
although no further explanation appears to have been forwarded
as to the shape of the excretion curves.
A further publication by Hobkirk, Anuman-Rajadhon, Nilsen
and Blahey (Clin Chem 16: 235, 1969) has confirmed the
elevation of ring D (X -ketols in diabetic pregnancy mentioned
above. One wonders whether this is due to a difference in
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peripheral conversion of oastrogens and their metabolites in
the tissues of the diabetic mother or to foetal production.
It certainly may be of some interest with respect to the
measurement of oestriol alone or * total oestrogens' in the
maternal urine with a view to monitoring the risk of foetal
loss. Along these lines it should be noted that S. L. Cohen
has recently claimed (43, 44) through somewhat indirect means,
that in diabetic pregnancy a group of chemically labile
oestrogens (including perhaps 2- and 6-hydroxylated compounds)
i3 vastly increased as compared with normal pregnancy. As far
as the present author is aware, no study has been reported on
oestrogen metabolism in non-pregnant diabetic humans.
Measurement of the specific radioactivities of seven
urinary metabolites of intravenously administered oestradiol-6,
—37*~ H in the pregnant woman showed that the values for the
individual ring D oc -ketols (16 <x -hydroxyoestrone and 16-
ketooestradiol) were some twofold those of the 16-desoxy
oestrogens but were in turn considerably (four to seven times)
higher than that of oestriol (Hobkirk and Nilsen, J Clin Sndocr
26: 525, 1956). This suggested that a urinary metabolite such
as 16-ketooestradiol was probably not, for the main part, a
conversion product of the foetal oestriol pool since, if it
were, there would presumably have been a marked lowering of
specific radioactivity to a value somewhat similar to that for
urinary oestriol. Following publication of the above study
Diczfalusy (45) showed that 16*-hydroxyoestrone, a major
foetal steroid, is largely converted to oestriol in the placenta
and forms a major source of urinary oestriol in pregnancy.
Also, Reynolds et al. in 1968 (46) have suggested that urinary
16 a-hydroxyoestrone in particular may be largely a maternal
metabolite in pregnancy. All of this information raises the
question of the origin of 16-oxygenated oestrogens other than
oestrici in pregnancy arid points out the necessity for an under¬
standing of this in the measurement of urinary oestriol or
♦total oestrogens', particularly in diabetic pregnancy, as a
means of studying foetal viability.
Results obtained by Siiteri and MacDonald in 1966 (47) and
by Adlercreutz and Luukkainen in 1970 (39) show that about 50%
of the oestradiol produced in pregnancy arises in the maternal
compartment whereas only some 10% of oestriol is so produced.
This information, together with the specific radioactivities of
the various urinary oestrogens published by the author (Hobkirk
and Nilsen, J Clin dndocr 26: 625, 1966) would indicate that a
much greater fraction of the ring D oc-ketols and 16-epioestriol
than of oestriol, is of maternal origin. The specific activi¬
ties alone might indicate that the above maternal fraction for
the ring D oc-ketols and 16-epioestriol should be closer to
that for oestradiol, i.e., 50%, than for oestriol, i.e., 10%.
However, this assumes some linearity between urinary specific
activity and dilution with endogenous metabolites of various
origins and may not be warranted in view of the complexity of
the prevailing circumstances. The most definitive data now in
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existence (39), in which these steroids were measured by the
newest techniques in maternal urine and plasma and in cord
plasma and amniotic fluid, show that at term about 30% of
urinary 16ot-hydroxyoestrone is of maternal origin while the
values for 16-ketooestradiol and 16-epioestriol are each 20%.
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5SCTI0N c
METABOLISM/INTERCONVERSION OF FREE OSSTRQGENS IN VITRO
AND IN VIVO
INTRODUCTION
Following the isolation of the ring Dcx-ketols and 16-
epioestriol over the period 1955-1958 (1, 3, 4) considerable
interest was evident in the interconversion of these and other
steroids and in their relationship to oestriol (48-52).
Certain related investigations were performed in the author's
laboratory using both in vivo (human) and in vitro (human and
other species) methods. Particular use was made of tissues from
the laying hen (Gallus domesticus) in this work since the in
vivo oestrogen metabolite interrelationships (both endogenous
and exogenous) were being actively studied by Common et al. (53-
57) in this species. Also, it had been noted that the hen
produced 16-epioestriol as a major 16-oxygenated metabolite
(58, 59). In vitro studies on chicken liver by Ozon and Breuer
(60) appeared in 1965.
In addition to the above, some information was obtained
regarding the formation of 2-methoxyoestrone using rat tissues
in vitro as the sources of enzymes.
Finally a study of the metabolic fate of the synthetic
oestrogen 17ot-ethynyloestradiol-17/3 -3-cyclopentyl ether was
performed in the human. This slow releasing precursor of
oestrogenic activity, due to storage in and slow release from
adipose tissue (as studied in the rat; see reference 61), had
attracted considerable attention as a potentially useful
clinical drug (62-64).
Discussion of Published Work (Appendix - Section C)
a) 16-0xyqenated Steroids. In the late 1950's the biosynthesis
of oestriol from oestradiol in vitro was a problem which had
defied elucidation. Thus, although the former was recognized
as a major metabolite in the human in vivo, several reports of
its in vitro formation had been negated due to demonstrated
inadequate purification of the product. In late 1958 and early
1959 three communications, in rapid succession, reported the
production of oestriol from oestradiol by foetal human (65),
rat (66) and laying hen (Mitchell and Hobkirk, Biochem Biophys
Res Commun 1: 72, 1959) liver preparations. In 1965 Ozon and
Breuer (60) demonstrated the 16<x-hydroxylation of oestradiol
by liver slices of chicken but also showed that 16^-hydroxyla-
tion, to form 16-epioestriol, predominated. In 1967 Raud and
Hobkirk (Biochem J 103s 724, 1967) showed that the inter-
conversion, 16-epioestriol oestriol was markedly in favour
of the 16 (S hydroxy form in homogenates of laying hen liver.
This appeared to be in some accord with the in vivo studies of
Common et al. (53, 59) and demonstrated conclusively that in
some species, at least, oestriol, although formed, need not be
entirely an end product of metabolism as it virtually appears
to be (apart from factors involving conjugation) in the human.
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In studies along related lines, 16-ketooestradiol- C,
made available by Dr. Mortimer Levitz, New York, was used as a
substrate to demonstrate considerable species difference with
respect to the stereochemical reduction of the 16-keto group by
erythrocytes (Trachewsky and Hobkirk, J Biol Chem 239: 3683,
1964). Thus rat cells reduced the substrate in the (i -configura¬
tion, yielding 16-epioestriol, while cat cells yielded almost
exclusively oestriol («-reduction)• The physiological impli¬
cations of these transformations are unknown and perhaps
unimportant but it appeared that such a system might offer a
useful model for study applicable to other tissues (e.g., liver)
where conversions of this type are of considerable quantitative
significance. An extension of the latter study, employing red
cell haemolyzates, established an absolute requirement for NADP
(NADPH) as a cofactor. Also, the conversions were shown to be
reversible, the rat preparation catalyzing only 16-ketooestradiol
^16-epioestriol, and the cat the interconversion, 16-
ketooestradiol ^ oestriol (Hobkirk, Nilson and Belenkie, Can J
Biochem 43: 1893, 1965). Similar specificities have been
demonstrated for 17-ketone and 17-hydroxyl groups of oestrone
and oestradiol, respectively, in certain species (67) and
Portius and Repke, in 1960 (68) had demonstrated the 16-
ketooestradiol^16-epioestriol conversion in rat erythrocytes.
However, after careful scrutiny of the latter report it was
considered that insufficient information regarding degree of
conversion and product identity was provided. In 1959 Breuer
(69) published data on the conversion of 16-ketooestradiol to
16-epioestriol by human erythrocytes. To date no further
published work has appeared on the topic of oxidoreduction at
carbon-16 by red cell enzymes. The data obtained by the author
support results of the study on avian metabolism in vitro in
that they provide more information about the occurrence of
enzymes, in certain species, capable of catalyzing conversion
of the D ring of phenolic steroid triols.
Various interrelationships of 16-oxygenated phenolic
steroids in the human in vivo have been studied in the author's
laboratory (Hobkirk, J Clin Endocr 23: 279, 1963; Hobkirk,
Nilsen and Purre, Can J Biochem 44: 1211, 1966). Attempts to
establish endogenous levels of ring D <X -ketols in non-pregnancy
urine, and as metabolites of labelled oestradiol, probably
yielded overestimates due to lack of knowledge regarding the
effect of purification on small weights of these, and to inter¬
ference by 2-hydroxy oestrogens now known to be major
metabolites of oestradiol in the human (70). Nevertheless,
several interesting points were elucidated regarding inter-
conversion of 16-oxygenated compounds. It was evident that
16-ketooestradiol was not a precursor of 16<X —hydroxyestrone
although it gave rise to oestriol and 16-epioestriol, in
agreement with Levitz et al. (50). Also, oestriol was metabo¬
lized only slightly to 16-ketooestradiol and 16-epioestriol,
once more in agreement with Levitz (49), whereas 16-epioestriol
appeared to be converted to a greater extent to oestriol, as
well as to 16-ketooestradiol, suggesting a more marked
biological conversion of the 16/5, 17/S-dihydroxy grouping than
of the 16<X, 17/3-dihydroxy structure in the human (in this case
the male). Diczfalusy et al, (71) have recently shown that
quantities of oestriol may be formed from 16-epioestriol by
maternal tissues of the pregnant woman. The present author's
data also demonstrated that both labelled 16-epioestrioi and
16-ketooestradioi gave rise in vivo to small amounts of 16(3-
hydroxyoestrone suggesting that the latter, or some fraction of
it, may arise via oxidation of preformed 16-oxygenated steroids
rather than by, or in addition to, direct hydroxylation as for
160(-hydroxyoestrone production. This is in some agreement
with certain data of Breuer et al, (72, 73) but at variance
with those of Fishraan et ai. (74, 75),
Breuer et al, (51) have devoted considerable attention to
16-ketooestrone (i.e., the 16,17-dione) as a possible inter¬
mediate in many of these interconversions. However, although
the latter steroid has been claimed as a urinary metabolite
(76) its existence is currently in question, A short communi¬
cation from the author's laboratory (Lucis and Hobkirk,
Steroids 1: 678, 1963) showed a product with the properties
of 16-ketooestrone to be formed from 16-ketooestradiol incubated
with human uterine fibroid tissue. The significance of this is
not known,
(b) 2-Methoxyoestrone. Cell-free systems (usually microsomes
plus supernatant) of rat liver tissue were demonstrated to
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hydroxylate oestrone at position 2, to methylate the 2-hydroxyl
group, thus forming 2-methoxyoestrone, and to reduce the latter
to some degree to 2-methoxyoestradiol (Lucis and Hobkirk,
Steroids 2: 669, 1963). The methoxylation could be inhibited
by oestriol, 3,4-dihydroxy benzoic acid and chlorogenic acid.
(c) l7oc-£thvnyloestradiol-17/3-3-cyclopentvl ether. At the time
of study this was known to be a long-acting oestrogen which, at
least in the rat, was stored in adipose tissue prior to being
released over a prolonged period (61). A study was made
(Williams, Layne, Hobkirk, Nilsen and Blahey, Steroids 9: 275,
1967) of urinary and tissue metabolites of the above-mentioned
14
compound labelled with C in the cyclopentyl ether group and
3
H in the steroid. Excretion in the urine following a single
3 14
oral dose was prolonged - 50 to 100 days. H and C were
excreted in a non-uniform manner and three main metabolites
3
were detected. One was identified as H-ethynyloestradiol
3while a second, more polar compound, containing only H, was
probably a hydroxylated form of the latter (see reference 77).
3 14
A third metabolite contained *H and C and was thought to be
a hydroxylated form of the administered compound (see reference
77). Virtually no unchanged 17o<-ethynyloestradiol-3-cyclopentyl
ether was excreted in the urine. A compound similar to it was
recovered from adipose tissue but no radioactivity could be
measured in a variety of other tissues including blood, ovary,
ovarian tube, endometrium and uterine wall. Thus, in the human
the long-term activity of this synthetic oestrogen is probably
-24-
due to its slow release from adipose tissue with the production
of active oestrogen such as 17<x-.ethynyloestradiol#
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SECTION D
URINARY OESTROGEN CONJUGATE PATTERNS BASED MAINLY
ON DIRECT HYDROLYTIC PROCEDURES
INTRODUCTION
With the availability of more or less specific methods
for hydrolysis of steroid glucosiduronates ( (3-glucuronidase)
and sulphates (solvolysis) it became possible, and advisable,
to investigate the 'conjugation pattern' of oestrogen metabo¬
lites in human urine (both pregnant and non-pregnant). Such
studies had, of course, been performed to some extent, over the
years (78-80), but little or nothing was known regarding, for
example, conjugation of the phenolic steroid ring D oc -ketols
until Smith and Kellie's observations were published in 1967
(81). Initial work on the conjugation of the classical
oestrogens in glucosiduronate and sulphate forms had resulted
in very variable results (79, 82, 83) so that it was considered
worthwhile to follow this avenue of investigation, particularly
in view of the increasing interest in steroid sulphates in
biochemistry and metabolism (84, 85).
Discussion of Published Work (Appendix - Section D)
Conjugation patterns in the non-pregnant human female
were established following intravenous administration of trace
3
doses of H-oestradiol (Hobkirk, Nilsen and Blahey, J Clin
Endocr 29: 328, 1969). Of the urinary "^H extractable after
successive treatment with ^-glucuronidase and solvolysis,
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some 10-15% usually corresponded to 'sulphate*, i.e., was
solvolyzed. Of this, a large fraction, in some cases virtually
all, appeared to be oestrone sulphate. In only a few instances
was it possible to identify with certainty non-ketonic steroids
or ring D oc -ketols which had been conjugated in a sulphate
form. In one particular subject a large percentage of extract-
3
able urinary H (some 50%) behaved like sulphate. It should
be pointed out here that because of the successive fi-
glucuronidase/solvolysis treatment, steroids with more than one
hydroxyl group, conjugated with both glucuronic acid and
sulphuric acid, would end up in the 'sulphate* (solvolyzed)
fraction. In the above-mentioned subject all of the steroid
fractions sought were identified partially in a solvolyzable
form and oestrone-3-sulphate was shown by direct means to be
the main single component so conjugated. The significance of
this is not clear, nor is the question of how intimately such
a feature is concerned with changes (within the normal range)
in renal function. Endogenous oestrone in human females was
also measured in glucosiduronate and sulphate forms and on the
average the latter were calculated to be 32 and 37%, respec¬
tively, of total urinary oestrone at days 14 and 22 of the
normal cycle. These values, however, include the elevated
oestrone sulphate found in the subject discussed above.
However, even with omission of these results, 25 and 28% are
the values obtained. Thus urinary oestrone-3-sulphate may be
a more quantitatively significant urinary metabolite in the
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human than earlier indicated.
Because of the hydrolytic sequence employed the above
study did not differentiate between sulphates and sulpho-
glucosiduronates (see above). Further data became available
on such endogenous conjugates in human pregnancy urine although
still in a somewhat indirect fashion (Tan, Anuman-Rajadhon and
Hobkirk, Clin Ghim Acta 31s 783, 1971), Even so it was
concluded that conjugates other than monoglucosiduronates of the
phenolic steroid ring D ck-ketols (as a percentage of the total
individual steroid fraction) were greater than for oestriol.
However, there was little or no 16 oc-hydroxyoestrone sulphate
present although considerable amounts of the sulphoglucosidur-
onate of this steroid were found, and significant levels of
both monosulphate and sulphoglucosiduronate of 16-keto-
oestradiol were measurable. Whether this reflects a lack of
sulphurylation of 16K-hydroxyoestrone, or a feature of renal
function, is not known at present. A recent paper by Ahmed and
Kellie (85a) indicates that the sulphoglucosiduronate of 16oc-
hydroxyoestrone accounts for 3ome 20% of total conjugates of
this steroid in late pregnancy; in good agreement with Tan et
al. The studies of Smith and Kellie (81) and those of Bugge,
Nilsen, Metcalfe-Gibson and Hobkirk (Can J Biochem Physiol 39:
1501, 1961), together with the above, show the necessity for
taking the monosulphate and double conjugate groupings into
consideration when hydrolyzing ring D oC-ketol conjugates in
pregnancy urine.
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Unpublished Data Related to the Above
(a) Serial analysis of ring D cx -ketols in pregnancy. Figs 2
and 3 show excretion patterns for 16 <X -hydroxyoestrone and
16-ketooestradiol in the 'glucosiduronate* and 'non-glucosi-
duronate' forms following successive ^-glucuronidase
incubation and solvolysis. The curves for all forms appear to
follow closely that for urinary oestriol, with the typical
increase in rate of excretion at about 30 or more weeks,
Adlercreutz and Luukkainen (39) have now presented similar data
for 'total* urinary levels of these steroids using gas liquid
chromatography combined with mass spectrometry.
(b) Specific radioactivities of conjugated oestrogen metabo¬
lites in pregnancy urine after a single intravenous
3
injection of oestradiol-6t7- H. In an earlier publication
(Hobkirk and Nilsen, J Clin Sndocr 26: 625,1966) it was con¬
cluded, on cursory examination, that the specific activities of
•glucosiduronates' and 'sulphates' (or non-glucosiduronates) of
any single oestrogen metabolite in such experiments were, to
all intents and purposes, the same, and values were therefore
given for 'combined* conjugated forms. The results of two
further experiments, in which specific activities were estab¬
lished by a double isotope procedure following successive ($-
glucuronidase hydrolysis and solvolysis, are shown in Table 4.
As in the earlier studies the values for the ring D <x -ketols
were much closer to those of oestrone than to those of oestriol.
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sulphoglucosiduronate forms) were somewhat similar to or greater
than those for the glucosiduronates. The differences which
occurred were not great enough to suggest highly differing
percursor or pool origins, except perhaps in the case of
oestradiol. In that instance the higher values for the
•sulphate' could have been due to the rapid excretion of a small
3
percentage of the injected H-oestradiol which had become con¬
jugated without mixing with the main body pool,
(c) Conjugation of urinary oestrogen metabolites in pregnant
and non-pregnant subjects. Published data (see Section D,
above) and additional unpublished material are collected in
Table 5. The main (in a quantitative sense) metabolites only
are presented. Broadly speaking, it is seen that the degree
of conjugation of oestrone as its sulphate, although higher on
the average in its endogenous form in pregnancy than as a
3
metabolite of injected H-estradiol in the non-pregnant state,
covers a similar wide range. Also, in the non-pregnant state
the endogenous pattern is similar, although the mean value is
higher than for the corresponding exogenous value. The values
for 16oc-hydroxyoestrone and 16-ketooestradiol are virtually
identical in the pregnant (endogenous) and non-pregnant
(exogenous) groups. The same is true of oestriol. Thus it
might be claimed that the production of vastly increased amounts
of these steroids in pregnancy does not lead to a situation
where the enzymes and tissues involved in their conjugation and
distribution are unable to handle them, at least as based on
TABLE5
Percentages(m ana dran s)ofFourUri aryPhenolicSt roids Conjugatedas'N n-Glucosiduronate'(s lphate+s lphoglucosiduronate) inPregnanta dNon-pregnantWomen* 16<x-Hydrcxy-16-Keto-













Inonly8utf28werethessteroidsdefinitelyid ti dab ngth 'non-glucosiduronate*forms.Thev lu sgiv narf rth e8subjects.
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-30-
urinary patterns. However, where the ring D oc-ketols and
oestriol are concerned it was possible to definitely identify
the steroids in their 'non-glucosiduronate* forms in only a
small number of the non-pregnant subjects, i.e., 7 or 8 out of
28 (see Table 5). Had firm data been obtained for all these
3
(e.g., by injecting a larger dose of H-oestradiol) it is quite
possible that the average ^on-glucosiduronate' percentage
would have been lower in these latter cases. The wide varia¬
tion between individuals should also be borne in mind, as shown
in Table 5.
SECTION E
FORMATION, METABOLISM, INTERCONVERSION OF OESTROGEN SULPHATES
IN SPECIES OTHER THAN THE HUMAN IN VITRO AND IN VIVO
INTRODUCTION
With the increasing interest in steroid sulphates,
certain of which are now considered to be products of secretion
(86-88) and intermediates in biosynthetic processes (84, 85, 89,
90) rather than, or as well as, 'detoxification* products,
several aspects of this field of interest appeared suitable for
study. Thus, some consideration has been given to the effect
of steroid structure on enzymatic sulphurylation, as well as to
the age of the animal (rat) from which tissue was obtained for
in vitro work. Since the in vivo pattern of oestrogen metabo¬
lism in the chicken has been particularly well established (53-
59), certain aspects of sulphate conjugate metabolism were
investigated using this species both in vitro and in vivo. The
usefulness of this latter study was greatly increased by the
knowledge that sulphurylation may represent the sole type of
conjugation which occurs in the chicken, at least as reflected
in the products of urinary excretion (10a).
Discussion of Published Work (Appendix - Section E)
A soluble sulphurylating enzyme system from rat liver was
shown to display greater activity toward phenolic steroids
possessing ring D hydroxyl groups of the ft-orientation (e.g.,
lift -oestradiol, 16-epioestriol and 16-ketooestradiol-17/3) than
-32-
towards steroids with an <X.-orientated group in ring D (e.g.,
oestriol); Raud and Hobkirk (Can J Biochem 44: 657, 1966).
The disulphate conjugate was formed from oestradiol. In the
foetal rat at term no sulphurylation of oestrone or oestradiol
was observed with only minimal sulphurylation of aehydro-
isoandrosterone. Even at 10 days of age no activity was dis¬
played towards oestrone and as late as 30 days the observed
conjugation of each of the above three steroids was far from
the adult level.
A high speed supernatant fraction of chicken liver was
many times more active in sulphurylation than were similar
preparations of oviduct and vagina from the same species (Raud
and Hobkirk, Can J Biochem 46: 749, 1968). Moreover, the
latter system, in each tissue, demonstrated a much greater
activity towards the phenolic steroids than to dehydroisoand-
rosterone. This represents a curious finding since sulphuryl-
C
ation of 3 fi -OH, A. steroids is generally considered to be an
efficient biochemical mechanism in a variety of tissues from
many species, e.g., rat liver (Raud and Hobkirk, Can J Biochem
44: 657, 1966). These results appear to be in good agreement
with the ability of the chicken to sulphurylate oestrogens
in vivo (10a).
14 3
Incubation of C-oestrone and H-oestradiol-3-sulphate
with liver homogenates from laying hens (Raud and Hobkirk,
Can J Biochem 46: 759, 1968) furnished the following informa¬
tion: (a) There is interconversion in this system between free
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oestrone and oestradiol with production of the former steroid
predominating, just as for almost all in vitro and in vivo
situations thus far studied. (b) There is interconversion,
apparently in the intact conjugated form, of oestrone-3-
sulphate and oestradiol-3-sulphate, once more with the 17-keto
form predominating. This supplements earlier information
regarding direct interconversion of intact steroid conjugates
in other species and systems and may also be relevant to the
later in vivo work of Mathur (91) who showed in 1969 that, in
this species, metabolism of intact oestrogen conjugates
occurred.
The identification of disulphates of phenolic steroids as
metabolites in the urine of the laying hen (10a, 91) suggested
the necessity for studying the metabolism of labelled oestradiol-
3,17—disulphate in vivo in the same species. The results of
such a study (Mathur, Common and Hobkirk, Steroids 14j 389,
1969) indicated a very poor recovery of the label in the urine.
The sole metabolite identified was oestradiol-17-sulphate.
Thus a partial picture was obtained showing the possibility of
removal of the 3-sulphate group from the diconjugate.
SECTION F
METHODOLOGY FOR THE SEPARATION OF STEROID CONJUGATES
INTRODUCTION
Part of the foregoing work (Sections B and D) has yielded
data derived from experiments which either did not attempt to
differentiate between conjugated forms of steroids or which
relied almost wholly on the specificity (occasionally doubtful)
of enzymatic hydrolysis and/or solvolysis to cleave various
crude mixtures of glucosiduronates, sulphates and sulpho-
glucosiduronates in urine or extracts thereof. There is
clearly a limit to such methodology, particularly where the
metabolism of steroid conjugates is to be investigated.
Considerable advances have been made in the separation of intact
steroid conjugates (11, 12, 18, 85, 92, 93) although many of
these techniques are not without their problems. Moreover, a
relatively simple and efficient separation of oestrone-3-
glucosiduronate, oestradiol-3-glucosiduronate and oestradiol-
17-glucosiduronate, did not appear to have been achieved. A
better understanding of the in vitro biosynthesis of the
labelled forms of these conjugates (94-97) enabled standard
compounds to be prepared thus rendering the overall problem
much easier. A workable separation procedure involving simple
gradient elution of DEAE-Sephadex columns was devised, taking
advantage of the pioneering studies of Hahnel (11, 12).
Attempts were also made to apply this to the separation of
certain C19 neutral steroid conjugates.
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Discussion of Published Work (Appendix - Section F)
A relatively simple method involving linear concentration
gradients of NaCl in ^0 allowed separation for the first time
of a number of conjugates including the 3-glucosiduronates and
3-sulphates of oestrone and oestradiol, and the 17-gluco-
siduronate, the 3-sulphate-17-glucosiduronate and the 3,17-
disulphate of oestradiol (Hobkirk, Musey and Nilsen, Steroids
14: 191, 1969). It should be noted that the pioneering work
of Hahnel (11) did not result in the same efficient separations
obtained in the present author's laboratory, particularly
between the 3-glucosiduronates of oestrone and oestradiol and
even between sulphates and 16- or 17-glucosiduronates. In
order to separate the sulphates from glucosiduronates Hahnel
resorted to a very complex gradient (12)• During the prepara¬
tion of the various labelled conjugates in the present work it
was shown possible to produce oestradiol-3-sulphate-17-
glucosiduronate from oestradiol-17-glucosiduronate by the
sulphurylating enzyme system in guinea pig liver in a manner
similar to that described by Levitz et al. (95) for oestriol-
3-sulphate-16-glucosiduronate. This oestradiol conjugate had
not previously been reported as a biosynthetic product but its
chemical synthesis had been described (98).
A refinement of the procedure for the separation of the
3-glucosiduronates of oestrone and oestradiol and the 17-
glucosiduronate of oestradiol was subsequently reported
(Hobkirk and Nilsen, Anal Biochem 37: 337, 1970). This
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involves two separate NaCl concentration gradients on DEAE-
Sephadex with a Celite column partition chromatographic step
inserted between them. This procedure has been extensively
and successfully employed in the author's laboratory to study
the detailed metabolism of the glucosiduronates and glucosides
of oestrone and/or oestradiol (see Sections G and H, below).
These procedures, or modifications of them, have been or are
now being successfully used in a variety of studies in the
laboratories of D. S. Layne (University of Ottawa; personal
communication), K. F. Stoa, Bergen, Norway (99) and D. C.
Collins et al., Atlanta, Georgia (100, 101). Shortly after the
present author's first paper on the subject (Hobkirk, Musey and
Nilsen, Steroids 14: 191, 1969) two publications appeared on
the use of a number of Sephadex preparations in the attempted
separation of all the possible conjugated urinary metabolites
14
of injected C-oestradiol in the human (102, 103). These data
once more demonstrated the usefulness of Sephadex in this field
but the complexity of the study resulted in a failure to
identify the majority of the large number of separated or
partially separated peaks.
Attempts to apply the gradient elution technique to the
problem of neutral steroid separation has been only partially
successful (Hobkirk and Davidson, J Chromatoq 54: 431, 1971).
It resulted in the separation of the sulphates of testosterone
and dehydroisoandrosterone from each other and from the gluco¬
siduronates of these two steroids; the glucosiduronates were
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not, however, resolved* The free steroids were easily separated
(as one peak) from the conjugates.
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SECTION G
METABOLISM OF OESTRQNE AND OESTRADIOL GLUCOSIDURONATES
IN THE HUMAN IN VIVO
INTRODUCTION
Although considerable data have been accumulated as to the
metabolism of oestriol conjugates in the human by Levitz et al.
(85, 104), Dicsfalusy et al. (105-107) and Slaunwhite et al.
(92, 108, 109) very little of note had been published regarding
the metabolism of glucosiduronates of oestrone and oestradiol
prior to the present author's work. Indeed, it would seem that
only one publication had appeared, that being on the subject of
the metabolism of oestrone-3-glucosiduronate in pregnancy (110).
It was shown that a very small amount of the latter conjugate
was transferred intact from foetus to mother and that in the
foetus a limited degree of 16-hydroxylation occurred directly
to yield oestriol and/or 16<*-hydroxyoestrone glucosiduronates.
In addition, a small degree of direct reduction of oestrone-3-
glucosiduronate to oestradiol-3-glucosiduronate was indicated.
In the same study the high rate of urinary excretion of the
isotope following intravenous injection of singly labelled
oestrone-3-glucosiduronate into pregnant women was taken to
reflect a general lack of metabolism of the conjugate. During
the course of the present author's work it was shown by Roy and
Slaunwhite (111) that oestrone-3-glucosiduronate and oestradiol-
3-glucosiduronate were interconverted in their conjugated forms
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by a human placental dehydrogenase enzyme system in vitro.
However, the use of considerable concentrations of cofactors
made it difficult to draw conclusions regarding the preferred
direction of this interconversion.
The availability of a procedure for the direct separation
and purification of oestrone and oestradiol gluccsiduronates
(see Section F, above) rendered possible a study of the
metabolism of these conjugates in the human female. The reasons
for such a study included the basic lack of information in this
area, the necessity of knowing whether these glucosiduronates
are indeed real 'end products of oestrogen metabolism', and a
need to understand whether the same conjugates necessarily
represent 'unique metabolites' of secreted oestrogens, particu¬
larly with respect to measurement of production and secretion
rates from urinary metabolites of injected hormones (112-114).
Besides these points, the form(s) of the naturally-occurring
oestradiol glucosiduronate(s) was (were) unknown; i.e., whether
there existed the 3-raono, 17-mono, or 3,17-diglucosiduronate
form, or indeed, any combination of these.
Discussion of Published Work (Appendix - Section G)
3
The commercial availability of oestradiol-6,7- H-17-
glucosiduronate made possible a comparison of the metabolism of
14
this conjugate with that of unconjugated C-oestradiol (Hobkirk
and Nilsen, Steroids 13: 679, 1969). This study was performed
using conventional hydrolytic techniques followed by identifi¬
cation of the various free steroidal metabolites rather than by
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preliminary separation of the conj*ugates since the latter
procedure was not yet available. Thus little information on
specific conjugate structure was obtained for the urinary
metabolites. However, a great difference between the metabolism
of the free and conjugated oestradiol was apparent. Prom the
latter, little besides the glucosiduronates of oestrone and
oestradiol were excreted whereas administered oestradiol gave
rise to the usual multitude of metabolites including major
quantities of conjugated 16-hydroxy steroids, such as oestrioi.
The formation of oestrone glucosiduronate as a major metabolite
of oestradiol-17-glucosiduronate confirmed the removal of the
17-glucuronyl group without, however, leading to release of
oestradiol (or oestrone) into the main body pool, otherwise one
would have expected to find similar metabolites from the conju¬
gated and unconjugated percursors (i.e., oestradiol-17-
glucosiduronate and oestradiol). The possible presence of
oestradiol-3-sulphate-17-gluccsiduronate as a metabolite of
oestradiol-17-glucosiduronate was also suggested.
The above data necessitated the identification of the
urinary conjugated metabolites of oestradiol-17-glucosiduronate
and this was undertaken with the aid of the gradient elution
procedure described in Section F. Gestrone-3-glucosiduronate,
oestradiol-3-glucosiduronate and oestradiol-17-glucosiduronate
were identified as the main metabolites, together with small
amounts of cestradiol-3-sulphate-17-glucosiduronate and
oestrone-3-sulphate (Hohkirk and Nilsen, Steroids 14: 533, 1969).
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The relative amounts of these were not established with
certainty since identification was achieved at the expense of
quantitation. The route of conversion was not established but
it was suggested that a possible intermediate could be
oestradiol-3,17-diglucosiduronate, as follows: Oestradiol-17-
glucosiduronate —> oestradiol-3,17-diglucosiduronate —>
oestradiol-3-glucosiduronate —>oestrone-3-glucosiduronate. For
this to occur the facile conversion of oestradiol-3-gluco-
siduronate to oestrone-3-glucosiduronate should be demonstrable.
With this in mind the latter two conjugates were prepared, in
3
the author's laboratory, containing H in the steroidal moieties
14
and C in the glucuronic acid residues. A study of the metabo¬
lism of these, after their intravenous injection into normal
women (Hobkirk and Nilsen, Steroids 15: 649, 1970), revealed
direct interconversion within a relatively short time interval,
this being markedly in favour of oestrone-3-glucosiduronate
production in a ratio of about 4:1. Urinary excretion of the
labels was very rapid, in agreement with Zuconni et al. (110)
and little additional radioactivity was excreted beyond 6 hr
3
after injection. The latter consisted solely of H and had
apparently arisen via deconjugation (hydrolysis), interconver¬
sion of free oestrone and oestradiol, and reconjugation with
endogenous, unlabelled, glucuronyl groups. No oestradiol-17-
glucosiduronate was excreted in the labelled form and little
or no additional metabolites were detected. These findings
are not inconsistent with the possible occurrence of the scheme
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outlined above for the conversion of oestradiol-17-
glucosiauronate to oestrone-3-glucosiduronate, however, the
diglucosiduronate form of oestradiol has not yet been detected
in any situation.
Since there is little, if any, evidence for deconjugation
of oestrogen glucosiduronates, in the human, at sites other
than in the intestine (see studies on oestriol glucosiduronates;
references 92, 108), and in view of the partial deconjugation
of intravenous oestradiol-17-glucosiduronate and the 3-
glucosiduronates of oestrone and oestradiol found to occur (see
above), the labelled forms of these compounds were administered
orally to women (Hobkirk, Nilsen and Musey, Un Med Canada 100:
449, 1971). Almost the entire urinary radioactivity could be
accounted for as oestrone and oestradiol-3-glucosiduronates
after the ingestion of oestradiol-17-glucosiduronate. Very
small amounts of oestriol glucosiduronate(s) was detected while
the administered conjugate was apparently absent in its un¬
changed form. Orally administered oestrone-3-glucosiduronate,
3 14
containing H in the steroid and C in the glucuronic acid
3
group yielded little other than H-labelled oestrone-3-
glucosiduronate and oestradiol-3-glucosiduronate in the urine,
indicating efficient deconjugation and reconjugation. This
further suggested a hydrolysis-absorption-conjugation mechanism
at the gut level. In these experiments a considerable delay of
at least 3 hr occurred in urinary excretion of the radioactivity.
Over that period a very small amount of isotope ("^H plus *^C)
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3
appeared followed by a progressive, but slow, excretion of H
alone up to at least 72 or 96 hr. This was suggestive of a
rate-limiting step at some point in the overall absorption
(including deconjugation and reconjugation) mechanism.
Of paramount importance in these studies has been the
identification of the naturally-occurring urinary conjugates of
©estradiol. Labelled ©estradiol was administered intravenously
or orally to normal women, and the urinary conjugates were
investigated (Hobkirk and Nilsen, J Clin Sndocr 32: 779, 1971).
Within 2 hr of intravenous injection, labelled oestradiol-17-
glucosiduronate exceeded the 3-glucosiduronate by a factor of
more than 4. Thereafter virtually no further 17-glucosiduronate
was excreted whereas the 3-glucosiduronate increased cumulatively
over a 24 hr period and approached the level of the former
conjugate at that time. It should be noted that Hahnel, in
1967, claimed these two compounds, in their endogenous forms,
to be present in pregnancy urine in a ratio of about unity (115)
and in 1970 showed the same to be true of the two conjugates as
urinary metabolites of labelled oestradiol injected during
pregnancy (116). After ingestion of oestradiol no labelled
oestradiol-17-glucosiduronate was detectable in the urine but
the 3-glucosiduronate of oestradiol (besides that of oestrone)
was excreted in an increasing cumulative fashion over at least
24 hr. It is noteworthy that, following oral H-oestradiol,
urinary excretion of the label occurred without delay (i.e.,
within the limits that 2 hr was the first collection time;
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compare reference 117). Thus it would seem logical to suggest
that the delay in, and slow rate of, excretion, following upon
ingestion of oestrogen glucosiduronates (see above) is related
to the deconjugation, or hydrolytic step, prior to, or during,
the absorptive process.
The above data established, among other things, the
identity of the main urinary metabolites of oestradiol-17-
glucosidurcnate but yielded little information on precisely how
these metabolites arose or in what sequence. In order to
clarify these points, further work was carried out, and this
resulted in a fairly firm understanding of the overall metabo¬
lism of oestradiol-17-glucosiduronate, particularly with respect
to the role of an enterohepatic system (Musey, Green and Hobkirk,
J Clin Endocr 35: 448, 1972). When "^H-oestradiol-17-
glucosiduronate was injected intravenously into normal females
3
the excretion of H was rapid over about 0-2 hr (20-40% dose)
and then almost ceased over about 2-6 hr to be followed by a
recommencement of excretion up to at least 72 hr. In 0-2 hr
almost all of the label was in the form of oestradiol-17-
glucosiduronate (presumably unchanged injected material)
together with very small amounts of oestradiol-3-sulphate-17~
glucosiduronata. These two compounds more or less disappeared
from the urine thereafter, to be replaced by the 3-gluco-
siduronates of oestrone and oestradiol and very small amounts
of the glucosiduronates of other steroids such as oestriol.
3
When H-oestradiol-17-glucosiduronate was injected as above
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into women draining bile via T-tube the 0-3 hr urine contained
the compounds found in 0-2 hr in the normal subjects and the
0-3 hr bile contained major amounts of oestradiol-3-sulphate-
17-glucosiduronate and variable amounts of an as yet unidenti¬
fied sulphoglucosiduronate but no detectable monoglucosiduron-
ates of oestradiol or oestrone. Later samples of bile (up to
24 h.r) contained very small amounts of H, in the form of
sulphoglucosiduronates, and urine from 3-6 hr onwards contained
variable amounts of oestradiol- and oestrone-3-glucosiduronates.
It is likely that these latter arose via escape of some bile
into the intestine with subsequent metabolism of the sulpho-
3
glucosiduronate of oestradiol. Instillation of H-oestradiol-
3-sulphate-17-glucosiduronate into the duodenum of a normal
subject resulted in a marked delay (some 6 hr) in urinary
excretion of the label and then a rather slow excretion up to
at least 96 hr. The labelled metabolite pattern was very
similar to that found beyond 6 hr after intravenous injection of
oestradiol-17-glucosiduronate into intact subjects; i.e., the
3-glucosiduronates of oestradiol and oestrone were by far the
major compounds produced. It was also ascertained that a small
3
fraction (ca 7%) of an intravenous dose of oestrone-6,7- H-3-
14
glucosiduronate- C was excreted in the bile of a T-tube
subject, apparently in contrast to the absence of oestradiol-
17-glucosiduronate from the bile after intravenous injection of
its labelled form.
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These results explain the pathway of oestradiol-17-
glucosiduronate to its major urinary metabolites oestradiol-3-
glucosiduronate and oestrone-3-glucosiduronate as being via
biliary oestradiol-3-sulphate-17-glucosiduronate in the small
intestine. There is also agreement between these data and
those obtained for the metabolism of orally-administered
oestradiol-17-glucosiduronate and oestrone-3-glucosiduronate
(Hobkirk, Nilsen and Musey, Un Med Canada 100: 449, 1971) with
regard to the delay in intestinal absorption and the absence of
urinary oestradiol-17-glucosiduronate as an enteric metabolite.
Moreover, the cessation of excretion of urinary labelled
oestradiol-17-glucosiduronate within 2 hr after intravenous
3
injection of H-oestradiol to normal women (Hobkirk and Nilsen,
J Clin Endocr 32: 779, 1971) can possibly be explained by
synthesis and biliary excretion of oestradiol-3-sulphate-17-
glucosiduronate which, by a hydrolysis-absorption-reconjugation
mechanism would contribute, at least partly, to the continuing
urinary excretion of labelled oestradiol-3-glucosiduronate (and
oestrone-3-glucosiduronate) up to at least 24 hr after injection
of the free steroid. Alternatively, the urinary pattern of
oestradiol-17-glucosiduronate from precursor oestradiol could
reflect conjugation in (for example) the kidney, with consequent
rapid excretion. Kirdani et al. (118) have recently shown human
kidney to be capable of conjugating oestriol with glucuronic
acid at carbon 16 whereas oestrone was scarcely conjugated under
the same conditions. Recent unpublished results from the
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present author's laboratory show that intravenously injected
3 3
H-oestradiol in the human gives rise to urinary H-oestradiol-
17-glucosiduronate within 10 minutes of injection. Excretion
of the latter conjugate virtually ceases within about 60 minutes.
If 17-glucuronidation is indeed a renal activity there is little
need to invoke oestradiol-3-sulphate-17-glucosiduronate (via
oestradiol-17-glucosiduronate) as a major biliary metabolite of
blood-borne oestradiol or as a major precursor of urinary
oestrone-3-glucosiduronate ana oestradiol-3-glucosiduronate in
the human. However, until more definitive experiments can be
performed, the exact nature of the routes of formation and
metabolism of oestradiol-17-glucosiduronate must remain open to
speculation.
Metabolism of Oestrone and Oestradiol Glucosiduronates -
General Discussion
The data in Section G of this thesis establish, for the
first time, although not entirely completely, the inter¬
relationships of the naturally-occurring glucosiduronates of
oestrone and oestradiol. Apart from the work of Hahnel (115,
116) there has been little to suggest the number of gluco-
siduronate forms of oestradiol which may contribute to the
release of free oestradiol during incubation of urine or
urinary extracts with ^3-glucuronidase. It is quite evident
from the present author's studies that both possible roono-
glucosiduronates of oestradiol occur and that these may have
different biosynthetic pathways; moreover they may exhibit
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entirely different patterns of metabolism. Estrone-3-
glucosiduronate, in common with oestradiol-3-glucosiduronate,
could have several precursors and almost certainly more than
one tissue of origin. Such information may complicate calcula¬
tions of production or secretion rates of oestrogens where
urinary glucosiduronates are considered as more or less direct
metabolites of the secreted hormone(s). The situation becomes
even more complex when it is considered that both oestradiol
and oestrone may be secreted and, moreover, since the sulphates
of the latter two oestrogens might conceivably play a role as
precursors of the glucosiduronates. It may very well be, on
the basis of the information presented by the author's
laboratory that oestradiol-17-glucosiduronate is a unique
metabolite of oestradiol, formed directly from the parent
hormone•
One can speculate endlessly upon the relationship of
glucosiduronate conjugation and the role of such oestrogen
conjugates (if any) under physiological conditions. One
particular area which appears worthy of attention concerns the
presence of considerable amounts of highly polar oestrogen
conjugates in human bile. According to the author's work it
would appear that in order, for example, for biliary excretion
of oestradiol-3-sulphate-17-glucosiduronate, or other conjugate,
to lead to intestinal reabsorption of the oestrogen, a free, or
possibly protein bound, form of the steroid (partly oxidised to
oestrone) is probably an intermediate, perhaps in the gut wall.
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Thus •potentially-active' hormone might be delivered in this
fashion to the intestine where it could conceivably play a role
in maintenance of the circulatory system therein. Thisf of
coursef is merely speculation but it does suggest a reason for
enquiry into the overall handling of these steroid conjugates
in the human subject.
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SECTION Ii
METABOLISM OF OESTROGEN GLUCCSIDES IN THE HUMAN IN VIVO
INTRODUCTION
Conjugates other than glucosiduronates and sulphates have
been detected or identified in biological materials from time
to time. Within recent years much attention has been accorded
the N-acetylglucosaminides (119) and glucosides (120) of
phenolic steroids. These compounds have been shown to occur
particularly in the rabbit. The sole evidence for the occur¬
rence of steroid glucoside biosynthesis in the human has been
advanced by Layne et al. (121). These workers showed that
human liver and kidney tissues, in vitro, are capable of
catalyzing the transfer of glucose from adenosine diphosphate
glucose to the 17-hydroxyl group of 17<X -oestradiol. Although
such transfer appears to be specific for the 17oc-orientated
hydroxyl group of oestradiol it was deemed worthwhile to study
the metabolism of the 3- and 17-monoalucosides of 17^3-
oestradiol in the human so as to compare with the metabolism
of the closely related (structurally) glucosiduronates, as in
Section G, above. In addition, the metabolism of 17cX-oestradiol-
17-glucoside was studied since, at least in vitro, it can be
formed in the human.
Discussion of Published Work (Appendix - Section H)
17^-Oestradiol-6,7-"*H-3-f5-D-glucopyranoside-14C (generally
labelled) was synthesized and injected intravenously into human
females (Hobkirk, Nilsen, Williamson and Layne, J Clin Endocr 32:
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476, 1971). A rapid excretion of some 20% of each of the
administered, labels occurred within a 2 hr period, this
representing, almost entirely, unchanged injected conjugate.
Even within this time, however, a small amount of oestrogen
3
monoglucosiduronate, containing only the H label was excreted.
3
Beyond 2 hr only H-labelled metabolites were found, these
reflecting in pattern the metabolism of free oestradiol. Thus
it appears that by far the greater part of oestradiol-3-
giucoside is hyarolyzed at the glucosidic linkage with release
of oestradiol which in turn is metabolized in the same manner
as circulating oestradiol. This is very different from the
metabolism of oestradiol-3-glucosiduronate (Section G) and may
relate to a greater ease of transport of the uncharged conju¬
gate (glucoside) into cells and/or to the relative distribution
of ^3-glucosidase and ^-glucuronidase enzymes in the human.
3
When oestradiol-6,7- H-17-^-D-glucopyranoside was injected
3
intravenously into normal women about 5% of the H dose was
excreted in the urine within 2 hr (Hobkirk, Nilsen, Williamson
and Layne, J Clin Endocr 34: 690, 1972). In that time, in two
subjects, 1.9 arid 0.7% of the dose was identified as unchanged
monogluccside and 4.4 and 2.5% of the dose as a double conjugate
of oestradiol with glucose at C-17 and glucuronic acid at C-3.
Over the approximate period 2-6 hr after injection very little
3
H was excreted, then the label reappeared and excretion con¬
tinued up to at least 72 hr. Within the approximate time
interval 6-48 hr by far the main metabolites were oestrone- and
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oestradiol-3-glucosiduronates in addition to smaller amounts of
other phenolic steroid metabolites conjugated with glucuronic
acid. There was no obvious excretion of rnonoglucoside or double
conjugate at these later times.
It is abundantly clear from these results that the metabo¬
lism of the 3- and 17-monoglucosides of oestradiol are quite
different from each other in the human. It seems possible that,
3
in view of the excretion curve for H following injection of
3
H-oestradiol-17-glucoside, the double conjugate formed, namely
oestradiol-3-glucosiduronate-17-glucoside, could be largely
excreted via the bile with subsequent reabsorption and production
of the 3-glucosiduronates of oestradiol and oestrone as major
urinary metabolites; i.e., in a similar fashion as for the
enteric metabolism of oestradiol-3-sulphate-17-glucosiduronate.
There is little evidence to suggest the formation of free
oestradiol from intravenously injected oestradiol-17-glucoside
at sites other than enteric ones. This is in marked distinction
to the picture for oestradioi-3-glucoside in which extensive
hydrolysis occurred giving rise to free oestradiol and hence to
major amounts of more highly oxygenated steroidal metabolites.
3
The metabolism of intravenously injected H-17oc-oestradiol-
3
6,7- H-17-fi-D-glucopyranoside in normal women (Williamson, Layne,
Nilsen and Hobkirk, Can J Biochem 50: 958, 1972) was shown to
be somewhat similar to that of 17^3-oestradiol-17-glucoside.
Thus, a small amount of unchanged glucoside was excreted at an
early time together with a labelled double conjugate identified
with some cex'tainty as 17<*-oestradiol-3-glucos±duronate-17-
glucoside. However, the main, and almost sole, monogluco-
siduronate excreted was 17o(~oestradiol-17-glucosiduronate.
This latter increased with time as the excretion of the mono-
glucoside and mixed conjugate virtually stopped* A very small
amount of a compound tentatively identified as 17«-oestradiol-
3-glucosiduronate appeared in the urine beyond 6 hr, The route
and site of synthesis of 17cX-oestradiol~17~glucosiduronate from
the injected 17-moncglucoside is not at present clear*
General Discussion and Comparison of Metabolism of
Oestrogen Glucosiduronates and Glucosides
There is now adequate information, provided in the present
thesis, as to the great differences in metabolism of oestrogen
glucosiduronates on the one hand and glucosides on the other,
in the human subject. The obvious reason for this is the
presence or absence of the ionisable carboxyl group on the
carbohydrate moiety- This in turn is probably related to the
ability of the uncharged glucoside conjugate to penetrate cells
and/or to the distribution of ^-glucuronidase and ^-glucosidase
enzymes* The 3-glucoslde of 17/3-oestradiol is metabolized
largely by hydrolysis to free 17/3-oestradiol (Hobkirk, Nilsen,
Williamson and Layne, J Clin dndocr 32: 476, 1971) whereas the
3-glucosiduronate of 17|3-oestradiol undergoes very little
hydrolysis indeed (Hobkirk and Nilsen, .Steroids 15: 649, 1970)*
17£-Oestradiol-17~glucosiduronate undergoes metabolism largely
through production of 17/3-oestradiol-3~sulphate-17-
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glucosiduronate which is excreted in the bile and reabsorbed,
with deconjugation and reconjugation, to be excreted in the
urine as the 3-glucosiduronates of oestrone and oestradiol (see
above). The 17-glucosides of 17/3-oestradiol and 17o(-oestradlol
may be metabolized in a somewhat similar fashion to 17$-
oestradiol-17-glucosiduronate in that a double conjugate, in
these instances the 3-glucosiduronate-17-glucoside, is formed
as an intermediate in glucosiduronate production. However,
there is as yet no absolute evidence that the latter double
conjugate is excreted via the bile.
A knowledge of the metabolism of such conjugates may be of
importance in a better understanding of the distribution and
metabolism of certain steroidal preparations (including their
conjugates) which are used in clinical medicine. Moreover, it
is intriguing to enquire into the relationship between
oestrogens and mucopolysaccharide synthesis and metabolism
especially in view of the interesting finding of 17<X-oestradiol
specifically conjugated with both N-acetylglucosamine and
glucuronic acid in the rabbit (119). A recent review of the
subject by Layne (122) includes such points of interest.
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HYDROLYSIS OF ESTROGEN CONJUGATES
IN DIABETIC PREGNANCY URINES*
To the Editor:
The most acceptable conditions for the acid hydrolysis of urinary estro¬
gen conjugates, namely, boiling the urine with 15 volumes per cent of con¬
centrated hydrochloric acid for sixty minutes under reflux (1), have been
incorporated into 2 reliable procedures for measuring urinary estriol, es¬
trone and estradiol-17/3 (2, 3). Even under these circumstances, destruction
of estrogen still occurs, but it may be minimized by diluting the urine with
water prior to hydrolysis (4).
One substance reported to increase destruction of estrogen during acid
hydrolysis is glucose (5). In this laboratory, preliminary findings in a study
of estrogens in diabetic pregnancy indicated that estriol, estrone and es¬
tradiol excretion was markedly low in a number of cases. Because of the
difficulties involved in acid hydrolysis and the possible effect of urinary
glucose on recovery of estrogen from urine, we carried out the investigation
reported here.
materials and methods
Complete 24-hour urine specimens were collected and stored at 5° C. or in a deep¬
freeze until analyzed. Under these conditions there was no loss of estriol, estrone or
estradiol during the storage period. Determinations of sugar were semiquantitative,
using Clinitest tablets (Ames Co. of Canada, Ltd., Toronto).
AcicI hydrolysis was carried out on 100-ml. samples of undiluted urine, by the method
of Bauld (3). For diluted urine (mid or late pregnancy), samples containing 50, 25 or
10 ml. were diluted to 100 ml. with water to yield dilutions of 1 :2, 1 :4 and 1 :10 respec¬
tively, prior to acid hydrolysis. For a 1 :20 dilution, a 25-ml. aliquot of urine was diluted
to 500 ml. For early pregnancy or other urines with low estrogen levels, a 50-ml. aliquot
was diluted to 500 ml. to yield a 1:10 dilution.
For enzyme hydrolysis, a 10-ml. or 20-ml. volume of mid or late pregnancy urine
was adjusted to pH 6.5 (glass electrode) with dilute sodium hydroxide or acetic acid.
* Supported by grants from Ayerst, McKenna & Harrison Limited; The Banting
Research Foundation; Parke, Davis and Company; and the Women's Auxiliary of The
Montreal General Hospital.
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Table 1. Estrogen levels as measured in diabetic pregnancy urines using acid
hydrolysis after different degrees of dilution of the urine
(Results expressed as /ig. per 24 hours)
Urine specimen Estrogens
Degree of dilution of urine





















































* Sugar content not measured.
t Premarin (estrogen conjugate preparation—Ayerst, McKenna & Harrison, Mon¬
treal) in a dosage of 15 mg. daily was administered to the patient at this time.
This was incubated at 37° C. for twenty-four hours with 20 units of bacterial ^-glu¬
curonidase1 per ml. of original urine. After cooling, the solution was diluted to 100 ml.
for extraction. The conditions of incubation were chosen on the basis of results obtained
in comparative experiments (unpublished), in which acid and enzyme hydrolysis were
employed.
The chemical determination of estriol, estrone and estradiol was made in duplicate
by a modification of Bauld's method (3). This involved omitting saponification of the
estrone and estradiol fractions after chromatography, and dispensed with chromatogra¬
phy of the estriol fraction after saponification. This is permissible when estrogen levels
are high. Average recoveries of estriol, estrone and estradiol added to normal urine
after acid hydrolysis are 80, 90 and 90 per cent respectively, by this procedure.
RESULTS
Table 1 shows striking differences in estrogen levels between 1:2 and
1 Glucuronidase of bacterial origin (Sigma Chemical Co., St. Louis, Missouri). The
activity is expressed in Sigma units as defined by the manufacturers.
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Table 2. Comparison of acid and enzyme hydrolysis of estrogen conjugates in
diabetic pregnancy urines




No dilution 1:10 dilution hydrolysis
M4* estriol 2,310 11,440 11,000
(2% sugar) estrone 264 986 990
estradiol 33 360 646
M6f estriol 3,480 16,278 14,920.
(2% sugar) estrone 195 267 279
estradiol 40 157 159
Lo estriol 5,750 15,900 16,750
(2% sugar) estrone 113 142 163
estradiol 100 144 125
L„ estriol 14,000 16,459 17,000
(no sugar) estrone 175 166 163
estradiol 150 148 125
(1:2.5){ (1:25)
S estriol 15,350 22,115 17,750
(no sugar) estrone 300 470 318
estradiol 216 363 320
* Patient received 15 mg. of Premarin per day (see Table 1).
f Patient received 175 mg. of stilbestrol per day.
J Urine S was diluted to 2500 ml. before acid hydrolysis; this resulted in a dilution of
1:2.5.
1:10 dilution (urines Mx and M2) but no such variation between 1:4 and
1:10 for another urine, M3. In 2 other urines (Li and Bx) there were ap¬
parent differences between 1:4 and 1:10 dilutions. Also, an increase in
estriol was observed when urine Li was diluted from 1:10 to 1:20, although
estrone and estradiol values become inaccurate at the higher dilution. The
very large differences which may occur in estrogen levels between undi¬
luted urines, and urines diluted 1:10 before acid hydrolysis, are particu¬
larly obvious in Table 2 (urines M4, Ms and L2). The much smaller effect of
dilution for urine L3 (no sugar) suggests the relationship of urinary sugar to
destruction of estrogen. Although in urine S, with no sugar, there was an
increase in all 3 estrogens upon dilution, it should be noted that the lower
dilution in this case was 1:2.5 and the higher, 1:25.0. In general, estrogen
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Table 3. Effect of added glucose on the acid hydrolysis of urinary estrogen
conjugates in normal and diabetic pregnancy urines




dilution Estriol Estrone Estradio'
S 1:2.5 15,350 300 300
S 1:25 22,115 470 363
S+ 5% glucose 1.2.5 6,610 140 87
S+ 5% glucose 1:25 17,600 323 198
H 1:10 8,963 1,792 387
H+5% glucose Nil 1,353 401 44
H+5% glucose 1:10 7,255 1,444 333
* S = diabetic pregnancy urine containing no sugar.
H = normal pregnancy urine.
excretion values after enzyme hydrolysis showed good correlation with
those after acid hydrolysis of the 1:10 diluted urines M4, M5, L2 and L3
(Table 2). For urine S (1:25 dilution) lower values were found after en¬
zyme hydrolysis than after acid hydrolysis.
Table 3 shows that the addition of 5 per cent glucose to pregnancy urine
prior to acid hydrolysis resulted in loss of estrogen. Also, this could be
largely, if not wholly, compensated for by a tenfold dilution with water
prior to hydrolysis.
DISCUSSION
It is apparent that dilution of diabetic pregnancy urine before acid hy¬
drolysis results in a general increase in values for estriol, estrone and es¬
tradiol excretion. The extent of this increase seems to be variable for the 3
estrogens. Thus in 3 urines with similar sugar content (M4, M6 and L-2;
Table 2), acid hydrolysis after 1:10 dilution resulted in an increase varying
from 30 per cent (estrone in L2) to 1100 per cent (estradiol in M4) over that
for undiluted urine. In a sugar-free urine (L3) there was only a modest in¬
crease of estriol (15 per cent) on dilution. This is the expected observation
when normal (nondiabetic) urine is diluted 1:10 before acid hydrolysis (4).
The greatest destruction of estrogen occurs when acid hydrolysis is per¬
formed in undiluted urines containing glucose, and it is evident that uri¬
nary estrogen values based on these methods are open to considerable criti¬
cism.
The good agreement between estrogen values measured after acid hy¬
drolysis in a 1:10 dilution of urine and those after enzyme hydrolysis, al¬
though not constituting proof for completeness of estrogen release, suggests
that either procedure is capable of yielding more meaningful results than
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those obtained following hot-acid treatment of the undiluted urine. One
interesting feature (Table 2) is the significantly lower estriol and estrone
levels observed after enzyme hydrolysis than after acid hydrolysis of a
1:25 dilution of urine S. One possible explanation is the presence of estro¬
gen conjugates, other than glucuronides, not hydrolyzed by ^-glucuroni¬
dase and possibly destroyed during acid hydrolysis at lower dilutions of
urine.
It is concluded that any investigation of urinary estrogens (estriol,
estrone and estradiol) in diabetic pregnancy requires that hydrolysis of the
conjugates be effected either by acid hydrolysis following 1:10 dilution of
the urine or by incubation with /3-glucuronidase. There can be little doubt
that glucose is a major factor in loss of estrogen during acid hydrolysis oi
undiluted diabetic urines. This suggestion receives considerable support
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HYDROLYSIS OF CONJUGATED ESTROGEN FRACTIONS IN
HUMAN PREGNANCY URINE1
Sidsel Bugge, Mona Nilsen, Ann Metcalfe-Gibson, and R. Hobkirk
Abstract
The release of six estrogen fractions from conjugation in human pregnancy
urines has been studied using various hydrolytic methods. The estrogens con¬
cerned were estrone, estradiol-17/3 (estradiol), 2-methoxyestrone, 16-epiestriol,
and a ring D ketolic fraction (mainly 16a-hydroxyestrone). Considerable
amounts of urinary estrone and ring D ketolic estrogens may be conjugated in a
non-glucuronide form. In these cases an enzyme preparation containing 0-
glucuronidase and sulphatase, prepared from the digestive juice of the snail
Helix pomatia, proved to be superior to /3-glucuronidase enzymes of bacterial or
mammalian liver origin. Conventional hot acid hydrolysis yielded levels of
estrone, estradiol, estriol, and 16-epiestriol which agreed fairly well with those
obtained following snail enzyme hydrolysis. In some urines, hot acid treatment
was not suitable for hydrolysis of conjugated 2-methoxyestrone. Optimum
hydrolytic conditions for both normal and diabetic pregnancy urines were
realized by incubating for 24 hours with 500 units of the snail /3-glucuronidase
and 250 units of sulphatase/ml of urine at pH 5.2 and 37-38° C.
Introduction
The problem of hydrolyzing urinary estrogen conjugates prior to estrogen
analysis is not a new one. Within recent years, however, new problems have
arisen due to the discovery of labile ring D ketolic compounds (e.g. 16a-
hydroxyestrone) which cannot be treated by conventional hot acid hydrolysis
without destruction (1). Moreover, in urines containing glucose, destruction of
even the relatively stable 'classical' estrogens, namely, estrone, estradiol-17/?
(estradiol), and estriol, has been observed during hot acid treatment (2, 3).
Since the ring D ketolic estrogens seem to be of considerable importance in the
general scheme of estrogen metabolism (4), and since estrogen patterns in
diabetic pregnancy urines may be of interest (5), mild methods of hydrolysis,
such as incubation with /? -glucuronidase and sulphatase preparations, have
become increasingly necessary.
A number of investigators have reported upon the efficiency of enzyme
hydrolysis as compared with conventional hot acid treatment (2, 6-10). Such
studies have also yielded some indirect information regarding the mode of
conjugation of certain of the urinary estrogens. However, little is known about
the hydrolytic release of the more recently discovered metabolites such as
2-methoxyestrone, 16-epiestriol, and 16a-hydroxyestrone. Knowledge of this
sort might lead to a clearer understanding of the over-all metabolism of estrogen
secreted by the human subject.
'Manuscript received April 18, 1961.
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The present report concerns the use of various hydrolytic techniques for the
cleavage of conjugated estrogen metabolites in human pregnancy urine. The
compounds investigated include estrone, estradiol, estriol, 2-methoxyestrone,
16-epiestriol, and a fraction referred to as 'ring D ketolic', this latter apparently
consisting mainly of 16a-hydroxyestrone but also containing 16-ketoestradiol-
17/? and probably 16/?-hydroxyestrone. Particular attention has been given,
in the present study, to various aspects of the action of an enzyme preparation
from the digestive juice of the snail Helix pomatia.
Material and Methods
Urine Collection
Complete 24-hour specimens were collected without preservative from some
25 women, both normal and diabetic, during the last 20 weeks of pregnancy.
Following the final collection each urine was despatched to the laboratory
without delay and hydrolysis was immediately begun. Where delays were
necessary between the termination of enzyme incubation and subsequent
analysis the urine was frozen after incubation until required.
Chemicals
Organic solvents and other reagents were Reagent Grade and were purified
where necessary by published procedures (11, 12).
Enzyme Preparations
Bacterial ^-glucuronidase, Sigma Chemical Co.; mammalian liver ^-glucu¬
ronidase (Ketodase), Warner Chilcott Laboratories Inc.; molluscan ^-glucu¬
ronidase plus sulphatase (Glusulase), prepared from the snail Helix pomatia,
Endo Laboratories Inc.; molluscan ^-glucuronidase plus sulphatase, prepared
from the common limpet Patella vulgata; powder B of Dodgson and Spencer (13).
The unit of activity of each preparation was based on its ^-glucuronidase
content and is defined as the amount of enzyme liberating 1 fig of phenolphthalein
from a 0.001 M solution of phenolphthalein glucuronide in 1 hour at 37° C.*
The pH of incubation was 6.5 for the bacterial preparation, 5.0 for the liver
enzyme, 5.2 for the snail preparation, and 4.6 for the limpet material.
Hydrolysis of the Estrogen Conjugates
For enzyme hydrolysis, 10- or 20-ml volumes of urine were incubated, in
duplicate, with one or the other of the enzyme preparations at varying enzyme
concentrations, pH values, or for varying times, at 37-38° C. Adjustment of
pH for the various enzymes was made as described earlier (15). In most cases
penicillin (2000 units/ml of urine) was added prior to incubation (16).
Where hot acid hydrolysis was performed 10- or 20-ml volumes of urine,
diluted 1:10 with distilled water, were hydrolyzed by boiling for 1 hour under
*The unit of activity of the bacterial preparation should be modified by indicating that
assay was performed in the presence of chloroform. This exerts an 'activating' effect (14) and
the unit is less than is the case in the absence of chloroform when phenolphthalein glucuro¬
nide is the substrate.
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reflux with 15 volumes % of HC1 (11); this acid concentration referring to
diluted urine.
Splitting of residual labile estrogen conjugates (e.g. sulphates) following
enzyme hydrolysis was performed by adjusting the urine (from which free
estrogens had already been extracted) to pH 1 with HC1 and continuously
extracting with ether in an all-glass apparatus for 48 hours at room temperature
(17). Estrogen thus released was considered to have arisen from labile non-
glucuronide conjugates which were not hydrolyzed by the enzyme preparations.
Extraction and Analysis of the Estrogens
In all cases incubated urine was diluted to 100 ml with water prior to extrac¬
tion. In experiments where only estrone, estradiol, and estriol were to be
measured, hydrolysis was followed by the modified method of Bauld (3, 18).
For the analysis of six estrogen fractions, including the labile ring D ketolic
compounds, the method of Givner et al. (12) was employed, modified by omit¬
ting the second Girard separation and saponification of the estradiol and
2-methoxyestrone fractions following partition chromatography, and by
reducing solvent and reagent volumes where necessary. Where the ring D
ketolic fraction was not to be measured, as in analyses following hot acid
hydrolysis, the initial NaOH-bicarbonate treatment of the ether extract was
employed according to Bauld (11), followed by the Girard separation and
subsequent steps of the method of Givner et al. (12).
Recovery Experiments
For the purpose of checking the accuracy of the analytical methods, known
amounts of pure estrogens (5-25 fig depending on the compound concerned)
were added to 10- or 20-ml volumes of non-pregnancy (male or female) urine
which had been hydrolyzed either by the enzymic or hot acid method. These
urines were then analyzed by the techniques described above. Recoveries were
also measured of estrogens (excluding the ring D ketolic compounds) added to
urine prior to hot acid hydrolysis. In studying the recovery of the ring D
ketolic estrogens 16a-hydroxyestrone was normally employed as the representa¬
tive compound but some experiments were also carried out using 16-keto-
estradiol-17/3.
Results
Accuracy of the Methods
Table I deals with the accuracy of the analytical procedures. Recovery of
the various estrogens was not influenced by the enzyme preparation used.
With the possible exception of 16-epiestriol, recovery of the pure estrogens was
also independent of whether these were added to enzyme- or acid-hydrolyzed
urine. Recovery of added estrone, estradiol, estriol, and 2-methoxyestrone
was the same whether these steroids were added before or after hot acid
hydrolysis. Good agreement, considering the different techniques involved,
existed between the methods of Bauld (11) and Givner et al. (12) with respect
to recovery of estrone, estradiol, and estriol.
TABLEI
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Hydrolysis by Various Methods
The effect of varying incubation time on the enzymic release of the three
main estrogen fractions, estriol, estrone, and ring D ketolic estrogens, is shown










TIME OF INCUBATION (HOURS)
96
Fig. 1. Effect of incubation time on the liberation of estriol in normal human preg¬
nancy urine by fl-glucuronidase-containing preparations of bacterial, mammalian liver,
and molluscan origin. Conditions of hydrolysis as in Table I and in text.
2.0 r
24 48
TIME OF INCUBATION (HOURS)
Fig. 2. Effect of incubation time on the liberation of estrone in normal human preg¬
nancy urine by ff-glucuronidase-containing preparations of bacterial, mammalian liver,
and molluscan origin. Conditions of hydrolysis as in Table I and in text.
snail preparations gave rise to rather higher estriol levels than did conventional
hot acid hydrolysis. Continuous ether extraction following 96 hours of snail
enzyme activity released only an additional 3% of estriol while a further 2%,
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4%, and 10% was released by this procedure after incubation with bacterial
(48 hours), limpet (96 hours), and mammalian liver (96 hours) enzymes,
respectively. It was apparent from this that little estriol was present as a labile
conjugate. The difference between the liver enzyme and the other preparations
was considered to be due to slower hydrolysis of estriol glucuronide by the
former enzyme (19).
In a second normal pregnancy urine, maximum hydrolysis of estrone con¬
jugates was attained within 12 hours with all four enzyme preparations (Fig. 2).
However, this maximum was much greater in the case of the snail preparation,
the value being the same as that obtained by hot acid hydrolysis. Continuous
ether extraction following incubation with the other three enzyme preparations
released sufficient estrone to account for the observed differences, suggesting
considerable (40-50%) conjugation of the steroid in a non-glucuronide form
in this particular urine and perhaps even a labile conjugate, other than sul¬
phate, split by the snail preparation but not by the sulphatase-containing limpet
one. Very similar results were obtained for the ring D ketolic fraction in the
same urine (Fig. 3). Continuous ether extraction subsequent to enzyme hydrol¬
ysis resulted in no further measurable release of ring D ketolic estrogens,
time of incubation (hours)
Fig. 3. Effect of incubation time on the liberation of ketolic estrogens in normal human
pregnancy urine by /3-glucuronidase-containing preparations of bacterial, mammalian
liver, and molluscan origin. Conditions of hydrolysis as in Table I and in text.
presumably because of the labile nature of these compounds under acidic
conditions. It can be seen in Fig. 3 that a marked decrease occurred in the
ring D ketolic fraction when incubated with the snail preparation between
12 and 96 hours. This was also true of the estrone fraction in the same urine
(Fig. 2). Antibiotics were not used in these particular incubations. Even in
the presence of penicillin, however, a similar fall occasionally occurred in the
ring D ketolic fraction.
Table II compares the efficiencies of different hydrolytic methods for the
TABLEII
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release of estrone, estradiol, and estriol in a normal pregnancy urine. All four
enzyme preparations used yielded results which compared at least favorably
with those obtained by hot acid hydrolysis. When five normal pregnancy
urineswere separately hydrolyzed with hot acid, snail preparation, and bacterial
preparation, and also analyzed for estrone, the results (Table III) suggested
very variable amounts of this steroid to be present as non-glucuronide ('sul¬
phate') conjugates.
TABLE III
Liberation of estrone in normal human pregnancy urines by different hydrolytic methods
(Results expressed as mg/24 hours)
Normal pregnancy urines from different subjects
Hydrolytic*
method If 2f 3 4 5
Hot acid 2.4 1.9 0.59 0.69 0.77
Snail enzyme 2.4 1.9 0.62 0.69 0.76
Bacterial enzyme 1.6 1.1 0.55 0.65 0.59
Bacterial, as % of hot
acid or snail enzyme 67 58 90 94 77
*Enzyme concentrations and conditions of pH as in Table I; time of hydrolysis for enzymes, 24 hours,
tEstrone liberated by continuous ether extraction following action of bacterial enzyme accounted for difference
between the latter and the other hydrolytic methods.
Effect of pH on the Activity of the Snail Preparation
Aliquots of a normal pregnancy urine were incubated for 24 hours with
amounts of the snail preparation corresponding to 500 units of //-glucuronidase
activity/ml of urine at pH values of 4.0-6.5 at pH unit intervals of 0.5. Release
of the six estrogen fractions measured did not vary significantly over the pH
range studied except in the case of estriol which showed a considerable decrease
at 6.5 (70% of the level obtained between pH 4.0 and pH 6.0).
Effect of Variation of the Snail Enzyme Concentration
Aliquots of five urines were incubated with varying concentrations of the
snail preparation (100-1000 units of /?-glucuronidase/ml of urine). Table IV
contains the results obtained. In only three of the urines was measurable
2-methoxyestrone found (0.19-0.66 mg/24 hours). It was observed that 100
units of activity was sufficient for maximum hydrolysis of conjugated estrone,
estradiol, 16-epiestriol, and the ring D ketolic fraction in 24 hours, but not for
2-methoxyestrone or estriol. Five hundred units appeared to offer a safe com¬
promise since 1000 units did not result in any consistent increase in hydrolysis.
Effect of Variation of Incubation Time on Activity of the Snail Preparation
Aliquots of five pregnancy urines were incubated with the snail enzyme
preparation for varying times from 6 to 96 hours. In only two of these was
measurable 2-methoxyestrone found (0.19-0.30 mg/24 hours). The results in
Table V show considerable hydrolysis to have occurred in 6 hours for all
fractions, with 2-methoxyestrone and estriol lower than the others. In 16 hours
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96 hours' incubation did result, in some urines, in a further increase in the ring D
ketolic fraction. However, as has already been mentioned, decreased ring D
ketolic levels could also occur, even in the presence of antibiotics. For these
reasons an incubation period of 24 hours was considered to be most suitable.
The rapid release of estriol by this snail preparation (Fig. 4) was particularly
noteworthy in view of the slower hydrolysis by other enzyme preparations
(2, 19).
TIME OF INCUBATION (HOURS)
Fig. 4. Effect of incubation time on the liberation of estriol in normal and diabetic
pregnancy urines by the snail enzyme preparation. Conditions of hydrolysis as in Table I
for the snail preparation.
Comparison of Hot Acid with Snail Enzyme as Hydrolytic Methods
Aliquots of pregnancy urines (both normal and diabetic) were incubated for
24 hours at 37° C and pH 5.2 with a concentration of the snail preparation
equivalent to 500 units of /?-glucuronidase/ml of urine. Five estrogen fractions
(excluding the ring D ketolic estrogens) were measured, and their amounts
compared with those liberated in the same urines by hot acid hydrolysis after
1:10 dilution. The results for four fractions are shown in Table VI. Good
agreement was found between the two hydrolytic methods for the release of
estrone, estradiol, and estriol with the results slightly, although not significantly,
in favor of enzyme hydrolysis. The converse was true for 16-epiestriol although
again there was no significant difference. These findings are in agreement with
those of other workers who used limpet enzyme preparations (2, 20).
In four urines the 2-methoxyestrone released by acid amounted to 60-87%
(mean, 77%) of that obtained by snail enzyme hydrolysis. In two other urines
no measurable 2-methoxyestrone was found after hot acid hydrolysis although
0.2 and 0.3 mg of this steroid/24 hours was measured after incubation with the
snail preparation. These results are difficult to interpret since preliminary
TABLEV
Liberationofsixestrogenfracti nsnhumapre ancyurines*whincub tedf rv ryingtim sithhn ilnzymepreparat on (Meanresultswithanges)xpress dpercentageofv lubtai dft r24hourf chrine) Timeofhydrolysis(h ur ) Estrogenfractio61624
48
96
Estrone Estradiol Estriol 2-Methoxyestrone 16-epiEstriol RingDketolicfraction
95(89-103) 92(91-93)78(66-92)75 99(92-103) 90(88-93)
98(93-102) 99(88-109) 97(92-104)
100(97-103) 103(97-106) 95(88-100)
100 100 100 100 100 100
98(93-105)96(91-104)
101(96-107) 96(82-109) 99(94-100) 97(91-100)
95(89-104)
111(109- 12) 103(97-109) 97(82-111) 104(102-106) 96(76-115)
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TABLE VI
Comparison of hot acid and snail enzyme hydrolysis
(Results expressed as acid/enzyme X100; mean values are given with number
of duplicate analyses in parentheses)
Estrone Estradiol Estriol 16-epiEstriol Total*
95 + 7.6f 89 + 17.Of 89 + 6. 5f 109 + 16. 7f 90 + 6.7f
(15) (9) (9) (10) (8)
*Total refers to the addition of the four estrogen fractions in the table.
fStandard deviation.
experiments in this laboratory showed free 2-methoxyestrone to be stable to
hot acid hydrolysis in the presence of urine. In some urines, however, con¬
siderable 'background' chromogen contamination was produced in the
2-methoxyestrone fraction by acid hydrolysis. This could be particularly
troublesome when very low levels of this steroid were being measured. This
observation, together with the possibility that the effect of acid on free and
conjugated 2-methoxyestrone may not be the same, could perhaps account for
the above results.
Discussion
Since recovery of the various estrogens added to hydrolyzed urine was
independent of the hydrolytic method employed, the difference in estrogen
levels found after incubation of certain urines with enzyme preparations from
different sources was probably a true reflection of a variation in the ability of
these enzymes to split urinary estrogen conjugates under the experimental
conditions. The amounts of bacterial, mammalian, and limpet enzymes used
in the present study, although not necessarily ideal, have been shown by
others to yield optimum hydrolysis of estrogen conjugates given sufficient time
for action to occur (2, 21, 22). It is improbable that higher concentrations of
bacterial or mammalian preparations could have increased the extent of hydrol¬
ysis of conjugated estrone in those urines where the snail preparation released
significantly more of this steroid, since the difference was due to labile (non-
glucuronide) conjugates. There is no good evidence that enzymes capable of
splitting the latter are to be found in either the bacterial or mammalian liver
preparations. In the case of the limpet preparation, however, one would have
expected to observe a greater release of estrone provided that the non-glucu-
ronide conjugate was sulphate. This is discussed further below. These observa¬
tions, together with the facility possessed by the snail preparation for releasing
estriol and ring D ketolic estrogen metabolites, showed that this enzyme
mixture was a very suitable one for the present purpose. Slaunwhite and
Sandberg (23) have reported the snail preparation to be better than enzymes of
bacterial or mammalian liver origin for the hydrolysis of conjugated estrogens
in urine. These workers obtained maximum hydrolysis by incubating urine
for 96 hours at pH 5.5 and 37° C with 300 units/ml of the snail /^-glucuronidase
together with sulphatase. These results were based on the measurement of
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total radioactivity released in the urine following the administration of C14-
labelled estrogen to human subjects and therefore provided no information
regarding the effect of this hydrolytic procedure on individual metabolites.
It was established by Brown and Blair (2) that, provided urine was first
diluted 1:10 with water, no destruction of added free estrone, estradiol, or
estriol occurred during hot acid hydrolysis. Moreover, this method of hydrol¬
ysis was shown to yield levels of these three estrogens which compared very
closely with those obtained by incubating with the limpet enzyme preparation.
Thus it appeared likely that the limpet enzymes were capable of affecting more
or less complete release of the metabolites in question. By the same token it
could be suggested from the results of the present study that this is also true of
the snail preparation and that it extends to include 16-epiestriol. A few results
obtained showed that the snail preparation could be significantly more active
than the limpet one in releasing estrone and ring D ketolic estrogens. In the
case of estrone this was apparently due to a failure to hydrolyze non-glucu-
ronide conjugates since continuous ether extraction at pH 1 accounted for the
difference. This finding was surprising in view of the sulphatase present in the
limpet preparation, which enzyme would be expected to split estrone sulphate.
It is not clear at present whether a non-glucuronide conjugate, other than
sulphate, could have existed in this urine and might have been hydrolyzed by
some other enzyme present in the snail preparation but absent from the limpet
material. Bloch and Gibree (10) reported much higher (70-100%) levels of
estrone, estradiol, and estriol following incubation with 1500 units of snail
/^-glucuronidase, and at least 500 units of sulphatase/ml of urine for 24 hours
at pH 5.2 and 39° C, than after hot acid hydrolysis. However, these workers
used non-pregnancy urines of very low estrogen titer without dilution prior
to acid hydrolysis; these conditions were known to be quite destructive (2).
Jayle et al. (24) used 750-1500 units of snail ^-glucuronidase and at least
500 units of sulphatase/ml of urine for the hydrolysis of conjugated estrone,
estradiol, and estriol and obtained better results than with either bacterial
/^-glucuronidase or hot acid. In the present study, each 500 units of snail
/J-glucuronidase was accompanied by approximately 250 units of sulphatase
activity.
Comparison of hot acid and enzyme hydrolysis has not been possible for
conjugated ring D ketolic estrogens or 2-methoxyestrone due to the adverse
effect of hot acid on these fractions. Moreover, the picture is further compli¬
cated for 2-methoxyestrone by the number of pregnancy urines in which
measurable amounts of this steroid do not seem to occur (25). Thus no definite
conclusion has been reached regarding the quantitative release of these estrogens
by the snail preparation. However, it does seem likely that the hydrolytic
conditions finally chosen are capable of yielding approximately maximum
release of the six estrogen fractions concerned. In none of the experiments
performed was there any marked difference in hydrolytic efficiency by the snail
preparation whether normal or diabetic urines were studied. This showed that
\
!
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the enzymes were not adversely affected by the usual constituents of diabetic
urine.
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URINARY ESTROGENS IN NON-PREGNANT HUMAN SUBJECTS
MEASURED BY MODIFICATIONS OF BAULD'S METHOD.
R. Hobkirk and M. Nilsen
University Medical Clinic,




The chemical method of Bauld, and certain modifications of
it, for the measurement of urinary estrone, estradiol-17/? and
estriol may sometimes overestimate these compounds in males and
post-menopausal females. A more elaborate procedure, involving
a double partition chromatographic treatment together with the
Ittrich fluorimetric procedure, yields results which compare
more favourably with those obtained by the Brown and other
methods. For control male subjects the results obtained are
(fig./24 hours); estrone, average = 3.5, range = 0.8 - 7.1;
estradiol-170 = 0.9 (0.4 - 1.7); estriol = 6.1 (1.5 - 10.4).
In post-menopausal females estrone = 1.2 (0.2 - 3.1); estradiol
= 0.4 (0.0 - 0.9); estriol = 4.1 (0.6 - 10.4). The ring D
a-ketolic estrogen levels were of the same order as those of
estrone. In the males this group measured 3.8 (0.6 - 11.0)
and in the post-menopausal females, 1.2 (0.1 - 2.0).
INTRODUCTION
During approximately the last decade the measurement of
urinary estrone, estradiol-178 (estradiol) and estriol has been
mainly performed by the chemical procedures of Brown' and Brown
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et al3. These methods have been subjected to a considerable
degree of critical evaluation by investigators employing various
procedures including bio-assay3, countercurrent distribution and
isotope dilution4. Such studies have served to prove the
reliability of the Brown methods except for urines of estrogen
content lower than the useful sensitivity claimed for the pro¬
cedures. More recently Salokangas and Bulbrook5 combined the
method of Brown et al with the sensitive and highly specific
color reaction of Ittrich6 and concluded that the former procedure
yields an overestimation of the three estrogens which may be
particularly significant at low urinary levels. Finkelstein
et al7 have reported that Brown's method grossly overestimates
the three estrogens, even at the levels prevailing in the menstrual
cycle. However, these latter investigators did not appear to make
a direct comparison of their procedure with that of Brown, nor did
they publish normal values per 24 hours for their elaborate
purification technique.
Few investigators have employed the method of Bauld8 for
estrogen measurement. This is perhaps mainly due to the more
elaborate partition column systems which require some degree of
temperature control. So far as the present authors are aware the
results of only one direct comparison of estrogen levels by the
methods of Bauld and Brown have been reported9. This related to
urines of the menstrual cycle and there was promising agreement
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between the procedures. However, indirect evidence, in the form
of an examination of published results, may suggest that in male
or post-menopausal female urine the Bauld method, or modifications
of it, overestimates the levels of estradiol and estriol in
particular,1 0 /11
In order to explore some of the uncertainties associated
with the Bauld procedure, the technique has been combined with




Complete 24 hour urines were collected from hospitalized
patients having no evidence of liver or endocrine disease, and
from some laboratory personnel. Urines were analyzed as soon
after collection as possible. Where delays of more than four
days were necessary the material was frozen until required.
Materials
All chemical reagents and organic solvents were of good
reagent grade and were purified, where necessary, by established
methods. For fluorimetry a Farrand Model A fluorometer was
employed with an interference filter (546 mp) in the primary
position and an orange glass filter (max. transmission 585 mp)
in the secondary position. For spectrophotometry a Beckman Model
B instrument was used.
456 STEROIDS 3:4
Labelled Compounds
Estrone-16-14C (specific activity 40 ^c/mg.) was obtained froir
Radiochemical Centre, Amersham, England. Estriol-16-14C (specific
activity 22 /ic/mg.) and lS-ketoestradiol-lV/J-lS14 C (specific activity
20 /ic/mg.) were obtained from Dr. M. Levitz, New York. Estradiol-
17/3-6, 7-3H (specific activity 150 /ic//ig.) was obtained from New
England Nuclear Corp., Boston, Mass. All of these were chromato-
graphed in partition systems on celite and/or paper to obtain a
purity of at least 98%.
Method A
One-fiftieth aliquots of 24 hour urine specimens were diluted
to 50 ml. with water and incubated with 20 units/ml. of bacterial
/3-glucuronidase (Sigma Chemical Co., St. Louis, Missouri) at 37° C
and pH 6.5 - 7.0 for 24 hours. The ether extract of this was then
purified as described by Bauld8 using proportionately less sodium
hydroxide, sodium bicarbonate and water for washing. The benzene/
water partition and subsequent steps, including column partition
for the separation and purification of estrone, estradiol and estriol,
were also performed exactly as described by the latter author. One-
third aliquots of the column eluates were taken for fluorimetric
measurement by the Ittrich technique6 using tetrabromoethane as
solvent. Each compound was measured in terms of the pure material
as standard.
One-fiftieth urine aliquots were incubated as above and the
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ether extracts washed with sodium bicarbonate and water. A modified
Girard separation13 was then performed and the ketonic fraction was
chromatographed on celite in the system benzene/hexane/methanol/
water (5:5:7:3) collecting a fraction with the mobility of the
ring D a-ketols11. The Ittrich fluorimetric reaction was performed
on one-third aliquots of these eluates, results being calculated
in terms of 16-ketoestradiol-17£.
Method B
Aliquots ranging from 50% to 90% of 24 hour urines were
incubated and extracted as in method A using proportionately
greater volumes of ether. The ether extracts were washed with
sodium bicarbonate and water and subjected to the modified Girard
reaction. The non-ketonic fractions were refluxed with alkali, re-
extracted after pH adjustment and purified as described by Givner
et al13. The fractions were then resolved into estrone, estradiol,
ring D a-ketols and estriol on celite in hexane/benzene/methanol/
water systems as described by the latter authors. The estrone,
estradiol and estriol fractions were further purified by Bauld8.
The ring D a-ketols were reduced with sodium borohydride and the
major products resulting, namely, 16-epiestriol and estriol, were
separated and further purified by partition on a celite column
as described earlier11 12. Aliquots of column eluates ranging from
one-tenth to one-hundredth were taken for fluorimetric measurement
by the Ittrich procedure. Each compound was measured in terms of
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the pure material as standard.
Method C
This was exactly the same as method B except that one-third
or one-sixth aliquots of the column eluates were taken for
spectrophotometric measurement using the Ittrich technique with
tetrachloroethane as solvent, reading optical densities at 506,
538 and 570 mpi and applying the Allen correction14. Each estrogen
fraction was measured in terms of the pure material as standard.
Recovery of Radioactive Estrogens
A few recovery experiments, employing the above methods, were
carried out following the addition of small amounts of estrone-16-14C,
estriol-16-14C, lB-ketoestradiol-^^-ie-14 C and estradiol-178-6,7-3H
to urines after enzyme hydrolysis. Recovery of radioactivity was
determined on eluate aliquots in a Packard Tricarb Model 314 AX
liquid scintillation spectrometer, correcting for quenching where
necessary by the use of internal standards. Dried column eluates
were dissolved directly in the counting vials in 5 ml. of toluene
containing 0.3% of 2,5-triphenyloxazole and 0?01% of l,4-bis-2-
(5-phenyloxazolyl) - benzene except in the case of estriol and
16-epiestriol which were first dissolved in 0.1 ml. of methanol.
Counting efficiency for 14C was 73% and for 3H, 21%.
Effect of Column Eluates in Quenching of Fluorescence
Aliquots of column eluates in methods A and B were taken with
and without the addition of small amounts (e.g. 0.05 fig.) of the
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estrogens in question and treated by the Ittrich fluorimetric
procedure. Pure standard estrogens were run concurrently in order
to compare the effect of eluates on the fluorescence.
RESULTS
In Table 1 are shown levels of estrone, estradiol and estriol
as measured by methods A, B and C in six random urines. It can be
seen, as might be expected, that the recovery of radioactivity was
somewhat better in method A than in the longer procedures. Also,
the overall recovery, including fluorescence quenching effects, was
considerably lower than that of the radioactivity alone, indicating
that the greater part of the apparent loss in such procedures is
due to interference at the fluorimetric stage. For these reasons,
the results obtained by methods A and B were corrected for overall
losses so that the two procedures could be more closely compared.
The results obtained using method C were only corrected on the
basis of recovery of radioactivity. In all six estrone fractions
a well-defined maximum light absorption was observed at 538 m/j, in
method C, yielding corrected optical densities > 0.01. In all
instances the estrone levels were at or above the lower useful
limits of sensitivity of the methods which were for A, B and C,
0.6, 0.1 and 0.4 ^g/24 hours respectively with a reagent blank
equivalent to 0.002 ^g of estrone. Method B and C gave results
which agreed well while method A appeared to yield somewhat higher
levels. In the case of estradiol the lower useful limits of
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sensitivity for methods A, B and C were 1.0, 0.15 and 0.6 ^tg/24
hours respectively, with a reagent blank equivalent to 0.003 jj,g
of estradiol. For this reason it is difficult to compare the
estradiol results in Table 1 since many of them are below the
limits of sensitivity. However, urines 4, 5 and 6 suggest an
overestimation when using method A. Although the results
obtained by methods B and C agreed reasonably well, only the
fractions from urines 1 and 4 showed maximum light absorption at
538 mji in method C. The estriol fractions from all six urines
gave well-defined maxima at 5 38 m/j, in method C with corrected
optical densities > 0.01. The limits of sensitivity for estriol
measurement were about the same as given above for estradiol. The
three procedures compared quite favourably with A giving somewhat
higher results. In urine 2 method C gave a lower result than did
A or B.
Table _111 contains data on the measurement of ring D o;-ketols
by methods A, B and C. Although method C yielded in all cases a
maximum light absorption at 538 m/j, there was considerable back¬
ground color in some samples. This may partially explain the rather
poor agreement between the three methods. Moreover, the recovery
figures were disappointingly low. Method A yielded, in general,
higher results than did the other two procedures. To what extent
this may be due to the composite nature of the fraction measured
by method A and to the availability of only one of its components,
TABLE1
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namely lS-ketoestradiol-lTjS-lS-14 C, for recovery purposes, is
uncertain.
In Table 111 are shown levels of estrone, estradiol and estriol
as measured by method B in urines of control male subjects. These
results, and those in subsequent tables are means of at least two,
and at most four, 24 hour urines. Also shown in Table 111, for
purposes of comparison are results obtained by other workers. The
highest results appear to have been obtained by Givner et al using
Bauld's method. Morse et al also used Bauld's procedure. The
greatest contribution to Givner's figures was made by estriol. The
range of values found in the present study agreed quite well with
those of most of the remainder of the workers although there was
a tendency for the ratio of estriol to estrone to be higher in our
laboratory. Although the estradiol levels were consistently low
some was normally detected, in agreement with the others except
Preedy and Aitken. Total ring D a-ketols measured by method B
ranged from 0.6 to 11.0 pg/24 hours with an average of 3.8 fj,g/24
hours for the fifteen control males of Table 111.
Table JLV contains data for urinary estrone, estradiol and
estriol in post-menopausal females (in the present work, at least
five years post-menopausal). The results obtained in this laboratory,
using method B, agreed well with those of other workers although
they were higher than those reported by Jull et al. Using method B
the total ring D a-ketols ranged from 0.1 to 2.0 ^g/24 hours with
o
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an average of 1.2 j/g/24 hours.
In Table V are shown levels of five estrogen fractions,
measured by method B, in the urine of some males and post-menopausal
females. It should be noted that these figures, besides those
obtained by method B and shown in Tables 111 and IV, have not been
corrected in any way for methodological losses.
DISCUSSION
The original method of Bauld2 was claimed to possess useful
sensitivity down to about 3 jug of either estrone, estradiol or
estriol/24 hours. Below that level considerable errors might be
anticipated. Even above this level, however, it would appear that
overestimations may occur. Earlier results obtained by method A
for estrone and estriol in this laboratory11 were in the general
range obtained by other workers using other procedures but the
average figures appeared to be somewhat high. This may have been
due to overestimation by method A although in the present work the
most obvious error was in the estradiol fraction. Method B, while
yielding totals similar to those found by other investigators,
usually showed a higher estriol: estrone ratio for males than was
found by others. Whether this is due to the presence of an
additional compound in the estriol fraction, or to the selection
of the subjects studied, some being hospitalized, is uncertain.
Gallagher has claimed that estriol: estrone ratios are generally





















































































































females23. Method B gives an average ratio of 1.7 for the male
subjects studied and 3.4 for the females. Thus, it might be said
that such a trend is indicated.
The sodium borohydride reduction products of the ring D
a-ketols indicate that approximately equal amounts of estriol
(arising from 16 a-hydroxyestrone) and 16-epiestriol (arising
from 16-ketoestradiol-17/? and/or 16/?-hydroxyestrone) are probably
excreted. The total amount of ring D a-ketols is approximately
the same as for estrone. This is in agreement with earlier work
in this laboratory11. Accurate measurements of these compounds
must, however, await improved methodology.
The following trivial names have been used in the text:
Estrone = 3-hydroxy - 1,3,5 (10) - estratrien - 17 - one.
Estradiol-17/3 = 3, 17/?-dihydroxy - 1,3,5 (10) - estratriene.
Estriol = 3, 16a, 17/3-trihydroxy - 1,3,5 (10) - estratriene.
16-Ketoestradiol-17/? = 3, 17/?-dihydroxy - 1,3,5 (10) - estratrien-
16-one.
16a-Hydroxyestrone = 3, 16a-dihydroxy - 1,3,5 (10) - estratrien-
17-one.
16/3-Hydroxyestrone = 3, 16/3-dihydroxy - 1,3,5 (10) - estratrien -
17-one.
16-epiEstriol = 3, 16/?, 17/?-trihydroxy - 1,3,5 (10) - estratriene.
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SECTION B
URINARY OESTROGEN LEVELS WITHOUT REGARD TO
SPECIFIC MODES OF CONJUGATION
SOME ASPECTS OF THE ENZYMIC HYDROLYSIS OF URINARY
17-KETOSTEROID CONJUGATES1
R. Hobkirk and J.J. Cohen
Abstract
Four enzyme preparations containing ^-glucuronidase, of bacterial, mam¬
malian, and molluscan origin, have been shown to be equally effective in liberat¬
ing 17-ketosteroids (17-KS) of the 50-(etiocholane) configuration in normal
urine. The bacterial preparation releases steroids of the 5a-(androstane) con¬
figuration more rapidly than do the molluscan enzymes and with much greater
ease than does the liver enzyme. In view of the data obtained it seems unlikely
that the striking difference between the bacterial and liver enzymes can be due to
the hydrolysis of some labile conjugate, such as sulphate, by the former and not by
the latter. Possibilities that the difference is due to the hydrolysis of an unknown
type of urinary conjugate by the bacterial preparation, or to the low specificity
of the bacterial /3-glucuronidase, are discussed. The high degree of hydrolysis of
17-KS conjugates by the bacterial enzyme followed by solvolysis suggests this as a
most useful hydrolytic procedure.
Introduction
It is now generally recognized that the measurement of individual neutral
urinary 17-ketosteroids (17-KS) as a test of endocrine function is much
superior to the group assay of total 17-KS (1-6). In order to separate and mea¬
sure these steroids, which are present in urine as glucuronide and sulphate
conjugates, a hydrolytic procedure that results in no artifact formation is
required as a preliminary step (5, 7). This involves the use of enzyme prepara¬
tions from various sources containing /^-glucuronidase and in some cases
sulphatase (8-12). Quantitative hydrolysis of urinary 17-KS sulphates by
sulphatases is unlikely, because of the inhibitory effect of certain ions on these
enzymes and to stereochemical considerations (13-15), but these labile con¬
jugates are conveniently split by certain mild acid treatments (7, 16).
It has been reported that mammalian liver /^-glucuronidase was unable to
liberate the same amovv'ts of 17-KS from urine as did hot acid hydrolysis (17),
especially where steroids of the 5a-(androstane) configuration were concerned.
An extract from the snail Helix pomatia did not show this difference to such
an extent (18), and an enzyme preparation from the limpet Patella vulgata,
together with mild acid hydrolysis, has been shown to liberate a very high
percentage of urinary 17-KS (5, 19).
To our knowledge, a detailed investigation of the liberation of individual
urinary 17-KS by a bacterial enzyme preparation has not been reported upon.
A study has therefore been made comparing the ability of four enzyme prepara¬
tions of bacterial, mammalian, and molluscan origin to hydrolyze urinary
17-KS conjugates. Special attention has been paid to the hydrolysis of con¬
jugated 5ct-17-KS by the bacterial and mammalian liver enzymes. The steroids
measured were the three main C19 11-oxygenated metabolites of adrenocortical
'Manuscript received in original form July 21, 1959, and, as revised, March 4, 1960.
Contribution from Department of Metabolism and McGill University Clinic, The Montreal
General Hospital, Montreal, Quebec. The work was supported by National Research Council
Grant No. MT 532.
Can. J. Biochem. Physiol. Vol. 38 (1960)
770 CANADIAN JOURNAL OF BIOCHEMISTRY AND PHYSIOLOGY. VOL. 38, 1960
steroids, 3a,1 l/?-dihydroxyetiocholan-17-one (ll/?-hydroxyetiocholanolone),*
3a,ll/?-dihydroxyandrostan-17-one (ll/?-hydroxyandrosterone) and 3a-hyd-
roxyetiocholane-ll,17-dione (11-ketoetiocholanolone), together with the 11-
deoxy-steroids 3a-hydroxyetiocholan-17-one(etiocholanolone) and 3a-hydroxy-
androstan-17-one (androsterone), which are metabolites of both adrenal and
testicular origin. Beside these, urinary 3/?-hydroxy-A5-androsten-17-one(de-
hydroepiandrosterone), which is probably of adrenal origin, was measured.
Materials and Methods
Urine Collection
Complete 24-hour specimens were collected from normal males and females.
Collections were made in clean polyethylene bottles containing no preservative.
Three urine pools were prepared, one from female urine, the others (male
urines 1 and 2) from different male specimens. Three other 24-hour male
urines were used individually (male urines 3, 4, and 5). All urines were kept in
the deep-freeze until analyzed.
Chemicals
Organic solvents, with the exception of ethanol, were Reagent Grade.
Suitable purification was carried out where necessary. Girard Reagent-T
(Brickman Co.) was used as supplied. wi-Dinitrobenzene was purified by an
accepted procedure (20). Aluminum oxide (Woelm, almost neutral, grade 1)
was adjusted to contain 4.5% by weight of water. All other reagents were
Analytical Reagent Grade and were used as supplied.
Enzyme Preparations
Bacterial ^-glucuronidase— Sigma Chemical Co.
Mammalian liver ^-glucuronidase (Ketodase) — Warner Chilcott Laborato¬
ries Inc.
Molluscan /3-glucuronidase (Glusulase), also containing sulphatase, prepared
from the snail Helix pomatia — Endo Laboratories Inc,
Molluscan /9-glucuronidase, also containing sulphatase, prepared from the
common limpet Patella vulgata; powder B of Dodgson and Spencer (10).
The unit of activity of these preparations was based on their ^-glucuronidase
contents and was defined as that amount of enzyme which liberated 1 pg of
phenolphthalein from a 0.01 M solution of phenolphthalein glucuronide when
incubated for 1 hour at 37° C. The pH of the medium was 6.5 for the bacterial
preparation, 5.0 for the liver enzyme, 5.2 for the snail preparation, and 4.6 for
the limpet material.
Hydrolysis and Extraction of the Steroids
Volumes of urine containing 2—3 mg of total 17-KS, as measured after hot
acid hydrolysis, were incubated for 12-, 48-, and 96-hour periods at 37° C with
each of the enzyme preparations. Conditions of pH and enzyme concentrations
are given in Table I. For the bacterial and snail enzymes urine pH was adjusted
* For the sake of convenience the following abbreviations in nomenclature are used in this
paper: 11/S-hydroxyetiocholanolone, 11-OH-E; 11/3-hydroxyandrosterone, 11-OH-A; 11-
ketoetiocholanolone, 11-KE; etiocholanolone, E; androsterone, A; dehydroepiandrosterone,
DHA.
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with dilute NaOH or glacial acetic acid (18, 21). Acetate buffer was used for
the other two preparations (3, 5). The enzyme concentrations in Table 1 were
those found to achieve apparently maximum release of total urinary 17-KS
after incubation for 48 hours with normal urine.
Following incubation, neutral ether extracts were prepared in readiness for
Girard separation. Solvolytic cleavage of labile 17-KS conjugates, e.g. sul¬
phates, was performed on the urines both before and after enzyme hydrolysis.
In the latter case, urine, after extraction of 17-KS liberated by the enzymes, was
made 2 N with 50% H2S04, the subsequent steps being those originally de¬
scribed (16).
Where hot acid hydrolysis was performed following solvolysis the acidified
urine from the latter step, together with the alkaline washes of the ether extract
from the enzyme-hydrolyzed urine, was refluxed for 1 hour on a steam bath.
All analyses were performed in duplicate.
Separation and Measurement of 17-KS
The dried extracts were separated into ketonic and non-ketonic fractions by
a modification of the Girard reaction (22) performed at room temperature.
The ketonic fractions were then separated into their six main 17-KS by alumina
column and paper chromatography, essentially as described by Brooks (19).
Steroid containing zones on the paper chromatograms were eluted and analyzed
by a modified Zimmermann reaction (23), reading optical densities at 480, 520,
and 560 mfi on a Beckman Model B or Unicam SP600 spectrophotometer. Allen's
equation (24) was used to correct for non-specific chromogens. Each steroid
was initially measured in terms of DHA and then corrected for the appropriate
extinction coefficient. Portions of the ethanolic eluates from paper chromato¬
grams were treated with concentrated H2SO4 and scanned between 220 and
600 m/x (25) on the Beckman Model DK-2 recording spectrophotometer. The
spectra were compared with those obtained using pure steroids.
Reliability of the Mejfeod
Recovery of pure steroids added to hydrolyzed urine and taken through the
whole procedure was 87% +11 (standard deviation).
The precision of the method was assessed by calculation of an estimate of
the standard deviation (s) from the difference of duplicate determinations in a
series of measurements s being \/{S (d2)/t7\ where d is the difference between
duplicates and N is the number of duplicate analyses performed (26). For the
range 0.10 - 0.99 mg of any 17-KS/liter of urine, s = 0.076, while for the range
1.00-4.00 mg/liter, 5 = 0.20. The lower limit of sensitivity of the method is
0.15 mg of any one 17-KS/liter of urine.
Results
Release of 5a- and 5^-17-KS by Enzymes
Figure 1 shows total 5/5-17-KS (E + 11-OFI-E + 11-KE) liberated in normal
female urine during incubation for 12, 48, and 96 hours with each of the four
enzyme preparations. Good agreement for the different enzymes existed at
each time and the same was true for the individual 5/5-17-KS (not shown).
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time of incubation (hours)
time of incubation (hours)
Figs. I and 2. Effect of incubation time on the liberation of total 5/3-17-KS (E+ 11-
OH-E + 11-KE) (Fig. 1) and 5a-17-KS (A+ 11-OH-A) (Fig. 2) in normal human female
urine by /3-glucuronidase-containing preparations of bacterial, mammalian liver, and
molluscan origin.
However, the bacterial preparation caused much greater hydrolysis of con¬
jugated 5a-17-KS (A + 11-OH-A) in the same urine than did the liver enzyme
(Fig. 2) under the experimental conditions employed. The bacterial preparation
also achieved a more rapid release of these steroids than did the snail and limpet
enzymes (Fig. 2, Table I). A tendency for 17-KS levels to decrease when incu¬
bated for 96 hours with bacterial enzyme may have been due to bacterial
destruction since no antibiotics were used. In each of three separate urine pools
about two and five times more A and 11-OH-A, respectively, were released by
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TABLE I
Release of urinary androsterone by enzymes, results expressed as mg/liter of urine
Female urine Male urine 1
Time of incubation (hours)
Enzyme 12 48 96 12 48 96
Bacterial, pH 6.5,
75 units/ml
1.70 2.25 1.80 2.34 2.53 1.40
Liver, pH 5. 0,
300 units/ml
0.35 1.20 1.45 0.25 1.04 1.40
Snail, pH 5. 2,
500 units/ml
1.20 2.20 2.20 1.07 1.95 2.67
Limpet, pH 4. 6,
750 units/ml
0.50 1.85 2.20 0.74 1.57 1.99
75 units/ml of bacterial preparation than by 300 units/ml of liver enzyme
(Table III). An increase in liver enzyme concentration to 750 units/ml still
failed to equal the performance of the bacterial enzyme. E and 11-OH-E levels
were not significantly different in these urines regardless of whether bacterial or
liver enzymes were employed.
Hydrolysis of Labile 17-KS Conjugates
Minimal amounts of DHA (if any) were freed by bacterial and liver enzymes
(Table II) while the snail and limpet preparations hydrolyzed slightly more.
This might be expected because of the sulphatase content of the latter two.
TABLE II
Liberation of DHA in normal urine;* results expressed as mg/liter of urine
Free DHA after DHA liberated by solvolysis Total DHA (sum of previous
incubation with enzymes following incubation with enzymes two columns)
Enzymef Male urine 1 Female urine Male urine 1 Female urine Male urine 1 Female urine
Bacterial 0.21 0 1.33 0.32 1.54 0.32
Liver 0.24 0 1.55 0.32 1.79 0.32
Snail 0.38 0.12 1.22 0. 18 1.60 0.30
Limpet 0.50 0.29 0.86 (?) 1.36 0.29
*Solvolysis of the original urine before enzyme action showed male urine 1 and the female urine to contain 1.80
and 0.34 mg DHA/liter, respectively.
"{"Conditions of incubation as in Table I; time of incubation, 48 hours.
Virtually all the urinary DHA (as measured prior to enzyme action) was
liberated by solvolysis of the urine after incubation with bacterial or liver
preparation. Of the other 17-KS measured only E and A were detected in the
free form after solvolysis of the original urine from both males and females.
Out of 0.21 mg of A measured in this way in a female urine pool, 0.18 and 0.22
mg remained to be freed by solvolysis following 48 hours' incubation with
bacterial and liver enzyme respectively. Corresponding results for a male
urine pool were 1.03 mg of A before enzyme action with 0.72 and 0.92 mg
released by solvolysis after bacterial and liver enzyme action. These results
are interpreted as meaning that the activities (if any) of the bacterial and liver
enzymes towards labile 17-KS conjugates are similar.
^4 4^
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Hydrolysis of Total 17-KS Conjugates
Complete liberation of 17-KS in normal human urine was achieved by incu¬
bation for 48 hours with bacterial enzyme followed by solvolysis. Table IV
gives the levels of six 17-KS fractions freed by this procedure. Hot acid
hydrolysis after solvolysis resulted in a small positive measure for total 17-KS
but in no case was a typical Zimmermann-positive zone seen on paper chroma-
tograms of these extracts.
TABLE IV
Amounts of individual 17-KS released in normal male urine
by bacterial enzyme followed by solvolysis:* results expressed as mg/24 hours
Age
Urine specimen (years) DHA Jbi A lt-OH-E 11-OH-A 11-KE
Male urine 3 22 0.59 2. 96 4.79 0.31 0.88 0 .45
Male urine 4 22 2.10 2. 68 3.47 0.58 1.29 1 .00
Male urine 5 55 0 0. 89 0. 72 0.20 0.65 0 .46
^Individual 17-KS were not released in measurable amount by further hot acid hydrolysis.
Discussion
Incomplete hydrolysis of 5a-17-KS conjugates by mammalian liver ^-glu¬
curonidase has been reported by Wotiz et al. (17). In order to explain their
findings these workers suggested the presence of non-glucuronide conjugates
(possibly sulphates) in the urine. However, separation of 17-KS glucuronide
and sulphate fractions from urine has shown little or no 11-OH-A to be present
as the latter type of conjugate (5, 19, 27), which is in agreement with the results
in the present work. Also, any likelihood that the difference in activity between
the bacterial and liver enzymes might be due to sulphatase activity in the
former is further diminished by the finding that neither of these preparations
liberated much of the DHA or A present as labile conjugate. Phosphatase
activity has been shown to occur in the snail enzyme preparation (28), and a
complex containing DHA and phosphate has been identified in plasma (29).
If steroid phosphates were present in the urine, however, they would presum¬
ably constitute part of the labile conjugate fraction. Therefore any possibility
that phosphatase might play an important part in the bacterial enzyme
activity could be dismissed on the same grounds as for the sulphatase. An
alternative explanation would be to postulate the occurrence of a hitherto
unrecognized 5a-17-KS conjugate, of a non-labile nature, capable of being
hydrolyzed by a similarly hypothetical enzyme constituent of the bacterial
preparation. Experiments to test this possibility are at present being conducted
in this laboratory. The existence of a urinary conjugate of 11-OH-A, resistant
to hydrolysis by enzyme or mild acid treatment, has been reported (7). Al¬
though inhibitors of ^-glucuronidase (30, 31) in urine might be considered to
account for the lower activity of the liver preparation, the preferential inhibition
of 5a-17-KS conjugate hydrolysis would still remain to be explained.
Besides these possible explanations it is conceivable that the bacterial
/^-glucuronidase is generally a less specific enzyme than the mammalian liver
one and therefore able to achieve more rapid hydrolysis of a greater variety of
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glucuronides. That the action of the bacterial enzyme on 17-KS conjugates is
basically a manifestation of glucuronidase activity is supported by the essen¬
tially complete hydrolysis of urinary conjugates, primarily of the 5a-17-KS
type, by a sufficiently long incubation with the purified liver /^-glucuronidase
(31, 33). The complete hydrolysis achieved by the bacterial enzyme plus the
solvolytic procedure, together with the good agreement in individual 17-KS
levels obtained when compared with the results of other workers (3, 5, 19)
suggests this as a useful hydrolvtic method.
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ABSTRACT
Urinary levels of estriol, estrone and estradiol-17/3 (estradiol) increase dur¬
ing the last 20 weeks of pregnancy in a qualitatively similar fashion in both the
normal and diabetic states. The relative amounts of these estrogens found in the
urine suggest that they arise from the same source in both groups according to
the transformation, estradiol^estrone—»estriol. It also appears likely that there
is an additional source of estriol in the two groups, particularly in late preg¬
nancy. There is a tendency for estriol levels to be lower in diabetic than in non-
diabetic pregnancy. Considerable variability in the relative amounts of these 3
estrogens from one pregnancy to another, both diabetic and normal, suggests
the occurrence of a varying pattern of estrogen metabolism from one individ¬
ual to another.
INTRODUCTION
COMPLICATIONS during pregnancy in patients with diabetes mel-litus, particularly the high incidence of intra-uterine death, have
been recognized for some time. Despite this, little precise information is
available regarding the biochemical aspects of the problem. Abnormal
levels of gonadotropins and pregnanediol have been reported in diabetic
pregnancy (1) but the field of estrogen metabolism has been largely neg¬
lected. Rubin et al. (2), using a chemical method of assay, reported data on
Received December 4, 1959.
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a few patients showing that urinary estrogen excretion may be normal in
diabetic pregnancy uncomplicated by pre-eclamptic toxemia, but low
when toxemia is present.
The present investigation was undertaken with a view to ascertaining
whether or not diabetic pregnancy has associated with it any abnormality
in the urinary estrogen pattern. To this end estriol, estrone and estradiol-
17/3 (estradiol) were measured by an established chemical procedure (3).
The biochemical aspects of the study are presented in this paper.
MATERIAL AND METHODS
Subjects
The control group consisted of 10 pregnant women exhibiting no clinical abnormali¬
ties. The diabetic group, none of whom exhibited pre-eclamptic toxemia, numbered 14
pregnant women with varying degrees of diabetes mellitus, all of whom were maintained
with insulin. None of the subjects, normal or otherwise, was receiving any other type of
medication. The two groups were studied between the twentieth week of pregnancy and
delivery. Estrogen determinations were made weekly in the normal group, and from 3 to
15 estimations were carried out on each of the diabetic patients over the twenty-week
period.
Urine collection
Urine was collected as 24-hour specimens in specially cleaned polyethylene bottles
without preservative. Estrogen determinations were made as soon as possible thereafter.
When delay was necessary, the urine was stored in the refrigerator at 4°C. until the as¬
say could be performed.
Estrogen determination
Estriol, estrone and estradiol were measured chemically by the method described by
Bauld (3), or a modification of this procedure (4). An aliquot of from 10 to 50 ml. of the
24-hour urine specimen was taken for analysis, depending upon the stage of pregnancy.
Diabetic urines were diluted 1:10 with distilled water prior to acid hydrolysis in order
to overcome the destructive effect of glucose on the urinary estrogens (4). When the
larger urine aliquots were necessary, the original Bauld procedure was followed after
hydrolysis. This involves partition of a phenolic extract between benzene and water, with
subsequent partition chromatography of the benzene (estrone-estradiol) fraction and
saponification of the aqueous (estriol) extract. The next stage consists of saponification
of the separated estrone and estradiol, and partition chromatography of the estriol frac¬
tion. The 3 separated estrogens are then measured spectrophotometrically by the Kober
reaction. All analyses were performed on duplicate urine aliquots. When small volumes of
urine could be used (e.g., 10 ml.), saponification of the estrone and estradiol fractions
and chromatography of the estriol fraction were omitted (4, 5). The reliability of these
chemical procedures as carried out in this laboratory has already been established for
urines not containing glucose, as discussed elsewhere (5, 6).
To obtain information on recovery of the 3 estrogens in the presence of glucose, 10-ml.
portions of 7 nonpregnancy human urines were subjected to acid hydrolysis after 1:10
and 1:25 dilution both with and without the addition of 2-4 per cent glucose to the orig¬
inal urine. Prior to hydrolysis, 25-50 ng. of estriol, 10.9 ng. of estrone and 10 pg. of es-
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tradiol were added to each diluted aliquot. A total of 32 duplicate analyses was performed.
Percentage recoveries of estriol (with standard deviations) at 1:10 dilution, with and
without 2 per cent glucose, were 76 + 3.4 and 79 + 3.9, respectively. Corresponding values
for the recovery of estronewere 87 ± 1.9 and 92 ± 2.1, and for estradiol 77 + 3.1 and 83 ±2.5.
At 1:25 dilution there was no significant increase in recovery. Thus for estriol, with and
without 2 per cent glucose, the percentages were 78 + 1.0 and 79 + 3.7. In 2 experiments
in which 4 per cent glucose was added prior to 1:10 dilution, the mean recovery of added
estriol was 75 per cent. In the insulin-controlled diabetic group, the highest level of uri¬
nary sugar recorded was 2 per cent.
Recovery of estriol and estradiol was somewhat lower than might have been expected
from earlier work (5). The foregoing results, however, make it legitimate to compare
levels of the 3 estrogens in diabetic and in nondiabetic pregnancy urines diluted 1:10
before acid hydrolysis. Moreover, since further dilution does not significantly influence
recovery of added estrogen, it is likely that optimum levels of estriol, estrone and es¬
tradiol are measured at 1:10 dilution. It is accepted that the effect of acid hydrolysis on
free estrogens in the presence of glucose is not necessarily the same as on urinary estrogen
conjugates. Until these conjugates have been characterized, however, more precise in¬
formation will not be available.
RESULTS
Normal pregnancy
The urinary levels of estriol, estrone and estradiol between the twentieth
and fortieth weeks of pregnancy are shown in Figures 1, 2 and 3. Estrone
and estradiol showed parallel rises, each increasing by about 165 per cent
during the period studied. Estriol showed an even greater average increase
of about 320 per cent during this time. These findings, both qualitatively
and quantitatively, are in good general agreement with those reported by
Brown (7). The average ratio of estrone to estradiol (referred to hereafter
as Ei/E2) calculated at 20, 25, 30, 35 and 40 weeks varied only slightly,
lying in the range 3.2-4.7. Incidentally, the Ei/E2 ratios for individual
pregnancies (not shown) were in the relatively narrow range of 2.0-6.0.
The average ratio of estriol to estrone plus estradiol (referred to hereafter
as E3/Ei+E2) was in the range 7.0-9.0 at 20 and 25 weeks and then in¬
creased sharply to 13.0 at 30 weeks. This emphasizes the more rapidly in¬
creasing excretion of estriol at that particular time.
Detailed consideration of estrogen levels in the individual normal preg¬
nancies is not merited here, but it is of interest to note the distinctly dif¬
ferent E3/Ei+ E2 ratios for different pregnant subjects. An example is
shown in Table 1. One of these pregnant women (Subject A) had a low
ratio of 3.0-5.0 during the greater part of the 20-week period, with a rise in
the later stages, whereas the other (Subject B) had a much higher ratio
throughout, with a similar tendency toward an eventual increase. In all of
the 10 normal cases studied, there was a similar late and upward trend in
this ratio, despite its variable magnitude.
Fig. 1. Excretion of estrone during pregnancy in normal ( ) and in diabetic
( ) subjects. Vertical lines represent the range of estrone measurements in 10
normal pregnant women, the mean weekly values being joined by an unbroken line.
Each black dot represents an estrone measurement in any one of 14 diabetic subjects at
various stages of pregnancy, the mean weekly values being joined by a broken line.
Fig. 2. Excretion of estradiol during pregnancy in normal ( ) and in diabetic
( ) subjects. For key to other symbols (as applied to estradiol), see legend to
Figure 1.
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Fig. 3. Excretion of estriol during pregnancy in normal ( ) and in diabetic
( ) subjects. For key to other symbols (as applied to estriol), see legend to
Figure 1.
Diabetic pregnancy
In Figures 1, 2 and 3, the results for the 3 urinary estrogens in the
diabetic group are shown along with results obtained in the normal group.
This type of diagram was designed to show the range of urinary estrogen
levels in the diabetic subjects, and not the trend of excretion in individuals.
Estrone and estradiol values in the diabetic group showed considerable
scatter, but were mostly within the normal range, which was also wide.
Individual determinations below the normal range in Figures 1 and 2 rep¬
resent estrone and estradiol levels in 2 of the diabetic pregnancies studied.
Estrone levels at 28 to 35 weeks in another diabetic patient (Subject C,
Table 2; not included in Figure 1) were abnormally high. Omitting these
high results, the average Ei/E2 ratio for the diabetic group ranged from
3.2 to 3.5 when calculated at 20, 25, 30 and 35 weeks. This is similar to
the ratio for the normal group. On the other hand, values for urinary es¬
triol were almost wholly below the normal mean level, although about
half of the results were within the normal range. The average E3/Ei+E2
ratio was lower in the diabetic group than in the normal women but the
difference was not statistically significant. For the diabetic group, the
ratio was in the range 5.3-7.6 between 25 and 30 weeks. As in the normal
women, this ratio increased, and became 15.0 at 35 weeks. Thus there was
a qualitative similarity between the two groups in this respect.
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Individual diabetic pregnancies
A few comments on the estrogen excretion pattern in individual dia¬
betic patients are pertinent. In Subject C (Table 2) the urinary estrone
level was extremely high despite the normal estriol and estradiol levels.
This resulted in a greatly elevated Et/E2 ratio of 7.8-16.0 over the period
28-34 weeks. Although Subject D (Table 2) also exhibited an elevated
Ei/E2 ratio, this was due to a lowered excretion of estradiol rather than to
a raised excretion of estrone; in addition, the excretion of estriol was low.
Subject E showed a low excretion of estriol over the period 30-34 weeks,
with a fairly late increase to near-normal levels. This was associated with
low excretion of estrone and estradiol throughout the study period, to the
extent that the E3/Ei.-|-E2 ratio was always above 21.2 and rose to 57.0
at 40 weeks.
DISCUSSION
The average urinary Ex/E2 ratio over rhe period 20-40 weeks of preg¬
nancy is remarkably constant (3.2-4.7), and is also approximately similar
in both diabetic and nondiabetic pregnancies. This suggests that these 2
estrogens arise from a common source in both pregnancy groups—prob¬
ably placental estrone or estradiol or both—since a number of investigators
have reported that administration of estrone or estradiol to nonpregnant
human subjects results in similar urinary Ei/E2 ratios (6, 8, 9). Further¬
more, it is likely that at least part of the urinary estriol has the same ori¬
gin, since the metabolic relationship between the 3 "classic" estrogens
(estradiol^estrone—»estriol) is well known. However, as has been pointed
out by others (9, 10), during pregnancy a great deal more estriol is ex¬
creted relative to estrone and estradiol than can be accounted for by
metabolic transformation of the latter 2 estrogens, unless these are metab¬
olized to a different extent in pregnancy as compared with the nonpregnant
state. In this connection it has been reported that the conversion of exog¬
enous estradiol to urinary estriol is greater than normal in prostatic can¬
cer (11), myocardial infarction (8) and mammary cancer (12). It has also
been claimed that in pregnancy the high urinary estriol excretion can be
attributed to a greater transformation of estradiol (13), but this finding
could not be reproduced by Pearlman et al. (14) after administration of
deuterium-labeled estrone acetate in pregnancy. If there is no difference
in this respect between the pregnant and nonpregnant states it would seem
that there must be another source of urinary estriol, independent of es¬
trone and estradiol metabolism, in both normal and diabetic pregnancy.
Some support for this concept has arisen from in vitro observations on
placental and other tissues showing that estriol may be formed from andro¬
gens (15, 16) and perhaps by a route which does not involve estrone or
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estradiol (17). Such a mechanism might explain the finding in Subject E
(Table 2) of a markedly increasing estriol excretion with continuing low
estrone and estradiol excretions.
A variable E3/Ei+E2 ratio is not by any means confined to diabetic
pregnancies. Throughout 2 pregnancies uncomplicated by diabetes (Sub¬
jects A and B, Table 1), the values were strikingly different. This suggests
a tendency for the pattern of estrogen metabolism to vary from one preg¬
nant woman to another. Also, high Ei/E2 ratios, whether due to a high ex¬
cretion of estrone (Subject C, Table 2) or to a low excretion of estradiol
(Subject D, Table 2), suggest the possibility of a change in the extent of
interconversion between estrone and estradiol under certain circumstances.
These observations indicate the need for renewed and extensive studies of
estrogen biosynthetic pathways in pregnancy, and application of the find¬
ings to disorders of the pregnant state.
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Urinary Estrogens in Pregnant Diabetics
A Clinical Correlation
G. E. Joron, M.D., R. Hobkirk, Ph.D., P. R. Blahey, M.D., J. H. Routledge, M.D., and
A. F. Fowler, M.D., Montreal
It is well known that pregnancy in the diabetic is
subject to certain hazards, principally large fetal size,
hydramnios and intra-uterine death. In an attempt to
explain these abnormalities, measurements of hormones
known to vary in pregnancy have been made and are
recorded in the literature. Little attention has been
paid to the measurement of estrogens. As early as
1937 Smith and Smith1 reported the bioassay of serum
and urinary estrogens in pregnant diabetics. The levels
of estrogens were normal in some but were low in
others. In this latter group elevated levels of gonado-
trophins were often found and this combination was
considered to indicate a poor prognosis. This work was
extended by the original workers and White2 and led
to the claim that this unfavorable hormonal imbalance
could be corrected by the administration of estrogens.
In 1946 Rubin et al.3 reported chemical measure¬
ments of estrone, estradiol and estriol in the urine of
five pregnant diabetics. The levels of estriol were nor¬
mal in three and low in the two who showed evidence
of toxemia. Measurement of estrone and estradiol were
normal in all five. In contrast to the great clinical in¬
terest in the therapeutic use of estrogens there have
been few estrogen measurements reported in pregnancy
in the diabetic. This is probably due to the unreliability
of bioassay and the technical difficulties of chemical
analysis which existed. In recent years two different
chemical methods were developed in Marrian's labora¬
tory in Edinburgh for the estimation of the three clas¬
sical estrogens: estriol, estrone and estradiol. Brown's1
method was published in 1955 and Bauld's5 in 1956.
Both gave similar results and were much more relia¬
ble than earlier methods. This development gave a
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great impetus to the study of estrogen excretion in
normal and abnormal pregnancy. Unfortunately it was
soon observed that the presence of glucose in the urine
interfered with the determinations. Hobkirk0 found a
way of circumventing the interference due to glucose
and using his modification of Bauld's method published
the findings in fourteen diabetic and ten normal preg¬
nancies.7 The purpose of this report is to extend the
series and to describe the clinical features of the cases.
MATERIAL
Measurements of estrone, estradiol and estriol were
performed during the last half of twenty-six pregnan¬
cies in twenty-two diabetic patients. The average age
of the patients was twenty-seven and a half years; the
range was eighteen to thirty-nine years. The duration
of diabetes varied from zero to rwenty-eight years with
a mean duration of ten and a half years. In two pa¬
tients the diagnosis of diabetes was made during preg¬
nancy: One required insulin and one dietary restriction
only.
The outcome of pregnancy was as follows: There were
three intra-uterine deaths, one associated with diabetic
coma at twenty-seven weeks, and two in patients with
renal damage; one death occurred during delivery of
a breech; there was one unexplained death twelve hours
after cesarean section and one death four days after
delivery due to multiple congenital anomalies. Twenty
of twenty-six are living.
The classification of the maternal state according
to White's scheme is as follows: one class "A," five
class "B," thirteen class "C," four class "D," and three
class "F."
One patient received a variety of hormones for a
short time in an unsuccessful attempt to control hy¬
dramnios and the estrogen determinations which may
reflect this therapy have been omitted. One patient
was given progesterone for intermittent bleeding.
The results of the estrogen analyses were not used
to influence the clinical management of the cases.
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RESULTS
Figure i shows graphically 156 estriol assays car¬
ried out on twenty-four-hour collections of urine in
twenty-six diabetic pregnancies during the latter half
of gestation. The mean is plotted as a solid line.
The broken line represents the mean of fifteen nor¬
mal pregnancies, the shaded area the range of the
normal values. Approximately one half of the dia¬
betic urines are below the normal range. There
are a few values which are much higher. The mean
is lower than normal but tends to rise almost to
the normal level around the thirty-fifth week. In serial
determinations on individual patients this seems to be
the pattern most frequently seen.
Estriol Excretion in 26 Diabetic Pregnancies
Urinary
FIGURE I
Figure 2 shows the values for urinary estradiol ex¬
cretion in a series of seventeen diabetics and ten con¬
trols. Again the mean is plotted as a solid line. The
normal mean is the broken line and the shaded area
represents the range of normals. There is a considerable
scatter of normals in view of the quantities being
measured. The two diabetic values which are clearly
above the normal range belong to the only patient
in the group who developed pre-eclamptic toxemia.
' Figure 3 shows the values for urinary estrone ex¬
cretion in seventeen diabetics and ten controls. The
same method of expressing results is used as in the
previous figure. The three very high grouped values
all belong to one patient, and this patient alone ac¬
counts for the elevation of the mean above the
normal mean. No particular clinical abnormality was
observed during the course of this patient's pregnancy.
There were two intra-uterine deaths in mothers with
LirinQry Estradiol Excretions in 17Diabetic Pregnancies.
Estradiol
Duration of Pregnancy in weeks
FIGURE 2
diabetic nephropathy. The pattern of estriol excretion
in each case will be given in detail.
Case I.—F.S. This young woman of twenty-eight had been
a diabetic for eleven years. This was her first pregnancy. She
stated that she had been well until one year previously when
she developed a large mass in the abdomen which proved to
be her bladder. Investigation revealed that she had a neuro¬
genic bladder most probably due to multiple sclerosis. When
first seen at our hospital she was twenty-eight weeks' pregnant
and had been catheterizing herself twice daily for the previous
six months. The urine contained considerable pus and albu¬
men; the blood urea nitrogen was and remained within normal
limits during pregnancy. The pattern of estriol excretion is
illustrated in figure 4. The first two values were obtained
when she was first seen. She was sent back to her home in
the country, and on her return three weeks later the first
1 irinnrv Estrone Excretion in 17 Diabetic Pregnancies.
Estrone
Duration of Pregnancy in weeks
FIGURE 3
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FIG. 4. Case I, F.S., estriol excretion in a diabetic pregnancy
with intra-uterine death of the fetus.
analysis for urinary estriol on October 6 was normal—16.8
mg. per twenty-four hours. The obstetrician in charge esti¬
mated the size ot the baby to be too small to justify section
and it was decided to wait a bit longer. On October io she
began to complain of nausea and ate less. Twenty-four-hour
urinary estriol on October 13 was 12.6 mg., and on October
15 it was 6.9 mg. On October 17 the membranes ruptured
spontaneously and the fetal heart sounds were last heard later
the same day. A twenty-four-hour urine collection the fol¬
lowing day, October 18, contained only 3.5 mg. estriol; the
fetus was definitely dead. Although these events and determi¬
nations are reconstructed and reported chronologically, in fart
the results of these assays only became available some days
later.
Case II—I.D. This twenty-eight-year-old woman had been
diabetic for thirteen years and showed evidence of albuminuria
I.D. Age 28 Diabetic I3years
Urinary Estriol Diabetic Nephropathy, albuminuria, BUN 27mg \
in
25 First Pregnancy- i
per 24 hrs /
,y
15
Fetal heart last heard
25 30 35
— Pregnancy in weeks —
FIG. 5. Case II, I.D., urinary esfriol excretion in a diabetic
pregnancy resulting in fetal intra-uterine death.
and impaired renal function before her pregnancy. The uri¬
nary estriol excretion is represented in figure 5 as large dots.
Although estriol excretion was about half of normal on the
first estimation, this was not considered alarming; however,
the failure of the estriol excretion to rise after thirty-three
weeks was alarming. Because of the small fetal size, the risk
of neonatal death was considered too great to warrant section.
The fetal heart was last heard at thirty-five weeks. On sub¬
sequent visits, although the fetal heart sounds could not be
heard, the patient insisted that she could feel movements.
The analyses suggest that the baby died soon after the thirty-
fifth week as the last two estriol values are incompatible with
fetal survival at that stage of pregnancy.
DISCUSSION
Although knowledge of estrogen metabolism in nor¬
mal pregnancy is still rudimentary, it seems reasonable to
establish whether or not any striking differences exist in
diabetics. It is known that when death of the fetus occurs
estrogens are the first hormones to reflect this change.5
It is thought that estradiol and/or estrone are pro¬
duced by the placenta. Estriol is the principal estrogen
in terms of quantity found in the urine. In the normal
menstrual cycle and during the first trimester of preg¬
nancy all three estrogens rise or fall together, and it is
thought that estradiol and estrone are the precursors
of estriol. However, in the last trimester urinary estriol
increases so rapidly and to such a high level relative
to the other two that it has been suggested that there
must be another precursor. Recently Brown and Preedy"
have made the alternative suggestion that the renal
clearance of estriol increases towards the end of preg¬
nancy relative to estrone as a result of increased tubular
secretion. In very recent years a considerable number
of metabolites of estrogens in the human subject have
been reported. These include 2 methoxyestrone 16 epi-
estriol and the ring D Ketols of which i6x-hydroxy-
estrone and 16 ketoestradiol-iyP are the most important
compounds. These have been measured in a few diabetic
and normal pregnancies and have formed the basis of
separate reports.10,11
Since estriol represents by far the largest part of the
estrogens excreted in the urine in pregnancy—some 75
per cent—it is generally held to be the one most
representative of over-all estrogen production. Our re¬
sults indicate that in half of diabetic pregnancies the
urinary excretion of estriol is below the normal range.
Taylor has recently reported that estriol excretion in
seven diabetics was within the normal range.10 An
occasional patient has an extremely high excretion. In
determining if correlations exist between the clinical
course of the pregnancies and the estriol values we
are first confronted by the problem that there are so
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many variables that the small number of patients does
not permit firm correlations. There are a number of
single interesting observations, but, in a small series,
it is impossible to tell whether these are coincidences
only or could be substantiated by a larger series. In
an effort to find common factors one may easily gloss
over individual abnormalities which might have con¬
siderable significance.
Two intra-uterine deaths occurred in patients with
renal damage. In Case I there was a precipitous drop
in estriol excretion. It is our opinion that with the
new rapid methods of estimation intra-uterine death
could have been foretold and cesarean section would
then have become mandatory. In Case II, the failure
of the estriol excretion to rise after the thirty-third
week probably indicated impending intra-uterine death.
A third patient with nephropathy showed a similar
pattern of estrogen excretion but went into spontane¬
ous labor at thirty-seven weeks. Although primiparous,
she delivered a small healthy infant. It should be stressed
that it may be misleading to infer too much from
measurements of urinary estrogens in patients with
impaired renal function.
The diabetic who had the lowest estrone values on
two occasions delivered small babies after forty weeks'
gestation. The patient with very high urinary estrone
values had similar values on another pregnancy not
recorded in this series.
It is our impression that older women and those
with long-standing diabetes may have lower levels of
estrogen excretion if they have degenerative complica¬
tions.
We have the impression that women with higher
estrogen production have bigger babies (figure 6). The
weight of the infant at birth has been compared to
the weight for that degree of maturity given by stand¬
ard tables and is expressed as a percentage deviation.
The last urinary estriol excretion before delivery has
been compared arbitrarily to the normal for that period
of gestation and also expressed as a percentage devia¬
tion. Since estriol excretion in diabetics tends to be
low, most points are below the horizontal. Since in¬
fants of diabetics tend to be big, most of the points
are to the right of the vertical, i.e., in the right lower
quadrant. The lowest estrogen values and smallest babies
coincide and the highest excretions and biggest babies
coincide. Most other points would seem in a rough
way to lie between. This gives us the impression that
there is a correlation between the estrogen excretion
and baby size, the women with higher excretion hav¬
ing the bigger babies, and vice versa.
We can show no correlation of estrogens with ma¬
ternal weight gain, insulin requirement or change in
insulin requirement during pregnancy. The influence
of diet on estrogen excretion has not been studied. A
very much larger series of cases will be required be¬
fore firm conclusions as to the significance of estrogen
excretion studies can be made. Our knowledge of nor¬
mal estrogen metabolism must also progress. Notwith¬
standing the interest in the use of estrogens in diabetic
pregnancy for the last twenty-five years, progress has
been hampered by the difficulties of measurement. In
this study the chemical studies were so laborious and
time consuming that the results were not of use to the
clinician. Within very recent years, relatively simple
chemical methods have been described by Ittrich13'" for
total urinary estrogen measurement. The simpler of
these" yields values that agree closely with the total
of separate estrogen fractions.10 In analyses of urines
that contain sugar, the slightly longer procedure1' is
required. This yields values which may be significantly
lower than the true level present.11 This is probably due,
at least partly, to destruction of the labile ring-D Ketols
which may contribute substantially to the total, par¬
ticularly in diabetic pregnancies.
SUMMARY
Urinary estriol has been measured in the second half
of twenty-six diabetic pregnancies using Hobkirk's mod¬
ification of Bauld's method. Half of the values are
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URINARY ESTROGENS IN PREGNANT DIABETICS
The mean of diabetics is lower than the mean of nor¬
mal. Most values for estrone and estriol are within the
normal range but occasional values are much higher
or much lower.
Serial estriol determinations in two pregnancies in
diabetics with nephropathy which resulted in intra¬
uterine death are reported.
SUMMARIO IN INTERLINGUA
Estrogenos Urinari in Diabete de Pregnantia: TJn
Correlation Clinic
Estriol urinari esseva mesurate durante le secunde
medietate del pregnantia de vinti-sex diabeticas. Le
methodo usate esseva un modification per Hobkirk del
methodo de Bauld. Un medietate del valores es infra
le limites del area normal. Valores occasional es supra
illo. Le valor medie pro diabeticas es plus basse que
le valor medie pro normales. In le majoritate del casos,
le valores pro estron e estradiol es intra le limites del
norma, sed valores occasional es multo plus alte o multo
plus basse.
Determinationes serial de estriol in duo pregnante
diabeticas con nephropathia, resultante in morte intra-
uterin, es reportate.
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Observations on the Occurrence of Six Estrogen
Fractions in Human Pregnancy Urine
I. Normal Pregnancy*f
R. HOBKIRK, Ph.D. and MONA NILSEN
University Medical Clinic and Department of Metabolism,
The Montreal General Hospital, Montreal, Canada
ATTEMPTS at quantitative measure-
±\. ment of urinary estrogens in hu¬
man pregnancy have been to date almost
wholly confined to the three classic com¬
pounds, estrone, estradiol-17/3 (estradiol)
and estriol (1, 2). Within the last six
years, however, a number of additional
estrogen metabolites have been recog¬
nized either as metabolites of exogenous
steroids labeled with radioactive carbon
or as endogenous products excreted dur¬
ing pregnancy. Among the latter are 16-
epiestriol (3), 2-methoxyestrone (4) and
the ring D a-ketols such as 16a-hydroxy-
estrone (5), 16-ketoestradiol-17/3 (16-
ketoestradiol) (6), and 16/3-hydroxyes-
tror.e (6). A chemical method for the
separation and measurement of six uri¬
nary estrogen fractions (7) including
estrone, estradiol, estriol, 2-methoxyes¬
trone, ring D a-ketolic estrogens and 16-
epiestriol has made possible a more com¬
plete study of urinary estrogens. The
main purpose of the present work was to
provide a more complete picture of both
the qualitative and quantitative aspects
of excretion of these estrogen metabolites
during the last twenty weeks of preg¬
nancy. Particular attention was paid to
the reliability of the methods employed.
Received August 7, 1961.
* Supported by a grant from the National
Research Council of Canada.
f A preliminary account of this work was sub¬
mitted as a short communication to the First
International Congress on Endocrinology, Co¬
penhagen, July 1960.
ABSTRACT. A chemical method of ap¬
parently adequate reliability made it pos¬
sible to obtain a fairly accurate picture of
the qualitative and quantitative aspects of
the urinary excretion of 2-methoxyestrone,
estrone, ring D a-ketolic estrogens, estriol,
16-epiestriol and estradiol-17/3 (estradiol) in
human pregnancy. With the exception of 2-
methoxyestrone, these fractions increased
during the last 20 weeks of pregnancy. 2-
Methoxyestrone behaved in an irregular fash¬
ion and was frequently not present in measur¬
able amounts. Further fractionation of the
ring D a-ketolic estrogens showed the main
constituents to be 16a-hydroxyestrone and
16-ketoestradiol-17/3 (16-ketoestradiol). Dur¬
ing the last four weeks of pregnancy the
mean corrected values for the 24-hour excre¬
tion of the various fractions in 7 normal
pregnancies were: 2-methoxyestrone, 0.17 mg;
estrone, 1.4 mg; 16a-hydroxyestrone, 2.9
mg; 16-ketoestradiol, 2.0 mg; estriol, 26.4
mg; 16-epiestriol, 1.2 mg; and estradiol, 0.56
mg. The excretion of the 6 fractions taken
together agreed closely with total estrogen
excretion as measured by the Ittrich technique.
Materials and Methods
Subjects. Seven pregnant women exhibit¬
ing no clinical abnormalities and receiving no
medication were studied during the last 20
weeks of their pregnancies. In 4 of the sub¬
jects, urinary estrogen fractionation was per¬
formed at intervals of 2-4 weeks; in the re¬
maining 3, the analyses were carried out less
frequently. Thirty-six fractionations were
performed.
Urine collection. Complete 24-hour
specimens were collected in polyethylene
bottles, without preservative. Enzymic hy¬
drolysis of the conjugated estrogens was
commenced as soon as each urine collection
was completed. If, after hydrolysis, delay
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was necessary prior to subsequent analytical
steps, the urine was frozen until needed.
Estrogen separation and measure¬
ment. Volumes of from 10 to 20 ml of urine
were analyzed in duplicate by the method of
Givner et al. (7) modified to include the use
of smaller reagent and solvent volumes. Hy¬
drolysis of conjugates was achieved by incu¬
bating the urine with 500 units of /3-glu-
curonidase per ml and 250 units of sulfatase
(enzymes from the digestive tract of the
snail Helix pomatia)1 per ml for 24 hours at
pH 5.2 and 37°C—a procedure which has
proved to be very efficient in this laboratory
(8). Following incubation the urine was
diluted to 100 ml with water prior to extrac¬
tion of free estrogens and separation of these
by a modified Girard reaction (9). The
ketonic and nonketonic fractions were then
treated according to Givner et al. (7) up to
the stage of separation by partition chroma¬
tography. Estrogen fractions separated at
this stage were 2-methoxyestrone, estrone,
ring D u-ketols (as a group), estradiol, 16-
epiestriol and estriol. Saponification pro¬
cedures for the further purification of 2-
methoxyestrone and estradiol were omitted
since these resulted in no particular benefit
provided the Celite columns had previously
been packed sufficiently firmly to ensure
adequate separation of the estrogens from
nonspecific chromogens of similar chromato¬
graphic mobilities. Spectrophotometric meas¬
urement of each estrogen fraction (in terms
of the pure standard estrogens concerned,
and using 16 a-hydroxyestrone as standard
for the ring D a-ketolic fraction) was made
by a modified Kober reaction (7) applying
the Allen equation to correct for background
color (10).
Separation of the components of pooled
ring D a-ketolic fractions obtained from a
number of late pregnancy urines was
achieved by paper chromatography in the
system chloroform : formamide (6). Estrogen-
containing zones (visualized by the Folin
reagent) corresponding in mobility to 16 a-
hydroxyestrone, 16-ketoestradiol and (provi¬
sionally) 16 d-hydroxyestrone were cut from
the chromatograms along with appropriate
paper blanks, and eluted with ethanol. The
dried eluates were partitioned between ether
and water to remove residual formamide,
and the ether extracts were dried over an¬
1 Glusulase is the commercial name for a
snail enzyme extract available from Endo Labo¬
ratories Inc., New York.
hydrous sodium sulfate prior to colorimetric
measurement by the procedure described by
Ittrich (11), employing tetrachloroethane as
a solvent for the chromogen. Zones cor¬
responding to 16a-hydroxyestrone and 16-
ketoestradiol were measured in terms of pure
16a-hydroxyestrone and 16-ketoestradiol re¬
spectively. In the absence of a pure sample
of 16/3-liydroxyestrone, the provisional 16/3-
hydroxyestrone zone on the paper was
measured in terms of 16-ketoestradiol. Cor¬
rected optical densities of eluates from the
paper blanks were consistently zero, pro¬
vided previously washed paper was em¬
ployed for chromatography.
Measurement of total estrogens in
pregnancy urine. This was performed in
duplicate by the method of Ittrich (11) and
involved a direct Kober color reaction on
0.15 ml of urine followed by extraction of the
chromogen into a 2% p-nitrophenol solution
in tetrachloroethane. Optical density was
measured at 506, 538 and 570 m/i and the
Allen equation was used to correct for back¬
ground color. Total estrogen levels were ex¬
pressed in terms of estriol.
Reliability of the analytical methods.
a) Accuracy. Sixteen duplicate experiments
were performed in which known amounts of
pure estrogens (5-25 /!g, depending upon the
compound concerned) were added to 10 or
20 ml of nonpregnancy urine which had been
incubated with the snail enzyme prepara¬
tion. The described fractionation technique
was applied, and the recovery of each estro¬
gen measured. Percentage recoveries (±the
standard deviation) were as follows: 2-
methoxyestrone, 72+6.0; estrone, 85+3.7;
16a-hydroxyestrone or 16-ketoestradiol,
64 ±3.6; estradiol 80 ±6.4; and 16-epiestriol,
75+5.0.
The accuracy of the total estrogen method
was determined by measuring the recovery of
estrogens added to 0.15 ml of nonpregnancy
urine in duplicate analyses. When estriol
(1-4 ng) was added, the percentage recovery
figures were 95+5.9. In three experiments
using 4-8 ng of 16a-hydroxyestrone and
5-10 /ng of 16-ketoestradiol separately, the
values were in the range 93-101% and
83-86% respectively.
b) Precision. Results obtained from the
duplicate analysis of a number ( >30) of
pregnancy urines were employed to calculate
the degree of precision obtainable for the
measurement of the six estrogen fractions.
Table 1 gives a measure of the standard de-
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Table 1. Precision of the method for measuring 6 estrogen fractions
Estrogen fraction Range (mg/24 hrs.) N* sf
2-Methoxyestrone 0.12- 0.69 37 .044
Estrone 0.35- 0.99 54 .060
1.00- 2.35 42 .061
Ketols 0.40- 1.99 37 .10
2.00-10.50 43 .35
Estriol 3.00- 9.99 42 .29
10.00-29.5 30 .70
16-Epi'estriol 0.18- 0.49 41 .024
0.50- 1.30 44 .047
Estradiol 0.12- 0.29 41 .028
0.30- 0.95 40 .059
* Number of duplicate analyses.
f Measure of standard deviation (for derivation, see text).
viation (s) calculated from the expression
s = \/2d2/2N, where d = the difference be¬
tween duplicate analyses and N = the num¬
ber of duplicate analyses (12). Similar treat¬
ment of the results of total estrogen measure¬
ment showed s = 1.17 mg per 24 hours.
c) Sensitivity. Because of the elevated uri¬
nary excretion of estrogens during the last
twenty weeks of pregnancy, the sensitivity of
the fractionation procedure was adequate in
all cases for the measurement of 5 out of 6
fractions, the exception being 2-methoxy-
estrone. In the cases in which there was no
measurable 2-methoxyestrone, it should be
assumed that the 24-hour excretion of this
metabolite was less than 80 fig, since this was
the approximate sensitivity with which this
steroid could be detected under the experi¬
mental conditions. Analysis of larger volumes
of urine resulted in troublesome background
color in the 2-methoxyestrone fraction.
The lower limit for the measurement of
total estrogen lay between 1 and 2 mg per 24
hours (depending upon urine volume), i.e.,
well below the amount present in urine col¬
lected during the last twenty weeks of normal
pregnancy.
d) Specificity. Some information in support
of the specificity of the fractionation tech¬
nique has already been presented by Givner
et al. (7). In the present study, the additional
paper chromatographic evidence for the
identification of the separated estrogen frac¬
tions is in general agreement with their data.
However, the presence of a second phenolic
zone, of greater mobility than 16-epiestriol,
was repeatedly observed in the fraction asso¬
ciated with the latter compound. This may
have been an isomeric triol but it was ob¬
viously of much less quantitative significance
than 16-epfestriol. The 16-epiestriol-con-
taining fraction from pregnancy urine con¬
sistently gave rise to an extremely rapid
development of color in the first stage of the
Kober color reaction—an observation in
accord with the presence of an estrogen con¬
taining cis-hydroxyl groups in ring D (3).
Chemical reduction of urinary ring D a-
ketolic estrogen fractions with sodium boro-
hydride (5, 13) gave rise to Kober-positive
material, 98% of which was found in the
estriol and 16-epiestriol fractions following
column chromatography. Paper chromatog¬
raphy of the reduction products showed a
greater amount of estriol than of 16-epi-
estriol; a third very faint and uncharacter-
ized Folin-positive zone, less polar than
16-epfestriol, was also observed. Borohydride
reduction of the 16-ketoestradiol and 16a-
hydroxyestrone fractions separated from a
urinary ring D a-ketolic estrogen fraction by
paper chromatography yielded respectively
16-eptestriol and a mixture of two com¬
pounds, the main one of which was estriol
and the other possibly 17-epiestriol (5). A
third small component of the urinary ring D
a-ketolic fraction, more polar than 16-keto-
estradiol in the solvent system chloro¬
form :formamide, was provisionally con¬
sidered to be 16/3-hydroxyestrone. It was not
obtained in sufficient quantity to treat by
the reduction technique. These observations
showed that the ring D a-ketolic estrogen
fraction of the urine in late pregnancy, as
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DURATION OF PREGNANCY (WEEKS)
Fig. 1. Excretion of 6 urinary estrogen fractions
during the last 20 weeks of pregnancy in Sub¬
ject T.B. Results are uncorrected for methodo¬
logical losses.
obtained by the fractionation technique em¬
ployed, consists mainly of 16a-hydroxyes-
trone and 16-ketoestradiol.
Results
Pattern of the six estrogen frac¬
tions. Figure 1 shows the results ob¬
tained in a normal pregnancy in which
estrogen fractionations were performed
on the urine at intervals of two weeks.
There was a general increase in all six
fractions measured over the 20-week pe¬
riod. Noteworthy are the low excretion
of 2-methoxyestrone, the consistency
with which 16-epiestriol levels remained
higher than those of estradiol, and the
fact that ring D a-ketolic estrogen
levels were second, in a quantitative
sense, to those of estriol. These values
were not corrected for methodological
losses.
The results obtained in 4 normal preg¬
nancies, uncorrected for experimental
losses, are shown in Table 2. In each sub¬
ject estriol was by far the main urinary
metabolite, with the ring D a-ketols sec¬
ond in quantitative importance. The ex¬
cretion of estradiol was always at least
slightly lower than that of 16-epiestriol.
In Subject M.S., who during late preg¬
nancy excreted considerable amounts of
estriol and ring D a-ketols, no 2-me¬
thoxyestrone was detectable after about
week 31. This was in contrast to Sub¬
ject T.B. who, during weeks 36-40, ex¬
creted 0.19-0.32 mg of 2-methoxyestrone
despite the much lower levels of estriol
and ring D a-ketols than in Subject
M.S. It is also of interest that the uri¬
nary levels of estrone and estradiol in
these 2 subjects were similar, although
the amounts of the 16-oxygenated me¬
tabolites (estriol, ring D a-ketols and
Table 3. Urinary excretion (mg/24 hrs.) of 6 estrogen fractions in 7 normal pregnancies
(values are arithmetic means with ranges in parentheses)
Period of pregnancy (weeks)

















































* For key to abbreviations see Table 2.
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Table 4. Comparison of urinary excretion (mg/24 hrs.) total estrogens (Ittrich method) with
the excretion of 6 estrogen fractions in normal pregnancy
Total 6 Estrogen fractions 6 Estrogen fractions
Urine estrogens, (corrected for exptl. losses) (uncorrected for exptl. losses)
No. Ittrich
method Total % of Ittrich value Total % of Ittrich value
1 25.6 23.8 93 17.6 69
2 51.8 54.9 106 40.4 78
3 13.3 13.8 104 10.2 77
4 25.3 22.1 87 16.4 65
5 10.7 11.5 107 8.6 80
6 11.0 • 9.9 90 6.5 60
7 17.9 16.6 93 12.3 70
8 18.9 20.4 108 15.1 80
9 20.0 26.9 135 19.9 100
10 33.2 34.0 102 25.1 76
11 20.5 19.5 95 13.4 65
12 9.6 8.0 83 6.0 63
13 15.2 13.1 86 9.9 65
14 30.9 31.3 101 23.3 75
Mean +s.d. =99 +10 .1 % Mean +s.d. =73 + 13 .2%
16-epiestriol) were considerably higher
in Subject M.S. The onset of slight hy¬
pertension in Subject P.K. at about
week 34 approximately coincided with a
significant drop in urinary estrone excre¬
tion—a change which was not shared by
the other metabolites. The reason for
this is obscure.
Table 3 contains data on the mean
values and ranges for the 6 estrogen frac¬
tions over various periods during the last
twenty weeks of pregnancy in the 7 sub¬
jects studied. As before, all results were
uncorrected for experimental losses. The
ring D a-ketols and 16-epiestriol, like
estriol, tended to increase to a relatively
greater extent than estrone or estradiol
as pregnancy progressed. Estriol alone
accounted for 73+6.1 (s.D.)% of the
total of the six fractions over the
last twenty weeks; the corresponding
value for the ring D a-ketols was
13+3.1%. Thus these 2 fractions to¬
gether amounted, on the average, to
86% of this total.
Paper chromatography of mixtures
of pure 16a-hydroxyestrone and 16-
ketoestradiol, followed by elution and
colorimetric measurement, consistently
yielded 60- 70% recovery. Likewise, frac¬
tionation by this technique of 55 pig of a
urinary ring D a-ketolic fraction (in
terms of 16a-hydroxyestrone) yielded
22 jug of 16a-hydroxyestrone, 15.2 /ug of
16-ketoestradiol and (provisionally) 0.8
jj.g of 16/f-hydroxyestrone, i.e., a total re¬
covery of 38 pg or 69%. When these
values are used, and the levels of the
estrogen fractions in late pregnancy
urine are corrected for the average losses
known to be incurred during the over-all
fractionation procedure, the mean values
(weeks 36-40) in Table 3 become (in
mg/24 hours): 2-methoxyestrone, 0.17;
estrone, 1.4; 16a-hydroxyestrone, 2.9;
16-ketoestradiol, 2.0; 16/3-hydroxyes-
trone, 0.1; estriol, 26.4; 16-epiestriol, 1.2;
estradiol, 0.56; and total estrogens, 34.7.
Taking the highest values found during
the same period, the corrected figures
are: 2-methoxyestrone, 0.46; estrone,
2.1; 16a-hydroxyestrone, 5.5; 16-keto-
estradiol, 3.6; 16/3-hydroxyestrone, 0.1-
0.2; estriol, 41.7; 16-epiestriol, 1.9; es¬
tradiol, 0.75; and total estrogens, 56.0.
Total urinary estrogens. Table 4
shows the relationship between the six
estrogen fractions added together and
the total estrogens as measured by the
Ittrich procedure in 14 urines from five
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subjects. A close correlation was ob¬
tained considering the different methods
employed, and it was obvious that
the difference between the uncorrected
values for the 6 fractions and the Ittrich
totals was to a large extent the result of
methodological losses associated with
the longer fractionation technique.
Discussion
Appraisal of the reliability of the frac¬
tionation technique employed would in¬
dicate that it has been possible to
achieve the main objective of this study,
namely, to obtain a fairly accurate pic¬
ture, qualitatively and quantitatively, of
the pattern of six estrogen fractions in
normal human pregnancy urine. It
should be clearly understood that no
cognizance has been taken of a number
of other recently discovered estrogen
metabolites such as 2-methoxyestriol
(14), 18-hydroxyestrone (15) and 2-hy-
droxyestrone (16) which could perhaps,
although probably only to a small ex¬
tent, contaminate certain of the frac¬
tions actually measured.
A problem arose because 2-methoxy-
estrone was frequently not measurable
in pregnancy urines. At an early stage in
the study it was thought that this might
be due to technical factors such as the
occasional occurrence of an undesirable
background color in the 2-methoxyes-
trone fraction (see Methods). Moreover,
for some unknown reason, recoveries of
this steroid (average = 72%) were con¬
siderably lower than the values reported
by Givner et al. (7). Despite these pos¬
sible objections, however, it appears
that the virtual absence (<80 p.g per 24
hours) of 2-methoxyestrone in some preg¬
nancy urines is a true phenomenon. When
measurable amounts of the metabolite in
question were present, a typical Kober
color (X max. =550 m,u) was formed, and
a discrete Folin-positive zone with the
mobility of 2-methoxyestrone could al¬
ways be observed on paper chromato-
grams. The irregular occurrence of this
compound in these pregnancy urines
may have been dependent upon the de¬
gree of availability of factors (e.g.,
tetrahydrofolic acid) which may play a
part in the formation of 2-methoxylated
estrogen (17).
The qualitative and quantitative pat¬
terns of estrone, estradiol and estriol ex¬
cretion in the present study were similar
to those already reported both from this
laboratory (2) and elsewhere (1). How¬
ever, the present results and other data
from this laboratory (2) demonstrate
estriol levels which, although in the same
range as those of other workers, do not
approach the highest levels reported by
them to occur in late pregnancy (18). It
is unlikely that this represents technical
error; rather, it is a true variation. The
levels of 16-epiestriol reported in this
paper are consistent with those found by
others (19).
The urinary ring D a-ketolic estrogen
metabolites are obviously of consider¬
able quantitative importance in human
pregnancy. The ratio between 16a-hy-
droxyestrone and 16-ketoestradiol in the
present study was rather close to that
found by Layne and Marrian (6) in an
isolation experiment. However, the 16/1-
hydroxyestrone provisionally measured
in this laboratory represented a much
smaller fraction of the ring D a-ketols
than reported by the latter investigators.
One possible explanation for this would
be the ease with which 16/3-hydroxyes-
trone can be chemically rearranged to
yield 16-ketoestradiol. It is interesting
that, in general, the 16-oxygenated estro¬
gen metabolites (ring D a-ketols, estriol
and 16-epiestriol) increase to a greater
extent during the later stages of preg¬
nancy than do estrone and estradiol.
Moreover, unpublished results from this
laboratory have shown that in the non¬
pregnant state the urinary excretion of
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estrone is about equal to that of the ring
D a-ketols. These findings are not incon¬
sistent with the view that the ring D a-
ketols (probably precursors of estriol and
16-epiestriol) may arise in the placenta
by biosynthetic routes other than from
estrone and estradiol. Such a state of af¬
fairs has already been shown to exist for
16a-hydroxyestrone (20). Besides these
possibilities, it must not be overlooked
that the renal handling of estrogens may
play an important part in the urinary
pattern (21).
Any consideration of the Ittrich tech¬
nique for measuring total estrogens must
take into account the fact that it meas¬
ures a number of compounds of differ¬
ent extinction coefficients in terms of a
single estrogen (estriol)—a situation re¬
sembling that involved in the measure¬
ment of total 17-ketosteroids. Because of
this factor, a critical comparison be¬
tween the excretion of total estrogens
and the excretion of the 6 fractions is not
possible. However, in view of the close
similarity of the results obtained by
these two types of measurement, it is ap¬
parent that the estrogen fractions which
were studied must account for prac¬
tically all the quantitatively important
Kober-positive compounds in the urine,
and that the Ittrich method yields a
satisfactory measure of total estrogens.
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Observations on the Occurrence of Six Estrogen
Fractions in Human Pregnancy Urine
II. Diabetic Pregnancy*!
R. HOBKIRK, Ph.D. and MONA NILSEN
University Medical Clinic and Department of Metabolism,
The Montreal General Hospital, Montreal, Canada
AN EARLIER report from this labora-
jTm. tory (1) showed that the relative
amounts of estrone, estradiol-17/3 (es¬
tradiol) and estriol excreted in the urine
of pregnant diabetics over the last
twenty weeks of pregnancy were, in
some cases, more subject to variation
than in normal pregnancy. It was par¬
ticularly noticeable that the amount of
estriol excreted in the urine of diabetics
could be remarkably low. The finding of
a number of additional urinary estrogen
metabolites in the past six years has
prompted further investigation of this
subject. Since the excretion pattern of 6
estrogen fractions in normal pregnancy
has already been reported from this labo¬
ratory (2), it was obviously of interest
to extend this study to diabetic preg¬
nancy.
In the present work the 6 urinary frac¬
tions investigated were 2-methoxyes-
trone, estrone, ring D u-ketolic estro¬
gens (mainly 16a-hydroxyestrone and
16-ketoestradiol-17j3), estriol, 16-epies-
triol and estradiol. The opportunity was
also taken to compare the values ob¬
tained by a technique for measuring
total estrogens (3) with the values ob¬
tained for the 6 estrogens following frac¬
tionation.
Materials and Methods
Subjects. Analyses were performed on the
Received August 7, 1961.
* Supported by a grant from the National Re¬
search Council of Canada.
f A preliminary account of this work was sub¬
mitted as a short communication to the First
International Congress on Endocrinology, Co¬
penhagen, July 1960.
ABSTRACT. A study was made of the pat¬
tern of 6 urinary estrogen fractions, from the
twentieth week of pregnancy onward, in
women with diabetes mellitus. These frac¬
tions were 2-methoxyestrone, estrone, ring D
a-ketolic estrogens, estriol, 16-epiestriol and
estradiol-17/3 (estradiol). As in normal preg¬
nancy, 2-methoxyestrone behaved irregularly
and frequently was not present in measurable
amounts, particularly in urines containing
large amounts of estriol. The excretion of ring
D a-ketolic estrogen frequently was higher
than has been found in normal pregnancy, and
reached 16.2 mg per 24 hours in one case when
corrected for experimental losses. During ap¬
proximately weeks 35—37 of pregnancy, the
mean corrected values (mg per 24 hours) for
the various fractions in the urine of the dia¬
betic patients were: 2-methoxyestrone, 0.40;
estrone, 1.5; ring D a-ketols, 10.0; estriol,
24.7; 16-epiestriol, 1.0; and estradiol, 0.60.
The excretion of the 6 fractions taken to¬
gether and corrected for experimental losses
was usually considerably higher than the ex¬
cretion of total estrogens as measured by the
Ittrich technique in the same urines.
urines of 9 women during 10 pregnancies,
beginning from approximately week 20 of
pregnancy. In only 3 of these women was it
possible to study estrogen excretion beyond
week 36 because of termination (artificially
or otherwise) ofmost of the pregnancies at or
before this time. The subjects suffered from
varying degrees of diabetes mellitus but none
was toxemic during the period of study. Ex¬
cept for maintenance insulin, no medication
was given. Forty-two estrogen fractiona¬
tions were performed.
Urine collection. Complete 24-hour vol¬
umes were obtained under conditions de¬
scribed earlier (2).
Estrogen separation and measure¬
ment. Estrogen fractionation and sub¬
sequent estimation were performed exactly as
previously described for normal pregnancy
urine (2).
Measurement of total estrogens in
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pregnancy urine. It soon became evident
that the direct Ittrich technique for measure¬
ment of total estrogens (4), involving a
direct color reaction in the urine, was un¬
suitable for sugar-containing urines. This
could be attributed to a) a masking color
(X max. =510 mju) produced by the effect of
hot 65% sulfuric acid on glucose, and b) a
simultaneous destruction of estrogen under
these conditions. Because of this difficulty,
the "indirect" Ittrich technique (3), devised
to measure total estrogens in nonpregnancy
urines, was adapted to meet the situation.
For this purpose, duplicate 0.5-ml or 1.0-ml
volumes of urine were diluted to 10 ml with
j distilled water prior to hydrolysis of the
steroids at 100° C for sixty minutes with 15
j volumes % of concentrated HC1. This pro¬
cedure splits estrogen conjugates without
causing undue destruction of estrogens by
the sugar-acid mixture (5). Following hy¬
drolysis the phenolic fraction was extracted
and purified somewhat according to Ittrich
(3). The final dried extracts were dissolved
in ethanol and suitable aliquots were assayed
by the Ittrich modification of the Kober
color reaction (3), using tetrachloroethane as
the solvent for the chromogen. Optical
density was measured at 506, 538 and 570 mn
and corrected by the Allen equation (6).
Total estrogen was measured in terms of
estriol.
Reliability of the analytical methods.
The reliability of the fractionation technique
was no different from that already shown to
apply in the analysis of normal pregnancy
urine (2).
The accuracy of the total estrogen pro¬
cedure was studied by measuring the re¬
covery of 1-4 jug of estriol after addition to
0.5-1.0 ml of nonpregnancy urine, diluted
1:10 with water, prior to hot acid hydrolysis.
Under these conditions, recovery was 94 + 4.9
(s.d.) %. When 8 /ig of 16a-hydroxyestrone
and 10 /ig of 16-ketoestradiol were separately
added to nonpregnancy urine under the same
conditions, recoveries were only 44% and
57% respectively.
The precision of the total estrogen method
was obtained by estimating the standard
deviation (s) from the equation s = V2d~/'2N,
where d = the difference between duplicates
in a number of analyses ( >30) and N = the
number of duplicate analyses (7). In this
case, s =0.55 mg per 24 hours.
The sensitivity of this total estrogen
method was adequate for all urines con¬









DURATION OF PREGNANCY (WEEKS)
Fig. 1. Excretion of 6 urinary estrogen fractions
during the last 14 weeks of pregnancy in Pa¬
tient M.W. Results are uncorrected for methodo¬
logical losses.
Results
Pattern of the six estrogen frac¬
tions. Figure 1 shows the results, un¬
corrected for methodological losses,
obtained between weeks 21 and 34 in
Patient M.W. This particular patient
excreted the largest amounts of 2-me-
thoxyestrone that have been measured
thus far in this laboratory. It is particu¬
larly noteworthy that this high excre¬
tion co-existed with a rather low excre¬
tion of estriol. All 6 estrogen fractions
commenced to diminish at about week
30 of pregnancy in this patient and were
quite low just prior to delivery, which
occurred at week 35. The reason for this
change is not known.
Table 1 contains data on the uncor¬
rected levels of the six urinary estrogen
fractions in 4 diabetic women between
weeks 20 and 35 of pregnancy. It will be
seen that all 4 subjects excreted meas¬
urable amounts of 2-methoxyestrone at
some stage of the study period, al¬
though in 3 (Patients M.B., M.L. and
P.B.) this steroid apparently disap¬
peared from the urine (reached a value
less than 80 ,ug per 24 hours), to reappear
subsequently in 2 (Patients M.B. and
P.B.). At week 26, Patient M.B. ex¬
creted 7.9 mg of ring D a-ketols per 24
hours. Although this was not the highest
144 HOBKIRK AND NILSEN Volume 22
Table 1. Urinary excretion (mg/24 hrs.) of 6 estrogen fractions in 4 diabetic pregnancies
Patient Estrogen*




28 29 30 31 32 33 34 35
2-Meo-o 0.18 0.16 0.21 0.32 0.41 0.66 0.66 0.38 0.28
O 0.46 0.52 0.72 0.73 1.1 1.5 2.0 1.7 0.90
M.W. Ketols 0.41 0.62 0.89 1.1 1.6 1.7 2.3 2.2 1.0
T 2.6 3.0 3.4 4.5 6.5 6.7 10.1 7.4 7.6
epi T 0.16 0.17 0.22 0.18 0.21 0.44 0.45 0.30 0.26




2-Meo-o 0.46 0.55 0.61 0 0 0.45
O 1.4- 1.4 1.8 2.1 1.2 2.1
Ketols 2.0 2.3 5.8 7.9 4.6 6.1
T 5.3 5.8 9.2 11.8 9.2 10.8
epi T 0.43 0.32 0.57 0.66 0.51 0.51
D 0.53 0.49 1.3 0.96 0.58 0.55
2-Meo-o 0.25 0.17 0.15 0 0 0
O 3.8 3.0 5.1 5.2 3.2 3.
Ketols 3.4 2.2 5.2 6.3 4.8 6.
T 11.0 14.3 13.9 14.5 12.5 13.
epi T 0.56 0.61 0.61 0.62 0.46 0.
D 0.62 0.75 0.79 0.86 0.71 0.
2-Meo-o 0 0 0.21 0 0.20 0.32
O 0.60 0.62 1.1 1.4 1.4 2.2
Ketols 0.90 0.67 1.4 1.7 1.2 3.9
T 4.0 5.6 9.4 10.1 7.8 14.9
epi T 0.33 0.61 0.55 1.3 0.94 0.77
D 0.14 0.21 0.27 0.36 0.29 0.72
* 2-Meo-o =2-methoxyestrone; 0 =estrone; T =estriol; epi T = 16-epiestriol; D =estradiol.
absolute value found for this fraction, it
accounted for 34% of the total of the 5
fractions measured at that time. The
ratio of estriol to ring D a-ketols was
only 1.5. Patient M.B. also excreted re¬
markably large amounts of estradiol at
weeks 24 and 26 of pregnancy. The uri¬
nary estrone level in Patient M.L.
reached 5.2 mg per 24 hours, which is
well above the normal range. This was
the second pregnancy studied in this
woman, and it is noteworthy that on the
previous occasion (some three years be¬
fore) the corresponding values were 4.5-
6.0 mg per 24 hours during weeks 28-34
of pregnancy (1). It was obvious, there¬
fore, that this phenomenon was repro¬
ducible.
Since in most of these diabetic sub¬
jects pregnancy terminated some time
before term, it was not possible to ob¬
tain much data on excretion patterns in
late pregnancy. A few isolated results in
3 patients during weeks 35-37 are listed
in Table 2. As before, these values were
uncorrected for experimental losses. In
Table 2. Urinary excretion (mg/24 hrs.) of 6 estrogen fractions during
late pregnancy in 3 diabetic women
Week of Estrogen fraction*
Patients weeK 01
pregnancy 2-Meo-o O Ketols T epi T D
S.A. 35 0 2.3 10.5 23.7 1.1 0.56
36 0 1.7 10.2 23.1 0.86 0.65
M.C. 36 0.68 1.9 4.0 15.4 0.88 0.60
37 0.53 1.7 5.3 19.8 1.1 0.82
M.K. 36 0 0.37 6.2 29.4 1.0 0.27
* For key to abbreviations see Table 1.
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Table 3. Urinary excretion (mg/24 hrs.) of 6 estrogen fractions in 10 diabetic pregnancies
(values are arithmetic means with ranges in parentheses)
Estrogen* fraction
Period of pregnancy (weeks)
20-25 26-30 31-35 36-40
0.23 0.20 0.10 0.29
(0-.61) (0- .66) (0-.45) (0-.68)
0.91 1.5 1.4 1.3
(.17-1.8) (.64-2.2) (.74-2.4) (.37-1.9)
■ 1.8 3.2 5.9 6.5
(.41-5.8) (1.2-7.9) (1.0-10.5) (4.0-10.5)
6.1 11.5 14.8 18.5
(2.6-11.0) (6.5-22.0) (6.7-24.1) (11.2-29.4)
0.40 0.57 0.60 0.78
(.16-. 72) (.21-1.3) (.26-1.1) (.25-1.1)
0.36 0.50 0.45 0.47







* For key to abbreviations see Table 1.
f The high estrone values in Patient M.L. (Table 1) were omitted from this table.
Patient M.C. a measurable amount of
2-methoxyestrone was found, but in
Patients S.A. and M.K., although con¬
siderable amounts of ring D a-ketols and
estriol were excreted, no 2-methoxyes-
trone could be detected. Subject S.A. ex¬
creted the largest amount of ring D
a-ketols recorded thus far in this labora¬
tory, namely, 10.5 mg per 24 hours (un¬
corrected) or 16.2 mg per 24 hours when
corrected for experimental losses. This
accounted for 30% of the five fractions
measured in this case.
Table 3 contains data on mean values
and ranges (uncorrected for losses) of
the six urinary estrogen fractions in the
ten pregnancies studied. Over approxi¬
mately the last 20 weeks of pregnancy,
estriol accounted for 64+7.7 (s.D.)% of
the sum of the six fractions and the ring
D a-ketols accounted for 19 ±7%. These
two fractions, therefore, accounted for
about 83% of the total. The 16-oxygen-
ated estrogens showed a relatively
greater general increase over the 20-week
period than did estrone or estradiol.
When the average values for the frac¬
tions in weeks 36-40 of pregnancy were
corrected for known experimental losses
they became (mg per 24 hours): 2-me-
thoxyestrone, 0.40; estrone, 1.5; ring D
a-ketols, 10.0; estriol, 24.7; 16-epiestriol,
1.0; and estradiol, 0.60.
Total urinary estrogens. In Table 4
the values for total estrogens measured
by the Ittrich method are compared with
the sum of the values for each of the 6
estrogen fractions measured following
the fractionation procedure, in 9 dia¬
betic pregnancy urines. Unlike the pic¬
ture for normal pregnancy urine (2), the
sum of the 6 fractions was often consid¬
erably higher than the results obtained
by the Ittrich method. Although this
may be partly explained by the destruc¬
tion of ring D a-ketolic estrogens during
the preliminary acid hydrolysis in the
Ittrich procedure (see Methods), the
large difference is difficult to explain
adequately.
Discussion
The general pattern of the estrogen
metabolites studied in the urine of dia¬
betic pregnant subjects was very similar
to that seen in normal pregnancy (1, 2).
However, in individual cases there were
some interesting features. It has been
shown that the excretion of estriol in
diabetic pregnancy may be markedly
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Table 4. Comparison of urinary excretion (mg/24 hrs.) of total estrogens (Ittrich method)
with the excretion of 6 estrogen fractions in diabetic pregnancy
6 Estrogen fractions 6 Estrogen fractions
(corrected for exptl. losses) (uncorrected for exptl. losses)
Urine No. Ittrich method
Total % Total °^°
Ittrich value Ittrich value
1 15.8 22.4 141 16.7 106
2 16.8 20.4 121 15.9 95
3 21.2 20.7 96 15.3 72
4 17.6 26.2 150 19.6 111
5 21.9 . 27.9 127 21.0 96
6 22.8 34.3 150 24.6 108
7 24.4 37.1 152 27.6 113
8 25.0 29.2 117 21.6 86
9 30.2 32.8 109 24.0 79
Mean +s.d. =129 +20 Mean + s.d. =96 +14.7
lower than in normal pregnancy (1). The
results reported here, although not in
disagreement with this conclusion, show
that estriol excretion in some pregnant
diabetics may reach the upper limit of
the normal range. The previous finding
of a greater variability in the relative
proportions of estrogen metabolites in
the urine of diabetic pregnancy com¬
pared with nondiabetic pregnancy (1)
has been substantiated in the present
study by the finding of abnormally high
estrone excretion in one subject and high
estradiol excretion in another. The uri¬
nary output of ring D a-ketols in the
diabetic subjects rose significantly, and
on the average was twice that found
earlier for normal pregnancy (2). It
would be premature to make a compari¬
son in this latter respect between these
groups, but it is interesting that the ring
D a-ketolic fraction could make a much
higher contribution (up to 34%) to the
total urinary estrogens in the diabetics
than in the normal women (2). The ir¬
regular behavior of 2-methoxyestrone in
normal pregnancy (2) was duplicated in
the diabetic group. The highest urinary
outputs of this steroid in the diabetic
subjects tended to be associated with
relatively low outputs of the other estro¬
gen fractions. It is suggested that in such
cases an increased degree of hydroxyla-
tion at the 2-position of the estrogen
molecule, followed by methylation, was
taking place at the expense of the other
fractions.
In the diabetic pregnancy urines the
total estrogen levels, as measured by the
Ittrich technique, were related much
less directly to the sum of the six frac¬
tions than in the urine of normal preg¬
nancy (2). It is apparent, therefore, that
values for total urinary estrogens by the
Ittrich procedure (incorporating hot acid
hydrolysis and subsequent purification)
must be interpreted with caution.
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2-Methoxyestrone as an Estrogen
Metabolite in the Human Subject1
R. HOBKIRK, Ph.D. and MONA NILSEN
University Medical Clinic, The Montreal General Hospital, Montreal, Canada
IN PREVIOUS COMMUNICA¬TIONS from this laboratory (1, 2), it
was noted that in the pregnant human
urinary 2-methoxyestrone exhibited a
marked fluctuation throughout any one
pregnancy and also varied considerably
in amount from one subject to another.
This behavior was, in general, quite
distinct from that observed for five other
urinary estrogen fractions in the same
subjects. One limitation of this earlier
work resided in the lack of sensitivity of
the analytic procedure, so that 80 pg or
less of 2-methoxyestrone per 24 hours
could not be distinguished from a value
of zero. It was thus impossible to ascer¬
tain whether or not this metabolite was
excreted at all during some pregnancies.
In the present study, a rather more sensi¬
tive and specific technique was employed
to measure urinary 2-methoxyestrone at
approximately weekly intervals during
the last 25 to 30 weeks of pregnancy.
Simultaneous measurement of total uri¬
nary estrogens was also performed to
compare the excretion with that of 2-
methoxyestrone. In order to obtain fur¬
ther information on the problem, an
attempt was also made to study the
metabolism of exogenous 2-methoxyes-
trone in human males.
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Supported by a grant from the Medical Re¬
search Council of Canada and in part by a grant-
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abstract. During the last 20-30 weeks of
pregnancy, the level of 2-methoxyestrone in
the urine of 4 subjects ranged from less than
25 fjg/24 hr to about 1 mg/24 hr. The levels
fluctuated widely both in any one pregnancy
and from one subject to another. There was a
great difference in the trend of excretion of
this metabolite and that of total estrogens in 2
of the subjects. The behavior of 2-methoxy¬
estrone may be partly due to demethylation to
form 2-hydroxy steroids. Some evidence in
favor of this was obtained by studying the
metabolism of exogenous 2-methoxyestrone
in male subjects.
Materials and Methods
Subjects. Four pregnant women exhibiting no
clinical abnormalities and receiving no inter¬
fering medication were studied beginning at
12-19 weeks of their pregnancies. Total
estrogens and 2-methoxyestrone were meas¬
ured at intervals of approximately 1 week.
Seventeen analyses were performed on Sub¬
ject M.S., 22 on J.R., 21 on S.S. and 22 on
J.C. Two males, aged 47 and 64 yr, both of
whom had normal liver function, were em¬
ployed for the study of exogenous 2-meth¬
oxyestrone.
Urine Collection. Complete 24-hr specimens
were collected in polyethylene bottles with¬
out preservative. Enzymic hydrolysis was
commenced as soon as possible after collec¬
tion. Aliquots were also taken at this time for
measurement of total estrogens.
Measurement of 2-Methoxyestrone. Conjugate
hydrolysis was performed using the snail
enzyme preparation Glusulase2 under the
conditions described earlier (3). Fifty ml
volumes of urine were used for each analysis.
Free steroids were extracted with ether (4),
2 Glusulase is the commercial name for a snail
enzyme extract available from Endo Labora¬
tories, Inc., New York, N. Y.
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and the ether extract was considerably puri¬
fied by treatment with the NaOH-bicarbon-
ate step described by Bauld (5). The evapo¬
rated ether extract was fractionated by a
modified Girard reaction (6), and 2-meth-
oxyestrone was separated from the ketonic
fraction by partition column chromatog¬
raphy (6). An aliquot of the 2-methoxyes-
trone fraction was analyzed by the Ittrich
colorimetric procedure (7) using tetrachloro-
ethane as solvent. Spectrophotometric read¬
ings were made at 5B6, 5&8 and 600 mg
and corrected by means of Allen's equation
(8). Pure 2-methoxyestrone was used as a
standard.
Measurement of Total Estrogens. This was
done by the direct Ittrich method (9), as
previously described (1). Results were ex¬
pressed in terms of estriol.
Reliability of the Methods. The above ana¬
lytic procedure for 2-methoxyestrone re¬
sulted in an average increase in recovery of
12% compared with recovery experiments
reported earlier (1). Thus, the average re¬
covery figure for the present procedure was
84%, with a standard deviation of 6%. The


















Fig. 1. Excretion of 2-methoxyestrone and total


























Fig. 2. Excretion of 2-methoxyestrone and total
estrogens in Subject J.R. Results are uncorrected
for experimental losses.
as with the original technique (1). The sensi¬
tivity increased so that the smallest amount
which could be distinguished from zero was
approximately 25 ;ug/24 hr. The specificity
was improved by the use of the Ittrich colori¬
metric procedure, which excluded most of the
nonspecific chromogens. The reliability of
the total estrogen method has already been
reported upon (1).
Metabolism of Exogenous 2-Methoxyestrone.
Pure unlabeled 2-methoxyestrone, dissolved
in a small volume of propylene glycol, was
given intravenously to each of the 2 male
subjects. The weights of steroid administered
were 500 and 550 jig. Urine was collected in
each case for 4 days. Hydrolysis was per¬
formed as above, and the total ether fraction
was separated into 6 fractions by the proce¬
dure of Givner et al. (4). Analysis of each
fraction was performed by the Ittrich colori¬
metric method, as described above. In order
to obtain further information regarding the
identity of 2-methoxyestrone metabolites,
thin layer chromatography was employed, as
described by Lisboa and Diczfalusy (10),
both before and after reduction with sodium
borohydride.
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WEEKS
Fig. 3. Excretion of 2-methoxyestrone and total
estrogens in Subject S.S. Results are uncorrected
for experimental losses.
Results
Fig. 1-4 show the trend in excretion of
2-methoxyestrone and total estrogens in
Subjects M.S., J.R., S.S. and J.C., re¬
spectively. The results are uncorrected
for experimental losses. An abrupt peak
in the excretion of 2-methoxyestrone at
24 weeks, with no corresponding pattern
of total estrogens, can be seen for M.S.
(Fig. 1). Moreover, in this same subject,
the 2-methoxyestrone level failed to
increase with total estrogens after 28
weeks. A markedly different pattern held
for Subject J.R. (Fig. 2), in whom 2-
methoxyestrone and total estrogens ap¬
proximately paralleled each other.
Again, in Subject S.S. (Fig. 3), a low and
fluctuating 2-methoxyestrone level
seemed to bear little or no relation to the
total estrogen values. In Subject J.C.
(Fig. 4), both 2-methoxyestrone and
total estrogens were low, the patterns




















Fig. 4. Excretion of 2-methoxyestrone and total




















Fig. 5. Spectrophotometry curves of the Ittrich
chromogen formed by the 2-hydroxyestrone-like
fraction from male urine following injection of
2-methoxyestrone, and of authentic 2-hydroxy-
estrone.
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Except for the first three urines from
Subject J.C., measurable 2-methoxy-
estrone was present in all urines ana¬
lyzed. The levels of 2-methoxyestrone in
these four subjects are summarized in
Table 1. As before, no correction has
been made for experimental losses.
Following the administration of 2-
methoxyestrone to the male subjects, no
2-methoxyestrone was detectable in the
urine of one, while in the other case 34
pg, or 6% of the dose, was excreted in
four days. In both subjects, material
giving a positive Ittrich color reaction
occurred in the fractions having the
approximate chromatographic mobility
of the ring D a-ketols (6). An absorption
peak was observed at about 565 mp, as
for authentic 2-hydroxyestrone (Fig. 5).
Thin layer chromatography on silica gel
G in the system ethyl acetate: cyclohex-
ane:ethanol (45:45:10) (10), followed
by spraying with Folin and Ciocalteu's
reagent, showed the urinary fraction to
haveanRF value of 0.57 (RF of2-hydroxy¬
estrone = 0.57). After borohydride reduc¬
tion, two spots were visible on the chro-
matogram, a main one of RF 0.47 (Rf of
2-hydroxyestradiol-17d =0.47) and one
of lesser intensity with an RF of 0.57. This
suggested the presence of two phenolic
compounds, or incomplete reduction.
The study was hampered by the presence
of a yellow contaminant which was diffi¬
cult to remove. This, or partial break¬
down of the labile 2-hydroxy steroid,
may have been responsible for the
streaking which occurred on some of the
thin layer chromatograms. The 2-
hydroxyestrone-like compound appeared
to account for some 14% (uncorrected
for experimental losses) of the 2-meth-
oxyestrone dose.
Discussion
The data in this communication bear
out earlier reports (1, 2) that 2-methoxy-
Table 1. Urinary 2-methoxyestrone levels














10-14 3 0.10 0.07-0.14
15-19 10 0.06 Of -0.18
20-24 18 0.13 0.03-0.36
25-29 18 0.18 0.06-0.49
30-34 18 0.23 0.06-0.61
35 + 14 0.32 0.04-0.95
* Figures are uncorrected for experimental
losses.
f Zero indicates less than 25 ng/24 hr.
estrone is excreted in the urine of preg¬
nant women in a pattern which may
appear quite unrelated to the trend in
excretion of total estrogens. It is likely
that 2-methoxyestrone is always ex¬
creted during pregnancy, although often
in minute amounts. One possible reason
for the behavior of this metabolite could
be a variable degree of demethylation
with the formation of 2-hydroxy com¬
pounds. This has already been demon¬
strated by Brown (11) for the 3-methyl
ethers of estriol, estradiol-170 and es¬
trone. The identity of 2-hydroxyestrone
in the urine following 2-methoxyestrone
injection has not been proved beyond
doubt in the present work, but the sup¬
porting evidence is good. Recent work by
Fishman et al. (12) indicates the thyroid
to be an important factor in the conver¬
sion of exogenous estrone or estradiol-17/3
to estriol, on the one hand, and to 2-
methoxyestrone on the other. It is not
known at present whether or not thyroid
function may be responsible for the
urinary patterns of 2-methoxyestrone
seen in the pregnant subject.
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Contribution of Estriol to Total Urinary
Estrogens during Pregnancy
R. Hobkirk,1 Y. Anuman-Rajadhon,2 M. Nilsen, and P, R. Blahey
Estriol accounts for an average of 74% of the principal Kober-positive
steroids in the urine of 13 women during uncomplicated pregnancies.
This proportion is independent of the stage of pregnancy, from 20 weeks
until term. The average ratio of estriol to ring-D a-ketols (mainly 16a-
hydroxyestrone and 16-ketoestradiol-17j8) is about 5:1 over the same period.
In 17 pregnant women with diabetes, urinary estriol averaged 63% of the
"total steroids" during a similar period, and the average ratio of estriol to
ring-D a-ketols was 3:1. The quantitative importance of these ketolic steroids
may introduce a problem in deciding whether to measure estriol or "total
estrogens" when evaluating fetal viability in complicated pregnancies.
Measurement of urinary estriol [estra-1,3,5(10)-triene-3,16a,17/3-triol] appears to be a
useful index to viability of the human fetus (1-3).
It has been shown that the fetoplacental unit is
the main site of estriol synthesis during preg¬
nancy (4-6).
Many methods have been published for measur¬
ing estriol (7-9) and "total estrogens" (10-12) in
the urine during pregnancy. Although estriol is
almost certainly the main single component of the
total estrogens in pregnancy, the quantitative
relationships are not particularly clear. Confusion
has sometimes resulted from the use of the term
"total estrogens" to denote the "classical" com¬
pounds: estrone [3-hydroxyestra-l,3,5(10)-trien-
17-one], estradiol-17/3 [estra-1,3,5 (10) -triene-3,17/3-
diol], and estriol. It is now known that several
other phenolic steroid metabolites contribute sig¬
nificantly to total urinary estrogens (13).
Our paper establishes the contribution of estriol
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Hospital, and Department of Experimental Medicine, McGill
University, Montreal, Quebec, Canada.
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to total estrogen excretion and supplements data
already obtained in this laboratory (14, 15). In
view of the interest in the urinary excretion of
estriol and total estrogens during pregnancy com¬
plicated by diabetes (16-18), some comparison is
given for normal and diabetic women during their
pregnancies.
Materials and Methods
Total 24-h urines were collected without preser¬
vative in polyethylene bottles and, unless analyzed
immediately, were stored at — 15°C until pro¬
cessed.
Reagents
All reagents and organic solvents were purified
where necessary by published procedures (19, 20).
"Glusulase," a molluscan enzyme preparation
containing /3-glucuronidase (/3-d-glucuronide glu-
curonohydrolase, EC 3.2.1.31), and sulfatase
was purchased from Endo Labs., Inc., Garden City,
N. Y. A bacterial ^-glucuronidase preparation was
purchased from Sigma Chemical Co., St. Louis,
Mo.
Crystalline steroids (Mann Research Labs., Inc.,
N. Y.) were checked for purity by thin-layer
chromatography and melting point determina¬
tion.
} [Reprinted from CLINICAL CHEMISTRY, 16, 235 (1970).]
Copyright 1970 by the American Association of Clinical Chemists and reprinted by permission of the copyright owner.
Analytical Methods
Suitable volumes of urine (usually 50 ml) were
analyzed by a modification (21) of a procedure
published elsewhere (14)- In some instances, "total
conjugated" estrogens were hydrolyzed by Glusul-
ase (22) while in others steroid glucosiduronates
were hydrolyzed by bacterial /3-gluouronidase (21)
and the residual conjugates (mainly sulfates) were
cleaved by solvolysis in ethyl acetate and H2S04
(23). The various urinary estrogen fractions were
purified and separated by solvent partition, Girard
separation, and partition chromatography on a
Celite column.




gether with some 16/3-hydroxyestrone [3,16/3-dihy-
droxy estra-l,3,5(10)-trien-17-one], was measured
by twomethods. First, the portion of the column elu-
ate that contained the latter fraction was measured
speetrophotometrically in terms of 16a-hydroxy-
estrone (14)- Secondly, the fraction was chemically
reduced with NaBH4, 16a-hydroxyestrone being
converted mainly to estriol (24) and 16-ketoestra-
diol-17/3 (+16/3-hydroxyestrone) to 16-epiestriol
[estra-l,3,5(10)-triene-3,16/3,17/3-triol] (24). The
two steroidal triols were then separated on Celite
and measured individually (24)- For our purposes
these were added to yield "total ring-D a-ketols."
The spectrophotometric procedure of Ittrich (10)
was used throughout, except that tetrachloro-
ethane was used as the solvent for extraction of
the chromogen (20). Absorbance was measured at
506, 538, and 570 nm in each case and corrected
by the method of Allen (25). The corrected absorb¬
ance was related to the value obtained from known
amounts of the appropriate standards. Supporting
evidence for the identity of various fractions from
urine was obtained by applying aliquots to thin
(0.25 mm) layers of Silica Gel H on glass plates,
which were then developed in suitable solvent
systems (26). Spots on the plates were made visible
either by spraying with diazotized sulfanilic acid
or by spraying with a mixture of 2 ml of H2S04
per 100 ml of ethanol and then heating the plates
at 110°C. Mobilities of the various fractions were
compared with those of the appropriate pure
steroids. Values given in the tables below refer to
fractions with R, values corresponding to the
standard steroids in question.
To measure recovery, known amounts of pure
steroids, in the approximate proportions expected
in pregnancy (14), were added to nonpregnancy
urine and taken through the experimental pro¬
cedure. The results were similar to those already
published (14) but, when the ring-D a-ketolic
fraction was reduced, with subsequent extraction
and chromatography, about 10% less of it was
recovered than by direct spectrophotometry.
The average recoveries were estrone, 81%; estra-
diol-17/3, 83%; estriol, 81%; 16-epiestriol, 84%;
ring-D a-ketols (direct method), 65%; and ring-D
a-ketols (reduction method), 55%. All of the values
reported below have been corrected for these
average recoveries.
Results
Note that the excretion given for any one
steroid represents "total conjugated forms" of that
compound.
Table 1 contains data on five fractions from
urine obtained during 13 uncomplicated preg¬
nancies (51 analyses). The results are subdivided
into four time intervals, 20-24, 25-29, 30-34,
and 35 or more weeks of pregnancy. Estriol
averaged 74% of the total estrogens measured
during each interval. Ring-D a-ketols amounted
to about 20% of the estriol concentrations.
Table 2 shows similar data for 17 diabetic
Table 1. Amount of Five Estrogen Fractions
in the Urine of 13 Women during Uncomplicated Pregnancies
Estrogen fraction0 (mg/24 h) Ratio of
Weeks No. Ring-D E3 to ring-
pregnant analyses ei e2 a-ketols ei 16epiEi % Ei D a-ketols
20-24 9 0.906 0.26 1.7 8.8 0.42 73 5.2
(0.39-1.5) (0.16-0.34) (0.42-2.8) (3.0-13.1) (0.10-0.69) (61-79) (2.5-9.4)
25-29 11 0.98 0.34 2.4 11.6 0.52 73 4.8
(0.32-1.5) (0.21-0.44) (0.99-4.0) (5.0-17.7) (0.31-0.75) (61-81) (2.6-8.5)
30-34 12 1.4 0.48 3.2 16.3 0.77 73 5.1
(0.65-2.4) (0.34-0.76) (1.4-4.7) (8.9-21.7) (0.48-1.1) (62-81) (2.7-8.6)
35+ 19 1.3 0.46 4.6 24.0 1.1 76 5.2
(0.21-3.0) (0.11-0.74) (1.5-9.1) (8.7-41.7) (0.37-1.9) (67-89) (3.3-11.1)
a Ei, is estrone; E2, estradiol-17/3; E3, estriol; 16epiE3,16epiestriol.
6 Average, range in parentheses.
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Table 2. Amount of Five Estrogen Fractions
in the Urine of 17 Diabetic Women during Pregnancy
Estrogen fraction0 (mg/24 h)
Ratio of
Weeks No. Ring-D Es to ring-
pregnant analyses Ei E, a-ketols E, 16epiE3 % E» D a-ketols
20-24 14 1.4s 0.50 2.5 7.9 0.50 62 3.2
(0.20-3.1) (0.15-1.6) (0.63-9.0) (3.4-12.5) (0.21-0.95) (46-76) (1.3-7.3)
25-29 14 2.1 0.63 4.7 14.3 0.90 63 3.0
(0.75-5.9) (0.23-1.2) (0.88-12.2) (5.5-29.5) (0.17-1.8) (51-74) (1.5-6.7)
30-34 16 2.1 0.52 6.5 16.7 0.71 63 2.6
(0.87-6.1) (0.13-1.1) (1.4-16.7) (5.5-32.1) (0.23-1.2) (52-82) (1.8-7.5)
35+ 10 2.3 0.57 9.1 24.8 1.0 66 2.7
(0.43-6.0) (0.21-1.0) (4.6-16.2) (11.0-39.1) (0.33-1.5) (53-78) (1.5-4.7)
° Ei is estrone; E2, estradiol-17/S; E3, estrioi; 16epiE3, 16epiestriol.






" Mean ± SD.
Table 3. Excretion of Estrone and Ring-D a-Ketols






















women during their pregnancies (54 analyses).
Estrioi averaged 63% of the total and, once more,
did not change markedly between 20 weeks and
term, although individual values varied consid¬
erably. The ratio of estrioi to ring-D a-ketols aver¬
aged about 3:1. Once again, however, there was a
scatter of individual values, reaching as low as
1:3:1.
Ring-D a-ketols averaged higher in the diabetic
state than in normal pregnancy, a finding reflected
in the ratio of the estrioi fraction to ring-D a-ketols.
Estrone levels also appear higher in the diabetics.
However, none of these differences was statistically
significant (Table 3).
No particularly low estrioi levels were en¬
countered in the diabetic group, a finding perhaps
attributable to the fact that no patient showed
signs of intra-uterine death during the period of
investigation.
Discussion
The steroids we measured are by no means the
only estrogen metabolites present in human preg¬
nancy urines, but they represent the principal
steroids showing a strong extinction at 538 nm in
the Ittrich modification of the Kober color re¬
action. It has already been shown that the frac¬
tions measured by our analytical procedure
compare well as a whole with values obtained by
the direct Ittrich method for total estrogens (74).
Our data show that between 20 weeks and term,
estrioi is a fairly constant fraction of the total
estrogens. This might suggest that it is immaterial
clinically whether one measures estrioi or total
estrogens. However, we show here that as little
as 61% and 46% of the total estrogens measured
may be estrioi in uncomplicated pregnancies and
those with concurrent diabetes, respectively. The
greater part of the remainder is ring-D a-ketols.
Cohen recently claimed that even smaller propor¬
tions of estrioi may be found in some toxemic
pregnancies (27).
The rationale for measuring urinary estrioi
is that during the second half of pregnancy,
about 90% of it originates in the fetus (6) and
thus it may be useful as an index to fetal viabil¬
ity. Recent work, however, suggests that the
ring-D a-ketols, particularly 16a-liydroxyestrone,
present in pregnancy urine, originate from the
mother rather than the fetus (21, 28). For this
reason it may be argued that the determination
of the amount of estrioi in urine would be more
valuable than determination of total estrogens.
Cohen suggests the opposite, because estrioi may
sometimes be a very low fraction of the total (27);
therefore it might not accurately reflect the total
output of steroid by the fetus. The answer to this
question may depend on the origin of the urinary
ring-D a-ketols, particularly in a condition such as
pregnancy complicated by diabetes where these
CLINICAL CHEMISTRY, Vol. 16, No. 3, 1970 237
steroids appear to be of considerable quantitative
significance. Cohen also presented indirect evidence
for the presence of high levels of these latter
steroids in the total estrogen of diabetic pregnancy
urines {27).
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ABSTRACT. Estradiol-17/3-6,7-3H was injected
into 4 women in late pregnancy (33 weeks-term)
and 7 labeled metabolites were purified from the
urine. These were acetylated with acetic anhy-
dride-l-14C and the acetates were purified by
repeated crystallization with unlabeled carrier to
constant isotope ratio. The specific activities of
the 3H-labeled metabolites were calculated from
the 3H: 14C ratios and were found to be (cpm/,ug):
estrone 38-65, estradiol-17/3 45-77, 16a-hydroxy-
estrone 24-44, 16-ketoestradiol-17/3 25-36, 16-
epiestriol 22-36, estriol 6-8. That of 2-methoxy-
estrone was not similar to that of estriol. These
results may indicate that the endogenous 16-
oxygenated metabolites other than estriol are
mainly maternal conversion products of secreted
estrone or estradiol-17/3, with perhaps some part
arising through conversion in a fetal compart¬
ment. (J Clin Endocr 26: 625, 1966)
IT IS NOW well established that, follow¬ing injection of labeled estrone or estra¬
diol-17/3 (hereafter referred to as estradiol)
to pregnant women, the specific activity of
urinary estriol is markedly lower than that
of either estrone or estradiol (1, 2), the two
latter having approximately equal values.
Such a difference is not so apparent in the
nonpregnant subject. These findings have
been interpreted as indicating the produc¬
tion of considerable quantities of estriol, by
the fetoplacental unit, through a biosyn-
thetic pathway which may be at least
partly independent of estrone and estradiol
metabolism (3, 4). Thus, placental aroma-
tization of a 16-oxygenated Ci9 neutral
steroid (5) could be responsible for the
formation of the excess estriol which dilutes
the urinary estriol formed by peripheral
metabolism of estrone or estradiol in ma¬
ternal tissues. However, it should also be
pointed out that fetal liver has been shown
to be an active site of production of 16-
oxygenated estrogens from estradiol (6).
The above information prompted us to
Received January 6, 1966; accepted February 18,
1966.
Supported in part by the Medical Research Coun¬
cil of Canada.
investigate the specific activities of a num¬
ber of additional urinary metabolites of
injected estradiol-6,7-:iH in the human in
late pregnancy. Of particular interest is the
compound 16a-hydroxyestrone,x known to
be a normal urinary metabolite of some
quantitative significance in pregnancy (7-
10) and a good exogenous precursor of
urinary estriol in vivo in the nonpregnant
human (11, 12). If this steroid, as it
appears in pregnancy urine, were mainly
derived from a fetoplacental source, where
it may be a precursor of estriol, it might be
expected to have a specific activity similar
to that of the triol following labeled estra¬
diol injection. This has now been studied,
as have the specific activities of two addi¬
tional 16-oxygenated metabolites, namely,
16-ketoestradiol-17/3 (hereafter referred to
1 The following abbreviations and trivial names
are used in the text: 2-MeEi =2-methoxyestrone
[2-methoxy-3- hydroxy-1, 3, 5(10) - estratrien -17-
one]; 16a-OHEi =16a-hydroxyestrone [3,16«-di-
hydroxy-1,3,5(10) -estratrien-17-one ]; 16/S-OHEi
= 16/3-hydroxyestrone [3,16/3-dihydroxy-l,3,5 (10)-
estratrien-17-one]; i6-ke2 = 16-ketoestradiol-17/3
[3,17/3-dihydroxy-l,3,5(10)-estratrien-16-one]; ring
Da-ketols =16«-OHEi +16/3-OHE! -j-16-KE2; 16-
epiE3 = 16-epiestriol [3,16/3,17/3-trihydroxy-1,3,5
(10) -estratriene ].
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as 16-ketoestradiol) and 16-epiestriol, to¬
gether with that of 2-methoxyestrone.
Materials and Methods
Chemicals. Estradiol-17/3-6,7-3H of specific ac¬
tivity 40 MC/Vg was purchased from Merck,
Sharp & Dohme Ltd. Following celite column
partition (13) the peak tubes were collected
and a portion of the material (551,000 cpm)
was diluted with 30.8 mg of pure unlabeled
estradiol. After crystallization from methanol
the crystals and mother liquor had equal specific
activities of 17,900 cpm/mg, establishing the
radiochemical purity of the material. Acetic
anhydride-l-14C of specific activity 10 nc/mg
was purchased from New England Nuclear
Corp. Unlabeled estrone acetate and estradiol
diacetate for use as carriers were purchased
from Mann Research Laboratories, Inc., New
York. The monoacetate of 2-methoxyestrone
was prepared in the laboratory from free
steroid purchased from Organon Laboratories
Ltd., as was the triacetate of 16-epiestriol. The
triacetate of estriol was prepared in the labora¬
tory using estriol obtained from Parke, Davis &
Co. Acetylation was performed overnight at
room temperature in a pyridine-acetic anhy¬
dride (unlabeled) mixture under anhydrous
conditions. The residue was crystallized several
times from methanol-water mixtures. In all
cases the melting points agreed closely with the
theoretical. Unlabeled 16a-hydroxyestrone,216-
ketoestradiol (Steraloids Inc., Pawling, N.Y.)
and 16/3-hydroxyestrone, prepared by hydroly¬
sis (7) of the diacetate (Southeastern Bio-
chemicals Inc., Morristown, Tenn.), were used
as paper chromatographic standards. Desoxy-
corticosterone, for use as a standard in the
labeled acetylation procedure, was purchased
from Mann Research Laboratories, Inc. All
other reagents and solvents were purified
where necessary by standard procedures.
Injection of Subjects. Four young pregnant
women (LU, SA, SH, IS) between 33 weeks and
term were injected via an arm vein with about
7 /ic of estradiol-6,7-3H in 10 ml of 10% ethanol
in saline. Vials and syringes were washed fol¬
lowing injection and the radioactivity remain¬
ing was measured to correct for losses. This
amounted to less than 2% of the dose. Urine
was collected for 96 hr, pooled from each indi¬
vidual and frozen in polyethylene containers
until required.
2 Donated by Dr. A. E. Kellie, Courtauld Insti¬
tute of Biochemistry, Middlesex Hospital, London,
England.
Extraction and Separation. Suitable aliquots of
the pooled urines (approx j) were incubated
with bacterial /3-glucuronidase (14), the free
estrogens (G fraction) were extracted with
ether, and the residual urine was subjected to
solvolysis (15) to split estrogen sulfates (S
fraction). From this point until otherwise in¬
dicated, G and S fractions were kept separate.
Each was subjected to a modified Girard
separation (13). The nonketonic fraction so
obtained was further purified by partition be¬
tween toluene and n NaOH prior to treatment
of the phenolic extract by reflux with alkali
and re-extraction as described elsewhere (16).
The main components of the ketonic and non¬
ketonic fractions were separated by celite col¬
umn partition chromatography in hexane:
benzene/methanol :H-0 systems (13). The
main nonketonic metabolites, estradiol, 16-
epiestriol and estriol, were in some cases further
purified by thin layer chromatography (17)
prior to acetylation. The column fraction con¬
taining 2-methoxyestrone was further purified
by partition between hexane: benzene (3:1)
and n NaOH with re-extraction from the
aqueous phase following pH adjustment. The
estrone fraction was similarly purified using
toluene and n NaOH. The ring D a-ketolic
fraction was separated into 16/3-hydroxyestrone,
16a-hydroxyestrone and 16-ketoestradiol by
chromatography for 4 days at room temperature
(23 C) on Whatman No. 42 paper against
appropriate standards in the solvent system
toluene:propylene glycol. Under such condi¬
tions these 3 compounds migrate approximately
13, 23 and 35 cm, respectively, from the start¬
ing line. Areas corresponding to each compound
were cut from the chromatograms and eluted
with ethyl acetate. Residual propylene glycol
was removed by water washing and the ethyl
acetate extracts were evaporated. Because of a
lack of crystalline 16«-hydroxyestrone to use
as carrier, the separated ring D a-ketols were
reduced with sodium borohydride to the cor¬
responding isomeric triols (14). In this way
labeled estriol was obtained from urinary 16a-
hydroxyestrone and labeled 16-epiestriol from
16-ketoestradiol, and the triols were purified as
described below.
Acetylation with Acetic Anhydride-l-uC. The
separated estrogen fractions, after drying for
at least 16 hr in a desiccator, were acetylated
overnight in 0.2 ml of anhydrous pyridine with
0.1 ml of acetic anhydride-l-14C diluted with
fresh unlabeled acetic anhydride to give a
specific activity so that the final 3H: 14C ratios
of the acetylated steroids lay between 3 and 10.
The acetylation mixtures were partitioned be-
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Table 1. Pattern of urinary radioactivity (% of injected dose) following chromatography in
pregnant women and males receiving estradiol-6,7-3H
Subjects
Fraction* LU SA SH IS Males f
Gt st G S G S G S G S
2-MeE, 0.3 0.1 0.4 <0.1 0.8 0.3 0.2 <0.1 1.6 0.5
E, 4.1 1.2 3.3 0.3 4.7 0.7 4,1 2.5 8.0 2.0
e2 0.7 0.2 0.7 <0.1 0.6 <0.1 0.6 0.2 3.4 0.4
ring D a-ketols 4.6 1 .4 4.6 0.9 5.5 1.1 7.5 1 .9 6.2 0.6
16-epiE3 1 .4 0.1 1.1 0.2 1.0 0.2 1.0 <0.1 1.4 0.2
E, 9.4 0.6 6.5 0.2 4.5 0.4 4.6 0.3 5.8 0.4
* See footnote 1 for abbreviations.
f Average of 4 experiments (Hobkirk, unpublished observations),
j G =hydrolyzed by ^-glucuronidase; S= split by solvolysis.
tween diethyl ether and weak aqueous acid,
after which the ether extracts were dried and
evaporated. Unlabeled carrier steroid acetates
were added in suitable amount (15 mg upward)
to each fraction and each was crystallized from
methanol-water mixtures until, as far as possi¬
ble, 3H :14C ratios of successive crystals differed
by no more than 10% and until crystals and
corresponding mother liquors showed similar
agreement. The specific activities (cpm/jug) of
the isolated 3H-labeled metabolites were cal¬
culated from the equation:
cpm 3H n M
—
7771 x 77," X SAuoca X —
cpm 14C 103 N
(2)
where n = number of acetyl groups introduced
into the molecule, SAdoca = specific activity
(cpm/mg) of desoxycorticosterone acetate
acetylated by the same sample of acetic anhy-
dride-l-llC and M and N are, respectively, the
molecular weights of DOCA and the free estro¬
gen.
All radioactive counting was performed on a
Nuclear-Chicago Model 6725 liquid scintilla¬
tion spectrometer using the formula of Okita
et al. (18) to calculate the 3H and 1JC counts.
Efficiencies of counting for these 2 isotopes
were, respectively, approximately 25 and 60%.
The phosphor used consisted of toluene con¬
taining 0.3% of 2,5-triphenyloxazole and 0.01%
of l,4-bis-2-(5-phenyloxazolyl)-benzene.
Results
Table 1 contains data on the urinary
radioactivity in the column fractions col¬
lected. The fractions containing estrone,
ring D a-ketols and estriol contained most
of the radioactivity. In most cases some
activity was found in the S fractions but
this was much less than that in the G frac¬
tions. While these urinary patterns should
not be examined too critically, since they
only represent a general picture of radio¬
activity distribution, they are not dissimi¬
lar to those seen following administration
of estradiol-6,7-3H to male subjects (Table
1). Preliminary specific activity measure¬
ments on the column eluates, using the
spectrophotometric Ittrich modification of
the Kober reaction (19) as the means of
weight determination, showed no obvious
difference between G and S fractions for
any one steroid. For further analysis, there¬
fore, G and S fractions were combined for
each compound.
Table 2 shows the result of separation of
the individual components of the ring D a-
ketolic fraction. 16a-Hydroxyestrone was
Table 2. Radioactivity (% of dose) associated
with separated ring D a-ketols from urine of




LU SA SH IS
16/3-OHEi 0.3 .— — —
16«-OHE i 3.7 1 .4 3.3 6.3
16-KE, 1.3 0.9 0.6 1.8
* Each fraction is corrected for a recovery of 70%
during paper chromatography.
t G(/3-glucuronidase hydrolyzable) and S (split
by solvolysis) fractions combined prior to paper
chromatography.
{ See footnote 1 for abbreviations.
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Table 3. Specific activities (cpm/jug) of urinary metabolites of injected estradiol-6,7-3H
in subject LU calculated from successive crystallizations*
Metabolitef Crystals 1 Crystals 2 Crystals 3 Crystals 4 ML 4 Crystals 5 ML 5
2-MeEi 40 47 45
Ei 37 43 43 40
E2 — 46 47 45 — 45 47
16a-OHE i 28 28 29 27 29
16-KEo 31 28 lost 28 26
16-epiEs 24 25 28 28 25
E3 9 8 8 8 8
* Values are based on a dose of 5 X106 cpm and are rounded off to the nearest whole number,
f See footnote 1 for abbreviations.
the major compound present in each case.
In only one experiment was significant ra¬
dioactivity found in the 16/3-hydroxyes-
trone fraction. The results in Table 2 have
been corrected for a known recovery of 70%
of pure 16a-hyd roxyestrone and 16-keto-
estradiol during paper chromatography, so
as to make them more comparable with the
values of the other steroids which had not
been subjected to this process at this stage.
Even this correction, however, did not
invariably result in close agreement with
the radioactivity excreted in the ring D
a-ketolic fraction from the column (Table
1). This may be due to removal of other
labeled metabolites during paper chroma¬
tography.
Tables 3-6 contain data on the specific
activities of the 3H-labeled urinary meta¬
bolites measured by the double isotope
method. The results in each table are cor¬
rected to a common injected dose of 5 XlO6
cpm of estradiol-6,7-:iH and are rounded off
to the nearest whole number. The specific
activity of estriol is much lower than that
of estrone or estradiol, confirming the find¬
ings of others. The three other 16-oxy-
genated metabolites, 16a-hydroxyestrone,
16-ketoestradiol and 16-epiestriol, have
values which are similar to each other and
which resemble those of estrone and estra¬
diol much more closely than they do that of
estriol. The specific activity of 2-methoxy-
estrone was also very different from that of
estriol, although in no case was a mother
liquor obtained which corresponded well
with the crystals.
Discussion
The results obtained in the present work
for estrone, estradiol and estriol are similar
to those reported by others (1, 2). This can




where SA (metab.) = specific activity of the
Table 4. Specific activities (cpm/Vg) of urinary metabolites of injected estradiol-6,7-3H in
subject SA calculated from successive crystallizations*
Metabolitef Crystals 1 Crystals 2 Crystals 3 Crystals 4 ML 4 Crystals 5 ML 5
2-MeE, 24 28 28
Ei 36 37 38 38 36
E2 — 43 48 46 — 48 43
16«-OHEi 24 25 27 24 26
16-KE2 — 31 25 25 25 — —
16-epiEs 22 23 24 22 22
E3 7 7 7 7 7 — —
* Values are based on a dose of 5 X106 cpm and are rounded off to the nearest whole number,
f See footnote 1 for abbreviations.
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Table 5. Specific activities (cpm/Vg) of urinary metabolites of injected estradiol-6,7-!H in
subject SH calculated from successive crystallizations*
Metabolite f Crystals 1 Crystals 2 Crystals 3 Crystals 4 ML 4 Crystals 5 ML 5
2-MeEi 46 50
E, — 58 55 62 — 58 59
E2 (lost) — — — — — — —
16«-OHE i 35 39 38 39 35 — —
16-KE2 — 21 28 27 21 — —
16-epiE3 — 34 33 33 36 — •—-
e3 6 7 6 6 6 — —
* Values are based on a dose of 5 X106 cpm and are rounded off to the nearest whole number,
t See footnote 1 for abbreviations.
3H-labeled metabolite in question and t =
time over which urine was collected. This
expression has been used to calculate the
secretion rate of steroids, although it has
been pointed out that in the complex situa¬
tion associated with pregnancy such a cal¬
culation does not, in fact, provide a true
measure of secretion rate (2). Bearing this
in mind, the "secretion rates" (mg/24 hr)
in the present study are: estrone 19-33,
estradiol 16-27 and estriol 156-208.
The striking difference between the spe¬
cific activities of urinary 16a-hydroxy-
estrone and estriol suggests that the former,
in its endogenous form, is not principally
derived from fetoplacental sources, at least
in late pregnancy. Thus, if it were, one
might expect the specific activities to be
similar. That this is not so might con¬
ceivably relate to a very rapid turnover of
16a-hydroxyestrone within the fetopla¬
cental unit. 16-Ketoestradiol is usually
considered to be a metabolite of estriol in
the human (20), while 16-epiestriol may be
formed from 16/3-hydroxyestrone or by re¬
duction of 16-ketoestradiol (21). On the
basis of our present results, it seems un¬
likely that 16-ketoestradiol and 16-epi¬
estriol arise mainly from fetoplacental
estriol in view of the similarity of their
specific activities to that of 16a-hydroxy-
estrone. It should be pointed out that there
is little evidence at present in favor of
oxidative metabolism of estriol in preg¬
nancy (22, 23).
The results obtained during the present
work suggest that 16a-hydroxyestrone, 16-
ketoestradiol and 16-epiestriol excreted in
the urine in late pregnancy are largely the
result of peripheral metabolism in the ma¬
ternal tissues of secreted estrone and/or
estradiol. However, some part of these may
also be formed in a separate pool (perhaps
as precursors and metabolites of feto¬
placental estriol) to an extent which would
explain the difference in specific activity of
Table 6. Specific activities (cpm/Vg) of urinary metabolites of injected estradiol-6,7-3H in
subject IS calculated from successive crystallizations*
Metabolite f Crystals 1 Crystals 2 Crystals 3 Crystals 4 ML 4 Crystals 5 ML 5
2-MeEi 36 46 41 — — —
E, — 61 61 62 — 65 69
E2 — 65 82 73 — 77 75
16a-OHEi 41 44 42 43 — 44 43
i6-KE2 32 36 36 36 36 — —
16-epiE3 33 36 36 36 39 — —
e3 7 7 7 6 7 — —
* Values are based on a dose of 5 X106 cpm and are rounded off to the nearest whole number,
f See footnote 1 for abbreviations.
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these three metabolites compared with
those of urinary estrone and estradiol.
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SECTION C
METABOLISM/INTERCONVERSION OF FREE OESTROGENS
IN VITRO AND IN VIVO
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. conversion of l6-li'c-estrauiol-17P to
c-labeiled estrioi by avian liver slices
J. E. Mitchell and R. Hobkirk
Department of Metabolism and McGill University Clinic,
The Montreal General Hospital, Montreal.
The generally accepted pathway for estradiol - 17p metabolism as it
involves the three classical estrogens is :
estradiol< ■ > estrone —estrioi.
The conversion of estradiol to estrioi is well established in vivo, this
being an apparently irreversible reaction (Stimmel, 19ii7; Stealy and
Stimmel, 19b8). It is only recently that this transformation has been
reported to occur in vitro, the tissues employed being human fetal liver
(Engel et al, 1958) and rat liver (Hagopian and Levy, 1958). This
conversion of estradiol is apparently of more than academic importance
since it has been shown to proceed to a greater extent than normal in human
males with prostatic cancer (May and Stimmel, 19lt8) and myocardial
infarction (Bauld et al, 1957).
Certain evidence has accumulated in favour of the existence of an
additional biosynthetic pathway for estrioi involving neither estrone nor
estradiol (Brown, 1957; Ryan, 1958)* Besides these observations, interest
in estrioi has arisen from its apparent nonoccurrence in a number of
mammalian species. This is of particular interest in the rabbit which
does not exhibit spontaneous atherosclerosis.
In view of the finding of estrioi in avian excreta (Hurst, 1957)
and also in ovarian extracts from the laying hen (Layne and Common, 1958)
it seemed that in vitro experiments on hepatic tissue from such a source
might yield significant results.
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Experiments and Results
Slices of liver (5>00 mp.) obtained from a laying hen were incubated
with LiO jug. of 16-lkc-estradicl-r/p (2.7 ^uc./mg.) in £ ml. of Krebs-
Ringer-Phosphate solution, pH 7.1|, for 2 hours at 37° with shaking. After
incubation 1 mg. of pure unlabelled estriol was added as carrier.
Following the preparation of a lipid extract a ^-transfer distribution
in C5H5/H2O was performed with single withdrawal, and subsequent saponification
of the estriol-containing aqueous phase. Part of this material was
subjected to paper chromatography in the system CgHgrC^H^CltlVCH^OHr^O^:.!)
followed by radioautopraphy. This showed all of the radioactivity to be
associated with a spot of the same chromatographic mobility as pure estriol.
A second portion of the aqueous extract was subjected to a 2h-transfer
countercurrent distribution in CTICI3tCCl^(Ij :l)/CH^0H:H20^7:3) yielding
a curve for radioactivity which corresponded in position to that of the
















Fig. 1. 2li-Transfer countercurrent distribution in 70^ CH^OH/CHOl^sCCljj
(J;:l) of carrier estriol (open circles) and the radioactive
product obtained after incubating 16-"1' C-estradiol - 17P
with avian liver (triangles). The broken line represents the
theoretical distribution curve.
had a specific activity of 9,P00 counts/min./mg. at this stage. The
remainder of the material was chromatographed on paper in CHCiy'HCONf^
against pure estriol as standard. Elution of the estriol-c.ontaining zone
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was followed by chromatography on a celite partition column (Bauld, 1956)
in ClO^CI^Cl/CHjOHtHgO. The resulting estriol had a specific activity
of 10,000 counts/nin./ng. Part of this was methylated to yield the methyl
ether derivative which was subsequently partitioned in C^H^/HpO. The
organic extract, when chromatographed on alumina (Brown, 1955) yielded
estriol methyl ether of specific activity °,800 counts/min./mg.
Comment
The data outlined above constitutes good evidence for the conversion
of estr: diol - 17|! to estriol by avian liver, thus indicating that some,
at least, of the estriol associated with avian metabolism probably arises
by this route, The extent of the conversion found here was approximately 6%,
One of us (.!, K. M.) is the Lawrence de Coteau Research Fellow, Department
of Metabolism, The Montreal General Hospital, This work was also supported
in part by National Research Council of Canada Grant Mo, MT 532, and by
a grant from Parke, Davis and Co.
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Interconversion of 16-Epioestriol and Oestriol by Avian Liver
Tissue in vitro
By H. R. RAUD and R. HOBKIRK
University Medical Clinic, The Montreal General Hospital, Montreal, Quebec, Canada
(Received 3 October 1966)
1. [16-14C]16-Epioestriol and [6,7-3H2]oestriol were incubated both simul¬
taneously and separately at 40° with hen liver homogenates obtained from birds
in the laying stage. 2. Purification and identification of products was made by
ether extraction, Girard separation, Celite partition and paper chromatography
and crystallization to constant specific activity both with and without derivative
formation. Percentage conversions of the radioactive 16-epioestriol and oestriol
were calculated from these specific activities. 3. Oestriol yielded 16-epioestriol as
early as 5min. after exposure of steroid to the tissue. No production of oestriol
from 16-epioestriol was detectable in this time. 4. Considerablymore 16-epioestriol
was formed from oestriol than oestriol by the reverse reaction after 90min. of
incubation. 5. 16-Oxo-oestradiol-17j8 appeared in all cases to be the major
identified intermediate in the interconversion of 16-epioestriol and oestriol.
The endogenous metabolic pattern of steroidal
hormones of the more common test animals has
not been well defined. One species, however, about
which considerable information has been made
available in recent years is the fowl. It is remark¬
able that the laying hen possesses an oestrogen
pattern which qualitatively bears a very strong
resemblance to that of the human. Thus Ainsworth,
Carter & Common (1962), on intravenous adminis¬
tration of [16-14C]oestrone (3-hydroxy[16-14C]-
oestra-l,3,5-trien-17-one) to a laying hen recog¬
nized, ehromatographically, radioactive oestradiol-
17/3 (oestra - 1,3,5 - triene - 3,17/3 - diol), oestriol
(oestra-l,3,5-triene-3,16oc,17/3-triol) and oestrone
in the urine. Other radioactive metabolites
detected were 16-epioestriol (oestra-l,3,5-triene-
3,16/3,17/3-triol), 17-epioestriol (oestra-l,3,5-triene-
3,16a,17a-triol), 16-oxo-oestradiol-17/3 (3,17/3-di-
hydroxyoestra -1,3,5 -trien -16 - one) and 16-oxo-
oestrone (3 - hydroxyoestra -1,3,5 - triene -16,17 -
dione). Previously MacRae, Dale & Common (1960)
had demonstrated the conversion of [16-14C]-
oestriol into radioactive 16-oxo-ocstradiol-17/3 and
16-epioestriol in laying hens. No additional radio¬
active conversion product was detected in the
urine. Although the above compounds were
identified from chromatographic evidence, oestrone
(Ainsworth & Common, 1962), oestradiol-17/3
(MacRae, Zaharia & Common, 1959) and 16-
epioestriol (Hertelendy & Common, 1964) have
also been fully characterized in crystalline form
from hen urine or faeces or both. No oestriol has,
however, been isolated.
Intravenous injection of labelled oestradiol-17/3
into the laying bird resulted in a radioactive
oestriol/16-epioestriol ratio in excreta which was
considerably lower than that found in human urine,
where oestriol is a major metabolite (MacRae &
Common, 1960; Marrian & Bauld, 1955; Hobkirk,
Nilsen & Purre, 1966). After intravenous adminis¬
tration of 16-oxo[16-14C]oestradiol-17j8 to the non-
laying fowl, Ainsworth & Common (1963) identified
only radioactive 16-oxo-ocstradiol-17/3 and 16-
epioestriol in the urine. This again suggested the
equilibrium conditions in the hen to be such that
16-epioestriol is formed at the expense of oestriol.
On the other hand, Mitchell & Hobkirk (1959)
demonstrated a significant conversion of radio¬
active oestradiol-17/3 into labelled oestriol by hen
liver slices in vitro. Recently Ozon & Breuer (1965),
by incubating 16-oxo-oestradiol-17j8 with liver
slices from chicks of 10-20 days ofage and immature
pullets, have shown both 16-epioestriol and oestriol
to be formed in the ratio 3:2 in favour of the
former metabolite. They also demonstrated oestriol
to be an incubation product of 16a-hydroxyoestrone
(3,16a-dihydroxyoestra-l,3,5-trien-17-one) and of
oestradiol-17/3.
To obtain a more complete understanding of the
interconversion of oestriol and 16-epioestriol in
vitro, these two compounds, in radioactive form,
have been incubated with liver preparations from
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NAD, NADP and glucose 6-phosphate were purchased
from Nutritional Biochemieals Corp., Cleveland, Ohio,
U.S.A. ATP was obtained as the disodium salt from Sigma
Chemical Co., St Louis, Mo., U.S.A. 16-Oxo-oestradiol-17j3
was acquired from Steraloids Inc., Pawling, N.Y., U.S.A.
16-Epioestriol was purchased from Organon Inc., W.
Orange, N.J., U.S.A., and oestriol was a gift from Parke,
Davis and Co., Ann Arbor, Mich., U.S.A. Dr A. E. Kellie
of the Courtauld Institute of Biochemistry, The Middlesex
Hospital, London, W. 1, donated the 16a-hydroxyoestrone.
[16-14C]16-Epioestriol was prepared by chemical reduc¬
tion of 16-oxo[16-14C]oestradiol-17)3 of specific activity
0-04p.c/pg. as described by Hobkirk (1963). Successive
crystallizations with authentic carrier steroid of a sample
of the material eluted from a Celite partition column
showed it to be 99% [16-14C]16-epioestriol. It was used
without further purification. The 16-oxo[16-l4C]oestradiol-
17y3 was donated by Dr M. Levitz, New York University,
New York, N.Y., U.S.A. [6,7-3H2]Oestriol of specific
activity 52pC/pg., purchased from New England Nuclear
Corp., Boston, Mass., U.S.A., was purified by column
partition chromatography and shown to be at least 98%
pure by crystallization with pure unlabelled oestriol.
All other reagents were of suitable chemical grade and
were purified where necessary by published techniques
(Givner, Bauld & Vagi, 1960). Final distillation of organic
solvents was done in all-glass apparatus and these solvents
were stored in brown glass bottles.
Celite 535 (Johns-Manville Corp. New York, N.Y.,
U.S.A.) was purified, prepared and tested as described by
Bauld & Greenway (1957).
Methods
Assay of radioactivity. All measurement of radioactivity
was performed by liquid-scintillation spectrometry in a
Nuclear-Chicago Corp. no. 6725 dual-channel instrument
operating at an efficiency of 66% and 33% for 14C and 3H
respectively. In double-label counting less than 1% of 3H
appeared in the 14C channel while approx. 15% of 14C
appeared in the 3H channel. The radioactivity for all
samples was determined to within 5% probable error. The
material to be counted was dried in glass counting vials
and dissolved in 0-2ml. of methanol before dilution with
10ml. of toluene containing 0-3% of 2,5-diphenyIoxazole
and 0-01% of l,4-bis-(5-phenyloxazol-2-yl)benzene. Calcu¬
lation of 14C and 3H from double-labelled samples was
done according to the method ofOkita, Kabara, Richardson
& LeRoy (1957).
Preparation of homogenate. This was carried out as
partially described by Mitchell & Hobkirk (1959) and Lucis
(1965). Livers from White Rock hens, in the laying period
at the time of decapitation, were excised, rinsed free of
blood, weighed and immediately used. Krebs-Ringer
phosphate solution, pH7'4 (Krebs & Henseleit, 1932),
modified to contain K2HPO4 (0-1 m) rather than Na2HPC>4
(0-1 m) and fortified with 0-04M-nicotinamide, was used in
the proportion of Iml./lOOmg. wet wt. of whole liver
tissue. The tissue was homogenized for 30 sec. in a VirTis
45 homogenizer.
Simultaneous incubation of 14C- and 3H-labelled substrates.
To a series of 20ml. liquid-scintillation spectrometer vials
(Nuclear-Chicago Corp., Toronto, Canada) were added
9-1 xlO5 counts/min. of [6,7-3H2]oestriol and 9-9 xlO5
counts/min. of [16-14C]16-epioestriol in methanol. In each
case an appropriate amount of unlabelled pure standard
steroid, also dissolved in methanol, was added to give a
final weight of 50pg. of each substrate. Propylene glycol
(0-1ml.) was added to each vial and the methanol com¬
pletely evaporated in a gentle stream of air. In addition
to the substrates, cofactors were added as follows: NAD
(2-3pmoles), NADP (2pmoles), glucose 6-phosphate
(15pmoles), ATP (lOpmoles) and MgCI2 (279/rmoles).
To each of the vials was added 5ml. of the above liver
homogenate and incubation was carried out at 40° in an
atmosphere of O2+ CO2 (95:5) with regular mechanical
agitation in a Dubnoff metabolic incubator. Times of
incubation varied from 5 to 90min. Blanks were identical
except for boiling of the homogenate for 20min. before
addition to the incubation mixture.
Extraction of free radioactive material from the incubation
mixture. After incubation, 100pg. each of unlabelled
oestriol, 16-epioestriol, 16-oxo-oestradiol-17^ and 16a-
hydroxyoestrone were added to the incubation medium as
carriers. Simultaneously the protein of the mixture was
precipitated by the addition of 50ml. of acetone. The
mixture was kept overnight at room temperature (24°) to
complete the extraction. The acetone was removed by
filtration (Whatman no. 31 filter paper) and the tissue
residue rinsed with additional acetone (four 40ml. portions).
The washings and acetone extract were combined with
50ml. of distilled water and the acetone was evaporated
under reduced pressure. The aqueous residue was then
extracted with peroxide-free ether (four 60ml. portions).
The ether was evaporated off and the extracts were further
dried by placing over anhydrous CaCl2 in a vacuum
desiccator overnight. The aqueous portions of each sample
were stored for later extraction of conjugated material.
Purification and characterization of the radioactive incuba¬
tion products. The dried ether extracts were subjected to
a modified Girard separation for 18hr. at room temperature
(24°) as described by Givner et at. (1960). The ketonic
and non-ketonic fractions, after ether extraction, were
evaporated to dryness, dissolved in methanol and a
sample (one-hundredth) from each was reserved for assay
of radioactivity. The remaining material was chromato-
graphed on Celite partition columns according to the
method of Givner et al. (1960). This resulted in the separa¬
tion of fractions containing oestriol, 16-epioestriol and
ring-d a-ketolic oestrogens. [The last fraction would
consist of any 16a-hydroxyoestrone, 16/3-hydroxyoestrone
(3,16/S-dihydroxyoestra-l,3,5-trien-17-one) and 16-oxo-
oestradiol-17/3 formed during incubation.] Radioactive
eluates corresponding to each of these chromatographic
fractions were evaporated to dryness and redissolved in
methanol (3-0ml.). One-tenth of each was retained for
counting. A larger sample (two-thirds) was taken for
further purification and identification.
Successive crystallization of radioactive 16-epioestriol and
oestriol. The eluates obtained from the partition columns
were submitted to a final step for the achievement of radio¬
chemical purity. Pure crystalline unlabelled carrier of the
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appropriate type was added to all 16-epioestriol and
oestriol fractions and the mixtures were acetylated in
pyridine and acetic anhydride overnight. The samples were
successively crystallized several times from methanol-
water. The specific activities of the crystals (approx. lmg.
accurately weighed was counted in each case) became
constant and equal to that of the mother liquor on the
second crystallization.
Characterization of the radioactive ring-D a-ketolic fraction.
The ring-D a-ketols were examined by descending paper
chromatography in a toluene-propylene glycol solvent
system at 24° (Hobkirk et al. 1966). Whatman no. 42 paper
was impregnated with propylene glycol-methanol (1:1,
v/v), blotted to remove excess of solvent and dried in air
sufficiently long to remove methanol before chromato¬
graphy. The ring-D a-ketolic fraction from the Celite
column was applied to the starting line with small volumes
of methanol along with pure 16a-hydroxyoestrone (40pg.)
and 16-oxo-oestradiol-17jS (40 fig.) as standards. The paper
was developed for 4 days (overflow collected) in a jar
previously saturated with toluene for 24 hr. Radioactive
areas corresponding to standards were eluted with methanol
overnight. The eluates were filtered through sintered glass,
evaporated and redissolved in methanol (4-0ml.). One-
tenth was retained for counting. The remaining nine-tenths
of the radioactive fractions eluted from the paper was
transferred to centrifuge tubes and crystallized with pure
unlabelled carrier from acetonitrile as described by Levitz,
Oestriol
(9-1 x 105 counts/min.) +
16-Epioestriol
(9-9 x 105 counts/min.)
(3H: 100%) (14C: 100%)
Incubation for 90 min. at 40 °;
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Oestriol
(3H: 33%; "C: 10%)
16-Oxo-oestradiol-17j8







Scheme 1. Typical distribution of radioactivity during different stages ofextraction and purification of incubation
products. An example from a [16-14C]16-epioestriol+[6,7-3H2]oestriol experiment after 90min. incubation is
shown (see the Methods section). Figures are given as percentages of incubated radioactivity.
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Spitzer & Twombly (1956). The crystals were of constant
specific activity and equal to that of the mother liquor on
the second recrystallization. From the specific activities
thus obtained and knowing the weights of carrier used,
percentage conversions of the [6,7-3H2]oestriol and [16-14Cj-
16-epioestriol were calculated.
Extraction of possible conjugates. Although conjugation
in itself was not of major interest, the residual aqueous
fraction after ether extraction of free radioactivity was
treated as follows. The water fraction was gently heated
to remove any ether, cooled, 3M-NaCl added and the pH
adjusted to 2. After extraction with 3 vol. of ethyl acetate
(Burstein & Lieberman, 1958) the extracts were dried over
NaaS04 and evaporated in vacuo. The dry residue was
dissolved in methanol (5-0ml.) and a sample removed for
assay of radioactivity. The degree of 'conjugation' in this
tissue system was so low (0-5-2-0% of incubated substrate)
that extraction of this fraction was dispensed with in later
experiments.
Additional incubations. Confirmation of results obtained
from the experiment outlined above was sought by carrying
out further incubations with only a single substrate in any
one experiment and additional times of incubation. Two
series of incubations of this type were done. In the first of
these 1-0 x 106 counts/min. of [6,7-3H2]oestriol plus 50/tg.
of unlabelled oestriol were incubated for 1, 5, 30 and 90min.
Secondly, 8-6 xlO5 counts/min. of [16-14C]16-epioestriol
plus 50 fig. of unlabelled 16-epioestriol were incubated for
90min. only. Suitable blanks were carried out in each
case. All other experimental details were identical with
those of the double-labelled study described above. The
three series of experiments outlined were performed on
different occasions with livers excised from three individual
birds. In all cases duplicate incubations were performed at
each different incubation time.
RESULTS
The distribution of radioactivity obtained in a
typical double-labelled experiment is shown in
Scheme 1. Significant amounts of activity were
associated with the 16-epioestriol, oestriol and
ring-D a-ketolic fractions. As shown in Table 1,
virtually all of the radioactivity in the two triol
fractions remained associated with the carriers
during crystallization. However, on subfractiona-
tion of the ring-D a-ketolic fraction, in no case was
radioactivity found in the position of 16a-hydroxy-
oestrone or 16jS-hydroxyoestrone. In all experi¬
ments, 16-oxo-oestradiol-17 /3 eluted from ehromato-
grams and crystallized as typified by Table 1 was
the main metabolite. It accounted for 61-79% of
the total 3H of the ring-D a-ketolic fraction after
[6,7-3H2]oestriol incubation at various times and
65-100% of the ketolic 14C when [16-14C]16-
epioestriol was the substrate. The rest of the
radioactivity remained on the starting line of the
chromatograms and was not further investigated.
Table 2 indicates that oestriol may be metabolized
to 16-epioestriol very rapidly. In the first 5min. of
incubation (Expt. A) 15-9-17-5% of the oestriol
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30 and 90min. incubation periods the amount of
16-epioestriol had decreased but still remained
significantly high. This decrease was not repro¬
ducible on repetition of the study with liver tissue
obtained from another bird. Nevertheless, 5-2-
6-2% of 16-epioestriol was again formed after 5min.
of exposure of oestriol to the tissue (Table 2,
Expt. B). After 90min. of incubation 19-5% of
oestriol had been metabolized to the epimer. In
all cases a decrease in the percentage recovery of
unchanged oestriol accompanied increased 16-
epioestriol production. Material identified as 16-
oxo-oestrad iol -17/3 derived from oestriol also
increased with enhanced 16-epioestriol formation.
When 16-epioestriol was the substrate (Table 3),
duplicate 5min. incubations yielded no detectable
oestriol. Considerable conversion (8-1-8-6%)
occurred at 90min., however. A repeat of this
experiment on another occasion with a new liver
preparation again yielded oestriol (Table 3, Expt.
C), but less in this case (2-7-3-1% at 90min.). It is
noteworthy that 16-oxo-oestradiol-17j3 appeared
Table 2. Percentage conversion of [<5,1 -s~H.2\oestriol into labelled 16-epioestriol and
16-oxo-oestradiol-ll/3 at various times of incubation
Incubation, extraction and purification of products were performed as described in the text. The percentage
of substrate converted and unchanged was calculated from the product of the specific activity of crystals 2 (cf.
Table 1) and the weight of carrier (20mg.) added. Expts. A and B designate separate incubations with livers
from different laying hens; (1) and (2) represent duplicate incubations of the same preparation.
Time of Conversion into Conversion into Unchanged
incubation 16-epioestriol 16-oxo-oestradiol-17j3 substrate
Expt. no. (min.) (%) (%) (%)
A (1) 1 1-7 0-06 31-9
(2) 1 2-5 0-07 33-0
A (1) 5 17-5 0-10 17-7
(2) 5 15-9 0-09 18-1
A (1) 30 5-6 — —
(2) 30 6-0 — —
A (1) 90 8-1 1-2 9-4
(2) 90 8-3 1-4 9-8
A (1) Blank 2-2 0-04 40-2
(2) Blank 2-6 0-06 32-9
B (1) 5 6-2 0-14 56-6
(2) 5 5-2 0-12 57-0
B (1) 90 19-5 0-82 30-3
(2) 90 19-5 0-84 28-9
B (1) Blank 1-7 0-01 52-8
(2) Blank 2-2 0-02 53-2
Table 3. Percentage conversion of [l<5-1AC\\<5-epioestriol into labelled oestriol and
16-oxo-oestradiol-ll)2 at various times of incubation
Incubation was performed for 5 and 90min. only. All other details are as given in Table 2. Expts. B and C
designate separate incubations with livers from different laying hens; (1) and (2) represent duplicate incubations
of the same preparation.
Time of Conversion into Conversion into Unchanged
incubation oestriol 16-oxo-oestradiol-17)3 substrate
Expt. no. (min.) (%) (%) (%)
B (1) 5 0 0-35 79-5
(2) 5 0 0-40 69-9
B (1) 90 8-1 1-2 41-2
(2) 90 8-6 1-4 40-1
B (1) Blank 0 0-02 71-3
(2) Blank 0 0-03 72-2
C (1) 90 2-7 — 39-4
(2) 90 3-1 9-3 43-0
C (1) Blank 0 0-15 50-0
(2) Blank 0 0-21 53-2
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quantitatively related to increased product forma¬
tion onee more, with one exception. 16-Epioestriol
incubation at 90min. with tissue from one bird
resulted in 1-2-1-4% 16-oxo-oestradio!-17/3 forma¬
tion. Tissue obtained from another bird, however,
yielded 9-3% of the ketol under the same conditions.
As product identification was of primary interest
in this work such discrepancies between liver
activites of different birds were not too disturbing.
It is noted that consistently higher amounts of
16-oxo-oestradiol-17/3 were recovered when 16-
epioestriol was metabolized to oestriol than during
the reverse reaction. Also, it appears that a larger
fraction of the ring-D a-ketolic compounds was
identifiable as 16-oxo-oestradiol-17/3 when 16-
epioestriol was the substrate than on oestriol
incubation. Oestriol appeared to yield a larger
percentage of more polar unidentified material in
this fraction.
DISCUSSION
The above findings in relation to the inter-
conversion of oestriol and 16-epioestriol by liver
homogenates from the laying hen supplement in
part the studies in vivo ofMacRae et al. (1960) and
Ainsworth & Common (1963). Asmentioned above,
these authors showed 16-epioestriol to be the major
triol excreted by the fowl whereas oestriol was
either scarce or undetectable.
Considerably more 16-epioestriol was formed in
vitro from oestriol than oestriol by the reverse
reaction, at least under the experimental conditions
employed. Further, the 16a-to-16/3 epimerizing
systems appeared to be more rapid-acting, con¬
verting oestriol into 16-epioestriol almost immedi¬
ately on contact of substrate and tissue. The 16/8-
to-16a epimerization did not appear nearly so
active. This evidence in vitro appears to be in
agreement with the results of Common and co¬
workers. These authors, however, did not detect
any oestriol formation from 16-epioestriol in vivo.
Thepresentwork has shown this pathway to exist in
vitro. We have also shown that 16-oxo-oestradiol-
17/3 appears in all cases to be the major identified
intermediate in oestrogen triol interconversion, a
fact that has partially been borne out by Ozon &
Breuer (1965) on incubation of 16-oxo-oestradiol-
17(8 by hen livers and isolation of both epimers.
It should be indicated that recovery of radio¬
activity in these experiments never reached 100%.
Blank values in Tables 2 and 3 indicate cases where
only 50% or less of the material incubated was
extractable in unchanged form. Such a low
recovery may have resulted from the cumulative
effect of tissue binding, experimental loss at
different stages of purification and other factors
resulting in underestimation of the degree of
metabolism.
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In conclusion, it must be stated that up to the
present time only a few tissues in a limited number
of species have been shown to metabolize oestrogen
triols to a significant degree. King (1960) indicated
phenolic triol interconversion by rat kidney
preparations. Hobkirk, Nilsen & Belenkie (1965)
have demonstrated the dehydrogenation of oestriol
to 16-oxo-oestradiol-17j8 by cat erythrocytes and
considerable dehydrogenation of 16-epioestriol by
rat erythrocytes. The latter has also been reported
by Portius & Repke (1960). The results of the
present work now show that homogenates prepared
from the livers of laying hens are also capable of
effecting such conversions.
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Reduction of 16-Ketoestradiol-17|$ 16-l4C by Mammalian Blood*
D. Trachewsky and R. Hobkirk
From University Medical Clinic, The Montreal General Hospital, Montreal 25, Canada
(Received for publication, May 21, 1964)
Reduction of the ketonic group of lG-ketoestradiol-l?/!1 by
mammalian erythrocytes in vitro has been reported by two groups
of investigators. Breuer (1), employing human red cells, showed
the reduction product to be 16-epiestriol (16/3 reduction) in a
yield of 0.8%. Portius and Repke (2) also found 16-epiestriol
to be the transformation product when erythrocytes of human,
rat, and bovine origin were used. A preliminary report from our
laboratory (3) dealt with an apparent species difference in this
reduction, the major product being estriol (16a reduction) in
cat erythrocytes and, in agreement with the other investigators,
16-epiestriol in rat cells. This paper represents an extension of
aur preliminary work.
experimental procedure
Materials—All chemical reagents and organic solvents were of
good reagent grade and were purified where necessary by previ-
Dusly published procedures (4-6). 16-Ketoestradiol-17/3 16-I4C
ivas synthesized by Levitz and Spitzer (7) and was chromato-
graphed on Celite partition columns and paper to yield material
if at least 98% purity.
Whole blood (heparinized) was obtained from cat, cow, dog,
ruman, pig, rat (Wistar), and sheep. In each case, females were
jhosen, but no consideration was given to gonadal function.
Methods—Whole blood, plasma, erythrocytes, or leukocyte
iuspensions were incubated in Erlenmeyer flasks with labeled
iubstrate dissolved in 1 to 2 drops of propylene glycol for 30
ninutes or 2 hours in a Dubnoff shaking incubator at 37°. The
;as phase was 95% 0-2-5% C02 or 100% 02.
Where radioactivity was to be measured in plasma and eryth-
ocytes separately following whole blood incubation, the sepa-
ated plasma was extracted 3 times each with 1 volume of diethyl
ither, and the washed red cells were hemolyzed with ether-
thanol (3:1). Where identification of metabolites was to be
nade, the incubation was terminated by adding 5 to 10 volumes
if acetone-ethanol (1:1), and the mixture was allowed to stand
ivernight at 4°. The supernatant and washings of the pre-
ipitated residue were combined, the volatile solvent was removed
mder reduced pressure, and the residual aqueous phase, after
lilution with water to 50 or 100 ml, was extracted with ether as
lefore. These extracts were washed with m sodium bicarbonate,
hen with water, and dried over anhydrous sodium sulfate before
ieing evaporated to dryness. The residue was partitioned once
* Supported by the Banting Research Foundation. Part of
his work was submitted by Daniel Trachewsky as a thesis in
>artial fulfillment of the degree of Master of Science in the De-
artment of Biochemistry, McGill University, Montreal.
1 The trivial names used in the text and their systematic coun-
erparts are: lG-ketoestradiol-17/3, 3,17/3-dihydroxyestra-l,3,
(10) -trien-16-one; estriol, 3,16a, 17/3-trihydroxy-estra-1,3,5 (10) -
riene; 16-epiestriol, 3,16/3,17/3-trihydroxy-estra-l,3,5(10)-triene.
between 90% methanol and hexane (Experiment B). The 90%
methanol fraction, or the total ether-extractable residue (Experi¬
ment A), was subjected to a modified Girard separation (6), and
the nonketonic fraction was purified by alkaline treatment (8).
Estriol and 16-epiestriol fractions were separated out of the
nonketonic material by Celite column partition (6). In Experi¬
ment A, these two fractions were each partitioned between
benzene and water to exclude contamination of one compound
by the other. For further identification, the estriol fractions
were diluted with milligram amounts of carrier estriol followed
by crystallization before and after acetylation or methylation
(4). 16-Epiestriol fractions were diluted with smaller amounts of
carrier and purified by crystallization, methylation, acetonide
formation (9), and chromatography on a 15-cm Celite column in
the solvent system ethylene dichloride-80% methanol. Weight
of 16-epiestriol was determined by the Ittrich spectrophotometry
procedure (10) with tetrachloroethane as solvent.
In all of the study except Experiment B, radioactivity of
plated samples was measured in the Geiger region with a Nuclear-
Chicago model D-47 gas flow counting tube with thin end win¬
dow. Efficiency of counting for 14C was 19%. Correction for
self-absorption was made, where necessary, by the method of
Engel et at. (11). In Experiment B, a Packard Tri-Carb model
314AX liquid scintillation spectrometer, operating at an efficiency
of 70% for 14C, was employed. The material to be counted was
dissolved in 0.1 ml of methanol and diluted with 5 ml of toluene
containing 0.3% of 2,5-triphenyloxazole and 0.01% of 1,4-bis-
2'- (5 '-phenyloxazolyl)benzene.
A sufficient number of counts were accumulated for each
sample to ensure a counting error of less than 5%.
results
Distribution of Radioactivity in Blood—Table I shows the
distribution of radioactivity following incubation of the substrate
with whole blood from seven species. The larger part of this
activity was always found in the plasma, most of it being ether-
extractable. Only small amounts were to be found associated
with the erythrocytes. The largest degree of substrate reduction
occurred in blood from rat, cat, and sheep. Preliminary thin
layer chromatography (12), followed by elution and radioactivity
measurement of zones corresponding in mobility to those of
estriol and 16-epiestriol, showed that, with the exception of cat
blood, the main (or only) reduction product was 16-epiestriol.
Of the more easily accessible blood types, those of the cat and
the rat represented the greatest extremes in the ratio 16a: 16/3
reduction products.
Site of Reduction—Incubation of the labeled substrate with
plasma, leukocyte suspension, and erythrocyte suspension in
blood from the rat and the cat showed the reductive activity to
3683
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Table I
Distribution of radioactivity in blood after incubation with 16-ketoestradiol-17(i 16-lfC




Plasma ether extract Plasma residue Erythrocytes
c.p.m. X 10~' % original NK:K* c.p.m. X 10~' % original c.p.m. X 10~' % original NK:K
Cat 4.64 46.4 3.0 1.09 10.9 0.52 5.2 10.4
Cow 5.86 58.6 0.07 2.15 21.5 0.10 1.0 0.3
Dog 4.71 47.1 0.06 2.72 27.2 0.56 5.6 0.05
Human 5.00 50.0 0.26 2.25 22.5 0.33 3.3 0.16
Pig 5.64 56.4 0.26 1.64 16.4 0.19 1.9 0.56
Hal 7.39 73.9 5.5 1.63 16.3 0.13 1.3 0.84
Sheep 6.28 62.8 7.5 1.69 16.9 0.16 1.6 5.7
Average 56.5 18.8 2.8 (total = 78%)
* NK:K = ratio of nonketonic to ketonic counts.
I
Table II
Distribution of radioactivity following incubation of 16-hetoestradiol-17fi 16-liC with whole blood
Experiment Species Blood volume Incubated substrate
Recovered radioactivity
Ether-soluble Ketonic Nonketonic
ml eg c.p.m. X 10 ' c.p.m. X 10 4 % original c.p.m. X 10~4 c.p.m. X 10~' % original
Saline blank 3.6 5.84 5.80 99.3 4.20 0.140 2.4
A Cat 35 3.6 5.84 5.19 88.9 1.50 2.655 45.5
A Hat 20 3.6 5.84 4.95 84.8 0.675 3.815 65.4
B Cat 15 0.3 1.31 1.025 78.0 0.111 0.795 60.7
B Rat 15 0.3 1.31 1.025 78.0 0.048 0.965 73.6
Table III
Purification of estriol (cat) and 16-epiestriol (rat) in Experiment A
All crystallizations were done from methanol. Specific activi¬
ties of the methyl ethers were calculated in terms of weight of free
estrogen.

































be associated with the latter fraction. Packed red cells, 2.5 to
3.0 ml in an equal volume of 0.9% NaCl solution, reduced the
substrate to the extent of 25% and 50% in cat and rat, respec¬
tively. The degree of reduction was found to be approximately
as great after 30 minutes of incubation as after 2 hours.
Experiments A and B
The amounts of blood and substrate incubated, and the dis¬
tribution of radioactivity following the initial fractionation, are
shown in Table II. The apparent reduction was considerable in
both experiments.
Purification of Products
Experiment A—After benzene-water partition of the extract
from cat blood, 8500 c.p.m. were found in the aqueous phase.
Of this activity, 7500 c.p.m. were diluted with carrier estriol and
purified as shown in Table III. With the final specific activity
taken to be 440 c.p.m. per mg, the apparent conversion to estriol
following benzene-water treatment, and neglecting losses oc¬
curring prior to this step, was calculated to be 13%. The radio-^
activity in the 16-epiestriol fraction from the same experiment
amounted to 1700 c.p.m., 1540 c.p.m. of which were diluted with
1.33 mg of carrier 16-epiestriol. Following two crystallizations
from methanol, the specific activity fell from an initial value of
1160 c.p.m. per mg to 45 c.p.m. per mg. Thus, if any conversion
to this compound occurred, it was extremely slight.
In the rat blood experiment, 26,000 c.p.m. were associated with
the 16-epiestriol fraction following benzene-water partition.
Dilution of 13,000 c.p.m. with carrier 16-epiestriol was followed
by purification as shown in Table III. If the specific activity of
the purified material is taken to be 14.5 c.p.m. per pg, it can be
calculated that at the stage of benzene-water partition the con¬
version was 42%. The radioactivity associated with the estriol
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fraction amounted to only 1,000 c.p.m. This, and similar frac¬
tions from separate experiments were combined giving 2,185
c.p.m. and diluted with 5.99 mg of carrier estriol. After three
crystallizations from methanol, the specific activity of the
crystals fell from 365 c.p.m. per mg to 55 c.p.m. per mg. This
excluded the possibility of considerable substrate conversion to
estriol.
Experiment B—Fig. 1 shows the pattern of radioactivity and
3 000
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Estriol (cat) 16-Epiestriol (rat)




Celite column pool 144 Celite column pool + 110 55.6
-+- 15.22 mg of Mg of carrier; added be¬
carrier fore Girard
Crystals 110 Acetonidation, re-extrac¬ 51.4
Mother liquor 130 tion, hydrolysis (9)
Acetylation with Celite column, ethylene 54.7*
acetic anhy¬ dichloride-80% metha¬
dride and py¬ nol
ridine
Crystals 1 118
Mother liquor 1 116
Crystals 2 118
Mother liquor 2 119






Fig. 1. Celite column chromatography of the nonketonic
fraction from cat blood; Experiment B. The stationary phase
was 70% methanol and the mobile phase benzene. X X,
counts per minute; O O, weight. S.A., specific activity;
16-epiEa, l<?-epiestriol; E-t, estriol. Fractions of 3 ml each were
collected.
Table IV
Purification of estriol (cat) and 16-epieslriol (rat) in Experiment B
Crystallization of free estrogens was done from methanol and
of acetates from methanol-water. Specific activities of the ace¬
tates were calculated in terms of the free estrogen.
o 8 * * 16 * *24 32 40 48
Fraction No.
Fig. 2. Celite column chromatography of the nonketonic
fraction from rat blood; Experiment B. The stationary phase
was 70% methanol and the mobile phase benzene. X X,
counts per minute; O O, weight. 16-epiEa, 16-epiestriol;
E3, estriol. Fractions of 4 ml each were collected.
weight following the chromatographic separation of 16-epiestriol
(116 pg of carrier added prior to Girard separation) and estriol
(50 pg of carrier added prior to Girard separation) from the non¬
ketonic fraction of the cat blood experiment. Eluates containing
the estriol peak were pooled (2190 c.p.m.) and diluted with
carrier prior to the purification shown in Table IV. Some purifi¬
cation was achieved by the first crystallization. Calculation on
the basis of the final specific activity showed an apparent con¬
version to estriol of 35% at the stage of ether extraction following
incubation. A pool from the 16-epiestriol peak had a specific
activity of 4.2 c.p.m. per p.g, which on acetonide formation, re-
extraction, and hydrolysis remained substantially unchanged at a
value of 4.6 c.p.m. per yug. No further purification was at¬
tempted because of lack of radioactivity.
The pattern of carrier weight and radioactivity following
partition column chromatography of the rat blood nonketonic
fraction is shown in Fig. 2. The addition of carriers was the same
as for the cat blood. The pooled 16-epiestriol peak was purified
as shown in Table IV. The final specific activity was equivalent
to a conversion to 16-epiestriol of 55%. Pooling of the estriol-
containing fractions showed no trace of radioactivity.
DISCUSSION
The above findings in regard to the reduction of 16-ketoes-
tradiol-17/3 to 16-epiestriol by rat blood are in agreement with
those of Portius and Repke (2). However, these investigators
do not seem to have revealed the extent of this reduction nor did
they provide detailed information on identification of the product.
It is quite evident that the extent of reduction can be considerable
and that in cat blood the 16a isomer, estriol, is formed. Forma¬
tion of the opposite isomer in each species either does not occur or
does so only to a slight extent. The radioactivity that appeared
in the cat 16-epiestriol fraction and the rat estriol fraction in
Experiment A may have; resulted through contamination by the
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main metabolite due to interference by blood constituents not
removed prior to column partition. Thus, the incubated vol¬
umes were rather large in this experiment, and no preliminary
hexane-90% methanol partition was performed.
The question of the possible formation of additional metab¬
olites is of interest. In Experiment B, although 61% and 74%
reduction apparently occurred in cat and rat blood, respectively,
the actual formation of estriol and 16-epiestriol was only 36%
and 55% as estimated by isotope dilution. The difference could
perhaps be accounted for by metabolites of a more water-soluble
nature such as may have been responsible for that radioactivity
found to remain in the plasma of seven species following ether
extraction.
SUMMARY
Of seven mammalian species studied with respect to the
activity of their blood to reduce 16-ketoestradiol-17/3 16-I4C, the
cat and the rat were found to be extremely active. The reduc¬
tion product in the cat was estriol (16a isomer) and in the rat 16-
epiestriol (16/3 isomer). Formation of the opposite C-16 isomer
in each case was minimal if it occurred at all. Proof of identifi¬
cation of the products has been described.
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REVERSIBLE DEHYDROGENATION OF ESTROGEN TRIOLS BY SOLUBLE
PREPARATIONS OF RAT AND CAT ERYTHROCYTES1
R. Hobkirk, Mona Nilsen, and I. R. Belenkie
It has been reported in previous publications from this laboratory (1, 2)
that intact erythrocytes of rat and cat origin can reduce 16-KE2-16-C14 to
16-epiestriol2 (16/3 reduction) and estriol (16a reduction), respectively, as major
conversion products. In further unpublished experiments it was not possible
to demonstrate the reversal of these reactions in the presence of whole cells.
Moreover, the use of unfractionated red cell hemolyzates proved unsuitable,
probably as a result of binding of substrates or reaction products to protein,
since the recovery of extractable radioactivity was markedly low after incuba¬
tion. Soluble preparations of erythrocytes, which are active in catalyzing
dehydrogenation of the triols and for which the cofactor requirement has been
ascertained, have now been obtained.
Materials and Methods
All chemical reagents and organic solvents were of good reagent grade and
were purified, where necessary, by published methods (3-5). NADP, NADPH,
NAD, and NADH were purchased from Nutritional Biochemicals Corp.,
Cleveland, Ohio, or Sigma Chem. Co., St. Louis, Missouri. 16-KE2-16-C14
(44 jucuries/mg) and estriol (22 yucuries/mg) were purified by column, paper, or
thin-layer chromatography to yield material of at least 98% purity. 16-Epi-
estriol-16-C14 was prepared by chemical reduction of I6-KE2-I6-C14 as described
elsewhere (6). Estrone-16-C14 (Radiochemical Centre, Amersham, England;
45 jucuries/mg) and dehydroisoandrosterone (Merck, Sharpe and Dohme Ltd.;
140 yucuries/ing) were sufficiently pure for direct use, as were all unlabelled
steroids used. Whole blood (heparinized) was obtained from mature female
cats and white Wistar female rats.
Fractionated rat cell hemolyzates were prepared at 4 °C by treating packed
erythrocytes with H2O. To the mixture was added 0.5 volume of aqueous
(NII4)2S04 saturated at 4 °C to give 33% saturation. The precipitated material
was discarded and the supernatant adjusted to 66% salt saturation by adding
an equal volume of saturated (NPI4)2S04. The precipitate formed was centri-
fuged, dissolved in H20, and dialyzed overnight against distilled PI2O. The
contents of the dialysis bag were diluted with H20 so that 6 ml of the final
'Supported by the Medical Research Council of Canada and the Cooper Fund of McGill
University, Montreal.
2The following trivial names and abbreviations are used in the text: I6-KE2 = 16-keto-
estradiol-17/3 (3,170-dihydroxy-estra-l,3,5(lO)-trien-16-one); estriol = 3,16a,17/3-trihydroxy-
estra-l,3,5(i0)-triene; 16-epiestriol = 3,16/3,17/S-trihydroxy-estra-l,3,5(10)-triene; estrone =
3-hydroxy-estra-l,3,5(10)-trien-16-one; 16-ketoestrone = 3-hydroxy-estra-l,3,5(10)-triene-
16,17-dione; dehydroisoandrosterone = 3/3-hydoxy-A6-androsten-17-one; NADP and NADPH
= oxidized and reduced forms, respectively, of nicotinamide adenine dinucleotide phosphate;
NAD and NADH = oxidized and reduced forms, respectively, of nicotinamide adenine
dinucleotide; S.A. = specific activity.
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preparation was equivalent to 4 ml of original whole blood. Preparations of
cat erythrocytes were obtained in a similar manner, except that the material
precipitating between 33% and 83% salt saturation was used for incubation.
All incubations were performed at 37 °C with 95% 02 - 5% C02 or atmos¬
pheric air as the gas phase. Labelled steroid, diluted with unlabelled carrier to
provide weight, was dissolved in 1-2 drops of propylene glycol and incubated
with varying volumes (up to 6 ml) of enzyme preparation and 1.0 ml of 0.15 M
phosphate buffer, pH 7.4, containing 1.5 jmioles of cofactor. The total volume
was adjusted, where necessary, with H20 to 7 ml and the time of incubation
varied up to 2.5 hours. Suitable blank experiments were carried out simultane¬
ously. Incubation mixtures were cooled, diluted with H20, and extracted with
diethyl ether. The extracts were washed with NaHC03 solution and with H20,
and then dried over anhydrous Na2SC>4 before separation into ketonic and
non-ketonic fractions by a modified Girard reaction (2). Radioactivity was
measured by liquid scintillation spectrometry as previously described (2).
Identification of radioactive products was made by gas-liquid chromatog¬
raphy and by isotope dilution techniques.
Results
It can be seen from Table I that a consistent recovery of radioactivity was
obtained regardless of the substrate employed and that the presence of the
TABLE I













































































*In the H2O and enzyme blank (no cofactor) experiments incubation was for 2 hours. In the reaction mixtures
with cofactor, incubation was for 0.5 to 2.5 hours with 0.5 to 6 ml of enzyme preparation. In all cases the amount of
substrate was 0.1 /nmole (ca. 104 c.p.m.) and the temperature was 37°.
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enzyme fraction did not adversely influence the efficiency of the Girard separa¬
tion.
Table II demonstrates the conversions catalyzed by the enzyme preparations
and also the requirements for NADP or NADPH. The rat preparation did not
contain NADP-dependent 16a dehydrogenase activity with estriol as substrate
TABLE II
Effect of cofactors on C14-labelled substrate conversion by enzyme preparations*
Substrate conversion into ketonic or non-ketonic
products! (% substrate radioactivity converted)
Substrate Cofactor Rat preparation Cat preparation
16-Ketoestradiol-17/3 NADPH 29.9 30.0
16-I<etoestrad iol-17/3 NADH 0.3 0.3
16-Epiestriol NADP 73.7 0.0
16-Epiestriol NAD 0.8 0.0
Estriol NADP 0.0 9.7
Estriol NAD 0.3 0.5
Estrone NADPH 7.4 0.0
Dehydroisoandrosterone NADPH 55.9 1.1
♦Each incubation mixture consisted of 6 ml of enzyme preparation and 1 ml of 0.15 M phosphate buffer (pH 7.4),
together with 0.1 /zmole (ca. 104 c.p.m.) of substrate and 1.5 /xmoles of cofactor. Incubation was at 37° for 2 hours.
tEach value is the average for at least two experiments and is corrected for the experimental blank (see Table I).
but did catalyze the reduction of dehydroisoandrosterone and estrone in the
presence of NADPPI. The cat system was devoid of 16/3 dehydrogenase activity
when 16-epiestriol was the substrate; it did not reduce estrone and its activity
towards dehydroisoandrosterone wasminimal.
For both preparations increasing the enzyme concentration resulted in an
approximately linear increase in activity. When the time of incubation was
increased the activity also rose, but in a nonlinear fashion.
Gas-liquid chromatography of acetylated ketonic fractions obtained through
enzymic dehydrogenation of the triols showed a main symmetrical peak of
retention time (9.6 minutes) equal to that of 16-KE2 diacetate. Smaller un¬
identified peaks were also noted. A ketonic fraction containing 17,500 c.p.m.,
formed by the dehydrogenation of 16-epiestriol by the rat preparation, was
diluted with 140 yug of unlabelled carrier 16-KE2 (calculated S.A. = 125 c.p.m./
/ig). After Celite column partition (5) the average S.A. over seven collected
fractions was equal to 100 c.p.m./yug (range = 93-112 c.p.m./yug). Carrier
steroid weight was measured by the Ittrich spectrophotometric method (7).
Further elution of the column with methanol yielded additional unidentified
radioactivity (= 2800 c.p.m.). Chromatography of the eluted 16-KE2 on
Whatman No. 42 paper in toluene - propylene glycol showed all of the radio¬
activity to be associated with the carrier. After elution S.A. was equal to
93 c.p.m.//ig. These results suggest 16-KE2 to be the main but not sole com¬
ponent of the ketonic fraction. Table III contains data on the purification of
the non-ketonic fractions formed by reduction of 16-KE2. 16-Epiestriol was the
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TABLE III
Purification of non-ketonic fractions obtained by enzyme reduction of I6-KE2-I6-C14*
Non-ketonic fraction (rat) Non-ketonic fraction (cat)
Specific activity Specific activity
Purification step (c.p.m. per mg) Purification step (c.p.m. per mg)
Non-ketonic fraction





























♦Crystallization of free estrogens was done from methanol and of acetates from methanol-HaO. Specific activities
of the acetates were calculated in terms of the free estrogen.
sole product in the case of the rat preparation and estriol accounted for some
92% of the non-ketonic fraction when the cat preparation was employed.
The results in this note provide mainly qualitative information, since differ¬
ent enzyme preparations obtained over a period of some months have shown
a quantitative variation in activity. In contrast to the behavior of salt-frac¬
tionated enzyme preparations, non-ketonic metabolites formed through the
reduction of 16-KE2 by whole erythrocytes included considerable amounts of
unidentified material (2). In the present instance the identity of the ketonic
compound (or compounds), formed in addition to 16-KE2 from the triols, is not
known. It could perhaps have arisen through further dehydrogenation to 16-
ketoestrone, which has been claimed to be a substrate for, as well as a product
of, erythrocyte dehydrogenase enzymes (8, 9). The preparations described in
this paper appear to represent good examples of NADP-dependent 16a and
16/3 hydroxysteroid dehydrogenases of mammalian origin. Their occurrence
in cat and rat erythrocytes is interesting from the point of view of comparative
biochemistry. Further purification could lead to an opportunity to study
stereochemical steroid-enzyme relationships with particular reference to
carbon-16 of the estrogen molecule, in the general manner described by Langer
et al. (10) for the estradiol-17/3 dehydrogenase of human placenta.
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Ring D-a-Ketols as Metabolic Products
of Estrogen in the Nonpregnant Human1
R. HOBKIRK, Ph.D.
University Medical Clinic, The Montreal General Hospital, Montreal, Canada
Ring d-a-ketolic estrogens such as16a-hydroxyestron ,2 16-ketoestr -
diol-17/3 (16-ketoestradiol) and 16/3-
hydroxyestrone have been identified
both as urinary excretion products in
human pregnancy (1, 2) and as metabo¬
lites of CI4-labeled estrogens in the non¬
pregnant human (3, 4). Investigations
performed in vivo and in vitro with hu¬
man liver tissue have shown these same
compounds to be important precursors of
the various isomeric estriols (5-8). Ring
d-a-ketols may perhaps be formed from
estrone (or estradiol-17/3) via an inter¬
mediate such as 16-ketoestrone (9).
A previous communication from this
laboratory (10) showed the ring D a-
ketols to be quantitatively important
metabolites in human pregnancy urine.
However, little appears to have been
reported on these compounds as endog-
Received September 14, 1962.
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search Council of Canada and in part by a grant-
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1 Presented in part at the Fourth Annual
Meeting of the Canadian Federation of Bio¬
logical Societies, Guelph, Ontario, June, 1961.
2 The following trivial names are used in the
text: Estrone =3-hydroxy-l,3,5(10)-estratriene-
16-one; estradiol-17/3 = 3,170-dihydroxy-l,3,5
(lO)-estratriene; estriol =3,16«,17/3-trihydroxy-
1,3,5 (10)-estratriene; 16-epiestriol = 3,160,170-
trihydroxy-l,3,5(10)-estratriene; 16a-hydroxy-
sstrone = 3,16a-dihydroxy-l,3,5(10)-estratriene-




;riene-16,17-dione; 2-methoxyestrone = 2-meth-
)xy-3-hydroxy-l,3,5 (10)-estratriene-16-one.
ABSTRACT. Estriol, ring D-a-ketols and
estrone were measured in the urine of 9 normal
males aged 17-50 yr, and 12 postmenopausal
females, aged 47-72 yr. Mean values (ng/24
hr) with ranges were as follows: Males: estriol,
8.3 (3.9-13.5); ring D-a-ketols, 5.6 (2.3-10.1);
estrone, 5.0 (1.5-8.3). Females: estriol, 6.0
(1.5-14.9); ring D-a-ketols, 2.8 (1.3-4.2);
estrone, 2.2 (0.4-4.9). The ring D-a-ketolic
fraction appears to consist, on the average,
of approximately equal amounts of 16a-hy-
droxyestrone and a 16-ketoestradiol-170(16-
ketoestradiol) fraction perhaps containing
some 160-hydroxyestrone. Analysis of C14-ring
D-a-ketols from the urine of 3 subjects
given estrone-16-C11 suggests that 16a-hy-
droxyestrone and the 16-ketoestradiol frac¬
tion arise from estrone, perhaps via some com¬
mon intermediate. No proof could be obtained
for the conversion in vivo of 16-ketoestradiol to
16a-hydroxyestrone, either directly or via
the triols.
enous urinary metabolites in the non¬
pregnant human. The present report is
concerned with this latter aspect of the
problem. In addition, certain studies are
described regarding the transformation
of C14-labeled estrogens to ring D-a-
ketols, thus yielding information on the
mode of production of the latter. The
experiments described below on the
metabolism of injected estrone-16-C14,
16-ketoestradiol-16-C14 and 16-epiestriol-
16-C14 have already been reported by
others (4, 6). These have been repeated
here, using the same methodology as for
measurement of endogenous urinary ring
D-a-ketols so that the two types of
experiment could be more closely com¬
pared.
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table 1. Excretion of radioactivity by five subjects following injection of C "-estrogens
Material injected Days
Age of




A, male 45 estrone 47.4 0.865 4
B, female 52 estrone 75.6 1.38 4
C, female 50 estrone 31.6 0.577 1
D, male 60 16-ketoestradiol 47.0 0.70 2



















Subjects. Measurement of endogenous estro¬
gen metabolites was performed on 12 post¬
menopausal women and 9 males, all 21 of
whom exhibited normal liver function by at
least 2 biochemical tests. The metabolism of
C14-estrogens was studied in 5 subjects (2
postmenopausal females and 3 males) who
also had normal liver function.
Measurement of Endogenous Estrogen Metabo¬
lites. Upon completion of collection, each
24-hr urine was diluted to 2,500 ml with
distilled water, and quadruplicate 50 ml
volumes were incubated with 20 units of
bacterial /3-glucuronidase1 per ml for 24 hr at
pH 6.5 and 37 C (11). One duplicate pair was
analyzed for estriol and estrone by the
method of Bauld (12), using the fluorimetric
technique described by Ittrich (13) for the
final measurement. Tetrabromoethane was
used as solvent. The other duplicate pair was
analyzed for the ring D a-ketolic estrogen
fraction by the procedure of Givner et al.
(14), with a few modifications. The partition
column described by Givner etal. (15) for the
separation of ketonic estrogens was prepared
in benzene :hexane (1:1) in place of benzene
:hexane (1:49) as mobile phase; the station¬
ary phase remained as methanol:water
(7:3). The ketonic fraction from the Girard
reaction was transferred to this column in
3 X1 ml of mobile phase rather than by the
celite transfer technique (15). The initial 40
ml of this same mobile phase used to develop
the column eluted less polar ketones includ¬
ing estrone. Further elution with 100 ml of
benzene :hexane (1:1) yielded the ring D-a-
ketols. In trial experiments this resulted in an
over-all increase of 10-15% in recovery of
3 Obtained from Sigma Chemical Co., St.
Louis, Missouri.
pure 16a-hydroxyestrone or 16-ketoestradiol
over that described earlier (10, 14). Final
measurement of the ring D-a-ketolic fraction
was performed by the Ittrich fluorimetric
method (13) using tetrabromoethane as
solvent and 16a-hydroxyestrone as standard.
Recovery Experiments. Amounts of estriol,
estrone and 16a-hydroxyestrone or 16-keto¬
estradiol, ranging from 0.10-0.30 gg, were
added, in small amounts of ethanol, to 50 ml
volumes of incubated nonpregnancy urine.
Analyses were performed as described above
and recoveries, corrected for urine blanks,
were calculated.
Chemical Reduction of Ring D-a-Ketols.
Urinary ring D a-ketolic fractions and pure
samples of 16a:-hydroxyestrone and 16-keto¬
estradiol were reduced by treatment over¬
night in 50% aqueous ethanol with 10mg/ml
of sodium borohydride (1, 16). Following
suitable extraction, the triols formed were
separated into estriol- and 16-epiestriol-
containing fractions by column partition
(15). Measurement of these fractions was
performed by the Ittrich technique (13),
either fluorimetrically, using tetrabromo¬
ethane as solvent, or colorimetrically, using
tetrachloroethane as solvent. Where applica¬
ble, such fractions were also submitted to
radioactive counting.
Counting of Cu. All counting was done in the
Geiger region, using a Nuclear Chicago D47
gas flow counter with thin end window.
Samples were plated from ethanolic solution
in cupped nickel-plated planchettes (5/16"
Xl"). Direct counts on urine samples were
corrected for self-absorption by the internal
standard technique employed by Engel et al.
(11). Sufficient counts were collected to en¬
sure an accuracy to within ±5%.
Cu-Estrogens. Estrone-16-C14 (Radiochemical
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Table 2. Urinary excretion (/jg/24 hr) of endogenous estrogen metabolites by normal males
Age (yr) Estriol Ketols Estrone Total*
17 4.1 3.0 1.5 8.6
26 6.9 6.6 7.1 20.6
28 3.9 10.1 3.6 17.6
30 11.2 2.3 6.8 20.3
31 6.1 6.3 3.8 16.2
31 10.7 7.2 2.9 20.8
32 10.3 4.9 5.6 20.8
45 13.5 4.5 8.3 26.3
50 7.6 5.6 5.1 18.3
Mean (range) 8.3 (3.9-13.5) 5.6 (2.3-10.1) 5.0 (1.5-8.3) 18.8 (8.6-26.3)
* Total of the 3 fractions measured.
Centre, Amersham, England) was shown to
be radiochemically homogeneous by column
partition chromatography. Using the above
counting technique, the specific activity was
18,000 counts/min/jug.
16-Ketoestradiol-16-C14, prepared by Lev-
itz (17), was purified by column partition
(15). Further purification by paper chroma¬
tography in the system chloroform: form-
amide (2) yielded highly pure material of
specific activity 14,900 counts/min/^g.
A separate portion of 16-ketoestradiol-16-
C14 was reduced by sodium borohydride, as
described above. The triols formed were
saponified, re-extracted into ether and chro-
matographed on a partition column as de¬
scribed for nonketonic estrogens by Givner
et al. (15). The 16-epiestriol-16-C14 fraction
obtained had a specific activity of 11,000
counts/min/jug and was radiochemically
homogeneous when chromatographed on
paper in the systems benzene :hexane:meth¬
anol:water (4:1:4:1) and chloroform : form-
amide.
Administration of Cu-Estrogens. These were
administered intravenously in a small vol¬
ume of propylene glycol. Vials and syringes
were washed out with ethanol and the con¬
tents were analyzed to correct for losses of
the original material. Estrone-16-C14 was
given to 1 male (subject A) and 2 females
(subjects B and C) while 16-ketoestradiol-16-
C14 and 16-epjestriol-16-C14 were each given
to 1 male (subjects D and E, respectively).
Table 1 contains data on dosage.
Analysis of Urinary Cu-Metabolites. Total
counts were determined on all mines (Table
1), and, depending on the magnitude of
these, one-half aliquots or complete 24-hr
volumes were hydrolyzed by bacterial en¬
zyme, as described above. In the experiments
involving estrone-16-C14, 6 radioactive urin¬
ary estrogen fractions were separated by the
Table 3. Urinary excretion (yug/24 hr) of endogenous estrogen
metabolites by postmenopausal females
Age (yr) Estriol Ketols Estrone Total*
47 14.9 3.9 2.7 21.5
52 3.0 3.5 2.2 8.7
55 11.5 3.0 1.2 15.7
60 5.1 3.5 4.2 12.8
60 4.1 3.2 4.9 12.2
60 1.5 3.0 0.6 5.1
66 6.8 4.2 4.4 15 .4
66 4.3 1.4 1.6 7.3
67 3.0 2.7 0.7 6.4
69 3.7 1.3 0.6 5.6
71 10.8 1.9 3.1 15.8
72 2.9 1.8 0.4 5.1
Mean (range) 6.0 (1.5-14.9) 2.8 (1.3-4.2) 2.2 (0.4-4.9) 11.0 (5.1-21.5)
* Total of the 3 fractions measured.
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Table 4. Borohydride reduction products of pure 16a-hydroxyestrone and 16-ketoestradiol
Estriol fraction 16-epiEstriol fraction Total
Starting material
Mg % recovery iig % recovery /tg % recovery
6a-Hydroxyestrone
108 Mg 710 65.8 11.8* 10.9 82.8 76.7
16-Ketoestradiol
100 Mg 4.7 4.7 89.6 89.6 94.3 94.3
* The reduction product of 16«-hydroxyestrone appearing in the 16-eptestriol fraction is probably
17-eptestriol (1).
method of Givner et al. (14). In the 16-keto-
estradiol-16-C14 experiment, only the ring
D—a-ketolic fraction was analyzed and, after
the administration of 16-epiestriol-16-C",
the fractions containing the ring D—a-ketols,
16-eptestriol and estriol were each collected
and studied. In all cases the ring D-a-ketolic
fractions (with or without added carrier
steroids) were reduced with sodium boro¬
hydride (see above), and the triols formed
chromatographed on partition columns (15)
to yield 16-eptestriol and estriol fractions.
These latter were analyzed by the Ittrich
fluorimetric or colorimetric method, and
counted; from these data their specific activi¬
ties were determined.
Results
Tables 2 and 3 contain data on the
levels of endogenous estriol, estrone and
ring D-a-ketols in the urine of males and
postmenopausal females, respectively.
On the average, the ring D-a-ketols were
similar to estrone, although there were
variations from one individual to an¬
other. It should be noted that the results
in these tables are uncorrected for experi¬
mental losses. In trial experiments, re¬
covery values for pure compounds have
been: estriol, 78-93%; estrone, 85-95%;
16a-hydroxyestrone or 16-ketoestradiol,
64-80%. The reproducibility of the
analytic procedure for the concentration
ranges measured (Tables 2 and 3) was
obtained by calculating the standard
deviation of the difference between du¬
plicate analyses for the three urinary
fractions. For estriol this value was 0.37
pg, for estrone 0.30 pg, and for the ring
D—a-ketols 0.69 pg. A urinary ring D-a-
ketolic fraction, prepared by pooling
small portions of urinary fractions left
over following fluorimetry, was reduced
with sodium borohydride under the
usual conditions. It was found that 0.9
pg of original ring D-a-ketols (in terms
of 16-ketoestradiol) yielded 0.30 pg of
estriol and 0.33 pg of 16-epiestriol. The
apparent loss of material may be partly
accounted for by experimental losses, as
shown in Table 4 for the chromato¬
graphic separation of the borohydride
reduction products of authentic 16a-
Table 5. Radioactive fractions in the urine of subjects given C14-estrogens
Radioactivity in fractions as % of dose
Subiect* Estrogen ;
injected Estriol Ketols Estrone Estradiol ^Totalf
A estrone 9.7 6.1 7.0 2.6 2.6 1.3 29.3
B estrone 6.6 7.4 8.3 1.9 2.0 1.7 27.9
D t 16-ketoestradiol — 13.2 — — — — —
EJ 16-eptestriol 3.5 0.8 — — 11.9 — 16.2
* For further details see Table 1.
t Total refers to sum of fractions shown.
t Only the fractions shown above to contain radioactivity were measured in these subjects.
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Table 6. Analysis of borohydride reduction products of urinary C14-ring D-a-ketols following
administration of estrone-16-C14 to subject A*
Estriol fraction f 16-ep/'Estriol fraction I
C14-estrone
Mg counts /min counts /min/Vg Mg counts /min counts/min/ fj.g
1 2.0 4,000 2,000 1.6 3,800 2,380
2 0.8 3,200 4,000 0.9 3,900 4,340
3 0.7 440 630 1.0 850 850
4 0.8 260 330 1.2 490 410
Total 4.3 7,900 — 4.7 9,040 —
Mean specific activity § — — 1,840 — — 1,920
* For further details see Tables 1 and 5.
t Main reduction product of 16a-hydroxyestrone (see Table 4).
% Main reduction product of 16-ketoestradiol (see Table 4).
§ Calculated from total weights and counts over 4 days.
hydroxyestrone and 16-ketoestradiol.
Table 5 shows the pattern of six me¬
tabolites of estrone-16-C14 in two sub¬
jects in terms of radioactivity of the
fractions obtained from the partition
columns. This table also contains data on
the excretion of some radioactive frac¬
tions following the administration of
16-ketoestradiol-16-C'4 and 16-epiestriol-
16-C14.
Tables 6 and 7 contain information on
the borohydride reduction products of
the urinary ring D-a-ketols (no un¬
labeled carrier added) formed from
estrone-16-C14 in subjects A and B. In
both cases the specific activities of the
estriol and 16-epiestriol fractions (re¬
flecting those of 16a-hydroxyestrone and
16-ketoestradiol, respectively; see Table
4) were similar. Moreover, the weights of
both metabolites were also very similar
over the four-day study period. Only one
24-hour urine could be obtained from
subject C following estrone-16-C14 injec¬
tion. The ring D a-ketolic fraction
yielded, on reduction, 2.2 Mg of estriol
containing 3,000 cpm (specific activity
= 1,360 counts/min/jug) and 2.7 Mg of
16-epiestriol containing 4,300 cpm (spe¬
cific activity = 1,590 counts/min/jug).
In Table 8, results of specific activity
measurements are given for the reduc¬
tion products of urinary ring D-a-ketols
following administration of 16-ketoes-
tradiol-16-C14 to subject D and 16-epi-
estriol-16-C14 to subject E. In these
Table 7. Analysis of borohydride reduction products of urinary CI4-ring D-a-ketols following
administration of estrone-16-C14 to subject B*
Days following
Estriol fraction) 16-epiEstriol fraction)
C14-estrone
Mg counts/min counts/min/jug Mg counts /min counts /min/fig
1 0.7 3,500 5,000 1.1 4,700 4,270
2 1.4 8,600 6,150 2.1 10,100 4,800
3 1.6 4,700 2,940 1.9 5,100 2,680
4 3.8 3,900 1,030 3.2 2,300 720
Total 7.5 20,700 — 8.3 22,200 —
Mean specific activity § — — 2,760 — — 2,680
* For further details see Tables 1 and 5.
t Main reduction product of 16«-hydroxyestrone (see Table 4).
f Main reduction product of 16-ketoestradiol (see Table 4).
§ Calculated from total weights and counts over 4 days.
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Table 8. Activities of borohydride reduction products of urinary C11- ring D-
administration of C "-estrogens to subjects D and E*
-ketols following
Estrogen f
Estriol fraction! 16-epiEstriol fraction§
injected











* Prior to reduction of the urinary ring D-a-ketols, 108 fig of pure 16a-hydroxyestrone and 100
fig of pure 16-ketoestradiol (both unlabeled carriers) were added.
f For further details of amounts injected and of radioactive urinary fractions, see Tables 1 and 5.
j Main reduction product of 16«-hydroxyestrone (see Table 4).
§ Main reduction production of 16-ketoestradiol (see Table 4).
instances, known amounts of pure carrier
16a-hydroxyestrone and 16-ketoestradiol
had been added to the ring D a-ketolic
fraction prior to reduction. These data
indicate that little, if any, 16a-hydroxy-
estrone could have been excreted in the
urine as a metabolite of 16-ketoestradiol
or 16-e/nestriol. In order to obtain addi¬
tional proof that C14-estriol was a true
urinary metabolite, following adminis¬
tration of 16-epj'estriol-17-C14 to subject
E (Table 5), 10 mg of pure crystalline
carrier estriol was added to part of the
radioactive estriol fraction (9,000
counts/min) from the column and re-
crystallized three times from methanol.
Crystals and mother liquors were ana¬
lyzed at each stage and specific activities
were determined. Crystals 1, 2 and 3 had
specific activities of 760, 720 and 734
counts/min/mg, respectively, and the
corresponding mother liquors measured
700, 760 and 765 counts/min/mg. This
indicated production of C14-estriol from
16-epiestriol-16-C14, presumably via 16-
ketoestradiol.
Discussion
Initial attempts to measure urinary
ring D a-ketols in nonpregnant humans
by the procedure of Givner et al. (14)
were unsuccessful in this laboratory.
This was primarily due to background
color produced by urinary residues in the
Bauld modification of the Kober reaction
(18). The combination of techniques
described in this paper, including fluori-
metric analysis, has yielded results which
are considered to be meaningful.
In both males and postmenopausal
females, the levels of ring D-a-ketols, on
the average, are very similar to those of
estrone and less than estriol (Tables 2
and 3). A few points concerning possible
inaccuracies in the measurement of
these ketols should, however, be consid¬
ered. First of all, these compounds were
measured in terms of 16a-hydroxyes¬
trone, which, in the author's hands, has a
lower fluorescence intensity than does
16-ketoestradiol (ratio 0.83:1.0). This
would result in the overestimation of
total ketols. On the other hand, however,
the recovery of the ketols is lower than
that of estrone (see Results), so that the
relative levels given in the tables may
not be much in error. A second, and per¬
haps more serious question, concerns the
hydrolytic cleavage of the conjugated
ring D-a-ketols. It is difficult to compare
results obtained by enzymic hydrolysis
with any standard procedure, since the
ketols are unstable to hot acid treatment.
If the urinary ketols in the nonpregnant
state are conjugated to some extent as
sulfates, the levels given here will be low,
since the bacterial /3-glucuronidase prep¬
aration does not contain sulfatase activ¬
ity (19, 20). Unpublished results from
this laboratory show that this bacterial
enzyme preparation is an excellent tool
for splitting conjugated estriol, estrone
and estradiol in the urine of nonpregnant
humans. This supports the data reported
by Engel et al. (11).
When considered in the light of their
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borohydride reduction products, the
urinary ring D-a-ketolic fractions ap¬
pear to consist of approximately equal
amounts of 16a-hydroxyestrone and a
fraction containing 16-ketoestradiol and
perhaps 16/3-hydroxyestrone. It should
be noted that 16/3-hydroxyestrone as well
as 16-ketoestradiol would give rise
mainly to 16-epiestriol on reduction with
borohydride. On the basis of the present
study, a choice between these two com¬
pounds is not possible. If previous results
on pregnancy urine (2, 10) are any cri¬
teria, 16-ketoestradiol is likely to be
quantitatively more significant than
16/3-hydroxyestrone. The specific activi¬
ties of the chemically reduced ring D a-
ketols formed following injection ol
estrone-16-C14 to subjects D and E
(Tables 6 and 7) are in agreement with
the thesis that these ketols arise from
estrone, perhaps via some common inter¬
mediate such as 16-ketoestrone (9). The
possibility that 16a-hydroxyestrone is
readily formed from 16-ketoestradiol,
either directly or via the triols, is unlikely
in view of the studies made by Levitz
et al. (6). In the present instance it is
difficult to rule out the production of a
small amount of 16«-hydroxyestrone
from these sources, since 16-ketoestra¬
diol, when reduced, always gives rise to a
small amount of material in the estriol
fraction (see Table 4). Although 16-
ketoestradiol is a metabolite of the
triols (ref. 2 and Table 5), this conver¬
sion may be of minor quantitative sig¬
nificance when compared with its for¬
mation from estrone (Table 5). This
question will not be settled until the
urinary 16-ketoestradiol and 16/3-hy¬
droxyestrone are separated and indi¬
vidually measured.
It is of interest to note that if the ring
D-a-ketols in males and postmenopausal
females (Tables 2 and 3) are calculated
as a percentage of estriol, ketols and
estrone, the average values are 30% for
males and 25% for females. A similar
calculation for the radioactivity excreted
in these fractions following estrone-16-
C14 injection in subjects A and B (Table
5) gives values of 27 and 33%, respec¬
tively. Thus, by two different criteria the
patterns of estriol, ring D-a-ketols and
estrone are similar.
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Abstract
A tracer .dose of estradiol-17/3-6,7-3H was injected intravenously into male
subjects simultaneously with a "C-labeled steroid. The latter was either 16-keto-
estradiol-17/3-16-14C, 16-epiestriol-16-14C, or estriol-16-"C. All eight urinary meta¬
bolites of estradiol-17j3-3H studied, and the main metabolites of the 16-
oxygenated steroids, were predominantly split by /3-glucuronidase hydrolysis.
The major urinary metabolite released by solvolysis was estrone, as a conversion
product of estradiol-17/3-3H. After injection of estradiol- 17/3-3H together with
either 16-ketoestradiol-17/3-14C or 16-epiestriol-14C, urinary 16/3-hydroxyestrone
contained both isotopes. 16a-Hydroxyestrone, on the other hand, contained 3H
but only insignificant amounts of l4C. This suggests formation of 16/3-hydroxy¬
estrone but not 16a-hydroxyestrone from these injected 16-oxygenated steroids.
16-Epiestriol was metabolized to identifiable urinary metabolites to a considerably
greater degree than was estriol. This was confirmed in a further experiment in
which only 16-epiestriol-14C was injected.
Introduction
Considerable knowledge concerning the nature of the peripheral intercon-
version of phenolic steroids in the human has become available during the past
decade (1). Contributing largely to this has been the isolation of a number of
hitherto unknown urinary metabolites. Among the latter are several 16-
oxygenated steroids such as 16-epiestriol2 (2), IGa-hydroxyestrone (3), 16/3-
hydroxyestrone (4), and 16-ketoestradiol-17/3 (4) (hereafter referred to as
16-ketoestradiol) whose interrelationships have been at least partially resolved
(5-8). Gallagher et al., in a series of publications reviewed by Brown (9),
established the general pattern of these compounds, and others, as urinary
metabolites of injected estradiol-17/3 (hereafter referred to as estradiol) in the
human. However, very few studies have been published in which more than
the three 'classical' estrogens (estrone, estradiol, and estriol) were investigated
in one and the same subject (10, 11). In the present instance, the production
of some 16-oxygenated phenolic steroids has been studied following simul¬
taneous injection of estradiol-6,7-3H and certain 14C-labeled 16-oxygenated
steroids. In addition, some information has been obtained regarding the mode
of conjugation of eight urinary estrogen metabolites.
■Supported in part by a grant from the Medical Research Council of Canada.
2The following abbreviations and trivial names are used in the text: 16-epiE3 = 16-epiestriol
(3,16/3,17/3-trihydroxy-estra-l,3,5 (lO)-triene); I6-KE2 = 16-ketoestradiol-17/3 (3,17/3-dihy-
droxy-estra-1,3,5 (lO)-trien-lO-one); 16a-OHEi = 16a-hydroxyestrone (3,16cf-dihydroxy-
estra-1,3,5 (10)-trien-17-one); 16/3-OHEi = 16/3-hydroxyestrone (3,16/3-dihydroxy-estra-l,3,5
(10)-trien-17-one); E3 = estriol (3,16a,17/3-trihydroxy-estra-l,3,5 (lO)-triene); 16-ketoes-
trone = 3-hydroxy-estra-l,3,5 (10)-triene-16,17-dione; Ei = estrone (3-hydroxy-estra-l,3,5
(10)-trien-17-one); E2 = estradiol-17/3 (3,17/3-dihydroxy-estra-l,3,5 (lO)-triene); 2-MeEi =
2-methoxyestrone (2-methoxy-3-hydroxy-estra-l,3,5 (10)-trien-17-one); c.p.m. = counts per
minute; SA = specific activity; G = urinary steroid conjugate fraction split by ^-glucuronidase;
S = urinary steroid conjugate fraction split by solvolysis.
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Materials and Methods
Radioactive Steroids
Estradiol-6,7-3H of specific activity (SA) 40 yucuriesf/ig was purchased from
Merck Sharpe & Dohme and purified by Celite column partition chromatog¬
raphy (12). The material collected in the peak tubes was pure as judged by
crystallization with unlabeled carrier. 16-Ketoestradiol-16-14C3 (SA = 44
jicuries/mg) was obtained in an impure state. It was submitted to a modified
Girard separation (12) and the ketonic fraction was treated by thin-layer
chromatography (13). The eluted radioactivity was chromatographed on a
Celite partition column and then further purified by paper chromatography in
toluene - propylene glycol. The material so obtained was shown to be at least
98.5% pure by crystallization with unlabeled carrier steroid. 16-Epiestriol-
16-14C was prepared from the latter purified lG-ketoestradiol by reduction with
sodium borohydride and subsequent column partition chromatography (12).
After thin-layer chromatography and elution, the labeled material was found
to be at least 98% pure by crystallization with unlabeled carrier steroid.
Estriol-16-14C3 (SA = 22 /icuries/mg) was chromatographed on paper and a
partition column and shown to be at least 99% pure by crystallization with
unlabeled carrier.
Non-Radioactive Steroids
2-Methoxyestrone and 16-epiestriol were purchased from Organon Labora¬
tories Ltd.; estrone and estradiol from Mann Research Laboratories Inc.,
New York; 16-ketoestradiol from Steraloids Inc., Pawling, New York; and
16/3-hydroxyestrone diacetate from Southeastern Biochemicals Inc., Morris-
town, Tennessee. IGa-Hydroxyestrone4 and estriol5 were donated. Where
necessary these were crystallized to yield melting points which agreed closely
with the theoretical.
Chemicals and Reagents
Pyridine and acetic anhydride were fresh anhydrous materials. All other
reagents and solvents were of good grade and were purified where necessary by
standard procedures.
Administration of Radioactive Steroids
This was done via an arm vein as a single dose in 10 ml of 10% ethanol in
saline. Vials and syringes were washed out following injection and the activity
remaining was counted so that the absolute dose could be calculated. The
subjects injected were four males with no endocrine or liver abnormalities.
Urine Collection and Analysis
Urine was collected in each case for 9G hours after injection and frozen in
polyethylene bottles until required. Aliquots of, or total 96-hour pooled urines
3Generously donated by Dr. M. Levitz, New York Medical Centre.
■•Generously donated by Dr. A. E. Kellie, Middlesex Hospital, London, England.
5Generously donated by Parke Davis & Company, Ltd.
HOBKIRK ET AL.: INTERCONVERSION OF PHENOLIC STEROIDS 1213
were extracted serially following /3-glucuronidase incubation (14) and solvolysis
(15). These extracts correspond approximately to glucosiduronate and sulfate
conjugates, respectively, and are referred to as G and S fractions. Each extract
was submitted to a modified Girard separation and the ketonic fractions
obtained were chroinatographed on Celite partition columns (16). The corre¬
sponding non-ketonic fractions were further purified by alkaline treatment and
then subjected to column partition (16).
Ring D a-ketolic fractions were chromatographed on Whatman No. 42
paper in toluene - propylene glycol at 23° for 4 days against appropriate stan¬
dards. Under these conditions, 16/3-hydroxyestrone traveled 13 cm, 16c*t
hydroxy-estrone 23 cm, and 16-ketoestradiol 35 cm. The separated compounds
were eluted with ethyl acetate, the extracts washed with H20, and evapor¬
ated. Where insufficient unlabeled 16a-hydroxyestrone was available for
use as carrier (experiment 3) in subsequent isotope dilution, the fraction eluted
from the paper was reduced with sodium borohydride to yield mainly estriol
(14) and this was purified as the triol. In all cases 16/3-hydroxyestrone was
acetylated immediately after elution from the paper and purified as the
diacetate.
Eluted material from the columns and papers, containing known amounts of
radioactivity, was diluted with accurately weighed amounts (10-30 mg) of
appropriate unlabeled carrier steroids. This was followed by at least two
crystallizations (except for 16/3-hydroxyestrone and in some cases 16-keto-
estradiol) as the free compounds, from methanol. The crystals were then
acetylated overnight at room temperature in a mixture of 0.2 ml anhydrous
pyridine and 0.1 ml acetic anhydride. The acetates so formed were crystallized
at least twice from methanol-water mixtures. Crystallization was continued as
far as possible until successive SA values differed by no more than 5% and,
where appropriate, 3H:14C ratios became constant. Melting point determina¬
tions (microscope hot stage) helped to confirm the identity and purity of the
final products.
All radioactive counting was performed on a Nuclear-Chicago model 6725
liquid-scintillation spectrometer using the formula of Okita et al. (17) to calcu¬
late3! I and 14C countswhere necessary. Efficiencies of counting for these isotopes
were 25% and 60% respectively. Under these conditions the contribution of
314 to the 14C channel was less than 1% and that of 14C to the 3H channel
approximately 15%. The background count in each channel was about 30
c.p.m. The scintillation medium consisted of toluene containing 0.3% (w/v) of
2,5-triphenyloxazole and 0.01% (w/v) of l,4-bis-2-(5-phenyloxazolyl)-benzene.
Results
Table I shows the radioactivity and 3H:14C ratios of the injected steroids and
the recovery of these in the urinary extracts. Most of the extractable activity
had apparently been conjugated as glucosiduronate with small but significant
amounts, particularly as metabolites of estradiol, being released by solvolysis.
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TABLE I
Injection and urinary excretion of radioactive steroids in male subjects
Experiment No.
Steroids injected E2-3H + E2-3H + E2-3H + 16-epiE3-"C
16-KE2-»C 16-epiE3-"C E3-"C
3H injected (c.p.m.) 9.4 X 106 1.06 X 107 6.6 X 106
"C injected (c.p.m.) 1.02 X 106 1.25 X 106 1.64 X 106 0.24 X 106
3H:"C injected 9.2 8.5 4.0 —
3H (% dose) in urine extracts*
G 35.3 47.2 28.8 —
S 6.5 5.7 2.2 —
14C (% dose) in urine extracts*
G 43.4 66.6 42.7 41.5
S Trace Trace 2.6 f
*After hydrolysis, extraction, and Girard separation.
tNot done.
As expected, estrone, estradiol, and 2-methoxyestrone were detected in the
urine after injection of estradiol-3H in experiments 1-3. Identity was proved in
each case by crystallization to constant specific activity with the appropriate
carrier steroid. Detailed data are not shown for the purification of these
compounds.
Tables 11—IV contain detailed information on the purification of 16-oxy-
genated metabolites of injected estradiol-3!-! together with a 14C-labeled
16-oxygenated steroid in experiments 1-3. When 16-ketoestradiol was the
14C-labeled compound (Table II), all of the 10-oxygenated metabolites analyzed,
with the exception of IGa-hydroxyestrone, possessed 3H:14C ratios considerably
lower than that of the injected mixture. The amount of 14C associated with
IGa-hydroxyestrone was so small as to be insignificant. In the case of injected
estradiol-3!! plus lG-epiestriol-I4C (Table III), none of the latter isotope was
incorporated into IGa-hydroxyestrone. The other four metabolites were labeled
with both isotopes, with lG/3-hydroxyestrone and 16-ketoestradiol in particular
formed from injected lG-epiestriol to a greater extent than from estradiol. In
experiment 3 (Table IV) estriol was not significantly metabolized to identifiable
products. It should be noted that although the 16-ketoestradiol fraction, after
paper chromatography and crystallization as the free compound, contained
considerable radioactivity, little remained after crystallization as the diacetate.
Also, although the purified IGa-hydroxyestrone had a 3H:14C ratio of 13, the
contribution of 14C was so small as to be insignificant.
Table V shows the purification of three metabolites after injection of 1G-
epiestriol-14C alone. The results bear out those of experiment 2 (Table III)
indicating a significant conversion to 16-ketoestradiol and estriol.
The conversion of injected estradiol-3!! to urinary metabolites is shown in
Table VI. These figures were calculated as percentage of dose from the mathe¬
matical product of the final specific activity of the purified crystals and the
TABLEII
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TABLE IV
Purification of urinary 16-oxygenated metabolites following injection of E2-3H + E3-I4C
(3H:14C ratio = 4.0; experiment 3*)
Purification!
Isotope step
16a-OHEi 16-KE2J 16-epiE3 e3
G G G S G S
3H SA, calculated 1,040 4,000 1,570 190 3,900 570
SA, crystals 1 510 3,500 700 56 3,840 460
2 520 690 710 38 3,440 440
3 530 640 740 28 3,500 430
14C SA, calculated 22 220 180 23 28,200 2,860
SA, crystals 1 39 530 120 13 30,400 3,200
2 43 170 122 8 29,400 3,300
3 40 150 123 6 29,800 3,200
Final 3H:"C ratio 13 4.3 6.0 4.7 0.12 0.13
♦All SA values (c.p.m. per mg) are calculated for free steroids.
tAfter addition of appropriate unlabeled carrier; crystallizations 1 and 2 done on free steroids (methanol), 3 on
acetates (methanol-water) except as otherwise indicated.
^Crystallization 1 done on free steroid, 2 and 3 on acetate.
TABLE V
Purification of urinary 16-oxygenated metabolites following





SA, calculated 830 1830 390
SA, crystals 1 785 1905 400
2 742 1780 440
3 790 1760 430
4 — 1680 450
♦All SA values (c.p.m. per mg) are calculated for free steroids.
fAfter addition of appropriate carrier; crystallizations 1 and 2 done on
free steroids (methanol), 3 and 4 on acetates (methanol-water).
TABLE VI
Conversion (% dose) of E2-3H to urinary metabolites as calculated from crystallization data
Expt. 1 Expt. 2 Expt.. 3
Metabolite G S G S G S
2-MeEi 0.6 0.2 0.5 0.1 2.0 0.2
Et 5.4 1.9 7.9 2.4 4.7 0.3
e2 2.6 0.2 3.3 0.8 2.5 <0.1
16<*-OHEi 1.3 ca. 0.1 0.6 -— 0.3 —
16/3-OHE, 0.2 — 0.4 — — —
16-IVE2 0.6 0.2 1.2 <0.1 0.3 —
16-epiE3 1.1 0.1 2.0 <0.1 0.2 <0.1
e3 6.7 0.7 13.2 0.5 1,2 0.1
Total 18.5 3.4 29.1 3.8 11.2 0.6
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weight of unlabeled carrier employed for crystallization in each case. It should
be particularly noted that the values for the ring D a-ketols have been corrected
for a loss of approximately 30% during paper chromatography. Such a loss has
been found to occur in our laboratory for pure samples of these compounds.
Correction was made to compare more directly the figures for the separated
ring D a-ketols with those of the other metabolites which were not subjected
to paper chromatography. Even this correction, however, did not result in close
agreement between the radioactivity found in the ring D a-ketolic fraction
from the partition column, which was similar to that of the estrone fraction, and
that in the separated ring D a-ketols of Table VI. This discrepancy could either
be due to removal of contaminating radioactivity or to the known chemical
lability of these compounds. The latter possibility appears less likely since care
was taken to avoid vigorous chemical treatment (e.g. high temperature, alkali)
at all stages of the work. It can be seen that the 3H in the form of identified
urinary metabolites in Table VI amounted to 38-62% of the 3H in the urinary
extracts of these experiments (Table I).
Table VII contains similar data on the conversion of 14C-labeled 16-oxy-
genated compounds to urinary metabolites in four experiments. A survey of
TABLE VII
Conversion (% dose) of I4C-labeled 16-oxygenated estrogens to urinary metabolites as
calculated from crystallization data
Steroid injected
Metabolite
I6-KE2!4C 16-epiE3-14C Ea;-»C 16-epiE3-14C
G S G S G s G
16/3-OHEi 0.5 1.7 — —
I6-KE2 5.6 1.1 2.6 0.2 — 4.9
16-epiE3 4.5 0.5 32.8 0.7 0.1 <0.1 21.5
e3 21.0 2.5 10.4 0.3 42.7 2.7 4.9
Total 31.6 4.1 47.5 1.0 43.0 2.7 31.3
Tables II, III, IV, and V shows that the urinary metabolites of these compounds
were generally more radiochemically homogeneous following column or paper
chromatography than were the metabolites of estradiol-3!!. This is borne out
by the finding that of the 14C in the urinary extracts (Table I), 73-100% was
identifiable as the metabolites of Table VI.
Discussion
It can easily be seen from the results of this study that of eight urinary
metabolites of injected estradiol-3!! in the human male, by far the greater
portion appears to be conjugated as glucosiduronate, or at least is released by
fi-glucuronidase treatment. The main component of the fraction released by
solvolysis, in all probability representing sulfate conjugates, is estrone. In most
instances, small but detectable amounts of the other identified phenolic steroid
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metabolites appeared to be conjugated in the latter form. The individual ring D
a-ketols, as urinary metabolites of injected estradiol-3H, appear to be con¬
siderably less quantitatively significant than was reported earlier from this
laboratory (14). However, it should be noted that the latter results were
obtained by a much more indirect approach. Also, there remains the possibility
that the chemical lability of these compounds may have contributed to losses
during separation.
The identified urinary metabolites of injected 16-oxygenated phenolic
steroids are obviously almost wholly in the form of glucosiduronates. The pat¬
tern of conversion products of 16-ketoestradiol-14C in the present work agrees
well with that reported by Levitz et al. (7). Both in this experiment and in the
one where 16-epiestriol-14C was injected together with estradiol-3H, urinary
16/3-hydroxyestrone was significantly labeled with both isotopes whereas
16a-hydroxyestrone, although containing 3H, was practically devoid of 14C.
This suggests the latter to be predominantly a hydroxylation product of
estrone and the 16/3 isomer a product, at least partially, of a preformed 16-
oxygenated compound. Although the conversion to 16/3-hydroxyestrone was
not large in either experiment, the possibility that it could have arisen from a
contaminant of the administered 14C-labeIed steroids appears remote since the
purity of the latter was such that only a very high degree of conversion of any
hypothetical contaminant could have provided the results obtained. Such
efficient metabolic conversions are not generally encountered among the
phenolic steroids.
The considerable degree of conversion of 16-epiestriol to 16-ketoestradiol and
estriol as compared with that of estriol to 16-ketoestradiol and 16-epiestriol
supports an earlier finding in this laboratory (14). Perhaps significant is the
finding of an extremely high conversion of injected 16-epiestriol to estriol in a
subject who showed a considerable production of the latter compound from
administered estradiol. It should be noted that Nocke et al. (8) reported the
conversion of administered 16/3-hydroxyestrone, not only to urinary 16-
epiestriol (13.8%) but also to estriol (13.3%) in man. As discussed by these
authors, this might relate to the conversion of 16-epiestriol to estriol via
16-ketoestradiol or to the oxidation of 16/3-hydroxyestrone to 16-ketoestrone
with subsequent reduction to the triols. The part which might be played by
16-ketoestrone in the present work has not been evaluated.
In the experiment involving estriol administration, little, if any, metabolism
of this compound occurred as judged by urinary metabolites. However, it
should also be noted that in this subject very little of the triols was produced
from estradiol as compared with the other experiments. Indeed, more 2-meth-
oxyestrone than estriol was formed from estradiol in this case, a pattern found
in hyperthyroidism (18), although no features of this disorder were apparent.
Levitz et al. (6) were first to show the conversion of estriol to 16-epiestriol via
16-ketoestradiol in man. More recently others have been unable to confirm
this finding (19).
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NOTES
FORMATION OF 16-KETO ESTRONE FROM 16-KETOESTRADIOL-l 7p BY
HUMAN UTERINE FIBROID IN VITRO
O. J„ Lucis and R, Hobkirk
McGill University Medical Clinic, The Montreal General Hospital
Montreal, Canada
Received April 24, 1963
Interconversion of estrone and estradiol-17p by human liver,
kidney and breast tissue has been demonstrated in vitro 1. Breuer 2
has shown conversion of 16-ketoestradiol-17(3 to the isomeric triols,
16-epiestriol and estriol by slices of human liver. Isolation of Cl4-
labelled 16-ketoestrone from urine following an injection of estrone-
16-C!4 suggests that this metabolite may function as an intermediate
in estrogen triol formation Human tissues convert 16-ketoestrone to
16-ketoestradiol-17p, estriol and 16-epiestriol in vitro According
to Szego and Roberts 4 estriol in immature rats induces a more rapid
uterine weight increase than does estrone or estradiol-17p.
In human females during the age of reproduction fibroid tumours
(leiomyomata) are commonly found in the myometrium. The histological
origin of these tumours is still an unsolved problem, nevertheless it is
believed that they grow under the influence of circulating estrogens
We wish to report upon the in vitro metabolism of estrogens
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by human fibroid. Uterine tidsue was obtained from a 45-year old
female who had a hysterectomy because of paraovarian cyst and
leiomyomata (fibroids). The patient was nulliparous with normal
menstrual periods, and the surgery was done in the early proliferative
phase of the menstrual cycle.
Fibroid tissue was dissected from surrounding uterine
muscle, minced, and incubated in Krebs Ringer phosphate buffer +
200 mg % glucose, at pH 7.4 under 02 atmosphere at 37.5°C for 3 hrs„
The incubation vessel contained 3.0 g tissue, 20 ml incubation medium
and 2„9 pg 16-ketoestradiol-17p-l6-Cl4 (16KE2) (205,600 cpm counted
at 60% efficiency). Prior to the experiment 16 KE 2 was purified by paper
chromatography. After incubation the aqueous medium and the tissue
were extracted according to the following scheme :
Fibroid 3. Og + 16 KE 2 (205, 600 cpm)
I
Acetone extract of tissue Ether extract (inc. medium)




Girard T reaction 6
Ketonic Fraction Non-ketonic Fraction
121,300 cpm 13,800 cpm
The ketonic fraction, to which 25 p.g l6-ketoestradiol-17p
carrier had been added, was chromatographed on Whatman No. 1
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chromatographic paper in the system n-hexane : benzene : 7 0% methanol
(20: 80: 100) with a pilot of 16-ketoestradiol-17p on a separate strip.
The radioactive zones on the paper were located by means of a 4 IT
recording and integrating strip Scanner (Atomic Accessories, Inc.).
As shown in Fig. 1 radioactive zones less polar than 16-ketoestradiol-
17p were present. On repeated chromatography in the system methyl-
cyclohexane : toluene : 80% methanol (225:275:5 00) the less polar
component which had the same mobility as authentic 16-ketoestrone
(Rf 0.3), was separated from 16-ketoestradiol (Rf 0.1). This zone was
eluted, combined with 230 pg of unlabelled 16-ketoestrone carrier and





Rf 0 0-50 0-66 0-7 100
Figure 1. Isolation of 16 Keto Estrone C*4 by Paper Chromatography.
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associated with the 16-ketoestrone carrier,, After elution this zone
contained 3565 cpm when counted in a Packard Liquid Scintillation
spectrometer at 60% efficiency and accuracy 1 5%. The amount of 16-
ketoestrone was determined quantitatively by a modified method based
on that of Mitchell and Davies ^. The isolated metabolite had a specific
activity of 4970 cpm/pM. It was reduced by sodium borohydride
(10 mg/ml) in 5 0% ethanol at room temperature for 18 hrs„ The reduced
material was extracted with peroxide-free ether and chromatographed
on Whatman No. 1 paper in the system n-hexane : benzene : 70% methanol
(20: 80: 100). Two polar zones with the cliromatographic mobility of
estriol (Rf 0.05) and 16-epiestriol (Rf 0.32) were isolated, The specific
activity of the estriol was 5090 cpm/pM and of the 16-epiestriol 4980
cpm/pM which indicates that both the radioactivity and the weight
were derived from the parent substance.
Radioactive l6-ketoestradiol-17(3-C^ when incubated without
the tissue and subjected to the same procedure of separation did not
yield any radioactive product which would correspond to 16-ketoestrone.
This strongly suggests that the 16-ketoestrone was formed by the
fibroid tissue. Chromatographic separation of the non-ketonic fraction
from the tissue incubate yielded two radioactive zones which had the
chromatographic characteristics of estriol and 16-epiestriol using paper
and thin layer chromatography8. These zones did not appear when the
16 KE 2 was incubated without the tissue.
The recovery of unaltered 16 KE ^ after incubation with tissue
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followed by extraction, chemical and chromatographic separation was 11%
whereas in the absence of the tissue it was of the order of 78%, thus
showing that l6-ketoestradiol-17p is rapidly metabolized by the fibroid
tissue. The ketonic fraction from the tissue incubate was composed of
60% of a highly polar zone, 18% of unaltered 16 KE ^ and 3% of 16-
ketoestrone. In the non-ketonic fraction substances with the chromato¬
graphic characteristics of estriol and 16-eplestriol accounted respectively
for 16% and 11% of the radioactivity, the remainder was less polar.
These findings indicate that uterine fibroid tissue in vitro can
carry out reduction at Cf6 and also oxidation at C17 of the estrogen
molecule.
Reduction at C 17 of estrone 16-0*4 anc[ formation of labelled
estradiol-17(3 has been observed in our laboratory with human endo¬
metrium, Fallopian tube and fibroid tissue. The conversion occurs to
an extent of 1 to 2% per gram of tissue Apparently normal myometrium
so far has shown little activity in converting estrone to estradiol-17(3.
Formation of estrogen triols from labelled estrone by these tissues has
not been obtained as yet*
The following trivial names are used in the text:
16-ketoestradiol-l7p-16-C*4 = [i6-l4c] 3, 17(3-dihydroxy-l, 3, 5 (lO)-
estratriene-16 -one
Estrone = 3-hydroxy-l, 3, 5 (I0)-estratriene~17-one
16-ketoestrone = 3-hydroxy-l, 3, 5 (l0)-estratriene-16, 17-dione
16-ketoestradiol-17p = 3, 17p-dihydroxy-l, 3, 5 (I0)-estratriene-l6-one
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Estradiol-17(3 = 3, 17(3-dihydroxy-l, 3, 5 (l0)-estratriene
Estriol = 3, 16a, 17(3-trihydroxy-l, 3, 5 (lO)-estratriene
16-eplestrlol = 3, 16(3, 17p-trihydroxy-l, 3, 5 (lO)-estratriene
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Abstract
This communication deals with the biosynthesis of 2-
methoxyestrone from estrone and 2-hydroxyestrone. Cell free
preparations (8000 g supernatant) from livers of immature female
Wistar rats contain enzyme systems which activate methionine,
orthohydroxylate estrone, transfer the methyl group from methionine
to position 2 of 2-hydroxye strone and reduce the 17-keto group.
The orthomethyl-transferase activity may be partially blocked by
large amounts of 2-hydroxye strone. Ortho methylation of estrone
is inhibited by estriol, epinephrine, 3, 4-dihydroxy benzoic acid
and chlorogenic acid.
The isolation and identification of 2-methoxyestrone as a
natural urinary metabolite of labelled estradiol-17p in human
subjects was first achieved by Kraychy and Gallagher.1 Soon
afterwards, Loke and Marrian isolated this metabolite from the
2
urine of pregnant subjects. Studies by Hobkirk and Nilsen reveal
that the urinary excretion of 2-methoxye strone by pregnant humans
seldom follows the pattern of other estrogen metabolites and shows a
marked variation among individuals.^ Recently Breuer^ showed that
2-methoxyestradiol-17(3 and 2-methoxyestriol also appear in
human urine. Methylation of 2~hydroxyestradiol-17(3 to 2-methoxy-
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estradiol-17p has been demonstrated "in vitro" by liver tissues
from rat, rabbit and human.5 As shown by King^, rat liver
preparations in vitro transform estriol to 2-hydroxyestriol and 2-
methoxyestriol.
We wish to report on the formation of 2-methoxyestrone
from estrone and 2-hydroxyestrone by rat liver preparations in vitro.
Materials and Methods;
Tissues for incubation were obtained from immature female
Wistar rats weighing 50 + 5 grams. The animals were sacrificed by
a blow on the head and the liver was removed immediately. A 10%
(w/v) homogenate was prepared in 0.25 M sucrose and the sub¬
cellular fractions were separated by means of a refrigerated
Beckman Spinco Type (Model L) Ultracentrifuge. The nuclei and
cell debris were sedimented at 700 times gravity and the mitochondria
at 8000 times gravity for 30 minutes. The supernatant obtained
after centrifugation at 8000 times gravity is referred to in the text as
the "microsomal" preparation; it contains microsomes + soluble
fraction. For incubation 5 ml of disrupted cell preparation were
diluted with 5 ml of 0.2M phosphate buffer pH 7.4 containing 1.5 pM
methionine methyl-^C (sp.act. 6. 3lxlO^cpm/fxM) * as a methyl donor,
estrone and co-factors ** 2.3 pM NAD, 2^M NADP, 15 |j.M glucose-
6-phosphate, 10.0 (iM adenoisine triphosphate and 279 pM magnes¬
ium chloride. For some experiments estrone-16-^C and non-
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labelled 1-methionine were used. This mixture was incubated for
2 hours under oxygen atmosphere at 37.5°C in a Dubnoff Metabolic
Incubator. Immediately after incubation the preparation was
extracted with peroxide-free ether. The extract was evaporated
to dryness and subjected to a Girard T separation^ for 18 hours at
room temperature. After this reaction the non-ketonic fraction was
extracted with peroxide free ether. The aqueous residue containing
the ketonic Girard complex was hydrolyzed with sulfuric acid and
the liberated ketonic material was extracted again with ether. Ether
extracts were evaporated to dryness and chromatographed. The
radioactivity of extracts and eluates was measured in a Packard
Liquid Scintillation spectrometer with an efficiency for carbon-14
of 60%. Radioactive zones on paper chromatograms were detected
by means of an integrating and recording 4lT window less gas flow
strip scanner (Atomic Accessories Inc.). In some instances radio-
autography was also used.
Isolation of 2-Methoxyestrone
The ketonic fractions from the incubation media, when
chromatographed on Whatman No. 1 filter paper in the propylene
glycol: methylcyclohexane system, separated into several radio¬
active zones. The zone having the mobility of 2-methoxyestrone
(2 MeE}) appeared only when estrone or 2-hydroxyestrone (2-OHE^
was present in the incubation medium (Figure 1). On further chroma-
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Isolation of 2 Methony Estrone — C
cpm. 2MeE,
14
Figure 1: Isolation of 2 methoxyestrone- C„ Scanning patterns
of chromatograms. 2 MeE, and 2 MeE2 = areas of authentic pilots.
tography in the methylcyclohexane : toluene : 80% aqueous methanol
system (MeCy:Tol:MeOH) (225:275:500) this zone remained homo¬
geneous and the radioactivity did not separate from the authentic
2-methoxyestrone carrier. After elution and subsequent chemical
reduction with sodium borohydride (10 mg/ml in 5 0% ethanol for 18
hours at room temperature) both the carrier and the radioactivity
remained together and behaved like 2-methoxyestradiol-17p (2MeE2).
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Pooled 2-methoxyestrone methyl-^C was chromatographed on a
celite column using the solvent system n-hexane: benzene: 70%
7
methanol (98:2:100) . The isolated 2-methoxyestrone fraction
when chromatographed on Silica Gel G (Stahl) thin layer system "A"8
had the same mobility as authentic 2-methoxyestrone. A portion of
2-methoxyestrone methyl-^C was diluted with authentic non-
labelled 2~methoxyestrone to a specific activity of 44, 200 cpm/jaM
and acetylated with acetic anhydride in pyridine for 18 hours at
room temperature. The acetylated material was chromatographed in
the propylene glycol: methylcyclohexane system and it showed
only one radioactive zone of Rj 0.39 (2-methoxyestrone pilot
Rj 0.14). A part of the chromatogram when tested with dilute
(i: 10) Folin reagent for free phenol group showed only a slowly
developing trace of blue color in the 2-methoxyestrone acetate
region, and no color in the 2-methoxyestrone region. Free 2-
methoxyestrone in comparable amount under the same conditions
with Folin reagent rapidly yields a dark blue color. The specific
activity of the eluted 2-methoxyestrone methyl-^C acetate zone
was 44,100 cpm/p.M, thus showing no change in specific activity
following acetylation. The weight of 2-methoxyestrone and its
acetate was determined by the Ittrich modification of the Kober
q
reaction .
Factors affecting 2-methoxyestrone formation:
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TRANSFER OF -C14^ FROM METHIONINE TO ESTRONE BY RAT
LIVER PREPARATIONS
Figure 2: Formation of 2 methoxyestrone-methyl-^C by cell-free
preparations.
C - no ATP
+ ATP 10 |jlM
Total bar - radioactivity in ketonic fraction.
Shaded bar - radioactivity in 2-methoxyestrone zone.
The dependence of methoxylation on exogenous ATP and the
location of the enzyme systems involved has been studied. Cell-
free rat liver preparations failed to incorporate radioactivity from
14
methionine methyl- C into the ketonic fraction in the absence of
ATP. The whole homogenate was most efficient in methoxylation
but the microsomal fraction (8000 g supernatant) contained the
necessary enzymes for these reactions. (Figure 2). In the
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presence of ATP 2-methoxyestrone was formed and it accounted
for less than one half of the total radioactivity present in the
ketonic fraction. The remainder was more polar material which
has not been identified.
The formation of 2-methoxyestrone from estrone and 2-
hydroxyestrone by rat liver "microsomal preparation" has been
investigated. The concentrations of all the co-factors and
methionine methyl-^C were identical in the samples. As the
amount of estrogen increased, the radioactivity in the ketonic
fraction and in the 2-methoxyestrone zone increased (Figure 3);
2-hydroxyestrone led to a much greater formation of 2-methoxy-
estrone than did estrone as a substrate. The non-ketonic
fractions showed an increase in radioactivity as the amounts of
estrone or 2-hydroxy*estrone were increased in the incubation
mixture (Table l). On chromatography in the MeCy:Tol:MeOH
system this fraction yielded a radioactive zone which had the
same mobility as 2-methoxyestradiol-17(3,and two other zones,
one retained on the starting line and the other less polar than
2MeE2« On thin layer chromatography the 2MeE2 zone behaved
like authentic 2-methoxyestradiol-17(3,, It is of interest to note
that 2-hydroxyestrone yielded proportionately more radioactivity
in the non-ketonic fraction and in the 2MeE2 zone than did estrone.
It is unlikely that the 2-hydroxyestrone used for incubation could
contain 2-hydroxyestradiol-17p since on chromatography this
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FORMATION OF 2-METHOXYESTRONE
Figure 3: Formation of 2 methoxyestrone by rat liver "microsomal"
preparation (8000 g supernatant).
Dotted line - radioactivity in the ketonic fraction.
Solid line - radioactivity in 2 methoxyestrone zone.
steroid did not separate or yield any compound which would
correspond to 2-hydroxyestradiol~17(3<) Also, estrone used for
incubation was free from other contaminants. These results
suggest that the rat liver "microsomal" preparation carries out
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3,4 DIHYDROXY BENZOIC ACID
_L
7 .8 1.0 VM INHIBITOR
Figure 4: Inhibition of 2-methoxyestrone formation from estrone
and methionine-methyl-^C by rat liver "microsomal" preparations
(8000g supernatant).
Initial concentration of estrone = 0.37 (J.M, indicated by arrow.
Amount of 2-methoxyestrone formed in absence of inhibitor = 100%
position 2 of ring A and reduction of the 17 keto group.
The effect of tyrosine, estriol and various catechols on
orthomethylation has been investigated. Rat liver "microsomal"
preparations were incubated with 0.37 (J.M of estrone in the
14
presence of methionine methyl- C and co-factors as outlined
earlier (Figure 4). Tyrosine had no effect on 2MeEj formation.
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Increasing doses of estriol decreased the formation of ZMeE^-^C
only to a certain degree. Epinephrine produced a more pronounced
inhibitory effect with the same pattern. Plant catechols, such as
3, 4 dihydroxy benzoic acid and chlorogenic acid, markedly
inhibited estrone conversion to Z-MeE^-^C.
Incubation of rat liver microsomal preparations with estrone
and increasing amounts of estriol produced two effects. As the
initial concentration of estriol increased the synthesis of 2-methoxy-
estrone decreased and estriol became metabolized to increasing
amounts of non-ketonic material which behaved chromatograph-
ically on paper in the hexane : benzene : 70% methanol (20:80:100)
system, and on thin layer systems, as 2-methoxyestriol. When
estrone was incubated in the absence of estriol, the non-ketonic
fraction did not contain any zone which would correspond to
2-methoxyestriol (Figure 5).
It has been suggested by King^ and also by Breuer^ that
methylation is preceded by 2-hydroxylation. An attempt was
therefore made to block ortho-methyl transferase activity with
large amounts of 2~hydroxyestrone. In this series of experiments
estrone-lO-^C and unlabelled methionine were used, the co-factors
concentration being the same as in previous experiments. Estrone
14
16- C was metabolized to a product which had the same chroma¬
tographic characteristics as had 2-methoxyestrone. As the initial
concentration of 2-hydroxyestrone in the incubation medium
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TRANSFER OF METHIONINE-METHYL-C14 GROUP TO ESTROGENS
Figure 5: Transfer of methionine methyl-1group to estrone and
estriol by rat liver "microsomal" preparation (8000g supernatant).
MeE^ - 2-methoxyestrone
MeE3 - 2-methoxyestriol
increased an increment was observed in the radioactivity which had
the chromatographic mobility of 2-hydroxy estrone in the MCy:Tol:
MeOH paper chromatographic system and in system "A" for thin
layer chromatography (Table 2), The chemical instability of this
compound made further characterization of the 2-hydroxyestrone
zone difficult.
Discussion:
Ortho methylation of estrone by rat liver subcellular fractions
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Table
Formation of labelled 2-hydroxye strone from estrone-16-14C
















Estrone-16-14C 0.37 (xM = 982,700 cpm
in the presence of methionine involves a series of biochemical re¬
actions, which includes activation of methionine, ortho-hydroxy-
lation of estrone and the transfer of the methyl group from S-adenosyl-
10,11
1-methionine to 2-hydroxye strone. It has been shown by Cantoni
that mammalian liver tissue contains a methionine-activating enzyme.
In the activation reaction adenosine triphosphate (ATP) in the presence
of magnesium ions reacts with methionine forming S-adenosyl-1-
methionine (SAMe) and releases phosphate and pyrophosphate. It is
well known that SAMe functions as a methyl donor in a variety of
biochemical methylation reactions. In their studies of catechol¬
amine metabolism Axelrod and Tomchick12 isolated from the soluble
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fraction of rat liver an enzyme, ortho methyl transferase, which
catalyzed the transfer of the methyl group from SAMe to position 3
of epinephrine. Recently Breuer et al ^ showed that this enzyme
also methylates 2-hydroxyestradiol-17p to 2-methoxyestradiol-17|3.
In this latter reaction the Km of 8.7xlO"*^M is higher than that for
epinephrine (Km1.2xl0 ^M) suggesting that 2-OH-E2 has a lesser
affinity for the enzyme. These findings may explain the inhibitory
action of epinephrine in 2-methoxyestrone formation by the rat
liver subcellular fraction. Inhibition of ortho-methylation by the
plant catechols, chlorogenic and 3,4 dihydroxy-benzoic acid, may
be explained on similar grounds. Mashri et al1^ have shown that
rat liver slices in vitro, when incubated with 3,4 dihydroxy benzoic
acid, give rise mainly to 3-methoxy, 4-hydroxy benzoic acid and
its glycine conjugate and also to a small amount of 3-hydroxy, 4-
methoxy benzoic acid. In the present study no attempts were made
to separate epinephrine, 3, 4 dihydroxy benzoic acid or
chlorogenic acid metabolites.
Formation of 2-hydroxyestrone from estrone by rat liver
subcellular fractions has been shown, althougn definite proof, in
the form of the isolation of this intermediate, is still lacking.
Kingk, however, has demonstrated the formation of 2-hydroxy-
estriol from estriol by rat liver microsomes. It is of interest to
note that estriol when incubated together with estrone reduced the
yield of 2-methoxyestrone and gave rise to 2-methoxyestriol. This
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observation may be the result of a more efficient 2-hydroxylation of
estriol than of estrone and the availability of a 2-hydroxylated
compound which acts as a rate-limiting factor in ortho methylation.
The far greater yield of 2-methoxyestrone from 2-hydroxye strone
than from estrone is in favour of this explanation. Ortho-methyl-
ation reactions of catechols are rather widespread in mammalian
organisms and the activity has been demonstrated in kidney, adrenal,
ovary and testis1^. Tissue mince from human endometrium,
Fallopian tube, fibroid tumor, functioning ovary and menopausal
ovary activates methionine-methyl-^C without exogenous ATP and
forms methoxy estrogens from 2-hydroxyestradiol-17(3 and 2-hydroxy-
estrone*^. Biochemical methylation is one of the mechanisms of
inactivation of endogenous and exogenous catechols. In the case
of estrogens 2-hydroxylation reduces the biological potency some
100-fold and a subsequent methylation of 2-OH-estrone and 2-0H-
estradiol-17p reduces the activity a further 10-fold as shown by
Martin1^ using the intravaginal blue tetrazolium assay. In other
reports where uterine weight assay has been used, the potency of
2-methoxy estrogens may be even lower. 2-Methoxy and also 2-
hydroxy estriol are inactive in the mice vaginal assay. ^ Recently,
Mittermayer and Breuer^ demonstrated that rat liver microsomes
catalyze the demethylation of 2-methoxyestradiol-17p to 2-hydroxy-
estradiol-17(3. This reaction, however, occurred to a rather small
extent of about 2.5%. In vivo administration of 2-methoxyestrone
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to human subjects is apparently followed by demethylation with the
in 1 Q
excretion of 2-hydroxyestrone . Brown has demonstrated in vivo
the demethylation of estrone, estradiol 17p and estriol 3-methylethers,
In terms of biological potency demethylation may represent an activat¬
ion mechanism. The nature of the demethylating enzyme system and
its tissue distribution is still not known.
The following trivial names and abbreviations are used in the text:
Estrone = 3-hydroxy - 1,3,5(10) - estratriene -17- one.
(Ex)
Estradiol 17|3 = 3, 17(3 -dihydroxy - 1,3,5(10) estratriene.
(e2)
Estriol = 3, 16a, 17p —trihydroxy - 1,3,5(10) estratriene.
(e3)
2 Hydroxyestradiol 17(3 = 2,3,17(3 -trlhydroxy- 1,3,5 (10) -
(2-0H-E2) estratriene.
2 Hydroxyestrone = 2,3, -dihydroxy - 1, 3, 5 (10) - estratriene
(2-OH-E^ -17-one.
2 Methoxyestrone = 2-methoxy, -3-hydroxy- 1,3,5 (10) -
(2-MeEj) estratriene -17-one.
2 Methoxyestradiol 17p = 2 methoxy-3,17p -dihydroxy -
(2-MeE2) 1,3,5 (lO)-estratriene.
2 Methoxyestriol = 2-methoxy-3,16a , 17p -trihydroxy - 1,3,5
(2-MeEg) (10)-estratriene.
Results in part presented to the Canadian Federation of
Biological Societies, London, Ontario, June 1963
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ABSTRACT
The metabolic fate of orally administered 17a-
ethynylestradiol-3-cyclopentyl ether (EECPE) labelled
with 3H in the steroid nucleus and with 14C in the cyclo-
pentyl group has been studied in women in two independent
laboratories. Radioactivity was excreted over a period
of up to 127 days, and unchanged EECPE was recovered from
fat at 2 and 3 days after ingestion. Substantial quanti¬
ties of ethynylestradiol were identified in the processed
urine by recrystallization with carrier. Three other
urinary metabolites were detected; the least polar con¬
tained 3H and ltfC but was not EECPE. This metabolite is
probably present in the urine over the entire excretion
period. The most polar metabolite contained only 3H and
was quantitatively prominent in urines from the first few
days collections but disappeared from the excretion pattern
with time. A metabolite of intermediate polarity increased
in relative amount during the collection period.
INTRODUCTION
Etherification at position 3 has been reported (4,5) to in¬
crease the oral and decrease the subcutaneous activity of ethynyl
estradiol (EE). Meli and co-workers (5) have shown that storage in
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and release from body fat is the mechanism responsible for this in¬
creased oral acitivity, in rats, of ethynylestradiol-3-cyclopentyl
ether EECPE. as compared with EE. These investigators (6) have
also shown that the estrogenic material stored in rat perirenal fat
is unaltered EECPE . The results of Epstein at al_. (7) have indi¬
cated that EECPE has a prolonged estrogenic effect in humans. The
present report is the result of two independent studies undertaken
to provide information on the storage, rate of excretion and metabo¬
lism of radioactive EECPE in human subjects in vivo. Where the ex¬
perimental procedures differed between laboratories both are given.
Experimental procedure A was carried out at The Worcester Founda¬
tion for Experimental Biology and experimental procedure B was car¬
ried out at The Montreal General Hospital.
EXPERIMENTAL PROCEDURE
A. Worcester Laboratory
The subjects were two physically normal women who were hospi¬
talized for mental disease. Subject A.P. was 35 years old and
weighed 174 lbs., while subject J.A. was 29 years old and weighed
156 lbs. Labelled EECPE was obtained from Warner-Lambert Research
Institute, Morris Plains, New Jersey. Each subject received 995 yg
of EECPE, absorbed on 215 mg of USP lactose and containing 25 yc of
11+C and 250 yc of 3H. The tritium was at positions 6 and 7 of the
steroid nucleus while the 11+C was at position 1' of the cyclopentyl
ring. The material was administered orally.
Daily urine collections were made for the first 6 days after
administration, and 24-hour samples were obtained at intervals dur¬
ing the next 127 days and assayed for radioactivity in a Packard
Tricarb Liquid Scintillation spectrometer. Appropriate correctioni
for quenching and for the contribution of one isotope to the assay
of the other were made as previously described (8).
Several of the 24-hour urine samples were extracted with
chloroform to give the "free" fraction of the excreted radio¬
activity. The urine was then incubated with Ketodase for 24 hours
as described by Flood, ejt a]L. (8) and extracted with chloroform.
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The incubation was repeated for a further 24-hour period and the
chloroform extraction was again carried out. In the case of the
first 24-hour samples the residual urine was extracted with ethyl
acetate at pH 5.0 then after saturation with sodium chloride at
pH 1 (9). A final extraction with butanol was then carried out.
The radioactive metabolites in the glucuronoside fraction of
the urine samples were initially separated by countercurrent dis¬
tribution in the system ethyl acetate-cyclohexane-ethanol-water
1:1:1:1 as described by Gallagher, ej: al. (10). Preliminary identi¬
fication of ethynylestradiol was made by thin layer chromatography
on silica gel and then confirmed by recyrstallization to constant
specific activity with the authentic compound.
B. Montreal Laboratory
Three female subjects (A.C., C.L. and E.B.), aged 27, 53 and
39 years, respectively, were investigated. All three suffered
from cancer of the cervix but none was terminal during the study.
Each was given 190 pg of the labelled EECPE described in Experi¬
mental Procedure A, in a single oral dose. The radioactive dose
in each case was 50 yc of 3H and 5 yc of 11+C. Complete 24-hour
urines were collected daily from subjects A.C. and C.L. for 53 and
25 days, respectively. Subject A.C. underwent a hysterectomy two
days after administration of the dose and at this time various
tissues, including fat, were obtained. Subject E.B. underwent a
similar operation three days following EECPE administration. In
this case only fat was obtained.
All urines were assayed for radioactivity using a Nuclear-
Chicago model 6725 dual channel liquid scintillation spectrometer.
All samples were corrected for quenching and the 3H and 1£*C counts
calculated by a standard method. Various individual urines were
extracted with ether following incubation with bacterial 6-glu-
curonidase at pH 6.5 (11). The residual urine was extracted at the
same pH with ethyl acetate and then again, with the same solvent,
at pH 1, following saturation with NaCl. Finally, butanol extrac¬
tion was performed. The various extracts were assayed for radio¬
activity and the ether extract obtained following B-glucuronidase
hydrolysis was subjected to partition chromatography on a Celite
column with a stationary phase of 80% methanol. Elution was car¬
ried out by the stepwise addition of increasing concentrations of
benzene in n-hexane.
Tissues other than fat were homogenized in acetone and radio¬
activity was assayed. Fat was homogenized with acetone, the filter¬
ed extract evaporated and the resulting material partitioned between




The excretion pattern of both % and 1 4C from the subjects
A.P. and J.A. is shown in Fig. 1, expressed as percentage of the
administered dose present in each 24-hour urine sample. During







12 3 4 5 16 28 39 53 78
Days after dose
Fig. 1. Urinary Excretion of Labelled Quinestrol.
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subject A.P. excreted 14 percent of the 11+C dose and 8 percent of
the 3H dose, while subject J.A. excreted 19 percent of the 1LfC
and 8 percent of the 3H. For the following 100 days there was a
continuous slow excretion of both isotopes. At day 127, very small
amounts of radioactivity were still being excreted by A.P., while
no radioactivity was detectable in the urine of J.A.
Essentially the same pattern was obtained for subject A.C.
(Fig. 2) over 53 days of continuous collection. Similar results





















10 20 30 40 50
DAYS AFTER ADMINISTRATION
60
Fig. 2. Urinary excretion of total radioactivity in subject
A.C. Recovery after 53 days: 3H = 35%, 1I+C = 48%.




































































aEnzyme=bacterial^-glucuronidase,so vent=ether. kpHusedwas6.5. cRepresentsthpooledurinofb thsubj ctsfothredays.
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Table 1 shows the percentage of the urinary radioactivity from
A.P. and J.A. which was extracted from the individual urines of
days 1, 28, 53 and the combined urines of days 98, 99 and 100.
14 3
Only small amounts of either C or H were extracted from the
urine by chloroform prior to hydrolysis. A considerable amount of
3 14
H but very little C was extracted after treatment with 3-glu-
curonidase (Ketodase, Warner-Chilcott). Most of the 14C was in a
highly polar form and was only extracted by ethyl acetate or butanol
at pH 1.
Also included in Table 1 are the results for the extraction
of radioactivity from the first day's urine of subject A.C. As
1 4
above, the majority of the C was in a highly polar form result¬
ing from rupture of the ether linkage of the EECPE and further
degradation of the cyclopentyl fragment. The figures for A.C.
were qualitatively similar to those for A.P. and J.A. although a
slightly different extraction scheme was followed. The quantita¬
tive differences may be due in part to less complete hydrolysis
by the bacterial glucuronidase than by Ketodase and to the greater
solubility of the metabolites in chloroform as compared to ether.
Only the chloroform and the ether extracts following enzymatic
hydrolysis were further examined.
The countercurrent distribution pattern of the 3H in the glu-
curonoside fractions of the urines from days 1, 53 and 98-100 are
shown in Fig. 3 for J.A. and A.P. Three major peaks of radio¬
activity, A, B and C, are evident. Peak A disappears from the
distribution pattern with time, while the relative size of peak B
282 STEROIDS
Fig. 3. Countercurrent distribution of the tritium extracted with
chloroform, after Ketodase treatment, from the urine of women receiv¬
ing doubly labelled ethynylestradiol-3-cyclopentyl ether. The system
was ethyl acetate-cyclohexane-ethanol-water 1:1:1:1.
to peak C increases. Peak C was found to consist almost entirely
of a material containing 3H but no lltC which was similar to ethynyl-
estradiol on thin layer chromatography. An aliquot of peak C from
the distributions for each of days 1, 53 and 98-100 was added to
authentic ethynylestradiol. Constant specific activity was ob¬
tained on recrystallization in each case, at 76, 58, and 84 per¬
cent of that calculated from the radioactivity of peak C for the
respective days (Table 2.).
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Table 2.
Crystallization of radioactivity from Peak C, fig. 3, and Peak 2,
fig. 4, with carrier ethynylestradiol
mg carrier d.p.m. d.p.m./mg at % of Peak
used (%) constant s.a. as E
Day 1 103 2.93 x 105 2200 78
Day 53 65 1.7 x 105 1500 58
Days 98-■100 66.5 1.65 x 105 2200 84
Peak 2, fig.4 47.6 1.66 x 105 3000 85
When a portion of the glucuronoside extract of the day 1
urines of J.A. and A.P. was distributed in the countercurrent
system carbon tetrachloride-methanol-water 10:7:3, a relatively
small peak of radioactivity, less polar than ethynylestradiol,
containing both 3H and 1was detected. On thin layer chromato¬
graphy this material was not identical with EECPE. This peak
appeared to be present in similar extracts from days 98-100, how¬
ever, the absolute amount was too small for further study. This
material is probably that described below as peak 1 from day 1
of subject C.L. and day 15 of subject A.C.
All four radioactive peaks detected on countercurrent distri¬
bution were examined on thin layer silica gel plates containing
silver nitrate, prepared and used as described by Ercoli, et al.
(12). In each case the radioactivity remained at the origin in
various ethylacetate-cyclohexane systems, indicating that the
materials contained an unaltered 17a-ethynyl group.
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FRACTION NUMBER (5 MLJ
Fig. 4. Celite partition of ether extract of day 1,
subject C.L.; 15 x 1 cm. column; recovery from column,
3H = 98.7%, 1I+C = 85%. dpm 3R: dpm ll+C of Peak 1 = 10.3
Figure 4 shows the chromatographic separation achieved on the
ether-soluble radioactivity following 8-glucuronidase hydrolysis
of day 1, subject C.L. Three peaks can be seen, one of which,
peak 2, containing only 3H, was shown, by crystallization with un-
labelled standard to be composed at least 85% of ethynylestradiol
(Table 2.). Peak 1 contained both 3H and llfC and was more polar
than EECPE. Peak 3 contained only 3H. Approximately 17% of the
3H activity in the ether extract was present in peak 1, 40% in peak
2 and 34% in peak 3. The pattern obtained by similar treatment of
an extract of day 15 from subject A.C. was similar. In this case
peak 1 accounted for 23%, peak 2 for 48% and peak 3 for only 13% of
the total extract.
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The countercurrent pattern (Fig. 3) shows the disappearance
of peak A and the appearance of peak B with time. Both of these
peaks were more polar than EE and probably are both included in
peak 3 of the chromatographic workup.
In subject A.C. no radioactivity could be detected two days
after EECPE administration in ovary, uterine wall, endometrium,
tube or whole blood. However, a methanol extract of fat (abdominal
wall + omentum) contained 11100 d.p.m. of 3H and 1240 d.p.m. of 1.
This material, when chromatographed, showed 92% of the 3H and 80%
of the ltfC to be eluted in the position shown to be occupied by pure
EECPE in Fig. 2. The 3H/ 14C ratio of this material was 10.3.
Considerably more fat was obtained from subject E.B., and a methanol
extract contained 110,000 d.p.m. of 3H and 10,400 d.p.m. of ll4C.
Again, all of this activity, when chromatographed, was eluted at
the polarity of EECPE with a 3H/11+C ratio of 10.3. Because of the
lipophilic nature of the radioactive material in question, con¬
siderable partition between hexane and methanol was performed in
order to remove as much contaminating fatty material as possible.
This resulted in considerable loss of radioactivity so that a
quantitative value for EECPE in the fat was not obtained. Neither
was it possible to prove that all of the radioactivity in the fat
was EECPE. Following addition of 41.7 mg of unlabelled EECPE to
the radioactive fraction isolated (41,000 d.p.m. 3H; 4330 d.p.m.
14C), 3 crystallizations were done from methanolwater. This resulted




Crystallization of radioactivity from fat with unlabelled EECPE.
Specific activity (d.p.m./mg)
Crystallization "^C ^H/^C Ratio
1 623 84 7.4
2 683 93 7.35
3 702 90 7.8
DISCUSSION
The very slow excretion of the administered radioactivity indi¬
cates that EECPE, or some derivative thereof, is stored in the
body of human subjects for a long period of time. In the case of
subject A.P. traces of radioactivity were still detectable in the
urine 127 days after administration of the dose. The physiological
potential of a single dose of EECPE is therefore of long duration.
Since EECPE was recovered from fat 2 and 3 days after inges¬
tion, it is probable that it is stored unchanged. In any case, the
storage form is one which permits the slow release of ethynylestra-
diol, since this compound was rigorously identified in all the
urine samples examined. The slow release of this estrogen would
explain the clinical observations of J.A. This subject received
the single oral dose of EECPE on day 19 of her menstrual cycle.
She did not menstruate until day 55. Her next period was 47 days
long, followed by one of 33 days, after which she resumed a normal
28-day cycle. No clinical observations were made on A.P., who was
anovulatory, or on the hysterectomized subjects.
The results indicate that all the excreted metabolites retain
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the ethynyl side chain. Metabolite 1, (Fig. 4) is the only metabo¬
lite which retains the ll+C label. It is not known whether the
cyclopentyl group on this compound has been altered or whether
it remains intact.
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ABSTRACT. The mode of conjugation of
urinary metabolites of injected 17/3-estradiol-6,
7-3H was studied in 10 nonpregnant human fe¬
males. Estrone was the major identified con-
stitutent of a fraction released from conjugation
by solvolysis and this "estrone sulfate" ac¬
counted for 2-65% of total urinary estrone. In
one instance, in an apparently normal young
female, estrone-3-sulfate was directly identified
as a quantitatively major metabolite, exceed¬
ing the glucosiduronates of both estrone and
estriol. The considerable "sulfate conjugation"
of estrone and of other estrogen metabolites in
this subject was apparently a reproducible find¬
ing. Besides estrone, 2-methoxyestrone was
regularly identified in the subjects studied, as a
component of the fraction released by solvolysis
AN INCREASING interest in estrogen. conjugates, including the sulfates, has
been apparent over the years. In 1938 es¬
trone sulfate3 was identified as a constituent
of pregnant mares' urine (1) and in the
following year was shown to be present in
human pregnancy urine (2). More recently,
detailed information has become available
on the mode of conjugation of certain urin¬
ary estrogenmetabolites following injection
Received October 22, 1968.
Supported by Grant MT 532 from the Medical
Research Council of Canada.
1 Presented in part at the Third International
Congress of Endocrinology, Mexico City, July 1968.
2 Medical Research Associate of the Medical
Research Council of Canada.
3 The following abbreviations and trivial names
have been used for steroids: 2-methoxyestrone
(2MeO —Ei) =2-methoxy-3-hydroxyestra-l,3,5(10)-
trien-17-one; 16a-hydroxyestrone (16aOHEi) =3,
16a-dihydroxyestra-l,3,5(10)-trien-17-one; 16-ke-
toestradiol-17/3 (16KE2) =3,17/3-dihydroxyestra-l,
3,5(10)-trien-16-one; 16-epiestriol (16epiE3) =estra-
l,3,5(10)-triene-3,16/3,17(3-triol; EL=estrone; E2
= 17fJ-estradiol; E3 = estriol; estrone-3-sulfate =3-
yl-sulfate-estra-l,3,5(10)-trien-17-one. G =fraction
extractable with diethyl ether following incubation
with /3-glucuronidase; S = fraction extractable with
ether following solvolysis (after pre-extraction of
G fraction) or fraction extractable with ether fol¬
lowing incubation with phenolsulfatase.
and this conjugated form accounted for up to
63% of total urinary 2-methoxyestrone. En¬
dogenous urinary "estrone sulfate" in the normal
menstrual cycle varied considerably between
subjects and accounted for 0-71% of total
estrone. Other metabolites of labeled 17/3-estra-
diol, including the latter itself, 16<x-hydroxy-
estrone, 16-ketoestradiol-17/3, 16-epiestriol and
estriol, were less frequently identified following
solvolysis of urine originally incubated with /3-
glucuronidase, i.e., as "sulfates" and/or double
conjugates such as "sulfoglucosiduronates." In
3 out of 11 studies 16a-hydroxyestrone and 16-
ketoestradiol-17/3 were identified in this form
(16-52% of total) but estriol conjugated in this
way formed no more than 7% of total estriol.
J Clin Endocr 29: 328, 1969)
of labeled precursors into the nonpregnant
human female (3-5). However, there ap¬
pears to be little knowledge as to the gen¬
eral pattern of individual phenolic steroid
conjugates to be expected in the nonpreg¬
nant female. The present study was under¬
taken with a view to ascertaining the signi¬
ficance or otherwise of estrone sulfate in the
urine of the nonpregnant female, both as an
endogenous compound and as a metabolite
of injected 17/3-estradiol-6,7-:!H (3H-E2).
During the course of the investigation some
information was also obtained as to the
conjugation of urinary 2-methoxyestrone
(2 MeO-Ei), estradiol-17/3 (E2), 16a-hy-
droxyestrone (16aOHEi), 16-ketoestradiol-
17/3 (16KE2), 16-epiestriol (16epiE3) and
estriol (E3).
Subjects
Subjects injected with 17Q-e.stradiol-6,7- H. Ten
females were studied. Six of these (MOL, 29 yr;
VA, 40; TR, 25; MO, 42; SO, 23; GZ, 42) had
normal cycles as judged by biphasic tempera¬
ture curves, urinary pregnanedioi levels and
endometrial biopsies. MOL and VA were
studied only at about the time of ovulation,
3H-E2 being injected at about day 12 of the
cycle. MO, SO and GZ were injected in the
328
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luteal phase (about day 19). TR was studied on
2 separate occasions, in each half of the cycle, at
an interval of about 22 months. Two subjects
(CO, 25 yr; PI, 23) were suffering from amen¬
orrhea at the time of injection. Two others (OD,
57 yr; RO, 60) were post menopausal. None of
these subjects was on any type of medication
and no evidence was obtained for any endocrine,
hepatic, renal or cardiac disorders.
Subjects in whom endogenous EXS and EXG were
measured. This group consisted of 10 females
(20 41 yr) exhibiting normal and regular cycles.
One of these was studied on 2 occasions, some
3 months apart. No subject was on medication
at the time of study and no clinical disorders
were present. Measurements were made on 24
hr urines collected at about days 14 and 22 of
the same cycle in each case.
Materials and Methods
Radioactive compounds. During the course of
the study 2 batches of 3H-E2 were used. One,
of specific activity (SA) 4-0 /xCi/jUg, was pur¬
chased from Merck, Sharp & Dohme Ltd., and
was purified as described in an earlier publica¬
tion (6). The second, of SA 20 ,uCi//ug, was ob¬
tained from New England Nuclear Corp., Bos¬
ton, Mass., and was purified in the same man¬
ner. Estrone-6,7-3H (3H-Ej), of SA 10 /iCi/jug,
was purchased from New England Nuclear
Corp. This was chromatographed on a Celite
partition column (7) and the eluted material
shown to be at least 99% pure by crystalliza¬
tion with the unlabeled form of the steroid.
These labeled estrogens were stored in benzene :
methanol (1:1) at —15 C and their purities
checked at suitable intervals by chromatog¬
raphy and reverse isotope dilution.
Estrone-6,7-3H-3-sulfate (SA 8 /xCi//xg) in
the form of its NH4+ salt was purchased from
New England Nuclear Corp. This material was
chromatographed on a 20 g column of alumi¬
num oxide (Woelm, neutral, activity grade I)
in methanol containing a small concentration
of NH,OH (2 -3 drops conc. NHjOH/100 ml).
Radioactivity with the mobility of estrone sul¬
fate (fractions 5-8; each 10 ml) was collected
and the purity of the material checked by re¬
verse isotope dilution with authentic unlabeled
estrone-3-sulfate (see below). The results were
confirmed by conversion to free estrone and
then to estrone-3-acetate with crystallization
at each stage. The data showed that the labeled
estrone sulfate was about 99% pure. It was
stored in methanol with the addition of 1-2
drops of conc. NH4OH at —15 C and its purity
was checked periodically.
«-Hexadecane-l,2-3H (original SA 2.46 /xCi/
g) was purchased from The Radiochemical
Centre, Amersham, Bucks., England. This was
used for the preparation of absolute counting
standards and was stored at 4 C. During the
course of the study the half-life employed in
calculating radioactive decay was 12.26 yr.
Nonradioactive steroids. All unlabeled steroids
in their free forms were purchased from Mann
Research Laboratories, Inc., New York. The
purity of these was checked by thin-layer
chromatography (8) and by melting point
determination (microscope hot stage). Un¬
labeled estrone-3-sulfate (Na+ salt) was synthe¬
sized in the laboratory by the method of Fieser
(9). Extraction and purification was performed
as described elsewhere (10). The NH.i+ salt was
prepared by solution in m NH.OH and was re-
extracted with n-butanol. The crystalline ma¬
terial exhibited an infrared spectrum (KBr disc)
identical with that of estrone-3-sulfate and on
heating decomposed and finally sublimed at
230-233.5 C. On solvolysis (11) or hydrolysis
with phenolsulfatase (12) it gave a quantitative
yield of Eu It was stored, in the dry state, for
up to 3 weeks in an evacuated desiccator over
anhydrous CaSO, at —15 C without apparent
structural alteration.
Other chemicals and reagents. Bacterial /((-glu¬
curonidase powder (Type II) was obtained from
Sigma Chem. Co., St. Louis, Mo., and Mylase
P, containing sulfatase, was purchased from
Mann Research Laboratories, Inc. Aluminum
oxide, Woelm, activity grade I, was obtained
from Alupharm Chemicals, New Orleans, and
was stored in tightly stoppered bottles. Acetic
anhydride was refluxed with fused sodium
acetate and distilled twice, under anhydrous
conditions, before use. Pyridine was similarly
treated but with barium oxide. Tetrachloro-
ethane and p-nitrophenol were treated as de¬
scribed elsewhere (13), as were Celite and all
organic solvents used for extraction and chro¬
matography (14). Sodium borohydride powder
was stored in a desiccator over calcium chloride.
Phosphors, for liquid scintillation spectrometry,
are described in a later section of this paper.
Injection of subjects and urine collection. Purified
3H-E2 (about 15 gCi) was injected into an arm
vein in 10 ml of 10% absolute ethanol in physio¬
logical saline. The dose given in each case was
corrected for the radioactivity remaining in the
syringe and vial following injection. Urine was
collected in polyethylene bottles without preser¬
vative for 4X24 hr periods in each case. The
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collections were either immediately processed
or frozen at —15 C until required.
Where endogenous estrone was to be mea¬
sured total 24 hr urines were collected and
stored under the above conditions.
Hydrolysis, extraction and separation of radio¬
active metabolites. Suitable volumes of 4-day
urine pools (§—f of total volume depending on
content of radioactivity, volume, etc.) were
extracted with ether to remove unconjugated
estrogens ( <1% of the dose). The residual
urine, from which excess ether had been re¬
moved, was adjusted to pH 7 with n NaOH or
glacial acetic acid and buffered with 1/10 vol
of 0.1m KH;P04-NaOH buffer, pH 7. This was
incubated for 24 hr at 38 C with 20 U/ml of
bacterial /3-glucuronidase (15). A further addi¬
tion of the same amount of enzyme was followed
by a second 24 hr incubation. Radioactivity
released by this process was extracted with
ether, the extract was washed with 1/10 vol of
m NaHC03, then with 1/20 vol of H O and
finally dried over anhydrous Na.S04 prior to
evaporation to yield a "glucosiduronate" (G)
fraction. The residual urine was adjusted to
pH 2 with 7n H.SO,, made 3m with NaCl and
extracted with 3 vol of ethyl acetate. The
steroid sulfates were solvolyzed at 38 C with
H SOi as described by Segal et al. (11). The
radioactive material so released was termed the
"sulfate" (S) fraction.
The G and S fractions were separately but
identically fractionated into their constituent
labeled steroids by a procedure described earlier
(6). This involved Girard separation, liquid/'
liquid partition and Celite partition column
chromatography. Following the latter, 2MeO-
Ej and E, fractions were further purified by
alkaline treatment and re-extraction (6). The
sole deviation from the original procedure con¬
cerned the column ring D a-ketolic fraction
(containing 16aOHE, and 16KE2), which in
this study was directly reduced with NaBH,
(16). This yielded the triols, 16epiE3 mainly
from 16KEo (but also from 16/3-hydroxyes-
trone) and E3 mainly from 16aOHEi, which
were extracted from aqueous solution with
ether, partitioned between toluene and n
NaOH, re-extracted from alkali with ether fol¬
lowing pH adjustment, and finally washed with
m NaHCOs and H O prior to separation into
16epiE3 and E3 fractions on a Celite partition
column (7).
Individual column eluates, or fractions
thereof, of known radioactivity content were
diluted with weighed amounts (10-30 mg de¬
pending on the radioactivity available) of the
appropriate pure unlabeled steroids and crystal
lized from methanol until 2 successive SA value;
for the crystals agreed within the experimenta
error and matched the values for the cor
responding mother liquors (ML). Radiochemi
cal homogeneity was confirmed by crystalliza
tion in the form of the acetate derivative fron
methanol rHoO. Acetylation was performec
overnight at room temperature in a mixture o
equal volumes of pyridine and acetic anhydride
On occasion, other derivatives were prepared
e.g., in the case of 2MeO-Ei in which crystalli
zation was first carried out in the free form
then after formation of the 3-acetate, anc
finally, following preparation of 2MeO-E.-3
17-diacetate by reduction with NaBH., and re
acetylation. Melting points of the final crystal
line derivatives were checked on a microscopi
hot stage.
The mathematical product of the weight o
carrier steroid added and the final SA of tb
pure crystals (in terms of free steroid) in eacl
case yielded a value for the amount of radio
activity in the form of that particular steroid
This value was related as a percentage to tb
total radioactivity (G+S) extracted. Thesi
final values were corrected for the average
losses (ranging from 60% recovery for ring I
a-ketols to 85% for E,) known to occur for th
various pure steroids through the different ex
traction, Girard and column partition stages
This was not considered to be of much impor
tance for the more chemically stable steroid
since the main object of the study was to com
pare the relation between G and S forms of th
various metabolites. However, particularly ii
the case of the more labile and poorly recoverei
ring D a-ketols (14), such a correction allowed
better comparison between the different metat
olites, stable and otherwise.
Stability of estrone-3-sulfate during (3-glucurom
dase incubation. Since the above study depend©
upon differentiation between "glucosidurc
nates" and "sulfates" by the hydrolytic st
quence /3-glucuronidase followed by sulfatast
it was necessary to ascertain the stability of
compound such as estrone-3-sulfate durin
incubation with the /3-glucuronidase prepare
tion. A number of urines from normal female
not injected with radioactivity were each inci
bated with 2.29 XlO5 dpm of pure :iH-estrone-l
sulfate and /3-glucuronidase under the cond
tions described above for urines containin
radioactive metabolites. Any radioactivity r<
leased from conjugation was extracted wit
ether and assayed. In some cases the residu:
urine was submitted to solvolysis (11) and tt
free 3H-E, recovered was estimated as a pe
centage of added :iH-estrone-3-sulfate.
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Extraction and purification of urinary *H-estrone
sulfate in the intact form. Urine from a subject
njected with : H-E . was extracted with ether at
rH 6.5-7 and then with ethyl acetate at neutral
)H following solution of 20 g NaCl/100 ml of
irine. This latter "sulfate" fraction was evapo¬
rated in the presence of added NH4OH and
;hen submitted to a simple partition in a sep-
iratory funnel between n-butanol and O.In
MaOH. The butanol fraction was washed with
i small volume of saturated NaCl solution,
rvaporated, and chromatographed on alumi-
lum oxide as described above. The "estrone
sulfate" fraction eluted was then chromato-
jraphed on a 75 g Celite partition column in
soluene:«-butanol:0.1n NH(OH (6:4:5) in the
general manner described by Siiteri (17). Radio-
ictivity of mobility similar to that of estrone-
1-sulfate was pooled, evaporated, and crystal-
ized with pure unlabeled estrone-3-sulfate
NH4+ salt). Radiochemical purity was con-
irmed by further crystallization as free E4 and
hen as Er3-acetate as described above for
;ommercial 3H-estrone-3-sulfate.
Measurement of endogenous EiG and EiS. One-
hird aliquots of 24 hr urines were pre-extracted
pH 6.5-7) with ether, and purified 3H-estrone-
l-sulfate (2.29 X105 dpm; <.02 /xg) was added
is internal standard after 20 g NaCl/100 ml had
>een dissolved in each urine. The "sulfate"
faction was extracted with ethyl acetate and
jurified by partition between n-butanol and
>.1n NaOH then by chromatography on alumi-
lum oxide as described above. The radioactive
faction so obtained was incubated at pH 6 in
1.1m acetate buffer for 18 hr with 2.5 mg/ml of
sulfatase-containing Mylase P (4). The steroid
faction released from conjugation was ex-
racted with ether and the extract was purified
)y shaking with NaOH/NaHC03, NaHC03
md H20 (18) prior to drying over anhydrous
<fa>S04. Estrone was then separated via a
lirard reaction (7) and finally by a Celite par-
ition column in the system benzene :0.8n
JaOH (18). The estrone fraction was collected
md analyzed as described below.
The residual urine, following ethyl acetate
extraction, was adjusted to pH <2 and ex-
racted with 3 vol of ether: ethanol (3:1). Al-
hough no labeled estrone-3-glucosiduronate
:as available to check the efficiency of extrac-
ion, it was ascertained that 17/3-estradio 1 -6,7-
rI-17-glucosiduronate (New England Nuclear
'orp.) was quantitatively extracted by this
rocedure. In the absence of labeled estrone
lucosiduronate a known amount of pure 3H-Ei
L.5XlOr> dpm, <.01 gg) was added to the
extract as a means of partially correcting for
losses, although not including losses during sub¬
sequent hydrolysis with ^-glucuronidase. The
ether: ethanol was evaporated to dryness and
incubated at pH 7 for 24 hr with bacterial f-
glucuronidase as described above. Free estrogen
was extracted with ether and E4 was separated
and purified as described for E4 released from
urinary E4S.
Duplicate column eluates (usually 10-20%
aliquots) containing E4 from urinary E4S and
E,G were measured spectrophotometrically by
a micromodification of the Ittrich procedure
(19). The chromogen formed by heating with
0.9 ml 65% (v/v) HBO., was diluted with 1.1
ml H 0 and extracted with 1.5 ml tetrachloro-
ethane containing 2% (w/v) p-nitrophenol.
The optical density (OD) of the latter extract
was measured at 506, 538 and 570 m/x in a
Unicam SP 600 visible light spectrophotometer
fitted with a condensing lens, using micro cells
of 0.8 ml capacity and 20 mm light path. The
OD at peak wavelength (538 m/x) was corrected
by the method of Allen (20) and related to
suitable standards of known E4 content. A
minimum of ca. 0.05 /xg of Et can be measured
in this way and the relationship between cor¬
rected OD and weight is linear up to at least
1 /xg. Aliquots of each column eluate were
assayed for 3H content to yield recoveries of
added 3H-estrone-3-sulfate and 3H-Ei, and
these values were used to correct for methodo¬
logical losses. Recovery of TI-E i from added 3H-
estrone-3-sulfate was 70-80%. Recovery of
3H-Ej added to partially correct for losses dur¬
ing extraction and purification of E4 from E]G
was 75-85%.
By this technique the lower limit of sensi¬
tivity for the measurement of E4 originating as
urinary E4S was about 0.8 /xg 24 hr, and for E4
from urinary EtG, about 1.5 /xg/24 hr.
In order to obtain additional evidence for
the identity of the endogenous material mea¬
sured spectrophotometrically as Et, suitable
aliquots of column eluates (where Et was suffi¬
ciently high) were rechromatographed on 15 cm
Celite columns in the solvent system re-hexane :
benzene :70% methanol (1:1:2) (7), collecting
3 ml eluate fractions. 3H content and E i weight
were determined in each fraction and plotted
against fraction number. A close correspon¬
dence of points was accepted as further proof
of identity.
Measurement of radioactivity. In all cases this
was performed by liquid scintillation spec¬
trometry in 20 ml screw-cap glass vials
(Wheaton Glass Co., Millville, N. J.).
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Table 1. Purified urinary labeled metabolites (% of total G+S extract)
following injection of 3H-E2
Steroid fraction
Subject 2MeO-Ei Ei E2 16aOHEi i6ke2 16epiE3 Ea
MOL 4..0 0.37 9..5 0..42 8.4 * 5.,2 ** 3.4 ** 3 .0 * 14.,1 *
VA 3..6 <0.1 18..2 0.,75 7.3 * 3..8 ** 5.2 ** 2..4 * 10..7 *
(June '66) 0..83 0.64 9..9 7..1 7.3 * 4..3 1.2 3.5 2.5 4..0 * 26..2 *
(April '68) 0 .40 0.69 10 .1 18..9 8.9 1.8 2..0 1.0 2.0 2.2 2 .7 0.68 14.. 7 1.1
MO 2 .3 1.3 14..5 2..7 7.5 * 4 .0 ** 3.5 ** 2..6 * 11 . 7 *
SO 7,.5 1.2 15 .5 4..5 3.6 * 1 .1 *4 0.80 ** 1..4 * 4..3 *
GZ 4..9 0.33 19..2 0..97 t * 4..0 ** 3.2 ** 3..4 * 11 .9 *
CO 1 .6 0.25 13 .4 0 .90 10.2 0.5 2.,5 0.48 1.5 0.86 4 .2 0.66 25 .0 1.0
PI 1 .6 1.0 15..1 1..1 5.5 * - lost lost 4..6 * 16 .4 *
OD 3 .2 <0.3 15..2 0..34 6.1 * 1.. 7 ** 2.6 ** 2 .5 * 17 .5 *
RO 1 .7 <0.7 18 .0 1 .3 5.6 * 4..3 ** 4.6 ** 1 . 5 * 19 .8 *
ge (G+S) 3 .4 20 .7 7..3 3. 6 3. 6 3 .1 16 .0
* Radioactivity was so low as to exclude positive identification.
** Radioactivity was low, amounting, even before rigorous purification, to no more than 10% of the purified 16aOHEiG and i6ke2g
fractions.
f No accurate value was obtained due to a very large decrease in SA on crystallization.
Total urinary radioactivity was counted in a
dioxan scintillation medium [770 ml dioxan, 230
ml ethanol, 134 g naphthalene, 10 g 2,5-
diphenyloxazole (PPO) and 250 mg 1,4-bis-
2-(5-phenyloxazolyl)-benzene (POPOP)]. Urine
extracts, column eluates, crystals, etc., were
counted with or without the addition of meth¬
anol, as the occasion demanded, in toluene con¬
taining either 1 g/1 of PPO and 0.3 g/1 of
POPOP or 7 g/1 of butyl PBD [butyl derivative
of 2-phenyl-5-(4-biphenylyl)-oxadiazole-l,3,4;
Nuclear Chicago Corp.], Quench correction
was made by the internal standard procedure
and all counts were converted to dpm. Counting
was performed on a Nuclear-Chicago 6725 or
6850 spectrometer. Except in some cases for
urine radioactivity sufficient counts were ac¬
cumulated to ensure a counting error of no
more than ±3%.
Results
Following the injection of 3H-E2 the aver¬
age excretion of radioactivity in the urine
in four days was 63 % of the dose. Of this an
average of 50% of the urinary Ti was ex-
tractable by the methods used. In every
case the G fraction contained more 3H than
did the S fraction, but the G: S ratio with
respect to radioactivity varied widely, from
1.3, in the case of subject TR on one occa¬
sion, to 10, for subjects MOL and GZ. The
average G:S ratio was 6.5.
Table 1 contains data for individual me¬
tabolites in the G and S fractions as a per¬
centage of the total extract (G+S) in each
case. All of the values were based on rigor¬
ously purified fractions as outlined in the
Materials and Methods section. Ei was
quantitatively the most important of the
steroids identified in the S fraction. Also,
although not a major metabolite, 2MeO-
EiS accounted for a very considerable per¬
centage of total 2MeO-Ei. Ei and to a lesser
extent 2MeO-Ei were the only steroids con¬
sistently identified as components of the S
fraction. EiS as a percentage of total Ei
ranged widely from about 2 to 65%. It is
noteworthy that subject TR, on two sepa¬
rate occasions, excreted the S form of these
steroids to a considerable extent. Thus, in
the first study (TRI) 2MeO-EiS and EiS
accounted for 44 and 42% of total 2MeO-Ei
and Ei, respectively. In the second study
(TRII) the respective values were 63 and
65%. In this latter case EiS was the major
urinary metabolite identified, exceeding
both E iG and total E 3. Table 1 also shows
the infrequency with which the nonketonic
metabolites, E2, 16epiE3 and E3, could be
identified in the S fraction. Thus, E2S was
found to account for 17 and 5% of total E2
in subjects TRII and CO, respectively;
E 3 S was 7% of total E 3 on two occasions in
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Table 2. Stability of estrone-6,7-3H-3-sulfate (2.29 X105 dpm) during incubation with urine
+ /3-glucuronidase for 48 hours at 38 C and pH 7
Urine no.
Ether-soluble E,
dpm X 10~ % original
Ei recovery after solvolysis
dpm X10-4 % original
1 0 0 *
2 0.45 2.0 —
3 0.53 2.3 —
4 0.16 0.7 21.6 94
5 0.065 0.3 19.5 85
6 0.58 2.5 20.4 89
7 0.62 2.6 — —
8 0.29 1.2 22.1 96
9 0.38 1.6 — —
10 1.02 4.4 — —
11 0.81 3.5 19.5 85
Mean 0.45 1.9 20.6 90
Not analyzed.
TR and about 4% in CO; 16epiE3S was
about 20% of total 16epiE:i in subject TRII
and 14% in CO. The ring D a-ketols, in the
form of their major chemically reduced
products, were identified as components of
the S fraction only in those same two sub¬
jects. 16aOHEiS was 22 and 33% of total
16«OHEi in two studies on TR, and 16%
in CO. The respective values for 16KE2S
were 42, 52 and 36%. All of this suggests
the occurrence of individual conjugation
patterns.
In view of the variability of EiS between
subjects, as shown in Table 1, it became
necessary to enquire into the possibility
that this might in part be due to EiS hydro¬
lysis during /3-glucuronidase incubation.
The results in Table 2 indicate that a defi¬
nite, though small (0-4.4%), degree of hy¬
drolysis does result during this process.
These results render unlikely the possibil¬
ity that EiS could have contributed signifi¬
cantly to the EiG fraction in our studies.
Moreover, 85 to 96% of added 3H-estrone-
3-sulfate could be recovered as Ei following
solvolysis (Table 2).
Table 3 contains data regarding the ex¬
traction and purification of labeled 3H-es-
trone-3-sulfate from the urine of subject
TRII after injection of 3H-E2. In the exper¬
iment, 2.44 X10C dpm, out of a total urine
radioactivity of 19.07 XlO6 dpm, were
shown to be in the form ofestrone-3-sulfate.
This corresponded to 13% of the urinary
radioactivity, uncorrected for experimental
loss. Table 4 provides details for the crys¬
tallization of this labeled estrone sulfate
with authentic unlabeled carrier. The re¬
sults leave no doubt that estrone-3-sulfate
was a major urinary metabolite in the case
of subject TR.
Table 5 shows levels of endogenous EiG
and EiS, in terms of free Ei,rduring the
normal cycle. Subject TR, the individual
Table 3. Purification of urinary 3H-estrone-3-sulfate (subject TRII) following injection of 3H-E2
Stage of purification* dpm per 96 hr urine




Crystallization with estrone-3-sulfate and







Total urine radioactivity 19.07 X106
* For details see Materials and Methods section of text.
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Table 4. Purification by crystallization of urinary 3H-estrone-3-sulfate (subject TRII)
following injection of 'H-Ej
r, . Calculated SA Crystalli- gA gAPurification step (dpm/mg) za^on crystals ML
Estrone sulfate column fraction,
403,800 dpm 3H +40.42 mg
carrier estrone-3-sulfate (NHf salt);
crystallized from methanol-ether
Solvolysis of last crystals
—»Ei; crystallized from methanol
Acetylation of last crystals
—>E i-3-acetate; crystallized from
methanol-H+)
Melting point of final derivative
10,000* 1 7,240 **
2 7,544 7,590
3 7,520 7,620
10,240f 1 10,320 10,240
2 10,500 10,100
9 ,080f 1 9,110 9,000
2 9,090 9,140
= 123.5-126.5 C
* Assuming 100% 3H-estrone-3-sulfate.
** Not measured due to weight of colored impurities.
t Based on SA of preceding crystals.
already shown to produce estrone-3-sulfate
as a major metabolite from injected 3H-E2
(Tables 1, 3) was studied during two cycles,
and on days 8, 14 and 22 of the cycle
showed a relationship between endogenous
E iG and E XS similar to that for the exoge¬
nous forms. EiS accounted for up to 71 % of
total urinary Ei. Certain other subjects also
excreted EiS as an important fraction of
total Et; e.g., in ZA (luteal phase) EiS ac¬
counted for 51% and in MI for 62 and 57%
of total Ei in the proliferative and luteal
phases, respectively. As was the case for
exogenous metabolites (Table 1), endogen¬
ous E iS varied considerably in its quantita¬
tive significance from one subject to an¬
other. In the admittedly small group of
subjects studied, EiS as a percentage of
total Ei averaged 32 and 37% at about day
14 and day 22, respectively, of the normal
cycle.
Fig. 1 and 2 show superimposed radioac¬
tivity and weight of endogenous Ei in two
eluted fractions (Ei from EXG and EXS, re¬
spectively, both from subject TR, luteal
phase, April 1968) prepared from urines as
described in the Materials and Methods
section after pure 3H-Ei and 3H-estrone-3-
sulfate, respectively, had been added as
internal standards. Despite the small num-
Table 5. Endogenous E,G and E,S (as free E, in ng/24 hr) in
urine during the normal menstrual cycle
Subject Age(yr)
Day 14 of cycle (approx) Day 22 of cycle (approx)
E,G E,S EiG EiS
TR (Jan. 1968) 27 16.3 20.8 9.9 21.5
TR (April 1968) 27 5.1* 12.7* 12.1 29.1
SO 24 4.9 1.5 4.9 <0.2**
GA 24 20.8 2.2 11.4 3.7
CH 22 3.4 1.7 18.2 7.4
TY 20 6.6 0.9 3.7 0
GR 32 18.1 3.6 16.0 3.2
ME 25 12.0 4.7 8.6 1.0
ZA 29 8.4 3.8 4.6 4.8
MA 29 21.4 5.6 10.2 5.2
MI 41 5.5 9.0 6.1 8.2
Meanf 11.7 5.4 9.4 5.5
* Day 8 of cycle.
** Not significantly different from zero,
f Does not include TR (April 1968).
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FRACTION NO. (EACH 3ML.)
Fig. 1. Celite partition column chromatography
of an Ei fraction obtained from urinary EiG, sub¬
ject TR (April 1968), after the addition of pure








FRACTION NO. (EACH 3ML.)
Fig. 2. Celite partition column chromatography of
an Ei fraction obtained from urinary EiS, subject
TR (April 1968), after the addition of pure 3H-
estrone-3-sulfate to the urine.
ber of points on each curve there is good
agreement between weight and radioactiv¬
ity with no extraneous Kober-positive ma¬
terial in the elution pattern. Also, recover¬
ies of radioactivity and weight were similar
in each case. It should be noted that a
slight difference between the elution curves
of Fig. I and 2 could be attributed to a
temperature difference during chromatog¬
raphy. These data further indicate the
identity of the ketonic, Kober-positive
compound, purified and measured in this
study, to be Ei.
Discussion
Several technical points in the study
should be considered in relation to this dis¬
cussion since, in view of the hydrolytic pro¬
cedures adopted, absolute certainty regard¬
ing the identity of the individual conju¬
gates is lacking, except where urinary 3H-
estrone-3-sulfate was directly crystallized
with carrier. In the case of labeled 2MeO-
EtG and EiG fractions it seems more than
likely that these would indeed represent
the 3-glucosiduronates of the respective
steroids and would not be contributed to,
to any great extent, by the sulfate forms.
Nevertheless, it should not be overlooked
that some /3-glucuronidase preparations
will hydrolyze the linkage between steroids
and N-acetylglucosamine (21). However,
to date there is no reason to suspect the
presence of important amounts of urinary
Ei or 2MeO-Ei in such a conjugated form.
Available evidence is likewise in favor of
the radioactive fractions termed 2MeO-
EjS and EiS in this study being the 3-sul-
fates of these steroids. Steroids bearing
more than one hydroxyl group, however,
pose an uncertainty, particularly where the
S fraction is concerned. Thus, solvolysis
following ^-glucuronidase action may re¬
lease steroids originally conjugated as sul¬
fate (22), sulfoglucosiduronate (4) or even
perhaps doubly conjugated with sulfuric
acid and N-acetylglucosamine (21), al¬
though the available evidence suggests that
little of the latter may appear in the urine
(23). It is not possible in the present study
to differentiate between these possibilities
where E2S, 16epiE3S, E3S and ring D a-
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ketols S are concerned. Also, it may be that
minimal detection has been made of doubly
conjugated forms because of the hydrolytic
sequence used above since the reverse (i.e.,
sulfatase followed by fi-glucuronidase) pro¬
cedure is claimed to be more effective, at
least for the hydrolysis of E:i-3 sulfate-16-
glucosiduronate (24).
It must also be remembered that, where¬
as the values reported for endogenous EiS
have been corrected for all methodological
losses, the EiG fraction was only corrected
for such losses occurring following conju¬
gate extraction and hydrolysis. Thus, EiS
related to "total ET would yield a maxi¬
mal figure. However, it is unlikely that this
would result in a major error since the de¬
gree of extraction, as judged using 17/3-
estradiol-17-glucosiduronate, was com¬
plete, and furthermore, available evidence
suggests efficient hydrolysis of phenolic
steroid 3-glucosiduronates by /3-glucuroni-
dase preparations (15, 25).
Bearing in mind the above limitations of
the methodology employed, there can be
little doubt that estrone-3-sulfate may be
on occasion a quantitatively significant uri¬
nary metabolite, exogenous or endogenous,
in the nonpregnant human female. Thus,
in one apparently normal subject (TR)
this metabolite, from injected 3H-E2, ex¬
ceeded even EiG and E3G. Moreover, the
quantitative significance of S conjugation
in this subject appeared to be a reproduci¬
ble finding at intervals over a period of al¬
most two years. This finding related to the
conjugation of all the phenolic steroids
studied and suggests the necessity for fur¬
ther investigation into the reasons for such
an individual pattern; e.g., the part played
by the kidney.
Although E i was the main identified ste¬
roid component of the urinary S fraction
following :H-E> injection, it is clear that
EiS in relation to EiG, whether endogen¬
ous or exogenous, may show a considerable
variation and, on the average, EiG is
greater. McKenna et al. (26) have shown
that some 8% of the Ei in pooled late preg¬
nancy urine may be conjugated with sul¬
furic acid. Unpublished work from our lab¬
oratory suggests a higher figure although
variation between subjects is as wide as has
been found for nonpregnant females in the
present study. It should also be pointed out
that sulfate conjugation of urinary Ei may
be quantitatively important in the human
male (27, 28). The only steroid besides Ei
more or less regularly identified in the S
fraction during the present investigation
was 2MeO-Ei. Here again the individual
variation was very wide but it is interest¬
ing to note that the two steroids most con¬
sistently S conjugated (almost certainly
sulfate) are both ketonic in nature.
When compared with the case of 2MeO-
Ei and Ei the identification of E2S, 16epi-
E3S, E3S, 16aOHEiS and 16KE»S was sel¬
dom achieved in this study. It could be ar¬
gued that injection of a larger dose of 3H-E2
might have allowed more frequent de¬
tection of these forms. This could well be
so but it would not alter the relative differ¬
ences in conjugation noted above. Also, it
is possible that the S forms of the ring D a-
ketols are less stable during solvolysis than
is EiS or 2MeO-EiS. However, this would
not be likely to account for the lack of
stable steroids such as E3 and E2 in the S
fraction. Although the ring D a-ketols, par¬
ticularly 16KE2 (in its reduced form and
therefore possibly partly due to 16/3-hy-
droxyestrone), were identified to a signifi¬
cant extent in the S fraction, even if only in
three subjects, E3S accounted for no more
than 7% of total E3 in any case. Whether
these conjugation differences can be attrib¬
uted to such factors as specific tissue en¬
zyme activities, renal handling, plasma or
tissue protein binding, is not clear, and the
answers must await further work.
The pattern of urinary metabolites (aside
from the question of conjugation) of in¬
jected 3H-E2 appears generally similar to
that found by other investigators (29, 30) j
In the present study Ei was on the average)
the main steroid identified, with E3 a close
second. An average of 58% of the G+S
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urinary extract has been accounted for in
the form of identified steroids, which seems
reasonable since no attempt was made to
investigate the quantitatively important
2-hydroxyestrone [2,3-dihydroxyestra-l,
3,5(10)-trien-17-one] (30). The urinary
ring D a-ketols ranged from 1.9 to 11.5% of
the total extract and thus appear to be less
quantitatively significant than originally
thought on the basis of studies in our labo¬
ratory (16). This finding is presumably due
to the more rigorous purification procedures
employed in the present study than in ear¬
lier work.
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summary
Sequential solvolysis, and hydrolysis with /"(-glucuronidase followed by suitable
separation and purification steps has provided some data on the conjugation of
phenolic steroid ring Da-ketols in late pregnancy urine as compared with the pattern
for estriol. In 6 experiments i6a-hydroxyestrone was found to be, on the average,
80% in a form hydrolyzable by /(-glucuronidase, 2% in a form split by solvolysis
(presumably sulfate) and 18% in a form behaving on hydrolysis like a sulfogluco-
siduronate. The corresponding values for i6-ketoestradiol-i7/9 (including perhaps
some 16/f-hydroxyestrone) were 67%, 18% and 15% and for estriol, 94%, 2% and
5%. In 12 experiments the average "non-glucosiduronate" forms of i6a-hydroxy-
estrone, i6-ketoestradiol-i7/3 and estriol amounted to 21%, 38% and 5% of each,
respectively. The "non-glucosiduronate" conjugates of estriol were, by weight,
generally greater in amount than those of the ring Da-ketols. Qualitative supporting
evidence for the presence of these ring Da-ketol conjugates was obtained by direct
DEAE-Sephadex and Celite partition chromatography followed by suitable enzyme
hydrolysis.
INTRODUCTION
Isolation from pregnancy urine of 3,i6a-dihydroxyestra-i,3,5(io)-trien-i7-one
(i6a-hydroxyestrone; i6aOHEj), 3,i7/S-dihydroxyestra-i,3,5(io)-trien-x6-one (16-
ketoestradiol-17/f; i6KE2) and 3,i6/?-dihydroxyestra-i,3,5(io)-trien-i7-one (16/?-
hydroxyestrone; ib/lOIIE,) has been reported1-2. Little information has appeared
regarding the conjugation pattern of these ring Da-ketols although this group of
steroids is quantitatively important in pregnancy2"4. Isolation experiments have
shown that as much as 50% of urinary i6aOHE! may be doubly conjugated, with
1 Present address: Dept. of Medicine, Yale University School of Medicine, New Haven, Connec¬
ticut, U.S.A.
2 Present address: Dept. of Obstetrics and Gynecology, Siriraj Medical School, Bangkok, Thailand.
3 To whom reprint requests should be sent.
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sulfate at C-3 and glucosiduronate at C-16 of the steroid molecule [i.e. ibaOHE^SibG)
(ref. 5). Also, the presence of a sulfate conjugate of i6KE2 has been suggested6. The
present report presents data on the conjugation of these steroids in comparison with
that of estriol (E3).
materials
Complete 24-h urines were collected during the third trimester of pregnancy
and these were frozen immediately upon receipt in the laboratory until analyses
could be performed.
All chemical reagents, including organic solvents and supporting materials for
chromatographic columns and thin-layer plates, were obtained and purified where
necessary by published methods7'8. Bacterial /5-glucuronidase powder, type II, was
purchased from Sigma Chemical Co., St. Louis, Mo., U.S.A.,and Mylase P (containing
phenosulfatase) from Mann Research Laboratories, Inc., New York, N.Y., U.S.A.
These were used for hydrolysis of conjugates as described elsewhere7.
Unlabelled steroids were purchased from Mann Research Laboratories, Inc.,
except for ihaOHE,, which was a gift from Dr. A. E. Kellie, Courtauld Institute of
Biochemistry, Middlesex Hospital, London, England.
[6,7-3H]i7j8-Estradiol (3H-E2) of specific activity 40 C/mmole was purchased
from New England Nuclear Corp., Boston, Mass., U.S.A., and was suitably purified
prior to use7. [6,7-3H]Estrone-3-sulfate (3H-E,3S), of specific activity 2.8 C/mmole,
was purchased as the NH4+ salt from New England Nuclear Corp. and [4~14C]estrone-
3-gIucosiduronate (14C-E13G), of specific activity 27 C/mole, was biosynthesized
in our laboratory9. These conjugates were purified by DEAE-Sephadex and Celite
chromatography9.
methods
Differential hydrolysis of urinary conjugates
Unconjugated estrogens (negligible amounts) were extracted from the urine
with ether prior to conjugate hydrolysis in all experiments.
In 6 experiments utilizing urines from different subjects, separate urine aliquots
(usually one-sixth of 24 h) were subjected to solvolysis to split steroid sulfates (S)10
and to /^-glucuronidase treatment to hydrolyze steroid glucosiduronates (G)7. The
aliquots hydrolyzed with /^-glucuronidase were extracted with ether to remove free
steroids and the aqueous residues were subjected to solvolysis to yield a S+SG
fraction, i.e. steroids arising from original urinary steroid sulfates together with
those which were originally "doubly conjugated" and which had been partially split
by ^-glucuronidase to yield sulfates. Thus the value (S+SG)—S yielded a measure
of "sulfoglucosiduronates" (SG).
In 6 further experiments, using urine from different subjects than those above,
G and "non-G" (i.e. S+SG) fractions were obtained with no attempt to differentiate
between S and SG.
Separation of hydrolyzed steroids
Following extraction the steroids were separated by a combination of the
Clin. Chim. Acta, 31 (1971) 387-393
phenolic steroid ring ketols in pregnancy urine 389
Girard reaction, partition column chromatography, NaBH4 reduction of the ring
Da-ketols and further chromatography of the steroidal triols so formed3'7. The
separated steroid fractions were measured by an Ittrich-Kober spectrophotometric
reaction7-8 and further identification was obtained by thin-layer chromatography in
comparison with standard steroids8.
Recovery experiments
Known weights of the various pure steroids were added to human non-
pregnancy urine, or to extracts at various points of the experimental procedure,
and processed exactly as described for the urines above. This provided data on
experimental losses during the separation and purification techniques.
Further identification of the ring Doc-ketol conjugates
In one experiment [14C]Ej3G and [3H jE^S were added to an aliquot (one-
fifth of 24 h) of late pregnancy urine to act as internal standards. The urine was
passed through Amberlite XAD-2 resin11 and the conjugate fraction obtained was
chromatographed in a concentration gradient of NaCl (0-0.8 M) on DEAE-Sephadex9.
Fractions containing 3H and others adjacent to these (i.e. fractions behaving like
estrogen sulfates) were analyzed for steroid content following enzyme hydrolysis.
In 2 further experiments [3H]E2 was injected intravenously (arm vein) into
each of 2 subjects during the last month of pregnancy. Urine was pooled in each
case over the succeeding 48 h and an aliquot (one-sixth) of each pool was processed
by XAD-2 resin and DEAE-Sephadex chromatography as above. 3H-containing
fractions with the mobility of sulfates and/or sulfoglucosiduronates were subjected
to analysis on Celite columns in the solvent systems i-butanol-ethyl acetate-0.2%
NH4OH (ref. 12) (system A) and iso-octane T-butanol-MNH4OH (ref. 13) (system B)
before and after partial enzyme hydrolysis9'14. Following complete enzyme hydrolysis
the fractions were analyzed for steroid content as described above.
results
Conjugation of steroids as revealed by direct differential hydrolysis
Table I contains data on the levels of three conjugated forms of E3, i6aOHE1
and i6KE2. These values have been corrected for average losses occurring in the
experimental procedure. This gives a more realistic picture since the overall recovery
of ring Da-ketols (including reduction to, and separation of, the triols) is only 44-56%
while that of E3 is 74-83%. It was found that 94% of E3 was in the G form while
only some 2% was conjugated as S. Also, ibaOHEj S was extremely low. However,
i6KE2 (probably i6KE24-i6/?OHE, due to the methods used, although the latter
is much smaller than the former3) appeared to be conjugated 18% on the average
as S, while both ibaOHEj and i6KE2 were found in the SG form (ibaOHE, = 18%,
i6KE2 = 15%). E3SG, although representing only 4% of total E3, was by weight
the main "non-G" form detected for any of the steroids measured.
Some support for the validity of the expression (S+SG)—S was obtained by
measuring E4 in these urines following solvolysis alone and after /f-glucuronidase
treatment with subsequent solvolysis. In each case application of the above expression
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TABLE I
CONJUGATION OF RING DU-KETOLS AND ESTRIOL AS G, S AND SG IN NORMAL PREGNANCY URINE
(mg/24 h)
Expt. £3 i6aOHEl i6KEt
No. G S SG G s SG G S SG
1 10.5 0.18 0.30 0.89 0.04 0.48 0.56 0.23 0.32
2 14-3 0.22 °-93 1-4 0.02 0.30 093 0.14 0.27
3 14-3 0.22 2.0 6.7 0.04 1.8 3-4 o.45 1-3
4 37-1 0.46 1.2 2.4 0.18 o.59 2.3 0.82 #
5 36.2 0.63 1-4 4-7 0.18 0.46 2.9 1.1 0.27
6 38.8 0.97 0.83 2.0 * 0.48 i-5 034 0.32
Mean 25.2 °-45 I.I 3-o 0.08 0.70 1-9 °-5J 0.41
Mean as %
total for each
steroid 94 2 4 80 2 18 67 18 15
* Steroid not detected in measurable amount.
gave a result differing insignificantly from zero, thus showing that E, (with only
1 OH group) was not being artifactually measured in the SG form.
When ibaOHEj was added to non-pregnancy urine in 4 experiments, subjected
to solvolysis, and then to separation and purification including NaBH, reduction
to the triols, 58% (52-63) was recovered in the E3 fraction and 6% (5-8) in the estra-
i,3,5(io)-triene-3,i6/S,i7/S-triol (i6-epiestriol; i6epiE3) fraction, i.e. typical of direct
reduction of pure ibaOHE, (ref. 15). These recovery values were unchanged when
solvolysis was omitted and the remainder of the procedure carried out. This showed
the lack of a destructive effect of solvolysis itself on ibaOHEj and suggests that
the low values for ibixOHEjS in the pregnancy urines studied (Table I) are meaningful.
Table II contains data for G and "non-G" conjugates in a further 6 pregnancy
urines. E3, i6a()HE, and KE2 were conjugated on the average as "non-G" to the
extent of 4, 22 and 42%, respectively. This compared with 6, 20 and 33% for the
"non-G" conjugates of Table I. Thus for the 12 urines analyzed the average "non-
G" conjugation of E3, i6aOHEi and i6KE2 was 5, 21 and 38% respectively.
Additional identification of ring Doc-ketol conjugates
Following addition of ["CJE^G and [HljE^S to an aliquot of pregnancy
TABLE II





G S+ SG G S+SG G S+SG
1 8.4 0.26 o-73 0.44 2.2 2.9
2 11.0 0.06 °-55 O.I4 o-57 0.09
3 31-4 1.6 2-9 O.56 1.8 °-74
4 26.5 1.1 i-3 0.28 0.78 0.24
5 26.7 1.1 1.8 0.30 1-3 0-74
6 32.5 1-9 2-7 1.1 1.8 1.4
Mean 22.8 1.0 i-7 0.47 1.4 1.0
Mean as % total
for each steroid 96 4 78 22 58 42
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urine, well separated 14C and 3H peaks were obtained on DEAE-Sephadex chromato¬
graphy. Fractions in the region of the 3H eiuted, i.e. associated with steroid sulfates
(tubes 47-70, 10 ml fractions), were pooled and subjected to Mylase P hydrolysis
yielding 166 fig of Kober-positive steroid, together with the 3H label, in ether-soluble
form (fraction I). Further hydrolysis with /(-glucuronidase released 195 fig of steroid
accompanied by no 3H (fraction II). Fraction I consisted of E3 (112 fig) together
with a very small amount (7.5 fig) of ring Da-ketols (16KE2:1baOHE, ratio — at
least 4). Fraction II, probably sulfoglucosiduronate, gave on analysis 126 fig Es and
33 fig ring Da-ketols (78% corresponded to roaOHE. and the remainder to i6KE2).
The close association of doubly conjugated ring Da-ketols with the monosulfate
fractions differed markedly from the clear separation found between ry/l-estradiol-
3-sulfate and i7/J-estradiol-3-sulfate-i7-glucosiduronate9.
Following injection of [3H]E2 into one subject (C), DEAE-Sephadex chromatog¬
raphy yielded 2 broad peaks of radioactivity. The second of these (tubes 45-70)
was analyzed as shown in Table III. A portion of this unhydrolyzed peak yielded
one main peak (79% of applied 3H) at holdback volume (HBV) 1-2 (typical of
monosulfate) on Celite in system A. Rechromatography in system B resulted in a
peak, containing 67% of applied 3H, eiuted over tubes 11-18 (E^S eiuted over n-16).
TABLE III
ANALYSIS OF URINARY SULFATES AND SULFOGLUCOSIDURONATES AFTER INTRAVENOUS INJECTION
OF [*H]E,
(Subject C)
Steroid fraction Hydrolysis by Mylase P Subsequent hydrolysis by /}-
glucuronidase










* Negligible radioactivity or weight.
In a second injection experiment (subject CV) 2 broad peaks of 3H were again
obtained from DEAE-Sephadex. The first of these corresponded to glucosiduronate
while the second, partially separated into two (peak IIA, tubes 37-44, 16% of
recovered 3H; peak I IB, tubes 47-54, 12% of recovered 3H) was in the region of
monosulfate and possibly sulfoglucosiduronate. An additional small peak, peak III,
containing 2% of recovered 3H was present at tubes 55-80. Peaks IIB and III were
each chromatographed on Celite in system A and in each case some 3H was eiuted
in the region of monoconjugates. More polar material was eiuted with methanol in
each case and these fractions were combined ior analysis as shown in Table IV. The
data indicate that a considerable proportion of the material behaved as the sulfo-
glucosiduronates of i6aOHE1 and i6KE2 with the former predominating.
discussion
Other investigators have applied the technique of differential hydrolysis to
indicate the presence of mixed conjugates in urine1' and in plasma1'. Such a technique
can scarcely be described as ideal, particularly when applied to the problem of the
Clin. Chivn. Acta, 31 (1971) 387—393
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TABLE IV
stepwise celite chromatography and enzyme hydrolysis of urinary ring dot-ketol
sulfoglucosiduronates after injection of [3H]E2
(Subject CV)
Fraction Purification step
Polar fraction from Celite
75000 decomp./min 3H, 86 fig
steroid
J fraction from system B
J fraction from system B
Pooled free fractions after
enzyme hydrolysis
System B eluted 26800 decomp./min 3H, 55 fig steroid at
8 HBV*
^-Glucuronidase —> < 6% ether-soluble 3H; aqueous residue
in system A gave peak in fractions 14-22 (E,3S elutes in
11—16); subsequent Mylase P gave complete hydrolysis
Mylase P —> 6% ether-soluble 3H; aqueous residue in system
A gave peak in fractions 31-38 (E23G elutes in 25-35);
subsequent /J-glucuronidase gave complete hydrolysis
Girard separation -9-83% 3H ketonic, 18% non-ketonic;
ketonic fraction on Celite ->-65% 3H and 80% weight
corresponding to ring Da-ketols; NaBH4 reduction then
Celite chromatography -9-64% recovered 3H and 70%
recovered weight in E3 fraction (i.e. from i6aOHE3), 36%
3H and 30% weight in 16 epiE3 fraction (i.e. from i6KE3 ±
i6/?OHEj).
* Typical of sulfoglucosiduronate. This fraction gave immediate pink colour in Ittrich-Kober
reaction, typical of i6aOHE3.
conjugates of the rather unstable ring Da-ketols. However, supporting evidence for
the results of the present study resides in the absence of Ei from the SG fraction
as described above, and in the conjugation pattern found for Es which is strikingly
similar to that reported by others18-19.
Although the "non-G" conjugated forms of E3 appear to be present in greater
amounts than those of the ring Da-ketols, the percentage of the latter steroids in
the form of "non-G" is much greater than for E3. This is particularly striking with
respect to i6aOHE]SG, i6KE.2S and i6KE2SG. It is noteworthy, however, that the
S form of ibaOHEj is present in very small amounts indeed (average 0.08 mg/24 h)
when compared with E3S (0.45 mg/24 h) and i6KE2S (0.51 mg/24 h). The reason
for this finding is not clear at present. In any case it is evident that any procedure
for the total hydrolysis of ring Da-ketols conjugates in pregnancy urine must include
a means of splitting sulfate conjugates.
The data obtained in this study by chromatographing and differentially
hydrolyzing the urinary conjugates, while qualitative at best, suggests that where
sulfate groups are found these are at the C-3 position, in view of the hydrolysis
achieved by phenol-sulfatase. In the doubly conjugated forms, therefore, it is likely
that the glucuronic acid moiety is attached to ring D. The position of the glucuronic
acid in the ring Da-ketol glucosiduronates is at present unknown.
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SECTION S
FORMATION, METABOLISM, INTERCONVERSION OF OESTROGEN
SULPHATES IN SPECIES OTHER THAN THE HUMAN
IN VITRO AND IN VIVO
BIOSYNTHESIS OF STEROID SULFATES BY A RAT LIVER PREPARATION1
H. R. Raud2 and R. Hobkirk
Within recent years it has been indicated that biosynthesis of steroid sulfates
may be important in phenomena other than detoxification. Thus, attention
has been drawn to the interconversion of certain steroids in the form of sulfates
(1, 2), the secretion of dehydroisoandrosterone (DHA)3 sulfate by the adrenal
cortex (3), the importance of estrone sulfate in blood (4), and the quantitative
significance of estrogen sulfate formation by the human fetus (5). The present
report contains information on the activity of a soluble fraction from rat liver
with respect to sulfurylation of certain phenolic steroids and the manner in
which the age of an animal affects this conjugation.
Materials and Methods
16-KE2-16-hC (44 jucuries/mg) and estriol-16-14C (22 yucuries/mg) were puri¬
fied by column, paper, or thin-layer chromatography to yield material of at
'Supported by the Banting Research Foundation, Toronto, Ontario.
'Graduate student in the Department of Biochemistry, McGill University, Montreal, Quebec.
3The following trivial names and abbreviations are used in the text: DHA = dehydroiso¬
androsterone (3/3-hydroxy-A6-androsten-17-one); I6-KE2 = 16-ketoestradiol-17/3 (3,17/3-dihy-
droxy-estra-l,3,5(10)-trien-16-one); 16-epiestriol = 3,160,17/3-trihydroxy-estra-l,3,5(lO)-triene;
estriol = 3,16a,17/3-trihydroxy-estra-l,3,5(10)-triene; estrone = 3-hydroxy-estra-l,3,5(10)-
trien-17-one; estradiol-17/3 = 3,17/3-dihydroxy-estra-l,3,5(10)-triene; ATP = adenosine tri¬
phosphate.
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least 98% purity. 16-Epiestriol-16-14C was prepared by chemical reduction of
16-KE2-16-14C as described elsewhere (6). Estradiol-17/3-6,7-3H (New England
Nuclear Corp.) of specific activity 150 jicuries//ag was purified by column
partition chromatography and shown to be at least 98% pure by reverse
isotope dilution. Estrone-16-14C (Radiochemical Centre, Amersham, England)
(45 jicuries/mg) and DHA-4-14C (Merck Sharp & Dohme Ltd.) (140 /xcuries/
mg) were judged to be at least 99% pure after thin-layer chromatography.
35S-labeled inorganic sulfate (New England Nuclear Corp.) (1.3 mcuries/mg)
was used as obtained. ATP was purchased as the disodium salt from Sigma
Chemical Company, St. Louis, Mo. All other chemical reagents were purified,
when necessary, by standard procedures. Estrone and estradiol-17/3 sulfates
were synthesized as described by Fieser (7). The 3-methyl ethers of estrone
and estradiol-17/3 were prepared by the method of Brown (8).
A supernatant fraction (20,000 X g) was obtained from the pooled livers of
white Wistar rats as described by Bernstein and McGilvery (9). This was
fractionated with (NHOjSO^ and the material precipitating between 1.7 M
and 2.3 M salt concentration was used as the source of enzyme in all experi¬
ments. The procedure of incubation, extraction, and product identification is
outlined in the following scheme.
Incubation mixture: 0.1 ml (0.04 ^mole) labeled substrate (ca. 20,000 c.p.m.) in propylene
glycol; 0.5 ml buffered ATP, pH 6.8 (1 volume 0.3 M KH2POi, 1 volume 0.03 M K2SO4, 1
volume 0.005 M MgCU, 0.33 volume 0.08 M ATP disodium salt); 0.4 ml enzyme preparation
(equivalent to ca. 100 mg wet liver tissue).
Aliquots of all extracts were assayed for radioactivity by liquid-scintillation
spectrometry. An average of 81 ± 3.5% of the incubated radioactivity was
recovered in ether and ethyl acetate extracts. Because of a lack of pure steroid
sulfates of certain types, rigorous identification studies (i.e. crystallization)
were made only upon the incubation products of estrone, estradiol-17/3, and
DHA. In the case of the product of estradiol-17/3 incubation in particular,
celite partition column chromatography was carried out in the solvent system
isooctane - f-butanol - 1 M NH4OH (200:500:500) (10). The values for per¬
centage conjugation of estriol, 16-epiestriol, 16-ketoestradiol-17/3, and estradiol-
Incubation for 1.5 hours in air at 37 °C














17/3-3-methyl ether were obtained from the amount of radioactivity behaving
as sulfate conjugate during paper chromatography in toluene - w-butanol -
2.8% (v/v) NH4OH (3:1:2) (11), and subsequently associated with each of the
free compounds after solvolytic cleavage (12).
Results and Discussion
Table I contains data on the extent of estrogen sulfate formation by the
enzyme preparation from livers of adult female rats compared with the
TABLE I
Steroid sulfate synthesis by the enzyme preparation from adult
female rat liver*








♦Figures are averages from at least three experiments.
synthesis of DHA sulfate. At the substrate concentrations studied, conjugation
of DHA was considerably greater than that of any of the phenolic steroids
incubated. However, detectable conjugate formation was seen in all cases,
particularly of those estrogens possessing /3-orientated hydroxyl groups in the
D ring, namely, estradiol-17/3 and 16-epiestriol. As yet insufficient information
has been obtained to show the significance of this as a purely structural effect.
Solvolytic cleavage of the incubation products resulted in the release, in
ether-soluble form, of about 90% of the radioactivity present in the conjugated
fractions. Paper chromatography also showed these products to have mobility
similar to that of the standard steroid sulfates available. Dilution of the
labeled product of estrone incubation with unlabeled estrone sulfate to give
a calculated specific activity of 547 c.p.m./mg was followed by crystallization
from methanol-ether mixture. On successive crystallizations the crystals
showed a specific activity of 536, 526, and 511 c.p.m./mg; the respective mother
liquors had values of 525, 538, and 527 c.p.m./mg. This indicated that most
of this material was estrone sulfate. The similar degree of conjugation of
estradiol-17/3 and its 3-methyl ether (Table I) suggested that the former might
be conjugated only at C-17 by the enzyme preparation. However, incubations
in which 35S-labeled inorganic sulfate was used resulted in the formation of
conjugated estradiol-17/3 with a 35S/3H molar ratio of 2.05, compared with a
value of 1.03 for the 3-methyl ether of this compound. Moreover, partition
column chromatography of the estradiol product showed it to have the mobility
of estradiol-3,17/3 disulfate ; and dilution of this same material with the 3-mono-
sulfate and the 17-monosulfate of estradiol-17/3, separately, then crystal¬
lization, yielded virtually no radioactivity in the crystals. Thus, under the
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experimental conditions employed, it would appear that the product was the
3,17-disulfate of estradiol-17/3. Wengle and Bostrom (13) reported the forma¬
tion of both the disulfate and monosulfate of estradiol-17/3 when unfractionated
cell-free rat liver systems were employed.
Table If contains data on the effect of the age of the animal on the sulfurylat-
ing activity of the same enzyme system. It is obvious that such activity is
TABLE II
Effect of age of animal on steroid sulfate synthesis by the liver
enzyme preparation*
Age of animal
% conjugation of substrate
Estrone Estradiol-17/3 Dehydroisoandrosterone
Fetus (term)f 0 0 2.8±0.9
10 daysf 0 1. 6±0.4 13.1 ±0.7
30 days 0.8 ±0.3 5.2±0.4 46.2±1.5
Mature (75 days) 6.4±0.9 12.7±0.4 68.8±1.4
♦Figures are averages from at least two experiments.
|Not sex-differented; other age groups were female.
virtually absent in fetal liver but that it appears and increases with age. It
is not known whether this increase is related to the hormonal status of the
maturing animal. This phenomenon has already been described for DHA
sulfate formation by Wengle (14), who used unfractionated liver supernatant
preparations.
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The sulfurylation of estrone-6,7-3H, estradiol-173-6,7-3H, and dchydroisoandrosterone-4-,4C by
laying hen liver, oviduct, and vaginal preparations was investigated. Purification and product identifica¬
tion included ether and ethyl acetate extraction, paper chromatography, and isotope dilution, before
and after hydrolysis with a sulfatase preparation.
The esterifying enzymes were found in the 105 000 X g supernatants of the three tissues. The liver
preparation was many times more active in steroid sulfate synthesis than the corresponding oviduct or
vaginal fractions. Sulfurylation of dehydroisoandrosterone displayed the same cofactor, pH, and
temperature requirements as did that of estrone and estradiol-17p. The degree of dehydroisoandrosterone
sulfate synthesis was considerably lower than that of the estrogens, however. It is suggested that the
laying hen possesses an enzyme system which is more efficient for the sulfurylation of estrogens than of
other steroids such as dehydroisoandrosterone.
Introduction
The relegation of steroid sulfates purely to the
position of detoxification products by early
workers has recently been revised to bestow upon
these compounds greater significance in the areas
ofbiogenesis, metabolism, and possibly biological
activity. Purdy, Engel, and Oncley (1) have indi¬
cated that estrone sulfate is a major circulating
human estrogen. Since then the attention of in¬
vestigators has been directed toward steroid
conjugates, not only because they are excreted in
that form, but owing to the demonstration that
steroid sulfates may in some instances serve as
biosynthetic intermediates (2-7). Little if any
information related to the esterification of ste¬
roids, and specifically the sulfurylation of estro¬
gens, by avian species has been provided, however.
As a consequence, the present publication deals
principally with the sulfate esterification of phen¬
olic steroids by hen tissues.
Materials and Methods
Liver, oviduct, and vaginal tissue was obtained through
the courtesy of Dr. N. Nikolaiczuk, of the Department of
'Supported by the Banting Research Foundation,
Toronto, Ontario, and the Medical Research Council of
Canada.
2These data are taken from a thesis submitted by
H. R. R. in partial fulfilment of the requirements for the
degree of Doctor of Philosophy in Biochemistry, McGill
University. Present address: Endocrinology Division,
Department of Medicine, Harbor General Hospital,
1000 W. Carson Street, Torrance, California 90509.
'Medical Research Associate, Medical Research Coun¬
cil of Canada.
Animal Science, Macdonald College of McGill University,
Montreal, from yearling White Rock hens in the laying
state at the time of decapitation.
Adenosine triphosphate (ATP) was purchased from
Sigma Chemical Company, St. Louis, Mo. Mylase P
(containing sulfatase) is a product of Mann Research
Laboratories Inc., New York, N.Y.
Pure crystalline estrone (3-hydroxy-estra-l,3,5(10)-
trien-17-one), estradiol-17P (estra-1,3,5( 10)-triene-3,17P-
diol), and dehydroisoandrosterone (3P-hydroxy-A5-an-
drosten-17-one) were supplied by Mann Research Labor¬
atories. Estrone-3-sulfate and dehydroisoandrosterone-3-
sulfate were synthesized as described by Fieser (8).
Estradiol-17P-3-sulfate was prepared by sodium boro-
hydride reduction of estrone-3-sulfate. In the case of all
three sulfate preparations, any free unreacted steroid was
extracted from aqueous solution with diethyl ether, and
the remaining butanol-soluble conjugated material crys¬
tallized several times from methanol - diethyl ether.
Paper chromatography of the products in the solvent
system ethyl acetate - «-butanol - 0.2% (v/v) NH4OH
(7:1:8) (9) showed homogeneous behavior in each case.
Solutions of estrone-6,7-3H (150pCi/pg) and estradiol-
17P-6,7-3H (150pCi/pg) were purchased from New
England Nuclear Corp., Boston, Mass. Dehydroiso-
androsterone-4-14C (141 pCi/mg) was acquired from
Merck, Sharp and Dohme, Montreal. When necessary,
these were purified chromatographically and shown to be
radiochemically pure by crystallization with added carrier.
Crystallization was performed using methanol as solvent.
Agreement, within the counting error, of specific activities
of crystals and mother liquor was taken as proof of
purity. All other chemical reagents were purified, where
required, by standard procedures.
Measurement ofRadioactivity
Radioactivity was measured by liquid-scintillation
spectrometry in a Nuclear-Chicago model 6725 dual-
channel instrument. The material to be assayed was dried
in 20-ml glass scintillation vials, redissolved in the
750 CANADIAN JOURNAL OF BIOCHEMISTRY. VOL. 46, 1968
minimum volume ofmethanol, and this was diluted with
10 ml of toluene containing 0.3% 2,5-diphenyloxazole
and 0.01% 1,4-bis-2-(5-phenyloxazolyl)-l-benzene prior
to counting. Sufficient counts were accumulated to ensure
a counting error of less than ±5%. Quenching was
estimated by the internal standard technique, and all
counts were corrected to the efficiency of counting for
3H and 14C standards in 10 ml of the above scintillation
fluid containing no methanol, namely, 26 and 63%,
respectively.
TissuePreparation, Incubation, Extraction, andProduct
Identification
Pooled livers, oviducts, and vaginae, excised from hens
in the laying state, were fractionated by a method based
on that of Schneider and Lewbart (9). Tissues were
homogenized in a Virtis "45" homogenizer at 0 °C with
0.1 M phosphate buffer, pH 6.5, so that 10 ml of homog-
enate contained 2 g of original tissue. Nuclei and cell
debris were sedimented at 1000 x g for 10 min. The
supernatant fluids thus obtained were centrifuged at
105 000 X g for 45 min. The resulting 105 000 X g
supernatants were stored in 2-ml portions at —20 °C
and were used as the source of enzyme in all experiments.
All centrifuging was performed in a Spinco model L
preparative ultracentrifuge.
The procedure of incubation and extraction was
schematically presented in a previous publication (10),
but was slightly modified due to a different sub-cellular
fraction being employed in the present study. The basic
incubation system was of 3 ml total volume in all cases.
It contained 0.013 MMgCl2, 0.008 MK2S04, 0.014 M
ATP; estrone-6,7-3H, estradiol-173-6,7-3H, or dehydro-
isoandrosterone-4-14C (ca. 20 000 - 160 000 c.p.m.) di¬
luted with the unlabelled form to give a final incubated
concentration of 0.013 mM, the steroids being added in
0.1 ml propylene glycol; and 1 ml of the microsome-free
enzyme preparation in 0.1 M phosphate buffer, pH 6.5
(equivalent to ca. 200 mg wet tissue) after pre-incubation
for 10 min at 40 °C; the balance of the incubation
volume consisted of distilled water. Incubation was
performed in air at 40 °C for 2 h. Blank systems were
identical to the above except that they contained no
added ATP. Each of these experiments was performed in
duplicate on one occasion and then later repeated in
duplicate with tissue from other hens.
In the case of the liver preparation only, experiments
were also performed in which ATP and substrate con¬
centrations, as well as pH and temperature of incubation,
were varied. The effect of varying ATP concentration
over the range 0.0014-0.14M was investigated while
keeping the remainder of the basic incubation system
(see above) unchanged. Likewise, in another experiment,
substrate concentration was varied over the range 0.013
X 10~2 to 6.7 X 10~2 mM while otherwise preserving
the basic system. In two further experiments, both using
the basic incubation system, the pH of incubation was
varied at 0.5-unit intervals from 6.0 to 8.0, and the effect
of changing temperature was studied by incubating at
30, 37, 40, 42, and 48 °C.
Following all incubations, the reaction was arrested
by the addition of excess methanol and the precipitate
formed was centrifuged off. The latter was washed with
methanol, which was combined with the first supernatant
and evaporated in vacuo, with the addition of NH4OH to
prevent breakdown of steroid sulfates, to yield an aqueous
residue. This latter was diluted with H20 and extracted
with diethyl ether in order to remove free steroids. The
aqueous solution was then made 3 M with respect to
NaCl and extracted with ethyl acetate to remove steroid
sulfates. The ethyl acetate extract was dried over an¬
hydrous Na2S04 prior to evaporation in vacuo with the
addition of NH4OH. The residue was then dissolved in
methanol, made alkaline with NH4OH, and, if necessary,
stored in the refrigerator until required. The amount of
radioactivity in each extract was determined to give, in
each experiment, a measure of "total steroid sulfate
synthesized". The extracts were then further purified
(sometimes following pooling of extracts from duplicate
incubations) by methods described below, in order to
identify, and to estimate the degree of purity of, the
steroid sulfates formed.
In one experiment involving the basic incubation
system and the liver preparation, pooled ethyl acetate
(sulfate) fractions from duplicate incubations were sub¬
jected to descending paper chromatography as described
by Schneider and Lewbart (9) in an ethyl acetate - n-
butanol-0.2% (v/v) NH4OH (7:1:8) solvent system.
The radioactivity corresponding to appropriate reference
standards (estrone-3-sulfate, estradiol-17p-3-sulfate, or
dehydroisoandrosterone-3-sulfate) was eluted with meth¬
anol. The methanol was removed under reduced pressure
in the presence of NH4OH, and the residue was stored in
a vacuum desiccator over calcium chloride overnight in
the refrigerator. The eluates obtained from the chromato-
grams were redissolved in methanol, and an aliquot
(one-half) of each was submitted to successive crystalliza¬
tion, with the appropriate unlabelled pure crystalline
steroid sulfate as carrier, in individual tared centrifuge
tubes. Three crystallizations from methanol with the
addition of a few drops of dry diethyl ether were carried
out (11). The remaining one-half of the eluate was
hydrolyzed with Mylase P (sulfatase) for 17 h at 37 °C,
as described by Emerman et al. (12), and the resulting
free (unconjugated) material was successively crystallized
from methanol with pure unlabelled estrone, estradiol-
17p, or dehydroisoandrosterone as carrier until equal and
constant specific activity of crystals and mother liquor
was attained.
The conjugated (ethyl acetate) extracts of one further
set of experiments (in which estrone, estradiol-173, and
dehydroisoandrosterone had been incubated with the
basic system using the liver preparation) were diluted
directly with carrier estrone-3-sulfate, estradiol-173-3-
sulfate, and dehydroisoandrosterone-3-sulfate, respec¬
tively, followed by crystallization as described above.
This was done in order to estimate how much of the
radioactivity in these relatively crude extracts, prior to
any chromatographic step, consisted of the expected
steroid sulfates.
Direct crystallization following addition of carrier
steroid sulfates to the ethyl acetate extracts was also per¬
formed in the experiments in which ATP and substrate
concentration, and pH and temperature, were varied.
In the experiments involving tissue preparations of
oviduct and vagina, the ethyl acetate extracts were
incubated with Mylase P as described above, and the
ether-soluble radioactivity so released was diluted with
TABLEI
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the appropriate carrier steroid (estrone, estradiol-17p, or
dehydroisoandrosterone) and crystallized.
Some measure of percentage sulfurylation in each
experiment was obtained from the final specific activities
of the crystallized material. The mathematical products
of these values and the corresponding weights of carrier
steroids, or steroid sulfates, yielded figures for radio¬
activity in the form of steroid sulfate formed on incuba¬
tion. These latter values were then expressed as per¬
centages of incubated radioactivity. It should be stressed
that such a calculation does not take into account any
losses occurring in the experiment prior to dilution with
carrier steroid.
Results
Pooled ethyl acetate extracts from duplicate
experiments, using the basic incubation condi¬
tions and the liver-enzyme preparation, were
chromatographed on paper and the eluted zones
corresponding to the individual steroid sulfates
each divided into two parts. One half, crystallized
with carrier steroid sulfates, yielded results shown
in Table I. The other half, following sulfatase
hydrolysis, and crystallized with carrier-free ste¬
roids, gave the results shown in Table 11.11 can be
seen from Table I that 92-93% of the radio¬
activity eluted from the paper chromatograms as
estrone-3-sulfate and estradiol-17P-3-sulfate be¬
haved as these compounds during crystallization
in the conjugated form. Moreover, Table II
shows that the eluted radioactivity was for all
practical purposes quantitatively hydrolyzed by
Mylase P and that 91 and 96% of the free (un¬
conjugated) radioactivity behaved as estradiol-
17p and estrone, respectively, during crystalliza¬
tion. In the case of dehydroisoandrosterone-3-
sulfate crystallized in the intact form (Table I), a
greater relative decrease in specific activity was
noted than for the two estrogen sulfates. Thus
only about 77% of the radioactivity remained
associated with the crystals. Also, it can be seen
from Tables I and II that only about 84% of the
conjugated radioactivity was freed by Mylase P
and that 90% of this behaved like dehydroiso¬
androsterone on crystallization (Table II).
Table III contains data on the crystallization
of the three steroid sulfates formed in another
experiment using the liver-enzyme preparation
under the basic experimental conditions. In this
instance carrier steroid sulfates were added di¬
rectly to the ethyl acetate (conjugated) extracts
without any paper-chromatographic step. It can
be seen that, although the first mother liquor in
each case exhibited a higher specific activity than
did the corresponding crystals, indicating the
presence of an additional labelled component, the
specific activities of the third crystals, when
related to the initial calculated values, showed
that about 93-96 % of the radioactivity extracted
with ethyl acetate behaved like the steroid sulfates
under investigation.
Tables IV and V contain data on the purifica¬
tion of the conjugated material formed by oviduct
and vaginal tissue preparations, respectively,
under the basic incubation conditions. In the case
of these products only partial characterization
was attempted by crystallization of the free
steroids following sulfatase hydrolysis. In every
case more than 90% of the radioactivity in these
ethyl acetate extracts was released by Mylase P
hydrolysis. As can be seen from Tables IV and V,
a major fraction of the radioactivity remained
associated with the crystals although the counts
were so low in the case ofdehydroisoandrosterone
from the experiment with vaginal tissue as to
render the results meaningless. It appeared that
there was a greater decrease in specific activity of
estrone and estradiol-17(3 following hydrolysis in
the case of the vaginal tissue preparation than for
the oviduct.
Table VI contains data on the degree of steroid
sulfate synthesis by the three tissue preparations
under the basic experimental conditions. It should
be pointed out that the values given for per¬
centage substrate sulfurylated in the case of the
liver system are minimal since the sulfates were
subjected to a paper-chromatographic step during
purification, resulting in some experimental loss
of radioactivity. Percentage sulfurylation was
calculated as follows, taking as an example the
incubation of estradiol-17P-6,7-3H (155 000
c.p.m.). Following incubation, ether-extractable
(free) radioactivity amounted to 47 000 c.p.m.
The ethyl acetate soluble (conjugated) material
possessed most of the balance of the incubated
radioactivity (about 78 000 c.p.m.), and 73 700
c.p.m. with a mobility similar to that of estradiol-
17P-3-sulfate were eluted from the paper chro-
matogram. Crystallization with carrier indicated
this to be 93 % pure, giving a value of 68 500
c.p.m. for the estradiol sulfate formed, or 44.5 %
of the incubated radioactivity. The values for
sulfurylation of the three steroids by oviduct and
vaginal tissue preparations are based on crystalli¬
zation data following hydrolysis of the 'sulfate-
like' conjugates formed during incubation. It is
obvious, nevertheless, that much less synthesis
TABLEVI
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proceeded with these tissues than with the liver
preparation. It is also clear from the values in
Table VI that all three tissues systems were much
more active, under the experimental conditions,
in sulfurylating the two estrogens than was the
case with dehydroisoandrosterone as substrate.
Attempts to increase sulfurylation of dehydro¬
isoandrosterone relative to that of estrone and
estradiol-17(3 by the liver system through varia¬
tion of ATP concentration, pH, and temperature
were not successful. It was found that maximum
synthesis of all three steroid sulfates occurred at
an ATP concentration between 0.007 and 0.014M.
Thus, the relative pattern was as shown in Table
VI. Optimum sulfate synthesis for all three ste¬
roids also occurred at pH 6.5 and 40 °C, so that no
combination of conditions employed resulted in
any marked increase of dehydroisoandrosterone
conjugation over that found using the basic
incubation system described above. Also, de¬
hydroisoandrosterone at a substrate concentra¬
tion of 0.67 X 10~2 mM was sulfurylated to the
extent of 4.0 mpmoles of material incubated. A
10-fold increase in concentration resulted in no
further increase in sulfate synthesis. Estrone and
estradiol-17(3, on the other hand, had apparently
not reached an absolute maximum in product
formation, even at substrate concentrations as
high as 6.7 X 10~2 mM, the weight of these two
steroids sulfurylated being42.8 and 33.6 mpmoles,
respectively.
Discussion
It appears in the light of the present study that
the 105 000 X g supernatant fraction of hen liver
possesses a highly active enzyme system capable
of sulfurylating estrone and estradiol-17 [3 to form
the corresponding 3-monosulfates. The experi¬
mental procedures employed for the extraction
and purification of these products appear to have
been successful in preserving the structure of the
somewhat labile steroid sulfates, thus making it
possible to crystallize them in their intact form
as well as in the free form, following enzymatic
hydrolysis. The activity ofthe liver system towards
these two estrogens is considerably greater than
that of oviduct or vaginal preparations, partic¬
ularly since only partial identification can be
claimed for the products in the case of the two
latter tissues.
Dehydroisoandrosterone is also sulfurylated by
the liver system, while a compound resembling
dehydroisoandrosterone sulfate is formed by the
oviduct preparation. Little, if any, such material
was synthesized by the vaginal system. All three
tissue preparations exhibited a much greater
degree of sulfate conjugation of estrone and
estradiol-17(3 than of dehydroisoandrosterone.
Variation of incubation conditions in the case of
the liver-enzyme system did not result in any
increased sulfurylation of dehydroisoandroster¬
one as compared with that of the estrogens.
Earlier work in this laboratory (10) showed
that an enzyme fraction prepared from a 20 000
X g supernatant of rat liver by precipitation
between 1.7 and 2.3 M (NH4)2S04 was five to
eleven times more active in sulfurylating dehydro¬
isoandrosterone than estrone or estradiol-17|3.
Such salt-fractionated preparations of hen liver,
oviduct, and vagina were inactive in our hands.
Consideration of these findings suggests the
possibility that structurally different proteins are
operational in sulfurylation of steroids in varying
species of test animal. Furthermore, since the
laying hen is known to be continuously under the
influence of circulating estrogens (13-16), it
would seem logical that this species might possess
an enzyme system which is more efficient in the
sulfurylation of these phenolic steroids.
One further possible explanation for the low
degree of sulfurylation found for dehydroiso¬
androsterone in the present work might relate to
metabolism of this steroid during incubation to
products incapable of being conjugated with sul¬
furic acid, or perhaps, to the further metabolism
of synthesized dehydroisoandrosterone sulfate.
This, however, is speculative at the present time
and no attempt was made in this study to enquire
into such a possibility.
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In vitro metabolism of estrone-4-14C and estrone-6,7-3H-3-sulfate by
laying hen liver homogenates1
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Raud, H. R., and Hobkirk, R. In vitro metabolism of estrone-4-14C and estrone-6,7-3H-3-sulfate
by laying hen liver homogenates. Can. J. Biochem. 46, 759 (1968).
Estrone-4-14C and estrone-6,7-3H-3-sulfate were simultaneously incubated with hen liver homogenates
prepared from fowl in the laying stage. Purification and identification of conjugated metabolites was
made by two different methods: (a) an indirect procedure involving hydrolysis with a sulfatase prepara¬
tion, followed by ether extraction, Girard separation, Celite partition chromatography, and crystalliza¬
tion to constant specific activity of the resulting free estrogens; (h) a direct identification of estrogen
sulfates by paper chromatography in three different solvent systems, again followed by recrystallization.
The unconjugated (free) incubation products were identified by the former of the two methods.
Liver homogenates from the fowl were capable of catalyzing a rapid reduction of estrone to estradiol-
17P and of estrone-3-sulfate to estradiol-17P-3-sulfate, the latter apparently without removal of the
sulfate group. Under the conditions of the experiments, a slower dehydrogenation of estradiol-17P to
estrone and of estradiol-17p-3-sulfate to estrone-3-sulfate was also indicated.
Introduction
Steroid sulfates have previously been shown to
be of importance as intermediates in steroid
interconversions (1-3). The majority of informa¬
tion related to themetabolism ofestrogen sulfates
has resulted from in vivo studies (4-8). With
respect to phenolic steroid sulfate transformation,
in vitro work has been almost nonexistent (9, 10),
and has invariably involved species whose en¬
dogenous estrogen metabolic pattern is uncer¬
tain, and may, therefore, bear no relationship to
the true conditions prevailing in the test animal.
One species, however, whose endogenous
scheme of estrogen metabolism has been con¬
siderably elucidated is the fowl, the laying hen
possessing a pattern qualitatively similar to that
of the human (11-13). Consequently, it was
considered conceivable that liver tissue from this
source could metabolize estrogen sulfates, and
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laying period at the time of decapitation (obtained
through the courtesy of Dr. N. Nikolaiczuk, of the
Department of Animal Science, Macdonald College of
McGill University, Montreal) were the source of the
homogenate. Cofactors were acquired from Nutritional
Biochemicals Corp., Cleveland, Ohio, except for adeno¬
sine triphosphate (ATP), which was purchased from
Sigma Chemical Company, St. Louis, Mo. Mylase P
(sulfatase) was obtained from Mann Research Labora¬
tories Inc., New York, N.Y.
Estrone (3-hydroxy-estra-l,3,5(10)-trien-17-one) and
estradiol-17(3 (estra-1,3,5(10)-triene-3,l 7(3-diol), in pure
crystalline form, were purchased from Mann Research
Laboratories. Estrone-3-suIfate was synthesized as de¬
scribed by Fieser (14) and estradiol-17P-3-sulfate was
prepared from it by reduction with sodium borohydride.
Both compounds were purified by crystallization (15).
Solutions of estrone-6,7-3H (150 pCi/pg) and estrone-4-
14C (125 pCi/mg) were purchased from New England
Nuclear Corp., Boston, Mass., and the Radiochemical
Centre, Amersham, England, respectively. Estrone-6,7-
3H-3-sulfate was prepared from estrone-6,7-3H by chloro-
sulfonic acid sulfurylation (14). The conjugated estrone
so formed was extracted from aqueous solution, pH 10,
with n-butanol; the extract was evaporated, dissolved in
methanol, and chromatographed on paper in the solvent
system toluene - n-butanol - NH4OH - H20 (5:5:1:9)
(16). The area corresponding to the mobility of authentic
estrone-3-sulfate was cut out and eluted with methanol.
An aliquot of this, containing 77 400 c.p.m., was mixed
with 22.3 mg of unlabelled estrone-3-sulfate, giving a
calculated specific activity of 3471 c.p.m./mg, and crystal¬
lized from methanol - diethyl ether (17). Calculation of
the specific activities of the crystals and mother liquor
yielded values of 3492 and 3475 c.p.m./mg, respectively.
Recrystallization resulted in values of 3479 and 3476
c.p.m./mg for crystals andmother liquor, respectively.
Celite No. 535, supplied by Johns-Manville and
Company Ltd., was washed, and tested as described by
Bauld and Greenway (18).
All other reagents were of suitable chemical grade, and
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were purified, where necessary, by previously published
techniques (19).
The Radioactive-Tracer Technique
Measurement of radioactivity was performed by
liquid-scintillation spectrometry in a Nuclear-Chicago
model 6725 dual-channel instrument operating at an
efficiency of 63 and 26% for 14C and 3H standards,
respectively, in 10 ml of toluene containing 0.3% 2,5-
diphenyloxazole and 0.01 % l,4-bis-2-(5-phenyloxazolyl)-
1-benzene. Under these conditions, approximately 15%
of the 14C appeared in the 3H channel, with about 1 % of
the 3H counts spilling over into the 14C channel. Materials
to be counted were dried in 20-ml glass counting vials,
dissolved in the minimum volume of methanol, and
diluted with 10 ml of the above scintillation solution.
Counts were corrected by the internal-standard tech¬
nique, so that all values reported in this paper are for
efficiencies of 63% for I4C and 26% for 3H. Calculation
of 14C and 3H from doubly labelled samples was per¬
formed by the method of Okita et al. (20). The radio¬
activity of all samples was determined to within an error
of at most ± 5%.
TissuePreparation, Incubation, Extraction, andProduct
Identification
Livers were excised, rinsed free of blood, weighed, and
immediately used. The procedure of homogenate prepara¬
tion, incubation, extraction, purification, and identifica¬
tion of metabolites has previously been described (21),
and was adhered to in this study with a few notable
exceptions.
The tissue was homogenized for 30 s in a Virtis 45
homogenizer in 0.1 M phosphate buffer, pH 7.4, contain¬
ing 0.04 M nicotinamide. The ratio of buffer to wet
weight of tissue was 1 ml/100 mg. In each incubation,
5 ml of the homogenate was used with the following
added cofactors: NAD (2.3 pinoles), NADP (2 pmoles),
glucose-6-phosphate (15 pmoles), ATP (10 pmoles), and
MgCl2 (279 pmoles). Estrone-4-14C (6.0 X 105 c.p.m.)
and estrone-6,7-3H-3-sulfate (5.7 x 10s c.p.m.), diluted
with their unlabelled forms giving 50 pg of each, were
added to each incubation flask dissolved in 0.1 ml of
propylene glycol. Incubations were carried out in
duplicate for 5- and 90-min periods at 40 °C (21).
Suitable blank incubations, utilizing the above com¬
ponents together with tissue homogenates which had
been boiled for 20 min prior to incubation, were also
carried out.
The incubations were terminated by the addition of
excess acetone, the resulting protein precipitate being
washed with acetone and discarded. Acetone was re¬
moved under reduced pressure and the free estrogen
fraction extracted from the aqueous residue with diethyl
ether. The estrone and estradiol-17|3 components of this
were separated and purified, using the Girard reaction
and partition column chromatography in the general
manner described elsewhere (21). Radioactive estrone
and estradiol-173 fractions were diluted with the ap¬
propriate unlabelled carrier steroids, and crystallized to
constant specific activity and until the values for crystals
and mother liquors agreed within the counting error.
The mathematical product of the final specific activity of
the crystals and the weight of carrier steroid added prior
to crystallization then yielded some measure of the true
radioactivity present in each metabolite. This was related
to the incubated radioactivity to obtain percentage
conversion.
The residual aqueous fraction from the above, follow¬
ing extraction of free steroids with ether, was adjusted to
pH 12 with 1 IVNaOH and extracted three times with
an equal volume of water-saturated n-butanol to remove
estrogen sulfates. The butanol was evaporated under
reduced pressure while maintaining an alkaline pH; the
residue was dissolved in methanol, and one half was
chromatographed on Whatman No. 1 filter paper in
each of three solvent systems. These were: ethyl acetate -
n-butanol - 0.2% (v/v) conc. NH4OH (7:1:8) (22);
toluene -/z-butanol - NH4OH - H20 (5:5:1:9) (16); tol¬
uene - n-butanol - 2.8% (v/v) conc. NH4OH (3:1:2) (23).
The running times varied between 4 and 7 h. Radio¬
activity of mobility corresponding to that of authentic
estrone-3-sulfate or estradiol-173-3-sulfate was eluted
with methanol containing a small amount of NH4OH.
Each eluted fraction was diluted with unlabelled carrier
estrone-3-sulfate or estradiol-173-3-sulfate, whichever
was applicable, and crystallized from methanol - diethyl
ether (17). The final specific activities of the crystals were
again used to obtain the total amount of radioactivity
associated with the two estrogen sulfates, and this value
was in turn related to the incubated radioactivity as a
percentage. The remaining half of the butanol-soluble
radioactivity was subjected to hydrolysis with the Mylase
P enzyme preparation for 17 h at 37 °C (5), the freed
material was extracted with diethyl ether, separated into
fractions containing estrone and estradiol-173 by the
Girard reaction, and purified by Celite partition column
chromatography (19). Fractions with the properties of
estrone or estradiol-173 were diluted with the appropriate
carrier steroid and crystallized to constant specific
activity.
Results
Following incubation, it was immediately ob¬
vious that considerable amounts of both 14C-
and 3H-Iabelled materials were present in the free
(ether-extractable) form. The butanol-soluble
material, however, while containing significant
amounts of 3H originating from incubated es¬
trones-sulfate, was practically devoid of 14C
which would originate from incubated free es¬
trone. Thus in two experiments at 5 and 90 min,
respectively, only 7971 and 8528 c.p.m. of 14C
were found in the butanol fraction. These values
correspond to only 1.3 and 1.4% of incubated
activity and are even less significant when it is
considered that the blank incubation yielded
5613 c.p.m. in this 'conjugated' fraction. Since
these small amounts of radioactivity were not
rendered ether-soluble by Mylase P treatment,
they were not further processed.
Table I shows crystallization data for the 3H-
labelled butanol-soluble metabolites (from one
half of pooled butanol extracts of duplicate
experiments) in the conjugated form following
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TABLE I










+ 20 mg carrier 221 (calcd.)
Paper chromatographic pool
(38 140 c.p.m.)
+ 20 mg carrier 1907 (calcd.)
Crystallized from
methanol - diethyl ether
Crystallized from

























*After a 5-min incubation period.
tProduct directly identified by crystallization with pure unlabelled estrone-3-suIfate or estradiol-173-3-sulfate following paper
chromatography.
TABLE II
Typical identification of incubation products of estrone-6,7-3H-3-sulfate in free form following Mylase P










+ 20 mg carrier 207 (calcd.)
Celite column pool
(36 880 c.p.m.)
+ 20 mg carrier 1844 (calcd.)


























*After a 5-min incubation period.
tProduct indirectly identified by crystallization with pure unlabelled estrone or estradiol-173 following Mylase P hydrolysis
and column chromatography.
JLost.
paper chromatography. After three crystalliza¬
tions, about 86% of the radioactivity, behaving
like estrone-3-sulfate on paper, remained as¬
sociated with the carrier while 76% of the
presumptive estradiol-17[3-3-sulfate appeared to
be in the form of that compound. The other half
of the conjugate fraction from these same incuba¬
tions, following hydrolysis with the Mylase P
preparation and purification by the Girard reac¬
tion and partition column chromatography, was
then identified as free steroid by crystallization
with carrier. Table II shows the results of such
crystallizations, and it can be seen that about 88 %
of the radioactivity eluted from the column in the
position of free estrone remained associated with
the crystals after three crystallizations. The cor¬
responding value for estradiol-17(1 was 77%.
Table III shows data for the degree of conversion
of estrone-4-14C and estrone-6,7-3H-3-sulfate by
the liver homogenates. It should be noted that in
these experiments only estrone and its sulfate and
estradiol-17p and its sulfate were sought and
investigated. Percentage conversion was calcu¬








































































































♦Figuresarverag softwoexperiment ,eachinduplic t . •fValuescalculatedfollowingcryst l iz tiontconstantspe ifica tivity.
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experiment, when 5.7 X 10s c.p.m. of estrone-
6,7-3H-3-sulfate were incubated, 4325 c.p.m. of
'estrone sulfate' and 37 600 c.p.m. of 'estradiol-
17P sulfate' were eluted from paper chromato-
grams of the type described above. Following
crystallization with added carriers, in the con¬
jugated form, 3700 c.p.m. remained associated
with the estrone-3-sulfate carrier and 28 500
c.p.m. with the estradiol-17|3-3-sulfate carrier.
These corresponded to 0.65 and 5.0%, respect¬
ively, of the incubated substrate. It should be
noted that such a calculation does not take into
account experimental losses prior to the point of
addition of carrier steroid, thus the values given
in Table III are minimal in nature. It is apparent
from the data in Table III that interconversion
of estrone and estradiol-17P, both in the free
and sulfate forms, occurred.
Discussion
It is immediately apparent from the results in
this paper that free estrone may be metabolized
to estradiol-17p very rapidly by the liver homog-
enate. In the first 5 min of incubation, 11.4% of
the estrone was transformed to the dihydroxy
compound. After a 90-min incubation period this
conversion had decreased to an apparent value of
7.0% with a concomitant increase in estrone
from 20.0% at 5 min of incubation to 26.7 % after
90 min. The data suggest that the estrone to
estradiol-17P conversion by hen liver tissue is a
readily reversible reaction, with the estrone to
estradiol-17p transformation occurring almost
immediately after exposure of substrate to tissue.
In addition, other studies involving the simul¬
taneous incubation of equal weights ofestrone-4-
14C and estradiol-17P-6,7-3H by this tissue have
demonstrated that the reduction of estrone to
estradiol-17P is considerably more rapid than the
opposite oxidation reaction (24). However, it
must be emphasized that such a situation may
well be merely a reflection of the availability of
cofactors in the in vitro system studied. Since the
interconversion of estrone and estradiol- 17P in
free or sulfurylated form was of primary interest,
the metabolism of either estrone or estrone-3-
sulfate to other products is not reported upon in
this paper.
Perhaps the most interesting finding in the
present study concerns the metabolism ofestrone-
3-sulfate by the liver preparation. Table III indi¬
cates that the radioactive materials identified as
estrone-3-sulfate and estradiol-17P-3-sulfate were
exclusively 3H-labelled with no 14C detected in
either fraction. Since the 3H originates from the
incubated estrone-6,7-3H-3-sulfate while the cor¬
responding free estrone was 14C-labelled in the
incubation mixture, this would tend to indicate a
lack of sulfurylation of the free estrone-4-14C by
the whole liver homogenate. This latter finding
may be due to the presence of inhibitors of the
sulfurylation process, or perhaps to a low con¬
centration of sulfokinase or active sulfate syn¬
thesizing systems, especially since microsome-
free preparations of hen liver were highly active
in this respect (15). Whatever the reason, this lack
of esterification in combination with a 5.0%
conversion of estrone-6,7-3H-3-sulfate to estra¬
diol- 17P-6,7-3H-sulfate after only 5 min of incu¬
bation (Table III) was strongly suggestive of a
direct reduction without prior hydrolysis of the
sulfate moiety. After 90 min of incubation, the
level of this radioactive estradiol-17(3-3-sulfate
had diminished to 1.8 % of the incubated estrone-
3-sulfate, but was accompanied by an increase of
labelled estrone-3-sulfate from 0.7 % after a 5-min
incubation period to 4.7 % at 90 min. It is tempt¬
ing to suggest that such data indicate an initial
rapid reduction of estrone-3-sulfate to estradiol-
17p-3-sulfate followed by a slower reverse reac¬
tion in much the same manner as described above
for these two compounds in the free form.
However, the recovery of the sulfated metabolites
is very low (although fairly consistent), making
such a claim a difficult one to defend with the
information available. Nevertheless, the proof of
identity of the steroids, both in the free and con¬
jugated forms, is good enough to show the
presence of enzymes (or an enzyme) in the whole
homogenate capable of catalyzing, with added
cofactors, some degree of interconversion be¬
tween estrone and estradiol-17P on the one hand
and estrone-3-sulfate and estradiol-17P-3-sulfate
on the other.
It is noted from Table III that estrone-6,7-3H-
3-sulfate also gave rise to large amounts of free
estrone and estradiol-17p. Thus, 5 min of incuba¬
tion yielded 14.1% estrone-6,7-3H and 7.7%
estradiol-17P-6,7-3H. The corresponding figures
for 90 min were 17.1 and 5.0%, respectively. By
observing the high blank value for free estrone
production (6.5%), one is forced to conclude
that the hydrolysis of the substrate estrone-6,7-
3H-3-sulfate was a result of both enzymatic and
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non-enzymatic activity, the latter being the result
of the lability ofestrogen sulfates in general.
Finally, it must be emphasized that although
the total recoveries of metabolites reported in
Table III appear low, only the values for estrone
and estradiol-17 (3 in free or conjugated form were
reported, with figures for other metabolites of
estrone or estrone-3-sulfate being omitted. It
must also be pointed out that no correction has
been made for losses occurring during extraction
of tissue, purification, etc.
In conclusion, evidence has been presented
establishing the pattern of estrone and estradiol-
17p interconversion by hen liver to be a readily
reversible situation, with the estrone to estradiol-
17p transformation taking place almost instan¬
taneously. Furthermore, the respective C-3 ester
sulfates of these compounds can exhibit a quali¬
tatively similar behavior without prior hydrolysis
of the sulfate moiety. It should be noted that all
incubations were performed in phosphate buffer,
and since phosphate ion is known to inhibit
enzymic hydrolysis of steroid sulfates, the results
obtained may merely reflect the activity of a
suitable in vitro system. However, this does not
alter the finding that the tissue investigated ap¬
pears to possess the activity necessary to inter-
convert estrone-3-sulfate and estradiol-17p-3-
sulfate. To the knowledge of the authors, the only
other published works which have demonstrated
the capability of liver tissue to transform estrogen
sulfates in vitro without hydrolysis of the ester
grouping are those of Crepy and Jayle (9) and
Dahm and Breuer (10). They utilized tissues from
the rabbit and rat, however.
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ABSTRACT
3
Estradiol - 17p-6, 7- H-3, 17-disulfate was injected intra¬
muscularly into a mature non-laying hen. Very little (approximately
2%) of the injected material was recovered unchanged from the urine.
The only radioactive metabolite identified in the urine was estradiol-
17(3- 17-sulfate. The identification of this compound is based on: (a)
Mylase P enzyme incubations; (b) methylation followed by solvolysis
and thin-layer chromatographic identification of estradiol- 17(3-3 -
methyl ether; (c) acetylation of the latter and t. I.e. identification of
estradiol-17p-3-methyl ether - 17-acetate; (d) crystallization with
unlabelled estradiol - 17p - 17-sulfate; (e) solvolysis of the latter and
crystallization with unlabelled estradiol-17p.
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The hen is known to excrete steroid estrogens in urine mainly,
if not entirely, in conjugation with sulfuric acid (1). In a previous
study (2), it was found that this species is capable of metabolising
estrone sulfate to monosulfates and disulfates of the two estradiol
epimers without prior hydrolysis of the sulfate group; hence the di¬
sulfates of the two estradiol epimers were presumably formed by
sulfation of the C-17 hydroxyl group on each of the estradiol-3-
sulfate molecules.
The present study was undertaken to investigate the fate of in¬
jected estradiol- 17[3-3, 17-disulfate and to establish whether or not
the conversion of estradiol-3-sulfate to its disulfate form is a rever¬
sible process in vivo.
EXPERIMENTAL
Materials and Methods.
The experimental bird was a mature non-laying Rhode Island
Red hen modified surgically (3) so as to exteriorize the ureteral
openings and permit collection of the urine. Approximately 10 ml of
1 N NaOH solution was added to the collection tube each day in order
to maintain an alkaline pH. This was done to avoid any possible
breakdown of the urinary estrogen sulfates during collection of urine.
The pH values of the 24-hr urine collections on each of the five days
were found to lie between 8 and 9. The urine was removed from the
collection tubes several times daily and placed immediately in cold
storage at -15°C. The urine samples were processed immediately
after each 24-hr collection was completed.
Estradiol-17|3-6, 7-^H-3, 17-disulfate was synthesized from
estradiol- 17(3-6, 7-^H (specific activity 147 jac//Jg). This latter was
pur chased from New England Nuclear Corp., Boston, Mass. and
shown to be at least 98% pure by crystallization with unlabelled
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carrier. Sulfurylation was performed by the method of Fieser (4),
unreacted steroid was extracted with ether and the conjugate was ex¬
tracted with n-butanol from an aqueous solution of pHlO. The latter
material was chromatographed on a 40 g column of Woelm, neutral,
activity grade I, aluminum oxide in methanol with an increasing con¬
centration of NH4OH. The radioactivity was quantitatively eluted as a
sharp peak with methanol containing 0. 15% (v/v) conc. NH4OH. This
labelled material was then applied in aqueous solution to a DEAE-
Sephadex column (0.9 x 50 cm), which was then eluted with a linear
gradient of zero to 0. 8 M NaCl. Approximately 1. 5% of the applied
radioactivity was eluted at about 0. 4 M NaCl, which is characteristic
of a monosulfate conjugate (unpublished observation). No further
radioactivity was eluted up to 0. 8 M NaCl but continued elution with a
second linear gradient of 0.8 - 2. 0 M NaCl led to the appearance of a
symmetrical peak at about 1. 1 M NaCl. This accounted for 96% of
the chromatogr aphed material and it was recovered by treatment with
Amberlite XAD-2 as described by Bradlow (5). Chromatography on
Celite in the system iso-octane: t-butanol: M NH4OH (2:5:5 v/v) (6)
resulted in less than 1% of the radioactivity being recovered in the
form of free steroid or monosulfate. The presumptive disulfate was
eluted at about column volume 9. This latter material was not re¬
covered from unacidified 3 M NaCl by ethyl acetate extraction, in
contrast to the behaviour of monosulfates (7). Incubation of the di¬
sulfate with Mylase P (8) released no ether-soluble radioactivity but
enabled quantitative partition of the radioactivity into ethyl acetate
from 3 M NaCl suggesting the production of (presumably) the 17-
monosulfate. The latter was completely solvolyzed in ethyl acetate-
H2S04 to yield ether-soluble material. The disulfate (480, 000 dpm)
was mixed with 28. 1 mg of authentic unlabelled carrier (calculated
specific activity 17, 100 dpm/mg). Two successive crystallizations
from methanol-ether yielded crystals of specific activity 18, 300 and
18, 900 dpm/mg, respectively. A further 113, 400 dpm of the disul¬
fate were solvolyzed, mixed with 18. 1 mg of crystalline estradiol- 17p
(calculated specific activity 6270 dpm/mg) and crystallized twice as
above. Crystals of specific activity 6170 and 6200 dpm/mg were ob¬
tained.
Reference steroid estrogens were pur chased from Steraloids,
Inc., Pawling, N. Y. , U.S.A. or Mann Research Labs., New York,
N. Y. Reference estrone-3-sulfate was a gift from Dr. D.S.Layne,
Department of Biochemistry, University of Ottawa. Reference
estradiol - 17p-3-s ulfate and reference estradiol - 17(3-3, 17-disulfate
were gifts from Dr. R.Y.Kirdani, Roswell Park Memorial Institute,
Buffalo, N.Y.
Estradiol- 17(3- 17-sulfate was prepared by incubation of
estradiol-17|3-3, 17-disulfate with Mylase P (Mann Research Labs.,
New York, N.Y.) in 0. 1 M acetate buffer, pH 6. It was re-crystal¬
lized from m.ethanol: diethyl ether.
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Amber lite XAD-2 synthetic ion exchange resin was purchased
from Rohm and Haas, Philadelphia, Pa., U.S.A. Florisil (100-200
mesh) was purchased from Fisher Scientific Co., New Jersey, U.S.A.
DEAE-Sephadex, A-25, was purchased from Pharmacia (Canada)
Ltd., Montreal, Que.
All solvents, except methanol, were distilled before use. The
methanol was 'spectranalysed' grade, Fisher Scientific Co., Montreal.
Diethyl ether was purified as described by Bauld (9).
Thin-layer chromatography (t. I.e.) was performed on Silica
Gel G (Merck). The solvent systems used are listed in Table I. Vis¬
ualization of estrogens and of their derivatives was done as described
elsewhere (2).
TABLE I
Composition of chromatographic systems used.
System Composition by volume Reference
1 B enzene-ethyl methyl ketone-
ethanol-water (3:3:3:1) 10
2 2 -Propanol-chloroform -methanol -
10 N ammonia (10:10:5:2) 10
3 Chloroform-ethanol (3:1) 11
4 Cyclohexane: ethyl acetate (1:1) 12
5 n-Hexane: ethyl acetate (3:1) 2
6 Chloroform: diethyl ether (6:4) 13
Radioactivity was assayed (14) and acetylations were perform¬




Estradiol- 17(3-6, 7- H-3, 17-disulfate (14.6 x 10 dpm) was
dissolved in 0. 5 ml of dimethyl sulfoxide and injected intramuscular¬
ly into the experimental hen. Urine was collected over five success¬
ive 24-hr periods. Each 24-hr urine sample was separately filtered
and assayed for radioactivity.
Extraction of urinary steroids.
The urine from day-1 was passed through a column of Amber-
lite XAD-2, Steroids and steroid sulfates were eluted from the
column with methanol as described by Bradlow (5). Two other frac-
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tions, viz. , (a) filtered urine and (b) water-wash of the XAD-2 col¬
umn prior to its elution with methanol,were also obtained. Each of
these three fractions was assayed for radioactivity.
Aliquots of the fractions containing the filtered urine and the
water-wash of the column were hydrolysed separately by adding 15
volumes conc. HC1 per 100 volumes and then boiling the mixture for
1 hour under reflux. The hydrolysed solutions were extracted with
diethyl ether (3x1 vol) to remove any free estrogens. The ethereal
extracts were assayed separately for radioactivity.
Fractionation of urinary steroid extract.
The methanol eluate obtained from the XAD-2 column was
further fractionated on a Florisil column to yield (a) "free" estrogens,
(b) monosulfates of estrogens and (c) disulfates of estrogens as des¬
cribed elsewhere (1).
Disulfate Fraction.
Lack of sufficient radioactivity in the presumptive disulfate
fraction pr ecluded rigorous identification. This fraction was chrom-
atographed, however, in admixture with reference estradiol-17p-3,
17-disulfate in systems 1 and 2 and histograms of the chromatoplates
were prepared.
Monosulfate Fraction.
An aliquot of the monosulfate fraction was chromatographed
(t.l. c.) in system 1 along with reference estrone sulfate and estra¬
diol- 17(3-3-sulfate. Fractions containing estrone-3-sulfate and
estradiol-1 7p-"monosulfate" were obtained from the chromatoplate
as described elsewhere (2). The fractions thus obtained were desig¬
nated (a) presumptive estrone sulfate fraction and (b) presumptive
estradiol "monosulfate" fraction. Aliquots of each fraction were
assayed for radioactivity. The presumptive estradiol "monosulfate"
fraction was chr omatographed (t. I.e.) in systems 1, 2 and 3 along
with reference estradiol-17p-3-sulfate.
The following procedural steps were taken in order to estab¬
lish the identity of the presumptive estradiol-"monosulfate. " An
aliquot of the estradiol "monosulfate" fraction was incubated in 25 ml
of acetate buffer, pH 6, 0,with Mylase P enzyme preparation. A blank
incubation containing no Mylase P was performed simultaneously.
The incubations, in duplicate, were carried on for 24-hr at 37°C.
The incubated solutions were thereafter extracted separately with
chloroform (3x1 vol.) in order to remove any free estrogens which
might have been liberated as a result of Mylase P activity.
A fresh aliquot of the total monosulfate fraction was methyl¬
ated. The methylation product was adjusted to pH 10 with 5 N NaOH
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and extracted in n-butanol, the n-butanol was evaporated under re¬
duced pressure and the residue was dissolved in 1 ml of methanol.
To this was gradually added, with shaking to mix thoroughly, 2 00 ml
of ethyl acetate and the methyl ether(s) of the monosulfate fraction
were subjected to solvolysis for 48 hrs. (1). The solvolysed material,
after being washed with 1 M MaHC03 and H2O (2), was evaporated to
dryness under reduced pressure. The dry residue was chromato-
graphed (t.l.c. ) in systems 4 and 6, along with reference estradiol-
17|3-3-methyl ether. Histograms of the developed chromatoplates
were made and the position of the peak of radioactivity observed was
compared with that of the stain due to reference estradiol- 17(3-3-
methyl ether.
A further aliquot of the solvolysed methylated product was
acetylated and the acetylation product was chromatographed in system
5 in admixture with r efer ence estradiol-17p-3-methyl ether-17-
acetate. A histogram of the chromatoplate was made and the position
of the peak of radioactivity was compared as to chromatographic mob¬
ility with the stain due to the reference estradiol-17|3-3-methyl ether¬
s-acetate.
Yet a further portion of the total monosulfate fraction was
crystallised with reference estr adiol-17(3- 17-sulfate.
A fresh aliquot of the total monosulfate fraction was solvolysed
for 48 hr. The solvolys ed material was washed with 1 M NaHC03 and
H2O and the organic phase (ethyl acetate) was evaporated to dryness.
The dry residue was chromatographed in system 6 and zones corres¬
ponding in chromatographic mobility with reference estrone, estra-
diol-Sff, estradiol-17p and 16-epiestriol were removed from the
chr omatoplate, eluted with methanol and each fraction was assayed
for radioactivity. The fraction containing estr adiol-17(3 thus obtained
was crystallised to constant specific activity with reference estradiol-
17(3.
RESULTS
The recovery of administered radioactivity from the urine
from the first day was 8. 0%. The total recovery for days 1-5 was
11. 1%.
The recovery of the radioactivity from the Amber lite XAD-2
column (see Table II) was almost 100%. The steroid-containing
methanol eluate from the Amberlite XAD-2 column accounted for only
40% of the total radioactivity. Acid hydrolysis (by 15% vol HC1 conc.)
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of the filtered urine fraction and of the water-wash, followed by ether
extraction, did not yield any radioactivity in the ether extract, and
100% of the radioactivity was found in the aqueous phase in both cases.
TABLE II
Elution pattern of day-1 urine from Amberlite XAD-2 column.




Fraction dpm x 10 Percent of total
1. Filter ed urine 22. 0 18. 3
2. Water -wash 49. 8 41. 5
3. Methanol eluate 48. 0 40. 2
Total 119.8 100. 0
Percentage of total urinary activity
r ecover ed fr om the column 100
Elution of the steroid fraction from a Florisil column with an
increasing concentration of methanol in CHC13 was found to yield a
pattern almost identical with the one obtained in previous studies
(1, 2). The monoconjugate fraction accounted for over 95% of the total
radioactivity whereas the diconjugates accounted for only about 2% of
the total radioactivity. (Table III). The latter material had the
chromatographic mobility of standard estradiol-17p-3, 17-disulfate in
each of two t.l. c. systems.
The estrone sulfate fraction obtained from the presumptive
monosulfate fraction by t.l.c. exhibited practically no radioactivity,
which suggested absence of estrone. Practically all the radioactivity
was found to be in the estradiol "monosulfate" fraction, the chromato-
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graphic mobility of which corresponded to that of reference estradiol-
17p-3-sulfate in three 1.1. c. systems.
TABLE III
Florisil Column: Elution of the total steroid fraction of hens1 urine
and results of thin layer chromatography of resulting sub-fractions.









2 CHCl3:MeOH 80:20 3. 20 0. 7 Free estrogen
3 II II 70:30 129 27.8 Mainly single
conjugate + s ome
free estrogens
4 II II 55:45 320 68.9 Single conjugate
5 It II 40:60 7. 29 1.6 Mixture of two
conjugates
6 II II 75:25 3. 66 0. 8 Double conjugate
7 Methanol 1. 14 0.2 II II
Total 464 100. 0
Percentage of total radioactivity
r ecovered from Florisil column 96. 5%
TABLE IV
Radioactivity extracted by chloroform after incubation of the presump¬
tive estradiol "monosulfate" fraction of urinary estrogens.













1. Blank 773 24. 3 3. 1
2. Mylase P 773 28. 6 3.7
3. Blank 247 14. 8 6. 0
4. Mylase P 247 21. 7 8.8
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Incubation of estradiol monosulfate fraction with Mylase P did
not result in any increased amount of chloroform-extractable radio¬
activity over the corresponding blank used. This suggests that the
sulfate group of the estradiol monosulfate fraction was not at the C-3
position but rather at C-17 of estradiol-17p. The results from the
Mylase P incubations are presented in Table IV.
Further identification of the presumptive monosulfate fraction.
Methylation of the presumptive monosulfate fraction, followed
by solvolysis and subsequent development on a thin-layer chromato-
plate yielded one peak of radioactivity which corresponded in chrom¬
atographic mobility with the reference estradiol-17p-3-m ethyl ether
in systems 4 and 6. This suggested that the urinary extract after the
aforesaid manipulations yielded estradiol- 17p-3-methyl ether. This
was to be expected if the original material was estradiol -17(3- 17 sul¬
fate.
Acetylation of the methyl ether and subsequent chromatography
in system 5 once again yielded one peak of radioactivity which corres¬
ponded in chromatographic mobility with reference estradiol-17(3-3-
methyl ether -17-acetate.
These observations suggested strongly that the presumptive
monosulfate fraction was almost entirely estradiol- 17(3- 17-sulfate.
Crystallization of the presumptive estr adiol- 17(3 - 17-sulfate with un-
labelled estradiol-17p-17 sulfate yielded the results presented in
Table V, which confirmed the foregoing supposition.
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TABLE Y
Presumptive estradiol-17|3-17 sulfate fraction:- Crystallization with
reference estradiol- 17(3- 17 sulfate.
-3
dpm x 10 mg dpm x 10
mg
Original Pool 41. 3 20. 50 201
1st Crystallization
Crystals 33. 5 15.25 220
2nd Crystallization
Crystals 29. 7 13. 50 220
Solvolysis of the monosulfate fraction and subsequent chrom¬
atography on thin-layer chromatoplates in system 6 revealed the
following distribution of radioactivity on the chromatoplate: -
3.2% in the 16-epiestriol fraction; 82. 7% in the estradiol- 17(3
fraction; nil in the estradiol-lla fraction; and 1.6% in the
estrone fraction.
These values suggested the virtual absence of estrone and of
estradiol-1 la and the presence of a high proportion of estradiol- 17(3.
The 16-epiestriol fraction was not processed due to lack of sufficient
radioactivity. The radioactive estradiol-17(3 fraction was crystallized
to constant specific activity with reference estradiol-17p. The re¬
sults, which are presented in Table VI, confirmed the chromato¬
graphic identification of the estradiol-17|3.
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TABLE VI
Presumptive estradiol- 17(3- 17 sulfate: Identification of estradiol-17p
following solvolysis of-monosulfate fraction.
, -3
dpm x 10 mg dpm x 10
mg
Original Pool 114 43. 50 262
1st Crystallization
Crystals 95.2 35.91 265
2nd Crystallization
Crystals 69. 1 COr—1vO00 264
DISCUSSION
The recovery of tritium activity (11%) in the urine in the ex¬
periment now reported may be compared with the recovery of 16. 6%
of the radioactivity of injected estrone sulfate (2) and of 31% of the
radioactivity of injected estradiol- 17(3 (1) in other experiments. This
comparison might suggest that the recovery in the urine decreases as
the degree of sulfation of the injected steroid estrogen increases. A
satisfactory resolution of this problem is unlikely, however, until
more is known about the transfer of estrogens and estrogen conjugates
through the bile.
In the present work only 41% of the total urinary radioactivity
was recovered in the total urinary steroid ('free' + conjugated) frac¬
tion as compared with values of 97% and 93% when estradiol-17p (1)
and estrone sulfate (2), respectively, were injected. This suggested
that a relatively high proportion of injected estradiol-17p-3, 17-
PURCHASED BY U.S. DEPT. OF AGRICULTURE
FOR OFFICIAL USE
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disulfate was converted to highly polar compounds; and this suggest¬
ion was reinforced by the observation that acidic hydrolysis of the
urine fraction which had been filtered through the Amberlite XAD-2
column did not liberate any appreciable amount of radioactive material
extractable by diethyl ether. The radioactivity in that fraction, there¬
fore, could not have been associated with any of the better-known
steroid estrogens. Similar results were observed with aliquots of the
water-wash of the XAD column despite the fact that this fraction ac¬
counted for 42% of the radioactivity passed through the column.
The partially purified estradiol "monosulfate" fraction, when
incubated with the enzyme preparation Mylase P, did not release any
radioactivity which could be extracted with chloroform. This obser¬
vation, together with the behaviour of the monosulfate fraction on
t. I.e., showed that the injected estradiol- 17p-3, 17-disulfate had, in
fact, given rise to estradiol- 17(3- 17-sulfate. There can be little
doubt as to the identity of the main component of the monosulfate
fraction, the identification being based on the formation of well-
defined derivatives, crystallization with reference estradiol- 17(3-17
sulfate and with reference estradiol-17p following cleavage of the
sulfate group by solvolysis.
Mono- and disulfates of estradiols have been obtained from
3 35
urine following injection of estrone sulfate labelled with H and S
(2). The results now obtained indicate clearly that, at least as ref¬
lected in urinary metabolites, the formation of estradiol- 17(3-3, 17-
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disulfate from estradiol-17(3-3-sulfate in the hen is not a reversible
process. Instead the injected disulfate of estradiol- 17(3 loses the
sulfate group from its C-3 position to yield estradiol- 17(3- 17-sulfate.
In the previous experiment (2), the sulfate group at the C-3 position
remained attached to the estrogen molecule when estrone sulfate was
converted to the 3-sulfates of the two estradiol epimers and finally to
their disulfates.
In other experiments (17) the relative proportions of radio¬
active estr adiol-17(3 to radioactive estrone in the urine of a non-laying
14
hen following intramuscular injection of estrone-4- C or estradiol-
14
17(3-4- C were approximately 5: 1. If free estradiol-17(3 had been
formed from the injected estr adiol-17(3-disulfate in the present experi¬
ment,one would expect radioactive estrone to have been present in the
urine, unless estradiol-17(3 in this experiment was formed and recon-
jugated in a compartment lacking estr adiol- 17(3 dehydrogenase activity.
In point of fact, no radioactive estrone was detected in the urine des¬
pite attempts to find it.
In previous studies (1,2) the amounts of estrogen disulfates in
hens urine have' been found to account for only about 5% of the total
urinary steroid fraction; hence estradiol-17(3-17-sulfate derived
from estradiol- 17(3-disulfate should be at best only a very minor com¬
ponent of the total urinary monosulfate fraction. In the present ex¬
periment estradiol-17(3-3, 17-disulfate accounted for only about 2 per¬
cent of the total radioactive steroid fraction.
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The systematic and (in brackets) trivial names of steroids
mentioned in this paper are:-
3-hydroxy-estra- 1, 3, 5( 10)-trien-17-one (estrone):
estra-1, 3, 5( 10)-triene-3, 17a-diol (estradiol-17a):
estra-1, 3, 5( 10)-triene-3, 17|3-diol (estradiol- 17(3):
estra-1, 3, 5( 10)-triene-3, 16(3, 17|3-triol (16-epiestriol).
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ABSTRACT
17/3-Estradiol-3-sulfate (E2 3S) , 17/3-estradiol-17-sulfate
(Es 17S) , 17/3-estradiol-3-sulfate-17-glucosiduronate (Ea 3S17G)
ahd 17/3-estradiol-3, 17-disulfate (Es 3S17S) , all labelled with
3H, were prepared in the laboratory and identified by
chromatographic, hydrolytic and crystallization techniques.
Estrone-3-glucosiduronate (Ex 3G) and 17/3-estradiol-3-gluco-
siduronate(E33G), both labelled with 14C, were also
synthesized and similarly identified. Column chromatography
on DEAE-Sephadex in a linear gradient of 0 - 0.8M NaCl,
followed by 0.8 - 2.0M NaCl, resulted in a clear separation
of 17/3-estradiol(Es ) , Ejl 3G, 17/3-estradiol-17-glucosiduronate
(Es17G), estrone-3-sulfate(Ex 3S), E23S, E23S17G and E23S17S.
Eg3S was not separable from Es17S under these conditions.
The presence of urinary residues, while causing some changes
in the elution pattern, still allowed of a reasonable
separation. Some resolution of E-l 3G and Es 3G was possible
in a linear gradient (0 - 0.4M NaCl). Also, some separation
could be obtained between E23G and E217G in a non-linear
gradient (concave upwards; 0 - l.OMNaCl).
INTRODUCTION
The use of DEAE-Sephadex as a means of separating
certain groups of phenolic steroid conjugates has been
described by Hahnel etal (4,5). We considered that this
technique, in conjunction with other chromatographic
procedures, might be particularly useful where a study is
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made of the metabolism of a labelled compound such as 17/3-
estradiol-17-glucosiduronate(E217G; 6), which in the human
is known to give rise to little other than conjugates of
estrone(Ej ) and 17/3-estradiol (Ea ) in the urine (7). This
lack of complexity in the pattern of metabolites might
enable a relatively rapid identification of the major
conjugates to be made if it were possible to extend the
use of DEAE-Sephadex chromatography.
With the above in mind a number of glucosiduronate
and sulfate conjugates of labelled Ex and E3 were prepared
in our laboratory and, together with certain commercially
available compounds, their behaviour on DEAE-Sephadex
columns was investigated as described below.
MATERIALS
Amberlite XAD-2 resin was purchased from Rohm and Haas,
Philadelphia, Pa., and was soaked in Ha 0 while sucking off
suspended fines prior to use. DEAE-Sephadex (A-25; particle
size 40 - 120/i) was purchased from Pharmacia (Canada) Ltd.,
Montreal, and was steeped in water for at least 24 hr, fine
particles being removed by suction, prior to use. Celite
was treated as described elsewhere (8).
Mylase P, containing phenolsulfatase, was obtained
from Mann Research Labs., New York, and was used in
incubations in 0.1M acetate buffer pH 6, overnight (9).
Bacterial /3-glucuronidase powder (Type II) was obtained
from Sigma Chemical Co., St. Louis, Mo. It was used in
0.1M phosphate buffer, pH 7, at a concentration of 20 - 40
units/ml for a time of 24 hr (10).
Unlabelled steroids were purchased from Mann Research
Labs. Estrone-6,7-3H-3-sulfate(Ex3S), specific activity
(SA) = 7.8jic/jLig and 17/3-estradiol-6,7-3H-17-glucosiduronate,
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SA = 2.2gc/jig were purchased from New England Nuclear Corp.,
Boston, Mass., and were checked for purity as described
earlier (7,10). 17j9-Estradiol-6,7-3H, SA = 147gc/(ig, was
also obtained from the latter source and was at least 98%
pure as judged by crystallization with unlabelled carrier.
Estrone-4-14C, SA = 0.1gc/gg, was purchased from Radio¬
chemical Centre, Amersham, Bucks, England, and was found
to be radiochemically homogeneous on crystallization with
carrier.
Adenosine-5'-triphosphate (ATP) was obtained as the
disodium salt from Schwarz Bioresearch Inc., Orangeburg,
N.Y. Uridine-5'-diphosphoglucuronic acid (UDPGA) was
obtained as the ammonium salt from Sigma Chemical Co.
All solvents and reagents were of good quality and




XAD-2 resin columns were employed to recover steroid
conjugates from NaCl solutions following DEAE-Sephadex
chromatography, and from urine to which they had been added.
The salt solutions or urine were applied to the resin which
was then washed with H20 and eluted with methanol as
described by Bradlow (12).
All Celite columns used were of dimensions 1 x 20 cm
and each had 0.5 ml stationary phase per g Celite. The
holdback volume (HBV) of these was ca. 9 ml. Steroid
conjugates were transferred to the columns by dissolving
in 0.5 - 0.75 ml methanol, mixing intimately with 0.5 g
Celite, drying overnight in a vacuum desiccator and packing
on top of the already prepared column. The solvent systems
used were; system A - iso-octane:t-butanol:M NH^OH (2:5:5),
(13) ; system B - iso-octane:t-butanol:M NH4OH (2:10:10), (14) ;
system C - n-butanol:ethyl acetate:0.2% NH^OH (3:1:4), (15).
DEAE-Sephadex, added as a slurry in Hs0, was allowed to
settle under gravity in no. K9/60 Sephadex columns (Pharmacia
Ltd.) to yield gel column dimensions of 0.9 x 50 cm. Pure
steroid conjugates, and conjugates previously added to urine
and recovered through XAD-2 resin, were applied in 5 ml Hs0
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and washed into the column with a further 2 x 2.5 ml H20.
Where whole pregnancy urine was to he chromatographed, 20 ml,
diluted with 10 ml H20, were directly applied. Linear NaCl
gradients were applied from two identical 1000 ml poly¬
ethylene bottles (Fisher Scientific Co., Montreal, Catalogue
No. 2-962) connected by polyethylene tubing. The mixing
vessel (complete with magnetic stirrer), delivering into
the column, contained Hs0 or the lesser of two NaCl
concentrations. The linear systems used were; linear
gradient 1 - 500 ml H20 in mixing vessel, 500 ml 0.8M NaCl
in reservoir vessel; linear gradient 2 - 500 ml 0.8M NaCl
in mixing vessel, 500 ml 2.0M NaCl in reservoir; linear
gradient 3 - 400 ml H20 in mixing vessel, 400 ml 0.4M NaCl
in reservoir. In addition, one non-linear gradient was
used in which the mixing vessel contained 500 ml H2 0 and
the reservoir had 100 ml 1.0M NaCl (4). In this case the
ratio of the surface area of the mixing vessel to that of
the reservoir was 5:1.
Measurement of radioactivity
This was performed using either a dioxan scintillation
fluid, or a toluene system in which the sample had already
been dissolved in methanol. Details of this are published
elsewhere (10).
Preparation of 17g-estradiol-6,7-3H-3-sulfate(Ea3S)
Purified 3H-EX 3S was reduced with NaBH4 (16) and the
product extracted with ether whereupon 1.2% of the initial
3H was removed in the 'free' form. The conjugated material
was extracted with n-butanol at pH 10-11 and partially
purified by chromatography on A1203 in methanol containing
a small concentration of NH^OH (10). Further purification
was achieved by DEAE-Sephadex chromatography in linear
gradient 1 which yielded a single peak at ca. 0.45M NaCl,
and by Celite chromatography (system A) in which a peak was
eluted in HBV 3. In the latter system no more than 0.3% of
the SH could be accounted for in an unconjugated form. The
prepared material was hydrolyzed to an ether-soluble form
by Mylase P to an extent of more than 95%. At least 98% of
the 3 H was associated with a non-ketonic compound (Girard) .
Crystallization from methanol of 278,000 dpm (disintegrations
/min.) with 26.8mg unlabelled Es yielded crystals (XLS) of
SA = 10,800 dpm/mg and mother liquor (ML) of SA = 11,300 dpm/
mg (calculated value = 10,400).
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Preparation of 17g-estradiol-6, 7-3H-3, 17-disulfate (Ea3S17S)
3H-E2 was sulfurylated by the method of Fieser (17).
After removal of free steroid with ether the conjugate was
extracted into n-butanol (pH 10-11). It was then chromato-
graphed on Al203 in methanol containing 0.15 (v/v)% OH
yielding a single peak of radioactivity. This in turn was
run on DEAE-Sephadex in linear gradient 1 followed by 2.
About 1.5% of the applied 3H was eluted in the position of
monosulfate; the rest appeared as a symmetrical peak at ca.
1.4M NaCl. Celite chromatography in system A showed a
single radioactive peak at about HBV 9. The disulfate was
not extractable with ethyl acetate from unacidified 3M
NaCl but became quantitatively extractable after Mylase P
hydrolysis to yield 3H-17j3-estradiol-17-sulfate (Es 17S) .
This latter, and the disulfate itself, were quantitatively
solvolyzable in ethyl acetate-H2S04 (18). The 3H-ES
released was crystallized with carrier from methanol (45,400
dpm + 18.1mg carrier; calc. SA = 2500 dpm/mg) to yield XLS
and ML of SA = 2470 and 2480, respectively. When 48,000
dpm of the 3H-E33S17S were crystallized from methanol-ether
with 28.1mg unlabelled carrier (synthesized in our laboratory)
XLS and ML of SA = 1830 and 1890 dpm/mg, respectively, were
obtained (calc. SA = 1710).
Preparation of 17ff-estradiol-6,7-3H-17-sulfate
3H-E217S was prepared by Mylase P hydrolysis of the
labelled disulfate. It was purified by DEAE-Sephadex
chromatography using linear gradient 1 and by Celite
partition using system A. The purified compound was solvo-




This was synthesized by incubating 3H-E217G for 1 hr
at 37°C with a 105,000 x g supernatant fraction of female
guinea pig liver in phosphate buffer (pH 6.5) to which had
been added ATP, MgS04 and KCl (15,19). The incubation
mixture was diluted with 4 vols, of ethanol, proteins were
centrifuged off and washed, and the supernatant evaporated
and chromatographed on DEAE-Sephadex in linear gradient 1.
About 4% of the recovered 3H was eluted at 0.14M NaCl, 9%
at ca. 0.22M NaCl (100% hydrolyzable by ^-glucuronidase;
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presumably unchanged E217G), and 87% at about 0.6M NaCl.
The latter peak was applied to a Celite column which was
developed with 14 HBV's of system A without elution of any
radioactivity. Further elution with system B produced a
rather wide peak between HBV's 6 and 13. Rechromatography
on Celite in system C resulted in elution of the 3H between
HBV's 3 and 5. An aliquot of the latter material was
incubated with Mylase P resulting in <1% of the SH being
recoverable in an ether-soluble form. The water-soluble
material from this incubation was eluted at HBV 7 from
Celite in system A (i.e. typical of a monoglucosiduronate).
This, in turn was cleaved (>98%) by ^-glucuronidase. A
further aliquot of the presumptive mixed conjugate was
incubated with /^-glucuronidase (<1% 3H converted to ether-
soluble form) and the HsO-soluble product shown to be
eluted from Celite in system A in HBV 3 (i.e. typical of
a monosulfate). Incubation with Mylase P yielded 97%
hydrolysis. The ether-soluble radioactivity from the two
sets of incubations were pooled and an aliquot (406,000 dpm)
was crystallized from methanol with 23.8mg unlabelled E2
(calc. SA = 17,000 dpm/mg). XLS and ML, each of SA =
16,800, were obtained. The XLS were acetylated and crystal¬
lized from methanol-H20 to yield SA values of 12,900 and
13,200 dpm/mg for XLS and ML, respectively (calc. SA =
12,800).
Preparation of estrone-4-1 4C-3-glucosiduronate (E, 3G)
14C-E1 was incubated with a whole homogenate of female
rabbit liver in phosphate buffer, pH 7.5, with added UDPGA,
under the conditions described by Levitz et al (20) for the
biosynthesis of estriol-3-glucosiduronate. A deproteinized
extract of the incubation mixture was chromatographed in
linear gradient 1 on DEAE-Sephadex whereupon 83% of the
recovered 14C was eluted at about 0.15M NaCl and 17% slightly
later. The latter was completely hydrolyzed by ^-glucuroni¬
dase and the steroid released shown to be 100% non-ketonic.
The major peak was chromatographed on Celite in system A and
eluted in HBV 7-10. It also was quantitatively hydrolyzed
by /3-glucuronidase and at this stage the 14C-steroid released
was 85 - 90% ketonic. Further DEAE-Sephadex chromatography
was performed using the non-linear gradient (0 - 1.0M NaCl).
A sharp peak of radioactivity was eluted at about 0.15M NaCl.
Following /3-glucuronidase hydrolysis an aliquot of the free
material (65,000 dpm) was crystallized thrice from methanol
with 22.3mg unlabelled Ex (calc. SA = 2920 dpm/mg). The
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third XLS and ML had SA values of 2730 and 2700, respectively.
These XLS were acetylated and crystallized twice from
methanol-Hg0. The second XLS and ML had SA = 2290 and 2260
dpm/mg, respectively (calc. SA = 2360).
Preparation of 17j3-estradiol-4-1 4 C-3-qlucosiduronate (Ea 3G)
This was prepared by the reduction of 14C-E13G with
NaBH^ in methanol. The conjugate was recovered by treatment
with XAD-2 resin and was then subjected to DEAE-Sephadex
chromatography in linear gradient 3 and then in the non¬
linear gradient. In each case sharp peaks of radioactivity
were noted. Hydrolysis with /3-glucuronidase was quanti¬
tative and an aliquot of the released l4C (54,500 dpm) was
crystallized thrice from methanol with 26.7mg unlabelled Es
(calc. SA = 2040 dpm/mg). The third XLS and ML had SA values
of 1930 and 1960, respectively. The last XLS were acetylated
and crystallized twice from methanol-H20. The second XLS
and ML obtained had SA = 1460 and 1450 dpm/mg, respectively
(calc. value = 1490).
RESULTS
The 3-monosulfates of Ex and E2 were well separated
by DEAE-Sephadex chromatography using a gradient of 0 - 0.8M
NaCl (Fig. 1). This was so whether these two compounds were
chromatographed in the pure state, added to 20 ml pregnancy
urine diluted with 10 ml Hs0 and applied directly to the
column, or added to one-third of a 24 hr non-pregnancy urine,
and eluted from the XAD-2 resin prior to chromatography.
Widening of the peaks did occur in the presence of urine
residues. Thus, in the pure state Ex3S was recovered in
50 - 60 ml eluate and E23S in 60 - 80 ml. Following
addition to urine these values were 80 - 100 ml and 90 -




Fig. 1. DEAE-Sephadex chromatography (0 - 0.8M NaCl, linear
gradient) of 3H-E13S and 3 H-E2 3S: x - elution pattern of pure
conjugates in 4 separate experiments; o - elution pattern of
conjugates added to 20 ml late preg. urine diluted with 10 ml
Ha0; # - elution pattern of conjugates added to 1/3 of a 24 hr
non-preg. urine and processed on Amberlite XAD-2.
sulfates was quite consistent from one experiment to
another (Table I) and recovery from the Sephadex columns
was always in excess of 95%. When the separated peaks
were hydrolyzed with Mylase P it was shown that Ex was the
sole constituent of the first eluted and Es of the second
peak, thus establishing the relative positions of Ex 3S and
Es 3S.
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TABLE I
Elution of Ex3S and E33S from DEAE-Sephadex by a linear
gradient of 0 - 0.8M NaCl
Experiment Fractions (10 ml)
containing conjugates
E1 3S E2 3S
E-l 3S + E2 3S (pure) 44 - 49 55 - 62
II II II 46 - 51 57 - 64
II II II 46 - 50 57 - 63
II II II 45 - 49 57 - 62
Ex 3S + Es 3S + 20 ml late preg. 45 - 52 58 - 66
urine diluted with 10 ml H30
Ex 3S + Es 3S + 1/3 of a 24 hr non- 42 - 51 55 - 66
preg. urine processed on XAD-2
The linear gradient 0 - 0.8M NaCl also had a wide
applicability in the separation of several other Ej^ and E2
conjugates. Fig. 2 shows the elution pattern of a mixture
of purified 14C-E3, 14 C-Ex 3G, 3H-E217G, 3H-E1 3S, 3H-Es3S and
3H-E2 3S17G. These six compounds were clearly separable from
each other. Superimposed upon this is the pattern for the
five above-mentioned conjugates plus 14C-E23G/ all of which
had been added to one-third of a 24 hr non-pregnancy urine
and processed via the XAD-2 resin. The gradient employed
was not capable of separating Ea3G and ES3G, the latter
appearing as a shoulder on the peah of the former. Certain
shifts in the elution pattern were presumably caused by
the presence of urine residues; the most marhed occurring
200 STEROIDS 14:2
in the case of E23S17G which was eluted earlier than in the
pure state, resulting in a poorer separation between it and
E23S. E23S17S was not eluted over the range 0 - 0.8M NaCl
but appeared as a symmetrical peak between concentrations
of ca. 1.2 and 1.6M NaCl in a more concentrated system.
In all instances recovery of the added conjugates from the
DEAE-Sephadex column was at least 95%.
Table II shows the NaCl concentrations at which the
various compounds were eluted. E217S (not shown in the
Figs.) was apparently not separable from E23S in the 0 -
0.8M NaCl system.
0 10 20 30 40 50 60 70 80 90
FRACTION NO. (EACH 10ml)
Fig. 2. DEAE-Sephadex chromatography of compounds (0 - 0.8M
NaCl linear gradient): x - pure 14C-E2f 14C-E13G1 3H-E217G,
®H-E13S, 3 H-E2 3S and 3H-E23S17G; o - 14C-E13Glf 14C-E23G,
3 H-E3 17G, sH-E13S, 3 H-E2 3S and 3H-E23S17G added to 1/3 of a
24 hr non-preg. urine and processed on Amberlite XAD-2.
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TABLE II
Salt concentrations required for elution of pure compounds
from DEAE-Sephadex using a linear gradient of 0 - 0.8M NaCl
followed by 0.8 - 2. 0M NaCl
Compound NaCl concentration range (M)
E8 .05 1 • O
ei 3G . 17 - .19
Es 3G . 18 - .23 (approx.)
Ea 17 G .22 - .25
Ex 3S .37 - .41
Eg 3S .46 - .52
Eg 17S .46 - .52
Eg 3S17G .57 - .64
Eg 3S17S l.OO -1.2.0
Variation of the NaCl gradient achieved some, though
not complete, separation of Ex3G from E33G and of E33G
from E217G. Fig. 3 shows the pattern obtained for the
former two conjugates in the linear gradient 0 - 0.4M NaCl,
and Fig. 4 shows the separation achieved of the two Es
conjugates in the non-linear gradient (0 - 1.0M NaCl).
DISCUSSION
The labelled conjugates synthesized in our laboratory
for use in this study appeared, on the whole, to possess
the required degree of radiochemical homogeneity.
It is clear from the results presented above that
DEAE-Sephadex possesses a great potential for the separation
of phenolic steroid conjugates. Thus, not only does there
exist the possibility of separating lihe steroids conjugated
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30 40 50 60
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Fig, 3. DEAE-Sephadex chromatography of pure 1 4 C-E-l 3G and 1 4 C-
Es3G in 0 - 0.4M NaCl, linear gradient.
with the same acid at different carbon atoms of the steroid
molecule (4,5), but also the very clear resolution of
steroids differing only slightly in structure and conjugated
with the same acid at the same carbon atom. This is
particularly evident in the simple separation of Ex3S and
E23S and to a lesser extent for the 3-glucosiduronates of Ex
and Eg. The excellent separation of the two monosulfates
suggests that more than simple ion-exchange of the sulfate
group is involved. There can be no doubt about the ease
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Fiq. 4. DEAE-Sephadex chromatography of pure 1 4C-Es3G and
3 H-E217G in 0 - 1.0M NaCl, non-linear gradient.
with which monoglucosiduronates, monosulfates, mixed con¬
jugates and double conjugates may be separated on a linear
gradient of NaCl. This finding apparently differs in some
important respects from the findings of Hahnel et al who
experienced problems in separating monosulfates from 16-,
or 17-monoglucosiduronates (4,5).
Elution of the conjugates in aqueous salt solution
does not represent a major inconvenience since they may be
recovered, more or less salt-free, by the elegant XAD-2
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resin procedure described by Bradlow (12). Further
purification is then possible by means of Celite, paper,
thin-layer chromatography, etc.
In this study we have not determined the maximum
amount of extract (e.g. urinary residue) which can be
processed on a column of the dimensions employed. However,
the residue from as much as one-third of a 24 hr. urine
allowed of a remarkably good resolution. It must be ex¬
pected, nevertheless, that individual extracts will exhibit
variable behaviour. The maximum weight of steroid con¬
jugates which may be safely chromatographed has likewise
not been determined. In the studies described in this
paper very small amounts were involved except where
pregnancy urine was used in which case some 400^ig of 'total
estrogens' were chromatographed without marked effect (at
least on the pattern of Ex 3S and E23S) .
While it is clear that many conjugates of other
phenolic steroids are naturally-occurring and that these
would, if present, interfere to varying extents with the
compounds studied in the present work (4,5), chromato¬
graphy on DEAE-Sephadex offers a useful means of studying
the metabolism and interconversion of Ex and E2 conjugates
where no important contribution is made by other phenolic
steroids. In this respect the in vitro renal metabolism
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of Ex and Es conjugates has recently been investigated,
using this technique, in our laboratory (21).
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In an earlier publication from this laboratory (1) the separation of
monoglucosiduronate, monosulfate, sulfoglucosiduronate, and disulfate
conjugates of estrone (Ei)3 and/or 17/3-estradiol (E2) was described.
The technique involved elution of DEAE-Sephadex (A 25) columns with
simple concentration gradients of NaCl in H»0 and was based on the
original studies of Hahnel (2). It was also pointed out (1) that a certain
degree of separation of estrone-3-glucosiduronate (Ei3G) and 17/3-
estradiol-3-glucosiduronate (E23G) was possible, while the latter com¬
pound could be partially separated, in turn, from 17/?-estradiol-17-
glucosiduronate (E217G). More recently, continued experience with the
above method has resulted in practically complete separation of those
three monoglucosiduronates from each other. This procedure has proved
to be of particular value in the study of estrogen glucosiduronate metab¬
olism in the human (3, 4). The present report concerns the exact
methodology now being applied in our laboratory and the results which
may be expected from it.
MATERIALS
17/?-Estradiol-6,7-3H-17-glucosiduronate, specific activity (SA) = ca.
1 mCi/jumole, was purchased from New England Nuclear Corp., Boston,
Mass., and was purified as described elsewhere (5). The 3-gluco-
1 Supported by grant MT 532 from The Medical Research Council of Canada.
2 Research Associate of The Medical Research Council of Canada.
3 The following trivial names and abbreviations are used: estrone (Ei) = 3-hy-
droxyestra-l,3,5(10)-trien-17-one; 17/?-estradiol (E2) = estra-l,3,5(10)-triene-3,17/3-
diol; estrone-3-glucosiduronate (Ei3G) = 17-oxoestra-l,3,5(10)-trien-3-yl-/J-D-gluco-
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siduronates of estrone-6,7-3H and 17/6-estradiol-6,7-3H were synthesized
and purified as described earlier (1). Estrone-4-14C, SA = ca. 27 fiCi/
/xmole, and 17/3-estradiol-6,7-3H, SA = ca. 48 mCi//Amole, were both
purchased from New England Nuclear Corp.
Sephadex columns (K 9/60) of internal diameter 0.9 cm were purchased
from Pharmacia (Canada) Ltd., Montreal, as was Sephadex A 25 of
particle size 40-120 microns.
Liquid scintillation fluid, consisting of a toluene solution of 2-(4'-terf-
butylphenyl)-5-(4"-biphenylyl)-l,3,4-oxadiazole (butyl-PBD), was pur¬
chased as a concentrate from Nuclear-Chicago Corp. (a subsidiary of
G. D. Searle & Co.) and diluted, prior to use, with toluene, to give a
concentration of 7 gm/liter.
All other chromatographic materials, chemicals, and organic solvents
were obtained and purified where necessary by published techniques (6).
METHODS
Column preparation. Sephadex A 25 was mixed with distilled H204 in
the approximate proportion of 10 gm/150 ml. This mixture was stirred at
least six times, at intervals, and allowed to settle each time for about 30
min prior to sucking off the supernatant and suspended fines and replac¬
ing with H20 prior to stirring again. The gel so prepared was normally
used to pack columns the following day, or later. The tip of the column
was fitted with a short piece of rubber tubing which was closed with
a clip and the column filled to within 4 or 5 cm of the top with H20. The
A 25 suspension was thoroughly stirred and an aliquot removed by
Pasteur pipet fitted with a rubber teat. The tip of the pipet was intro¬
duced under the H20 surface in the column and the slurry expelled. In
this way the column was filled. When the upper 4-5 cm of the column
H20 had cleared of A 25 it was removed by Pasteur pipet and replaced
by a similar volume of the slurry. This was continued, with frequent
manual rotation of the column, until one-third to one-half of the column
length was filled with packed A 25 gel. The clip was then removed and
the column allowed to flow freely while continuing the addition of the
slurry, as above, until a bed height of 58 cm was obtained. (Several
columns can, of course, be prepared simultaneously.) On occasion the
prepared column was attached to a reservoir of H20 and allowed to run
overnight, although immediate use for chromatography of steroid con¬
jugates was found to be entirely successful. Columns were not reused in
this work.
The total bed volume of such a column was 37 ml and each gram of
4 No difference was noted between H20 which had been distilled once before use
and that distilled once and then passed through a mixed-bed ion-exchange resin.
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original dry A 25 occupied a packed volume of ca, 8 ml. Under a head
of 50 cm of H20 the flow rate varied between 40 and 50 ml/hr from one
column to another.
Preparation of samples for chromatography. Pure labeled steroids or
their conjugates were dissolved in 3-5 ml of H20 with brief warming in a
water bath at 50°C. Urine aliquots were chromatographed on Amberlite
XAD-2 resin5 and the conjugated steroid fraction recovered as described
by Bradlow (7). The conjugate fraction was dissolved in H20 as for the
pure compounds, and glucosiduronates of labeled Ei and E2 were added
prior to A 25 chromatography. Where compounds were chromatographed
on one column and were to be rerun on another, they were recovered from
aqueous solution by Amberlite XAD-2 chromatography, as above. For
purposes of further purification, urinary fractions, initially chromato¬
graphed on one A 25 column, were run on 1 X 20 cm Celite partition
columns in the system isooctane/fert-butanol/1 M NH„OH (2:5:5) (1, 8)
prior to rechromatography on a second Sephadex column.
A 25 chromatography. This was performed at a room temperature of
22-24°C although no attempt was made to create a thermostatically
controlled environment. Aqueous solutions (3-5 ml) were applied care¬
fully, in portions, by pipet, until all had been added. During this time
the column was open but special care was taken to ensure that the top
of the packed gel never became dry. The vessel which had contained the
fraction to be chromatographed was then successively washed with
2 X 2 or 3 ml of H20 and this was also added to the column. The column
was then attached to a gradient system of two identical 1000 ml bottles
(Fisher Scientific Co., Montreal, Canada, catalog #2-962—see ref. 1)
connected by a short piece of polyethylene tubing, and one of these, the
mixing vessel, was stirred magnetically. From this latter vessel a tube
carried the eluting fluid to the column. Three gradient systems were
employed: (a) 400 ml of H20 in the mixing vessel, 400 ml of 0.2M NaCl
in the donor vessel (gradient 0-0.2M NaCl); (6) 400 ml of H20 in the
mixing vessel, 400 ml of 0.4M NaCl in the donor vessel (0-0.4 M NaCl);
(c) 500 ml of H20 in the mixing vessel, 500 ml of 0.8M NaCl in the
donor vessel (0-0.8 M NaCl). The column was allowed to flow freely
under a head of ca. 50 cm of eluting solution, the rubber tip having been
removed. Suitable fractions (3-10 ml) were collected. At the completion
of the 0-0.4M NaCl gradient the gel bed showed a 24% shrinkage. A
31% shrinkage occurred in the 0-0.8M NaCl gradient.
Analysis of eluted fractions. Radioactivity was assayed on small
aliquots (suitably dried) of fractions by counting in 0.5 ml of methanol
3 Rohm and Haas, Philadelphia, Pa.
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Fig. 1. Chromatography of pure 3H-labeled Ei3G, E23G, and E217G on A 25 in a






and 10 ml of butyl-PBD in toluene, in a Nuclear-Chicago liquid scintilla¬
tion spectrometer as described elsewhere (9). Quenching was corrected for
by the internal standard technique. Optical densities of urinary chromo-
gens were measured in a Unicam SP 600 spectrophotometer.
RESULTS
Figures 1 and 2 show the elution patterns obtained by successively
chromatographing a mixture of pure 3FI-labeled Et3G, E23G, and E217G
on A 25 in 0-0.8M NaCl and then on a second column in 0-0.4M NaCl.
A partial separation of the compounds was seen in the first gradient (Fig.
1) while in the second gradient practically complete separation was
achieved (Fig. 2).
When the same three compounds were added to a 6 hr aliquot of
human female (nonpregnant) urine the pattern obtained in the 0-0.8M
NaCl gradient is that shown in Figure 3. Much of the urinary chromogen
was eluted prior to the monoglucosiduronate fractions, resulting in con¬
siderable purification. A considerable fraction of chromogen was firmly
adsorbed at the top of the A 25 column. During Celite partition chroma¬
tography of the pooled glucosiduronate fractions of Figure 3, little or no
chromogen was eluted with the 3H-label (9-10 holdback volumes). This
purified material, chromatographed on A 25 in 0-0.4 M NaCl yielded
the pattern shown in Figure 4.
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Fig. 2. Chromatography of pure 3H-labeled Ei3G, E23G, and E217G on A 25 in a





Table 1 contains data for the NaCl concentrations6 (read directly from
the linear gradient curves) at which the conjugates were eluted. It did
not appear that the presence of urine residues from up to 9 hr urine
volumes untowardly affected the behavior of the three compounds in
Fig. 3. Chromatography of 3H-labeled Ei3G, E23G, and EA7G, initially added to a
6 hr urine extract, on A 25 in 0-0.8 M NaCl.
5 Salt concentrations were calculated on theoretical grounds.
342 HOBKIRK AND NILSEN
Fig. 4. Chromatography of 3H-Iabeled Ei3G, E23G, and E217G, initially added to
a 6 hr urine extract, on A 25 in 0-0.4 714 NaCl, after prechromatography in 0-0.8 M
NaCl and on Celite.
question. The average eluate volume between the Ei3G and E23G peaks
was 40 ml in either gradient and the corresponding value for E23G and
E217G was 35 ml. The NaCl concentration required to elute any given
monoglucosiduronate was higher for the 0-0.8 714" NaCl gradient than
for the 0-0.4M NaCl system. This may relate to a combination of factors
TABLE 1
NaCl Concentrations for Elution of Estrogen Glucosiduronates from A 25 Columns
Molarity of NaCl for elution of peak fractions
Chromatography No. of
conditions Ei3G E23G E217G expts.
Pure conjugates 0.190 0.223 0.247 1
(0-0.8 714 NaCl)
Conjugates in urine" 0.193 0.224 0.257* 3
(0-0.8 714 NaCl) (.187-. 200) (.216-.240)
Pure conjugates 0.139 0.160 0.177 3
(0-0.4 714 NaCl) (.135-.144) (.155-.164) (.172-.184)
Conjugates in urine" 0.144 0.164 0.176* 10
(0-0.4 714 NaCl) (S.D. = .010) (S.D. = .011)
° Prechromatographed on Amberlite XAD-2 resin.
* E217G run in one experiment.
c Prechromatographed on Amberlite XAD-2 resin, A 25 (0-0.8 714 NaCl), and Celite;
conjugates added to 3-9 hr urine volumes.
ESTROGEN GLUCOSIDURONATE SEPARATION 343
such as the rate of change of salt concentration and the relatively high
flow rate of the columns.
Table 2 shows data for the behavior of "C-E, and 3H-E2 on A 25 in
four different systems. These two compounds were almost completely
separated as sharp peaks occurring at about 70 and 85 ml, respectively,
of column eluate in all of the systems. Thus the NaCl concentration
played no obvious role in the elution or separation of these compounds.
TABLE 2
Elution of Unconjugated Ei and E2; from A 25 Columns0
14C-Eu 3H-E2
Eluate vol. NaCl Eluate vol. NaCl
Ehiting at peak at peak at peak at peak
system (ml) (AO (ml) m
H20 65 80 —
0-0.2 M NaCl 70 0.018 85 0.021
0-0.4M NaCl 70 0.035 85 0.043
0-0.8 M NaCl 70 0.070 85 0.086
° 5 ml fractions collected in each case.
DISCUSSION
It is clear that linear concentration gradients of NaCl can separate,
more or less completely, the 3-glucosiduronates of E, and E2 and the 17-
glucosiduronate of E2. The separation of 3- from 16- or 17-gluco-
siduronates of phenolic steroids using nonlinear gradients was reported
by Hahnel (10). The separation achieved in the present study was
reasonably reproducible and has been of particular value in the study
of the metabolism of labeled E217G (3), and Ei3G and E23G (4), in the
human. In our hands urinary Ei and E2 monoglucosiduronates can be
highly purified by the above techniques when performed exactly as
described. The use of the 0-0.8M NaCl gradient allows of great purifica¬
tion, rather than separation, while the 0-0.4 ill NaCl gradient results in
separation. However, it should be pointed out that omission of the Celite
chromatographic step between the two A 25 columns can lead to unsuc¬
cessful separations in the 0-0.4M NaCl system. Also, although urine
residues up to 9 hr of nonpregnancy urine have been successfully
analyzed, the over-all performance benefits from the use of 6 hr, or less,
of original urine.
It was suggested elsewhere (1) that the separation of Ei3G and E23G
was unlikely to depend solely on ion exchange of the carboxyl group of
the glucosiduronate moiety. This is supported by the separation of Ei and
344 HOBKIRK. AND NILSEN
E2 in a manner independent of NaCl concentration. This would indicate
that certain groupings in ring D allow of separation through some "ad-
sorptive" process, not clearly defined. The later elution of the gluco-
siduronates than of the free steroids presumably relates to the presence
of the ionized carboxyl groups, and the greater degree of separation
between E,3G and E23G, than between E, and E2, to the slower elution
of the glucosiduronates. Thus the behavior of E,3G and E23G on A 25
depends upon the presence of the glucosiduronate moiety, differences in
ring D, and probably other factors (unpublished observations made in
this laboratory show that neutral steroid conjugates are eluted more
quickly than phenolic steroid conjugates). It should be noted that the
3-sulfates of E! and E2, which are eluted much later than Ei3G and E23G,
are in turn separated to a greater degree than are the glucosiduronates
(1).
SUMMARY
The application of NaCl gradient elution of DEAE-Sephadex columns
(0.9 X 58 cm) is described in detail for the separation of 3H-labeled
estrone-3-glucosiduronate, 17/3-estradiol-3-glucosiduronate and 17/3-
estradiol-17-glucosiduronate. When these three compounds were added
to urine, considerable purification was achieved in a linear gradient of
0-0.8M NaCl. Chromatography of the monoglucosiduronate fractions on
Celite columns, followed by a linear gradient (0-0.4M NaCl) on a fur¬
ther DEAE-Sephadex column, resulted in good separation of the three
conjugates from each other as colorless fractions.
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Behaviour of dehydroisoandrosterone, testosterone and their conjugates
on DEAE-Sephadex
Recent publications have shown the value of DEAE-Sephadex chromatography
in separating several types of phenolic steroid conjugates1-4. The present report con¬
cerns the behaviour of two neutral C19 steroids and their conjugates in simple NaCl
concentration gradients on DEAE-Sephadex columns.
Experimental
Reagents. DEAE-Sephadex (A-25) of medium porosity was purchased from
Pharmacia (Canada) Ltd., Montreal, Quebec, and packed to yield columns of 58 x 1
cm as described elsewhere4.
Steroids and conjugates. [7-3H]Dehydroisoandrosterone (DHA) of specific
activity (S.A.) 1.6 Ci/mmole was purchased from New England Nuclear Corp.,
Boston, Mass., U.S.A. and [4-14C]testosterone (T) of S.A. 29.2 Ci/mole was purchased
from Radiochemical Centre, Amersham, Bucks., Great Britain (now Amersham-
Searle). The conjugates were purchased from New England Nuclear Corp. These were
[7-3H]dehydroisoandrosteron-3-yl-/?-D-glucopyranosiduronate (DHAG) of S.A. 10
Ci/mmole, the NH4+ salt of [7-3H]dehydroisoandrosteron-3-yl-sulphate (DHAS) of
S.A. 10 Ci/mmole, [i,2-3H]testosteron-i7-yl-/?-D-glucopyranosiduronate (TG) of
S.A. 50 Ci/mmole, and the NH4+ salt of [7-3H]testosteron-i7-yl-sulphate (TS) of
S.A. 8 Ci/mmole.
Methods. Aqueous solutions of various mixtures of the above labelled com¬
pounds, containing a drop of methanol to facilitate solution of the free steroids, were
applied to DEAE-Sephadex columns which were developed with linear concentration
gradients of NaCl in H20 as described elsewhere2'4. The mixing vessel in each case
contained 400 ml H20 and the donor vessel contained 400 ml of either 0.2, 0.3, 0.4 or
0.8 M NaCl. 5-ml fractions of eluate were collected and radioactivity was deter¬
mined by liquid scintillation spectrometry6.
FRACTION NO. (Each 5 ml|
Fig. i. DEAE-Sephadex chromatography in a linear gradient (0-0.2 M NaCl) of: peak 1, DHA or
T; peak 2, DHAG or TG; peak 3, TS; peak 4, DHAS.
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Results and discussion
In none of the gradients could DHA be separated from T nor could DHAG be
separated from TG. However, the free steroids were easily separable from the gluco-
siduronates in all gradients. The sulphates, in turn, were well separated from the free
steroids and glucosiduronates and, furthermore, DHAS and TS were separable from
each other to varying extents in the different gradients. The greatest degree cf sepa¬
ration between the two sulphates occurred in the 0-0.2 M NaCl gradient (Fig. 1) and
in the 0-0.3 M gradient. The chromatographic mobilities of DHA and T were in¬
dependent of the gradient employed but, as expected, behaviour of the conjugates
was dependent on salt concentration. The sulphates of DHA and T were eluted in
positions similar to certain oestrogen monoglucosiduronates2'4 and considerably
before oestrogen monosulphates2.
It is of interest to note that when, in one experiment, employing the 0-0.2 M
NaCl gradient, labelled oestrone and 17/Toestradiol were chromatographed along with
3H-DHA, the oestrogens were eluted between fractions 12 and 20 while DHA ap¬
peared between fractions 6 and n. It would appear from this and from the behaviour
of the conjugates that the presence of a phenolic group allows a greater retention by
the DEAE-Sephadex (see ref. 4).
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SECTION G
METABOLISM OF OESTRONE AND OESTRADIOL GLUCOSXDURONATES
IN THE HUMAN IN VIVO
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ABSTRACT
17/3 -Estradiol-6,7-3H-17-glucosiduronate was injected
intravenously into 2 normal young females. In one, 17/3 —
estradiol-4-14C was simultaneously administered by the same
route. Most of the 3H was excreted in 48 hr., the main
urinary metabolites being estrone and 17/3-estradiol which
were liberated from conjugation by /3-glucuronidase hydro¬
lysis. These 2 steroids occurred in a ratio of about 1:1
and accounted for more than 80% of identified ^-metabo¬
lites. Estriol accounted for only 3% and other 16-oxy-
genated metabolites were of minor quantitative significance
as was 2-methoxyestrone. Smaller amounts of each steroid
were liberated from conjugation by solvolysis after
/3-glucuronidase incubation. When 17/3-estradiol-4-14 C was
administered along with the glucosiduronate, urinary
2-methoxyestrone, estrone and 17/3-estradiol 1 gluco-
siduronates' were produced to a greater extent from the
injected conjugate than from the free steroid. This was
also true of 17/3-estradiol liberated by solvolysis.
2-Methoxyestrone and estrone liberated by solvolysis had
3H/14C ratios similar to that injected whereas all of the
16-oxygenated metabolites, regardless of conjugation,
were formed preferentially from injected 17/3-estradiol.
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INTRODUCTION
Considerable interest has been evident over the last
few years in the metabolism of steroid conjugates. It is
generally considered that steroid glucosiduronates are
formed mainly, if not wholly, for purposes of excretion in
bile and urine. Sandberg and Slaunwhite have claimed that
injected estriol-16-glucosiduronate(3) is not metabolized
by the human but rather quantitatively excreted in the
urine(4). Recent work by Diczfalusy et al has indicated
the formation of estriol-3-glucosiduronate from injected
estriol-16-glucosiduronate in the pregnant human(5). There
was little, if any, metabolism of the steroidal moiety.
In the work described below, 17j3-estradiol-6,7-3 H-17-
glucosiduronate was injected into 2 females, in one case
simultaneously with 17|3-estradiol-4-14 C, and the urinary
metabolites were investigated in some detail.
MATERIALS AND METHODS
Unlabelled steroids, reagents, etc.
17j3-Estradiol-3-methyl ether was prepared in the
laboratory by the method of Brown(6). All other steroids
were purchased from Mann Research Labs. Inc., New York.
All of the compounds were checked for purity by thin-layer
chromatography and melting point (microscope hot stage)
determination.
All organic solvents and reagents were of analytical
grade and were purified where necessary by published methods
(7,8).
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Bacterial ^-glucuronidase (Type II) was purchased
from Sigma Chem. Co., St. Louis, Mo.
Radioactive compounds; their radiochemical purity
17j8-Estradiol-4-14 C, specific activity (SA) = 0.17fxc/jag
was purchased from New England Nuclear Corp., Boston, Mass.
and was found to be at least 98% pure by crystallizing with
unlabelled 17^-estradiol. It was used without further
purification.
17J8-Estradiol-6, 7-3 H-17-glucosiduronate, SA = 2.2)jlc/
jig, was also purchased from the above source. Approximately
1% of this was ether-extractable from aqueous solution.
The water-soluble portion was completely hydrolyzed by
incubation with bacterial )S-glucuronidase (9) and the ether-
soluble radioactivity was shown to be at least 96% composed
of 17)3-estradiol by crystallization with carrier.
384,000 Dpm (disintegrations per minute) of the original
labelled conjugate were methylated by the method of Brown
(6) . The product was incubated with )3-glucuronidase as
above and the ether-soluble radioactivity (377,300 dpm) was
extracted. A portion of this (137,200 dpm) was mixed with
13.7 mg of pure unlabelled 17|3-estradiol-3-methy 1 ether to
give a calculated SA of 10,000 dpm/mg. Crystallization from
methanol-H20 yielded crystals of SA = 9674 dpm/mg. The
latter were acetylated and recrystallized from methanol-
H2 0 yielding crystals of SA = 8306 dpm/mg. This compared
with a predicted SA of 8457 dpm/mg based on the SA of the
unacetylated material from the first crystallization.
Injection of radioactive compounds
Two young females, both having normal cycles, were
volunteers for this study. Labelled compounds were injected
intravenously in 10 ml of 10% (v/v) ethanol in saline. In
expt. 1, 55 x 10s dpm of 17)3-estradiol-6, 7-3 H-17-gluco-
siduronate were given, while in expt. 2, 22.2 x 10s dpm of
the latter were injected together with 4.18 x 106 dpm of
17)3-estradiol-4-1 4 C.
Urine collection
Following injection, urine was collected from each
subject for 4 x 24 hr in polyethylene bottles without




In expt. 1 the first 2 days' urine were pooled and
one-half of this was taken for analysis. In expt. 2 the
entire 4-day pool was used. The untreated urine was ex¬
tracted with ether to yield a 'free' (unconjugated)
steroid fraction, and this was repeated following
/3-glucuronidase hydrolysis, to yield a ' glucosiduronate 1
(G) fraction. The residual urine was solvolyzed giving a
'sulfate' (S) fraction. These steps are described else¬
where (9, 10). The G and S fractions were purified and
resolved into their component steroid fractions by Girard
separation, various extraction procedures and Celite
column partition chromatography (9, 10). The separated
fractions were mixed with the appropriate carrier steroids
and crystallized 3 times from methanol. At this stage the
SA values for crystals and mother liquors agreed for most
fractions. The third crystals were acetylated at room
temperature in a mixture of pyridine and acetic anhydride
and recrystallized from methanol-H20. The SA values for
the acetates were used to confirm the data obtained from
the free steroid crystallizations. Melting points of the
acetates were checked in order to confirm purity and
derivative formation.
Measurement of radioactivity
All counting was performed on a Nuclear Chicago
Liquid Scintillation Spectrometer. Urine was counted
directly in a dioxan scintillation medium (9). All
extracts, crystals, etc. were counted following solution
in 0.5 ml of methanol and dilution with 10 ml of toluene
containing 7 g/liter of butyl PBD [butyl derivative of 2-
phenyl-5-(4-biphenyly1)-oxadiazole-1,3,4]. Quenching was
corrected for, where necessary, by the internal standard
technique. Calculation of 3H and 14C in dual-labelled
samples was performed by the method of Okita et al (11).
All counts were converted to dpm and sufficient counts
were accumulated to ensure a counting error of no more
than ±5%.
RESULTS
Table I contains evidence for rapid urinary excretion
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TABLE I
Excretion and extraction of urinary radioactivity in expts.
1 and 2
Days following Expt. 1 Expt . 2
injection 3 H 3 H 1 4 C
Urine radioactivity (% dose)
1 73 58 37
2 12 13 16
3 3 0.8 6
4 1 0.3. 4
Tota 1 89 72 63
dpm x 10" 6
Urine pool 46.7 (2 days) 15.8 2.63(4 days)
Free-ether soluble 0.58 0.16 0.046
G fraction 40.2 12.6 1.06
S fraction 2.8 1.6 0.26
of the 3H label, primarily in days 1 and 2 following
injection. The excretion of 14C in expt. 2 was slower, 10%
of the dose appearing on days 3 and 4. Table I also shows
that, in expt. 1, 1% of the SH in the 48 hr urine pool was
ether-extractable, 86% was hydrolyzed by /3-glucuronidase
and 6% was solvolyzable. In the 4-day pool from expt. 2,
1% of the 3H was 'free, ' 80% was in the G fraction and 11%
was S, while for l4C the corresponding values were 2% free,
40% G and 10% S. The 3H/14C ratios were; urine pool = 6.0,
'free' = 3.5, G = 12.0, S = 7.1.
Table II shows the results of crystallizing the various
steroid fractions in expt. 1. The main metabolites, estrone
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G and 17/3-estradiol G, were calculated, from these data, to
be 94% and 90% pure, respectively, as eluted from the
partition columns. The other fractions were found to be of
variable purities prior to crystallization.
Table III contains information regarding the 3H/14C
ratios during crystallization of the metabolites isolated
in expt. 2. Individual SA values are not shown since those
with respect to SH were similar to those of expt. 1 (Table I)
and since the purification of urinary metabolites of
injected free 17j3-estradiol has been the subject of much
previous work (9, 12). As in expt. 1 SA values for crystals
agreed well in most instances with those of the mother
liquors at the third crystallization of the free steroids.
The 16-oxygenated metabolites, whether conjugated as G or
S, exhibited a lower isotope ratio than that of 5.3 which
was injected, indicating a lesser production from the
injected glucosiduronate than from free 17j3-estradiol.
Conversely, urinary estrone G, 17j3-estradiol G and 17/3—
estradiol S were derived to a much greater extent from
the injected conjugate than from the free steroid. This
was also true, to a lesser extent, of 2-methoxyestrone G.
2-Methoxyestrone S and estrone S, on the other hand,
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Table IV shows the amounts of radioactivity associated
with the purified steroid fractions isolated in the 2
expts. These values, uncorrected for methodological loss,
were obtained from the mathematical product of the SA of
the purified crystals and the weight of carrier steroid
used in each particular case. More than 80% of the
identified 3H-labelled metabolites consisted of estrone G
and 17/3-estradiol G whereas only 3% was attributable to
estriol G. Of the 14C-labelled metabolites identified in
expt. 2, estrone G and 17/3-estradiol G together comprised
33% and estriol G accounted for 27%. As a group, the
16-oxygenated metabolites of 17J8-estradiol-6, 7-3 H-17-gluco-
siduronate were of minor significance. In both expts.
3H-labelled 178-estradiol S, although not by any means a
major metabolite, exceeded 3H-estrone S.
DISCUSSION
The data presented above demonstrate very clearly
that the 17-glucosiduronate of 17/3-estradiol can be
metabolized in the human. The main urinary metabolites
are estrone and 17/3-estradiol, in a ratio of about unity,
both apparently conjugated with glucuronic acid. It is
not known at present how this conversion proceeds but,
in view of the considerably greater production of urinary
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from 17^-estradiol, it is conceivable that the administered
steroid glucosiduronate could have been further conjugated
(e.g. to form the diglucosiduronate) prior to removal of
the glucuronic acid at Cx7 to yield estrone glucosiduronate,
presumably via 17j3-estpadiol-3-glucosiduronate. Such a
metabolic pathway could perhaps explain the very low
production of 16-oxygenated metabolites from 17j3-estradiol
glucosiduronate. It is of interest to note, in passing,
that 3H-170-estradiol S exceeded, in both expts., 3H-
estrone S. This differs from the pattern obtained for the
metabolism of injected 17/3-estradiol (9) . It raises the
question as to whether the injected 17/3-estradiol-6,7-
3H-17-glucosiduronate might have been partly sulfury-
lated at position 3 to yield a mixed conjugate. It must
be borne in mind that our identification of 17j3-estradiol
S was made following serial /3-glucuronidase incubation
and solvolysis, thus it does not exclude the presence of
a monosulfate, a disulfate or a mixed conjugate, or any
combination of these.
The only urinary steroid fractions possessing
3H/14C ratios similar to that injected were 2-methoxy-
estrone S and estrone S, presumably representing the
3-sulfates of these steroids. The relationship between
the ratios of these fractions, the high isotope ratios
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of the other 16-desoxy-metabolites and the low ratios of
the 16-oxygenated steroids is not at all clear at present.
Further speculation would be unjustified at this time
since it is obvious that answers to many of the questions
posed above must await studies involving direct
separation and purification of individual conjugates.
It can be seen from the data presented in this
paper that a considerably greater fraction of the
metabolites of injected 17/3-estradiol glucosiduronate
were extracted from the urine and identified than is
generally true of metabolites of 17j3-estradiol (expt. 2,
above, and ref. 9). The presence of the glucuronic acid
residue presumably decreases the degree of metabolism
(e.g. as reflected in the small extent of 16-hydroxylation)
with an accompanying decrease in the amount of unknown
and less stable conversion products.
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ABSTRACT
Following intravenous injection of 17/9-estradiol-6, 7-
3H-17-glucosiduronate into a normal human female the urinary
conjugated forms of labelled estrone and 17/3-estradiol were
identified by DEAE-Sephadex and Celite partition chromato¬
graphy; comparison with certain authentic 14C-labelled
conjugates; enzyme hydrolysis; crystallization with carrier
steroids, including derivative formation. The main compounds
identified were estrone-3-glucosiduronate, 17/3-estradiol-17-
glucosiduronate and 17/3-estradiol-3-glucosiduronate in the
approximate proportions of 5.6:3.7:1. Some evidence was also
obtained for the presence of very small amounts of estrone-
3-sulfate and 17/3-estradiol-3-sulfate-17-glucosiduronate.
INTRODUCTION
It was recently shown (3) that intravenously injected
17g-estradiol-6, 7-3H-17-glucosiduronate (E3 17G; reference 4)
in normal human females resulted in the urinary excretion of
approximately equal amounts of estrone (Ex) and 178-estra-
diol (E2), both mainly in a form hydrolyzable by ^-glucuroni¬
dase. Very small amounts of 16-oxygenated metabolites were
found, suggesting interference with 16-hydroxylation by the
glucuronic acid residue. Since, in these experiments,
identification of the steroid metabolites was entirely based
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on purification following conjugate hydrolysis, it was
considered necessary to establish more directly the
identities of the specific conjugates. The present paper
deals with this identification.
MATERIALS
Amberlite XAD-2 resin was purchased from Rohm and Haas,
Philadelphia, Pa. DEAE-Sephadex (A-25) was purchased from
Pharmacia (Canada) Ltd. and was used for chromatography
(column dimensions 0.9 x 50 cm) as described earlier (5).
Celite was treated by conventional methods prior to use (6).
Silica gel HF254, for thin-layer chromatography (TLC), was
a product of Merck, Darmstadt, Germany, and was spread on
20 x 20 cm glass plates prior to activating at 110° for 1 hr.
All organic solvents and chemical reagents were of good
analytical grade and were purified, where necessary, by
standard methods (6,7).
Unlabelled steroids and their derivatives were purchased
from Mann Research Labs., New York, and were checked for
purity by TLC and melting point (microscope hot stage)
determination. 17/3-Estradiol-3-methy 1 ether (Ea 3MeE) was
crystallized x 2 from methanol-H20 prior to use.
Mylase P, containing phenolsulfatase, was obtained from
Mann Research Labs., New York, and was used for conjugate
hydrolysis in 0.1M acetate buffer, pH 6, overnight (8).
Bacterial /3-glucuronidase powder (Type II) was obtained from
Sigma Chemical Co., St. Louis, Mo. It was used in 0.1M
phosphate buffer, pH 7, at a concentration of 20 - 40 units/
ml for 24 hr (9).
Estrone-4-14C-3-glucosiduronate (Ex3G) was synthesized
by incubating pure E1-4-14C, specific activity (SA) = 0. ljiic/
fig (Radiochemical Centre, Amersham, Bucks, England) with a
rabbit liver homogenate as described earlier (5). The 14C-
Ex 3G was purified by DEAE-Sephadex and Celite partition
chromatography (5) . Following /3-glucuronidase hydrolysis,
at least 97% of the 14C-steroid released was shown (by
crystallization with carrier) to be Ex . 17j3-Estradiol-4-14 C-
3-glucosiduronate (E23G) was prepared from the above 14C-
Ex 3G by reduction with NaBH4 (5). The reduced material was
purified as for 14C-E13G and shown to yield Es (at least
97% pure) on /3-glucuronidase hydrolysis.
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3H-E317G (SA = 2.2 jLic/jjg) was purchased from New England
Nuclear Corp., Boston, Mass. and was found to behave in a
homogeneous fashion on DEAE-Sephadex and on Celite partition
columns (5). It was 97% pure by crystallization procedures
already described (3).
Urine was collected for 2 successive 24 hr periods
(pooled prior to analysis) from a normal young female who
had been injected intravenously with 55 x 106 dpm (disinte¬
grations per minute) of 3H-E217G (3). Some 85% of the dose
was excreted in 48 hr.
METHODS
Whole urine was processed on Amberlite XAD-2 as
described by Bradlow (10). The conjugate fraction so
obtained was chromatographed on DEAE-Sephadex in a linear
gradient of 0 - 0.8M NaCl (5) and radioactive peaks corres¬
ponding to monoglucosiduronates were successively re-
chromatographed on DEAE-Sephadex in a non-linear gradient
0 - 1M NaCl (11) and a linear gradient 0 - 0.4M NaCl (5).
In all cases the eluates were processed on XAD-2 resin in
order to recover the conjugates in methanol.
The various monoglucosiduronate peaks, and radioactivity
corresponding to monosulfate(s), were chromatographed on
Celite (1 x 20 cm column) in iso-octane:t-butanol:MNH4OH
(2:5:5; system A; ref. 12). Radioactivity corresponding to
mixed, or double conjugate(s) was chromatographed similarly
on Celite in n-butanol:ethyl acetate:0.2% NH^OH (3:1:4;
system B; ref. 13) .
Aliquots of individual 3H-monoglucosiduronate fractions,
with or without addition of appropriate 14C-conjugates, were
identified by further Celite chromatography in the conjugated
form, ^-glucuronidase hydrolysis (9), Girard separation (14),
Celite chromatography of the free steroids (14) and by
crystallization to constant SA or 3H/14C ratio with un-
labelled carrier steroids (including derivative formation).
Further aliquots of glucosiduronate fractions were methylated
by the procedure of Brown (15) to localize a free phenolic
group. Following hydrolysis (3) the resulting ether-soluble
radioactivity was submitted to TLC in eyelohexane:ethyl
acetate (1:1; ref. 16) in admixture with ca. 300 jug of the
appropriate standard steroids. Appropriate ultraviolet-
absorbing zones were eluted with ethyl acetate:methanol (1:1)
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and crystallized with carrier steroids. A presumptive
3H-E23G fraction was methylated with methyl iodide by the
procedure described by Sa'at & Slaunwhite (17) to localize
the non-phenolic hydroxyl group. After hydrolysis, the
steroidal moiety was successively chromatographed on Celite
in chloroform:carbon tetrachloride:methanol:H20 (40:60:70:30
system C; ref. 17) and benzene:0.8N NaOH (system D; ref. 18)
Presumptive 3H-monosulfate(s) was hydrolyzed with Mylas
P and the ether-soluble material submitted to a Girard
separation followed by crystallization with carrier steroid.
An aliquot of presumptive 3H-mixed conjugate(s) was
incubated with Mylase P (followed by ether extraction) and
the aqueous residue with -glucuronidase (followed by ether
extraction). A further aliquot was treated in the reverse
manner. Ether-soluble radioactivity was submitted to a
Girard separation and then to crystallization with carrier
steroid.
All final crystalline derivatives were submitted to
melting point determination.
All radioactive counting was performed on a Nuclear
Chicago Liquid Scintillation Spectrometer as described else¬
where (3, 9). The counting error was within ±5%.
RESULTS
Preliminary separation
Fig. 1 shows the pattern of radioactivity obtained on
DEAE-Sephadex chromatography of the urinary conjugates (one-
sixth of the 2-day pool). Peak 1 (fractions 14 - 30)
resembled Ex3G together with some E2 3G (5) and peak 2 (31 -
35) behaved like E217G (5). Peaks 3 (38 - 54) and 4 (68 -
77) were poorly defined but resembled monosulfate(s) and
mixed conjugate(s) , respectively (5). Further elution with
0.8 - 2M NaCl (5) failed to show the presence of disulfate
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metabolites. In the non-linear gradient, peak 1 was
resolved into 1A (61 - 70; resembling Ex3G in behaviour) and
IB (73-80; resembling E23G) as shown in Fig. 2. Peak 2
behaved as a single peak (79 - 95) in the latter gradient
(Fig. 3) .
Identity of peak 1A
Some 88% of the 3H in this peak was eluted from Celite
(system A) at about holdback volume (HBV) 10, most of the
remainder (not further processed) being eluted with methanol.
An aliquot of the apparent SH-E13G was completely hydrolyzed
by ^-glucuronidase and the ether-soluble 3H shown to be >90%
ketonic. Preliminary crystallization showed the latter to
be predominantly Ej . A second aliquot of the conjugate
fraction was eluted from DEAE-Sephadex (0 - 0.4M NaCl) as a
symmetrical peak at ca. 0.14M NaCl and was separable from
l4C-Es3G (peak at 0. 16M NaCl) and 3H-E217G (peak at 0.18M
NaCl) when chromatographed in admixture with them in the same
gradient. A third aliquot containing 1.65 x 10s dpm 3H was
mixed with 0.262 x 10s dpm 14C-E13G (3H/14C = 6.3) and re-
chromatographed on Celite (system A). The peak tubes were
pooled giving 1.34 x 10s dpm 3H and 0.222 x 10s dpm 14C
(3 H/14 C = 6.0) . This material was completely hydrolyzed by
/3-glucuronidase and an aliquot was mixed with unlabel led Ex
and crystallized as shown in Table I. This indicated a high
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proportion of the 3H in peak 1A to be identifiable with Ex3G.
TABLE I
Crystallization of 3H/14C-E1 from peak 1A
Purification procedure* SA(3H) SA(14C) 3H/14C
(dpm/mg)
402,700 Dpm 3H + 6,700 dpm 14C 15,800 2,630 6.0
+ 25.5 mg carrier Ex ; crystn. (calc.) (calc.)
from methanol
XLS 1 16,000 2,690 6.0
ML 1 17,300 2, 730
XLS 2 15,900 2,610 6.1
ML 2 16,100 2,860
Acetylation of XLS 2; crystn. 13,800 2, 260
from methanol-H20 (calc.) (calc.)
XLS 3 13,500 2, 240 6.0
ML 3 14,000 2, 450
XLS 4 13, 700 2, 250 6.1
ML 4 13,800 2, 310
*XLS = crystals; ML = mother liquor.
Identity of peak IB
Celite chromatography in system A resulted in elution
of a main peak (HBV 9; 83% of recovered 3H) with minor
amounts at HBV 14 (12%) and on elution with methanol (5%).
The two latter were not further analyzed. An aliquot of the
main peak was completely hydrolyzed by ^-glucuronidase, the
free material being ca. 90% non-ketonic and on preliminary
crystallization behaving like Es. Following mild methyl-
ation (15) and hydrolysis of a further aliquot of IB, TLC of
the products showed that ca. 40% of recovered 3H had the
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mobility of E2 and ca. 60% was similar to E33MeE.
Crystallization of these TLC zones with carriers gave the
results shown in Table II. These data strongly suggested
that peak IB was largely composed of a mixture of a mono-
glucosiduronate of E2 lacking a free phenolic group (E33G)
and another such compound possessing a free phenolic group
(Es17G). The presence of the latter was presumably due to
contamination by peak 2. A further IB peak was prepared
from a separate aliquot of urine exactly as before, except
that 5 ml fractions were collected from the 0 - 0.8M NaCl
gradient, and care was taken to exclude, as far as possible,
contamination by peak 2 during pooling of chromatographic
fractions. This IB peak yielded two peaks on rechromato-
graphy in 0 - 0.4M NaCl (Fig. 4). Fractions 57 - 63,
when pooled as peak 1B-(1), contained 538,000 dpm 3H,
while fractions 64 - 70, peak lB-(2), contained 208,000 dpm.
Identity of peak 1B-(1)
290,000 Dpm 3H from peak 1B-(1), mixed with 58,600 dpm
14
C-E3 3G (3 H/1 4 C = 4.9) were eluted from Celite (system A)
at about HBV 9 with an isotope ratio = 4.5. Mild methyl-
ation (15) of an aliquot, followed by hydrolysis and TLC
of the products, showed that only 3% of the recovered 3H
and 2% of the 14C possessed the mobility of E33MeE whereas
almost all of the remainder was associated with carrier E3.
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The results of crystallization of the latter with E2 (Table
III), together with the data presented above, strongly
indicated that peak 1B-(1) consisted largely of a mono-
glucosiduronate of E2 lacking a free phenolic group, i.e.
E23G. The remainder of peak 1B-(1), mixed with 14C-E23G
TABLE III
Crystallization of 3H/l4C-E2 from peak 1B-(1)
Purification procedure* sa (sh) sa(14c)
(dpm/mg)
3H/14C
83,500 Dpm 3H + 20,900 dpm 14C 3140 786 4.0
from TLC + 26.6 mg E2; crystn. (calc.) (calc.)
from methanol
xls 1 3140 766 i—4•
ml 1 3160 771
xls 2 3010 753 4.0
ml 2 3100 775
Acetylation of xls 2; crystn. 2300 576
from methanol-H80 (calc.) (calc.)
xls 3 2460 5 98 4.1
ml 3 2410 610
xls 4 2380 604 3.9
ml 4 245 0 5 94
*XLS = crystals; ML = mother liquor.
(3H/14C = 5.0) and chromatographed on Celite in system A
(3H/14C = 4.3), gave, on forced methylation (17) a hexane-
soluble material, 3H/14C = 4.4. Following hydrolysis the
ratio was 4.0. The labelled product was successively eluted
as a single peak of low polarity (considerably less polar






































































ratio of 4.2. It compared in mobility with 17j3-estradiol-
17-methyl ether.
Identity of peak IB-(2)
Chromatography on Celite in system A yielded a peak
corresponding to a monoglucosiduronate. Hydrolysis with
/^-glucuronidase was complete and some 94% of the ether-
soluble radioactivity was non-ketonic. Celite partition
chromatography in the system benzene:hexane:methanol:H20
(55:45:70:30; ref. 14) followed by benzene:methanol:H20
(100:70:30; ref. 14) yielded almost 90% recovery of the 3H
of which 93% corresponded to E2, 3% to 16-epiestriol and
4% to estriol. It was logical to assign the identity of
E2 17G (originally contaminating E23G) to this minor peak.
Identity of peak 2
A single peak was eluted at HBV 9 (monoglucosiduronate
region) from Celite in system A. An aliquot was completely
hydrolyzed by ^-glucuronidase, the ether-soluble material
being some 92% non-ketonic. The latter was shown to be
mainly Ee by preliminary crystallization. Mild methylation
(15) of an aliquot followed by hydrolysis and TLC resulted
in <2% of the recovered 3H being associated with carrier E2.
Virtually all of the remainder had the mobility of E23MeE.
Crystallization with carrier gave the results shown in Table
IV. A further aliquot of 2 was eluted from DEAE-Sephadex
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TABLE IV
Crystallization of 3H-E23MeE from peak 2
Purification procedure* SA(dpm/mg)
64,500 Dpm 3H from TLC 2590 (calc.)












*XLS = crystals; ML = mother liquor,
tInsufficient for counting.
(0 - 0.4M NaCl) as a single symmetrical peak at 0.18M NaCl
and separable from simultaneously chromatographed 14C-E23G.
These data identified peak 2 as being mainly composed of
Es 17G.
Identity of peak 3
Radioactivity isolated from separate 2 x one-sixth
aliquots of the 48 hr urine, and pooled to yield sufficient
3 H for analysis, when chromatographed on Celite in system A
yielded a well-defined peak (50% of the applied 3H) at HBV
2-3 (monosulfate region). There was also a poorly defined
elution of 3H at HBV 7; this was not processed. 136,000 Dpm
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from the first peak were hydrolyzed to an extent of 75%
by Mylase P; the ether-soluble 3H shown to be 92% ketonic.
94,000 Dpm of the latter were mixed with 17.9 mg carrier Ex
(calc. SA = 5250 dpm/mg) and crystallized twice from
methanol. XLS of SA = 4370 and 4090 and MLS of 5410 and
5090, respectively, were obtained. The second XLS were
acetylated (calc. SA = 3540 dpm/mg) and crystallized twice
from methanol-H20 giving XLS of SA = 3420 and 3440 and MLS
of 3770 and 3820, respectively. This suggested that
estrone-3-sulfate (Ex3S) was a component of peak 3.
Identity of peak 4
Radioactivity isolated from 2 x one-sixth aliquots of
the 48 hr urine pool, when chromatographed on Celite in
system B, resulted in elution of 54% of the applied SH at
HBV 4 (i.e. typical of a compound such as 17/3-estradiol-3-
sulfate-17-glucosiduronate; Es3S17G; ref. 5). The remainder
of the 3H was not investigated. Two aliquots, each
containing 44,000 dpm, when submitted to enzyme hydrolysis,
showed some 5% of the 3H to be ether-extractable after
Mylase P alone and none following ^-glucuronidase alone.
When each of the partially hydrolyzed fractions was then
incubated with the other enzyme, i.e. Mylase P followed by
^-glucuronidase, and the reverse, complete hydrolysis was
achieved and 96% of the ether-soluble product was non-
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ketonic. 83,600 Dpm of the latter were mixed with 27.5 mg
carrier E2 (Calc. SA = 3040 dpm/mg) and crystallized twice
from methanol,whereupon XLS of SA = 2880 and 2870 and MLS
of 3150 and 3000 were obtained. Acetylation of the second
XLS (calc. SA = 2190 dpm/mg) followed by two crystallizations
from methanol-H20 yielded XLS of SA = 2200 and 2130 and'MLS
of 2160 and 2300, respectively. These data supported the
presence of a mixed conjugate of E3, probably E23S17G, in
peak 4.
Relative amounts of conjugated metabolites
Following the purification steps described above, the
amounts of SH identified in the form of E-l 3G, Ea 17G and
E2 3G in one-sixth of the 48 hr urine were 1.89, 1.26 and
0.34 (all x 10s dpm), respectively; i.e. the three compounds
were present in the ratio, 5.6:3.7:1. This ratio should be
considered approximate only since no account was taken of
losses associated with the procedures employed and, on
occasion, following chromatography, peak tubes only were
pooled to afford a better opportunity of isolating each
compound in its pure form. Thus the 'real total' for each
conjugate is not known. Using these latter data the Ex + E2
monoglucosiduronate fraction can be calculated to be com¬
posed 54% of E-l 3G, 36% of Es 17G and 10% of E2 3G (approx.) .
The Ea3S and E23S17G fractions each accounted for about 1%
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of the total Ex + Es conjugated urinary fraction.
DISCUSSION
Earlier studies have shown that about 85% of identified
urinary metabolites of injected 3H-E217G in the human female
consisted of Ex and E2 conjugated in a form hydrolyzable by
/3-glucuronidase (3). The results of the present work thus
identify the major metabolite of Es17G as being Ex 3G. The
sequence of steps leading to the latter compound is not clear.
Urinary E217G is identified as the conjugate second in
quantitative importance to Ex 3G. It may represent unchanged
injected E217G but this will not be ascertained until studies
can be undertaken with doubly labelled conjugates. The
smaller amount of E23G identified could represent, wholly or
partly, an intermediate in the conversion of E217G to Ex3G.
It could also conceivably have arisen by metabolic reduction
of the latter metabolite. It would certainly seem logical
to suggest that E23G is an intermediate in the conversion of
Ea17G to Ex 3G, perhaps via a diglucosiduronate form.
Sufficient evidence would appear to have been obtained
for the presence of minor amounts of Ex3S and E23S17G in
this study. Identification of the latter supports an
earlier speculation that this mixed conjugate could be a
metabolite of Es17G (3).
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1• DEAE-Sephadex chromatography (0 - 0.8M NaCl, linear
gradient) of total urinary conjugate fraction from one-sixth
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Fiq- 2- Rechromatography of peak 1 on DEAE-Sephadex (0 - 1M
NaCl, non-linear gradient).
Nov. 1969 STEROIDS 549
x PEAK 2













8 16 24 32 40 48 56 64 72 80 88 96 104 112 120
FRACTION NO. (EACH 5ml)
Fig. 3. Rechromatography of peak 2 on DEAE-Sephadex (0 - 1M
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Fig. 4. Rechromatography of peak IB on DEAE-Sephadex (0 - 0.4
M NaCl, linear gradient).
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ABSTRACT
Estrone-6, 7-3H-3-glucosiduronate-1 4 C (3 H-E-l 3G-1 4 C) and
17/3-estradio 1-6, 7-3 H-3-glucos iduronate-14 C (3 H-E2 3G-1 4 C) ,
both of 3H/l4C ratio = 5.8, were each injected into two
normal young females. Seventy percent of each isotope was
excreted in the urine in 3 hr, and at 48 hr, when excretion
of the radioactivity had ceased, some 90% of 3H and 75% of
1 4 C had been excreted. Urinary metabolites were purified
and identified by Amberlite XAD-2 resin, DEAE-Sephadex and
Celite partition chromatography followed by derivative
formation, enzymic hydrolysis and crystallization with
carrier steroids. No urinary metabolites other than Ex3G
and E2 3G were identified. Within 3 hr of injection direct
interconversion of Ex 3G and E23G was observed as reflected
in the 3H/14C ratios of the urinary metabolites which were
the same as that injected. Under the experimental con¬
ditions the conversion, E2 3G -* Ex 3G, was much greater than
the reverse. From 3 to 6 hr after injection the urinary
metabolites possessed higher 3H/14C ratios (7.1 - 13.5) than
that injected, indicating partial deconjugation to have
taken place. From 6 to 24 hr after injection no 14C could
be detected with certainty to be associated with the 3H-
metabolites, showing that the latter had been produced
through a process of initial deconjugation, followed by
reconjugation with glucuronic acid of endogenous origin.
INTRODUCTION
Zucconi et a 1 (3) reported an extremely rapid urinary
excretion of radioactivity following intravenous infusion of
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labelled estrone-3-glucosiduronate (Ex 3G; reference 4) into
pregnant women. The results suggested little metabolism of
the estrogen conjugate. The same authors (3), however,
showed that the human fetus was capable of converting 3 H-
E13G-14C (i.e. Ex 3G labelled with 3H in the steroidal moiety
and 14C in the glucuronic acid residue) to 3H-17/3-estradiol-
3-glucos iduronate-1 4 C (3 H-E2 3G-14 C) of unchanged 3H/14C
ratio, thus proving the occurrence of reduction of the C-17
keto group without removal of the glucosiduronate function.
Moreover, it was indicated that 16a-hydroxylation of the
conjugated steroid could also take place. More recently,
Roy and Slaunwhite (5) reported upon the interconversion of
Ex3G and E23G in the presence of a placental dehydrogenase
enzyme together with suitable cofactors. These reactions
proceeded without removal of the glucuronic acid residue.
Finally, a recent speculation (6) regarding the metabolism
of 17j3-estradiol-17-glucosiduronate (E3 17G) to Ex 3G depended
upon the conversion of E2 3G to Ex3G in the form of an intact
steroid conjugate.
The present paper deals with the fate of 3H-E13G-14C





Chromatographic materials, organic solvents and other
reagents were obtained, purified when necessary, and used
as described in earlier publications (6,7,8,9). Unlabelled
steroids were purchased from Mann Research Labs., New York,
and were checked for purity by melting point determination
and thin-layer chromatography (TLC) . Bacterial /3-glucuroni-
dase powder (Type II) was obtained from Sigma Chemical Co.,
St. Louis, Mo. and was used at pH 7 at a concentration of
40 units/ml for 24 hr at 38°C. Ketodase (beef liver /3-
glucuronidase) was purchased from Warner-Chilcott, Morris
Plains, New Jersey, and was used for hydrolysis in amounts
of 250 - 500 units/ml at pH 5 in 0.05M acetate buffer at
38°C with incubation times of 20 - 22 hr.
Estrone-6,7-3 H of specific activity (SA) = 48 mCi/jumole
was purchased from New England Nuclear Corp., Boston, Mass.,
and was chromatographed on Celite prior to use (10). It was
at least 98% pure by reverse isotope dilution with un¬
labelled estrone. Uridine diphosphate glucuronic acid
(UDPGA)-14C (glucuronic acid uniformly labelled) of SA = ca.
230 /iCi/^mole was purchased from New England Nuclear
Corporation.
Synthesis of 3H-Ei 3G (see refs. 7, 11)
About 100 fiCi of estrone-6, 7-3 H were incubated for 1 hr
at 37°C with a whole homogenate of female guinea pig liver
in 0.1M phosphate buffer (400 mg liver/5 ml buffer) together
with 1 mg of unlabelled UDPGA (Sigma Chem. Co.). Protein
was precipitated with 4 vols of ethanol, the mixture cooled
overnight at -15°C, and centrifuged. The supernatant was
distributed between n-hexane and 90% methanol and the
methanolic phase evaporated prior to chromatographing on
DEAE-Sephadex in a linear 0 - 0.8M NaCl gradient (6,7; see
also METHODS, below). The peak corresponding to 3H-E13G was
recovered.
Synthesis of E-, 3G-14C
Approximately 50 jiCi of UDPGA-14 C were incubated with
0.1 jjmole of unlabelled Ex under the conditions described
above. DEAE-Sephadex (0 - 0.8M NaCl) chromatography re¬
sulted in the clear separation of 2 labelled peaks. The
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first eluted was UDPGA-14C or a metabolite thereof, the
second corresponded to E13G-14C.
3H-E1 3G-14 C
Appropriate quantities of SH-E13G and E13G-14C were
mixed to yield an approximate 3h/14C ratio of 6 and this was
purified by DEAE-Sephadex chromatography, first in 0 - 0.8M
NaCl and then in a linear gradient of 0 - 0.4M NaCl, and
finally by Celite chromatography in the system iso-octane:
t-butanol:M NH4OH (2:5:5; ref. 12). The purified material
had 3 H/14C = 5.8. An aliquot of this was completely hydro-
lyzed by £-glucuronidase (Ketodase). This hydrolysis was
58% inhibited by 5 x 10"3M saccharate (previously boiled in
pH 5 buffer) and 81% inhibited by 2 x 10*"2 M saccharate. The
3H released (rendered ether-soluble) by hydrolysis was
shown to be 99% Ex by TLC in chloroform:ethyl acetate (2:1;
ref. 13) with <1% corresponding to Es. Chromatography on
Celite, stationary phase 0.8N NaOH, mobile phase benzene,
followed by benzene:ethylene dichloride (1:1; ref. 14)
showed a maximum contamination by Es of 0.75%. NaBH^ re¬
duction of an aliquot of the synthesized 3 H-E1 3G-14 C
followed by £-glucuronidase hydrolysis and TLC gave rise to
3
H-E2 (ca. 98%) and 3 H-Ej^ (<2%) confirming the presence in
the original conjugate of a reducible 17-keto group.
Crystallization of the 3H, liberated by ^-glucuronidase
hydrolysis, with carrier Ex (calculated SA = 2890 dpm/mg)
yielded XLS (crystals) and ML (mother liquor) of SA = 2780
and 2730, respectively. Conversion to the acetate and
further crystallization (calc. SA = 2500 dpm/mg) resulted in
XLS and ML of SA = 2500 and 2570, respectively.
3 H-Ep 3G-1 4 C
An aliquot of the biosynthesized 3H-E13G-14C was re¬
duced with NaBH4 in methanol (7) and then neutralized with
acetic acid prior to evaporation, solution in H30, and
recovery through XAD-2 resin (15). The labelled material
was then chromatographed on DEAE-Sephadex (0 - 0.4M NaCl)
followed by Celite chromatography as for 3H-E13G-14C (above).
The purified material had a 3H/14C ratio of 5.8. An aliquot
was completely hydrolyzed by Ketodase and the 3H chromato¬
graphed on Celite (16). This showed that the maximum con¬
tamination with 3H-E1 was 0.5%. Crystallization of the 3H
released, with carrier E2 (calc. SA = 2180 dpm/mg), produced
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XLS and ML of SA = 2120 and 2300, respectively, while after
recrystallization following acetylation (calc. SA = 1670
dpm/mg) these values became 1710 and 1800, respectively.
Injection and urine collection
The labelled conjugates, dissolved in sterile saline,
were filtered through Swinnex-13 filters of pore size 0.22
microns (Millipore Corporation, Bedford, Mass.), ethanol was
added to a concentration of 10% and 10 ml were injected via
an arm vein. The four normal subjects studied were in the
first half of the cycle; subjects G and E were injected with
3H-E13G-14C and subjects J and A with 3 H-Es 3G-14 C. The
amounts of radioactivity administered ranged from 5 to 7 j;c
of 3H and 0.9 to 1.2 ^c of 14C. Urine was collected from
subjects G and J at 0 - 6, 6 - 12, 12 - 24, 24 - 48 and
48 - 72 hr. In subjects A and E collections were made at
0-3, 3-6, 6 - 12, 12 - 24 and 24 - 48 hr. Urine was
stored at -15°C until required for analysis.
METHODS
In a preliminary study of the steroidal metabolites in
the urine, aliquots of the latter were incubated with
bacterial 0-glucuronidase and analyzed by Girard separation
and Celite partition chromatography (8). The urine re¬
maining following |3-glucuronidase hydrolysis and extraction,
was subjected to solvolysis (17) in order to split steroid
sulfates.
Unhydrolyzed urine was processed on Amberlite XAD-2
resin (15). The resulting conjugate fractions were chroma-
tographed on DEAE-Sephadex in a linear gradient (0 - 0.8M
NaCl) essentially as described earlier (7) with some
modification. The dimensions of the gel were 0.9 x 58 cm
(total bed vol. = 37 ml) and the packed gel occupied a
volume of 8 ml/g of dry DEAE-Sephadex. The rate of flow
was 45 - 50 ml/hr. The total monoglucosiduronate fractions
thus obtained in each case were recovered via XAD-2 resin
and further chromatographed on Celite in the iso-octane
solvent system described above for the preparation of 3 H-E-l -
3G-14C. Eluted radioactivity was reapplied to DEAE-
Sephadex columns as above and chromatographed in the 0 - 0.4
M NaCl linear gradient. Radioactivity was assayed in the
various fractions at each stage of these procedures.
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Peaks of radioactivity with the chromatographic mo¬
bility of Ex 3G were identified as follows. An aliquot was
hydrolyzed by Ketodase and the liberated 3H crystallized
with carrier Ex in the free and acetylated forms until the
SA of XLS and ML were constant and equal within the required
limits (6). A further aliquot was reduced with NaBI^ (10
mg/ml) in H20, prior to pH adjustment to 6 and recovery via
XAD-2 resin. This was followed by Celite partition and
finally enzymic hydrolysis and crystallization of the 3H re¬
leased with carrier E2 as described above for Ex .
Radioactive peaks corresponding to E23G were identified
in suitable aliquots by hydrolysis and crystallization with
carrier E2 as for EL above. Further aliquots were methy¬
lated with dimethyl sulfate in borate buffer (18) followed
by extraction and hydrolysis (6). 3H-E2 and 3H-17j3-
estradiol-3-methy1 ether (E33MeE) were sought by TLC as
described elsewhere (6) so as to indicate the presence or
absence of a free phenolic group in the original conjugate.
On occasion further Celite chromatography of E23G peaks
eluted by the 0 - 0.4M NaCl system was performed in order
to obtain an additional value for the 3H/14C ratio.
For the peaks recovered from the columns the 3H/14C
ratio of each fraction was calculated and the average ratio
for each peak obtained. In each case this was checked
against the ratio of the pool of the fractions of the peak.
Radioactivity was measured using a Nuclear Chicago
Liquid Scintillation Spectrometer as described earlier (19).
Quench correction was made by the internal standard tech¬
nique. All values given are in dpm. For dual labelled
samples 3H and 14C were separately calculated as described
by Okita et al (20) .
RESULTS
The rates of urinary excretion of 3H and l4C were
similar in the 4 experiments and the mean curve is shown in
Fig. 1. The total recoveries of injected 3H and 14C were 90%
and 75%, respectively. Some 70% of each injected isotope
was excreted within 3 hr while from 3 to 6 hr a further 8%
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Fig. 1. Cumulative excretion of 3H and 14C following
injection of 3H-E13G-14C or 3H-E33G-14C into normal females.
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of the 3 H dose was excreted along with about 5% of the 14C
dose. Beyond 6 hr no further 14C could be detected whereas
an additional 12% of the 3H dose appeared from 6 to 48 hr
after administration. Little or no excretion of either
isotope was observed from 48 to 72 hr.
Urines obtained at 0 - 6, 6 - 12 and 12 - 24 hr from
subjects G and J contained, following hydrolysis, no
identifiable labelled metabolites other than Ej^ and E2 . In
each case fi-glucuronidase hydrolysis appeared to be complete.
Solvolysis released no more than 1% of the original urine
radioactivity.
Table I shows the 3H/14C ratios of the conjugate
fractions at various stages of the purification procedure
for subjects G and J. In each urine aliquot two peaks,
corresponding to Ej 3G and E23G were found after elution of
the DEAE-Sephadex column with 0 - 0.4M NaCl. For the 0-6
hr fractions 3H and 14C were found in each peak. The
patterns shown in Figs. 2 and 3 for G (0 - 6; Ex3G injected)
and J (0-6; E23G injected) are typical of the separations
achieved in this study. It appeared from these that the
transformations Ex 3G -» Es 3G and E2 3G -> Ex 3G could both
occur, particularly the latter, and, in view of the 3H/14C
ratios of the metabolites it was clear that these con¬
versions could involve the intact conjugates. Beyond 6 hr
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TABLE I
3H/14C Ratios of metabolites at various stages of
purification for subjects G and J*
Conjugate fractions
Purification step G J
0-6 6- 24 0-6 6- 24
Urine through XAD-2 6.8 ** 6.7 **
0 - 0.8M NaCl 6.1 ** 5.8 **
Celite partition 6.0 76 6.1 **
0 - 0.4M NaCl (peak 1-E-,, 3G) 6.2 62 6.0 **
( " 2-E2 3G) 7.5 ** 6.1 kk
Peak 1, reduced -» Celite 6.1 t 6.2 t
Peak 2 -» Celite 7.5 t 6.0 t




little or no 14C was associated with the urinary 3H-labelled
conjugates (Table I). The results in Table II for subjects
A and E are in agreement with those of Table I. The 3H/14C
ratios of the various metabolites in these experiments were
relatively constant throughout the purification procedure
employed. The total monoglucosiduronate fractions were
separated from most of the interfering urinary chromogens
by the 0 - 0.8M NaCl gradient although significant amounts
of chromogens were still present. Celite partition chroma¬
tography removed most of the latter while in the 0 - 0.4M
NaCl gradient the glucosiduronate peaks were purified to a
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Fig. 2. DEAE-Sephadex chromatography (0 - 0.4M NaCl) of
urinary metabolites of 3H-E13G-14C in subject G from 0 to
hr after injection.
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Fig. 3. DEAE-Sephadex chromatography (0 - 0.4M NaCl) of
urinary metabolites of 3H-ES3G-14C in subject J from 0 to
6 hr after injection.
TABLE II
1H/14 C Ratios of metabolites at various stages of







Urine through XAD-2 6.0 9.4 6.1 8.7
0 - 0.8M NaCl 5.9 10.5 5.7 8.4
Celite partition 6.1 10.7 5.8 8.9
0 - 0.4M NaCl (peak 1-EX3G) 5.9 13.5 5.7 8.1
II II II ^ II 2-E23G) 5.8 7.1 6.0 9.2
*3H-E-l 3G-14C injected into E; SH-E23G-14C into A; 3H/14C =
5.8 for both.
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Reverse isotope dilution of the 3H-aglycones derived
from the various purified Ex3G and E23G fractions showed the
latter to be 90 - 100% radiochemically pure in most cases.
The lowest purities (79 - 86%) were associated with the
Es3G fractions from 6-24 hr in subjects G and J, respect¬
ively. This may suggest additional metabolites in these
fractions. Table III shows data for the calculated SA
values for the 3H-aglycones after dilution with carrier, SA
values for the final crystals in the free form and also in
the acetylated form. Further details are not presented
since this technique is now so widely used. Chemical
reduction of Ex 3G fractions followed by hydrolysis and
crystallization of the 3H-aglycone with carrier Es confirmed
the presence of a free 17-keto group in the original
conjugate. Methylation of E23G fractions followed by
hydrolysis resulted in identification of at least 95% of the
radioactivity as being associated with free E3, thus
strongly indicating the absence of a free phenolic group in
the original conjugate. These data, together with the
behaviour on DEAE-Sephadex and Celite partition columns,
established the metabolites as the 3-glucosiduronates of Ex
and E2. In no instance was any evidence obtained for the
presence of labelled Ea17G.
Table IV summarizes the amounts (in terms of 3H) and
the final 3h/14C ratios of the metabolites isolated from 0
TABLEIII


























































































to 6 hr and from 6-24 hr in subjects G and J. After Ex 3G
injection in subject G, 7 9% of the total urinary 3H identi¬
fied in the 0-24 hr urine was excreted in the first 6 hr
as Ejl 3G with a 3 H/14 C ratio (6.1) slightly higher than that
injected. A further 9% appeared within 6 hr as E23G of
isotope ratio 7.5 indicating that it arose mainly by direct
reduction of Ex 3G. Beyond 6 hr, although very small amounts
of metabolites were excreted, E-l 3G predominated over E23G.
The absence of 14C suggested deconjugation followed by
equilibrium between Ex and Es prior to reconjugation with
unlabelled UDPGA and finally urinary excretion. Injection
of E2 3G (subject J, Table IV) was followed by a very con¬
siderable direct conversion to E! 3G, 29% of the 3H present
in the 0-24 hr urine being excreted in 6 hr as the latter
compound, with 3H/14C =6.1. As in the case of injected
Ex3G no 14C was associated with the metabolites in the
period 6-24 hr during which time 3H-E1 3G was approximately
four times greater than SH-ES3G.
Table V contains data for the metabolism of injected
Ex 3G and Es3G in subjects E and A, respectively, over the
periods 0-3 and 3-6 hr. Excellent evidence was obtained
for a direct Es 3G -> Ex 3G conversion, 32% of the 3H ident¬
ified in 0 - 6 hr after E23G injection appearing in the
first 3 hr in the form of Ex 3G with 3H/14C = 5.9. In this
same experiment it was also evident that some deconjugation
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TABLE IV
Relative amounts and 3H/14C ratios of metabolites
in subjects G and J
Urine 3H (0 - 6) 3H (6 - 24)
Expt me tab dpm* % of t 3 H/1 4 C dpm* % of t 3 H/14 C
xl0~6 0--24 hr xlO-6 0-24 hr
G Ex 3G 5.17 79 6.1 0.594 9 62
(E, 3G E23G 0.615 9 7.5 0. 16 3 *
injected)
J E1 3G 1.43 29 6.1 0.602 12 *
(E23G Eg 3G 2.76 56 6.1 0.173 3 *
injected)
♦Uncorrected for procedural losses during extraction and
purification.
i% of total SH identified as E1 3G + E23G in 0 - 24 hr.
^Apparently infinity.
TABLE V
Relative amounts and 3H/14C ratios of metabolites
in subjects A and E
Urine 3H (0 - 3) 3H (3 - 6)
Expt me tab dpm* % of t
3 H/1 4 C dpm* % of t CO HJ> & o
xl0~6 0-6 hr xl0~6 0-6 hr
A Ex 3G 1.74 32 5.9 0.243 5 13.5
(E23G Eg 3G 3.25 61 5.8 0.118 2 7.1
injected)
E E2 3G 6.06 88 5.7 0.360 5 8.1
(Ex 3G Eg 3G 0.448 6 6.0 0.06 1 9.2
injected)
♦Uncorrected for procedural losses during extraction and
purification.
of total 3H identified as Ex 3G + Es 3G in 0 - 6 hr.
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had occurred as reflected in the 3H/14C ratios of the 3-6
hr metabolites (Ex3G = 13.5, E33G = 7.1). This appeared to
be associated with an increase in the ratio of Ex 3G/E2 3G at
this time as compared with the 0 - 3 hr period. Table V
also shows a small, though definite, conversion of Ex 3G to
E23G within 3 hr and an increase in the 3H/14C ratios of the
urinary metabolites of Ex 3G at 3 - 6 hr (Ex 3G = 8.1, Es 3G =
9.2) .
In the two experiments where Ex3G was injected the
patterns of urinary metabolites during 0 - 6 hr (ca 80% of
the 3H dose excreted) were such that the EX3G:E23G ratios
with respect to 3H were 13:1 and 9:1. In the experiments in
which E2 3G was injected these ratios were 0.61:1 and 0.59:'
DISCUSSION
The above results clearly indicate the interconversion
of E13G and E23G in the human in vivo, without prior removal
of the glucuronic acid moiety. The transformation is
markedly in favour of Ex 3G production and occurs within 3 hr
of intravenous injection of the conjugates. Beyond 3 hr
there is evidence for some deconjugation although this is
not a major process in the metabolism of Ex3G or E23G. Such
deconjugation could, conceivably, be occurring in the gut, a
site already shown to be active in this respect where the
glucosiduronates of estriol are concerned (21, 22). No
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labelled phenolic aglycones other than Ex or E2 could be
detected in the present work nor was there any reason to
suspect the presence of E217G in any of the urines analyzed.
This, however, does not exclude the possible presence of
minor amounts of other compounds, particularly between 24
and 48 hr.
Zucconi et a 1 (3), following introduction of 3 H-Ej. 3G-
14 C into the human fetus in situ, recovered about 1 - 2% of
the radioactivity in the maternal urine and identified this
largely as Ex 3G of 3H/14C ratio equal to that administered
together with very small amounts of labelled E2 following
|3-glucuronidase hydrolysis. In view of the small degree of
conversion of Ej 3G to E23G in the present work it seems
possible that a similarly small fraction of the Ex3G trans¬
ferred to the mother could have been converted to E33G, thus
accounting for the findings of Zucconi et a 1.
It appears obvious that the metabolism of the 3-
glucosiduronates of Ex and Es is very different from that of
Es17G. Thus the major part of intravenously injected E217G
has been shown to be metabolized to Ex3G and E23G with the
former compound predominating (6). This, of necessity,
would involve considerable removal of the 17-glucosiduronate
group. Therefore it would appear that glucuronic acid
esterified at C-3 of Ex or Es is much less liable to be re-
6 STEROIDS 15:5
moved following intravenous injection in the human than is
the case when it is esterified at C-17 of Es.
It was speculated earlier (6) that Ea17G might be
metabolized via a diglucosiduronate form to E23G and hence
to Ex 3G. In order for this to be so it was necessary to
show that Eg3G could be directly dehydrogenated to Ex 3G.
The results in the present paper now show such a conversion
to be a distinct possibility.
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METABOLISME DES GLUCURONATES * D'QESTROGENE
ADMINISTRES PAR VOIE ORALE A LA FEMME NORMALE
R. HOBKIRK, M. NILSEN et P. MUSEY 1
introduction
Des etudes recentes demontrent clairement que,
chez la femme normale, le metabolisme du 17/3-oes-
tradiol-17 glucuronate * (E217G) circulant differe
considerablement de celui du 17/?-oestradiol-3-glucu-
ronate^fE-.G). 4> 2 Ainsi, le E217G est fortement de-
conjugue (a environ 65%) en cestrone-3-glucuro-
nate (Ei3G) et E23G comme metabolites urinaires
principaux, 1>3 alors qu'environ 30% sont elimines
dans les urines sous forme de E217G 1,4 (probable-
ment la substance injectee intacte). L'administration
intraveineuse de E23G (ou de Ei3G) marques, en
revanche, est suivie d'une elimination rapide de la
radioactivite dans les urines (70% en 3 heures) sans
qu'il se soit produit de deconjugaison.2 Apres trois
heures, on constate une deconjugaison legere (10-
15%). 2 II semble probable que la deconjugaison,
surtout celle des glucuronates d'oestriol, se produit
• dans le tractus intestinal.5'6 Si tel est le cas pour les
conjuges de l'oestrone (Ei) et du 17/?-cestradial (E2),
la difference notee ci-dessus pour le metabolisme du
E217G et du E23G pourrait s'expliquer par un degre
different de participation des deux composes dans
le systeme entero-hepatique. Pour tenter de mieux
comprendre le metabolisme de ces composes, nous
avons etudie le destin de l'Ei3G et de l'E217G inge-
res par la femme. Nous presentons ici cette etude, et
en comparons les resultats avec d'autres donnees pro-
venant de notre laboratoire.
materiel et methodes
pour VA, et 25/uc pour CL. Les urines ont ete re-
cueillies a intervalles appropries et congelees jusqu'au
moment de l'analyse. Tous les reactifs chimiques,
solvants organiques, enzymes, substances necessaires
a la chromatographic, etc. ont ete obtenus et le cas
echeant purifies dans les conditions decrites ailleurs. 7
Nous avons achete le 17/3-cestradiol-6,7-3H et le
17-/8-oestradiol-6,7-3H-17-glucuronate a la New
England Nuclear Corp. (Boston, Massachusetts) et
les avons purifies comme nous Pavons expose ail¬
leurs. 7'8 L'cestrone-6, 7- 3H-3-glucunorate-14C (mar¬
que de faqon non specifique) a ete prepare par bio-
synthese et purifie ainsi que nous l'avons deja expo¬
se. 2 Toutes les mesures de radioactivite ont ete rea-
lisees a l'aide de spectrometres a scintillation liquide
« Nuclear Chicago » ainsi que nous en avons fait etat
ailleurs.7 L'analyse des conjugues de Purine a ete
faite par chromatographic sequentielle sur resine
Amberlite XAD-2 9, Sephadex DEAE avec des gra¬
dients de concentration de NaCl2'8 et des colonnes
de fractionnement en Celite- 10 Apres avoir separe les
conjugues, nous avons identifie les steroi'des par
hydrolyse avec la j3-glucuronidase suivie d'un frac¬
tionnement de Girard et d'une chromatographic sur
colonne de fractionnement en Celite. 11 Ces opera¬
tions ont ete suivies de la cristallisation a activite
specifique constante a 1'aide de steroides porteurs
avant et apres formation d'acetate. 1>2'7
rLsultats
La Fig. 1 montre l'excretion de la radioactivite
apres administration buccale de E^G ou de E23G,
E217G et E2 marques. On constate un retard d'au
moins trois heures pour l'excretion apres l'adminis¬
tration des conjugues, mais non apres celle du stero'f-
de libre. Au dela de 3-6 heures, la courbe d'excre-
tion dans le cas des conjugues est semblable a celle
d'au dela de 6 heures apres l'injection intraveineuse
de E217G (Fig. 2). L'analyse des conjugues urinaires
apres l'administration buccale de EX3G marque a
3H/14C dans deux experiences produit les donnees
qui figurent dans les Tableaux I et II. En dehors
de la periode de 0-3 heures, ou 1-2% de la dose
administree a ete eliminee dans un rapport defini
3H/14C, il n'a pas ete retrouve de 14C dans Purine,
L'etude a ete effectuee au cours de la premiere
moitie du cycle menstruel de sujets volontaires et en
bonne sante. On leur a administre des oestrogenes
libres ou conjugues par voie intraveineuse (une seule
injection) en solution d'ethanol-saline 10% (v/v),7
les conjugues etant administres par la bouche dans
l'H20 et les oestrogenes libres dans l'ethanol-H20 a
10% (v/v). Les doses de 3H administrees sous forme
conjuguee etaient de 5/ic pour le sujet LO, 10/nc
* L'expression « glucuronate » est ci-apres utilisee com¬
me synonyme de « glucosiduronate », terme employe dans
le texte anglais.
1 University Medical Clinic, The Montreal General Hos¬
pital, Montreal.
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alors qu'environ 83% de la dose de 3H a ete elimine
en 96 heures. L'E217G n'a pas ete identifie comme
metabolite urinaire (Fig. 3) mais Ej3G et E23G re-
presentaient a eux deux au moins 90% de la radio¬
activite de l'urine pour la periode de 0-48 heures
lorsqu'une analyse detaillee a ete faite. II ressort
EXCRETION CUMULATIVE DE LA RADIOACTIVITE APRES
ADMINISTRATION PER OS
Heures apres
administration E^G e,3g esg
0 — 3 2 2** 0 0
3 — 6 16.0 0.5 0
6 — 12 17.5 2.3 0.4
12 — 24 30.5 5.7 1.1
24 — 48 18.3 3.0 3.6
Total 83.5 11.5 5.1
* Position de conjugaison avec 1'acide glucuronique non
determinee.
** Accompagne de 14C (3H/14C = 5.8). II n'a pas ete
trouve d'autre 14C.
TABLEAU II
Metabolites urinaires au 3H (en pourcentage de 3H identifie)
apres administration per os de 3H/14C-E13G
(3H/14C == 5.8) au sujet VA.
Heures apres
administration E^G E23G ESG *
0 — 3 3 9 ** 0.3 <0.01
3 — 6 10.6 1.6 0.05
6—12 25.0 6.0 0.3
12 — 24 21.6 6.9 0.8
24 — 48 16.5 4.3 2.2
Total 77.6 19.1 3.3
* Position de conjugaison avec l'acide glucuronique non
determinee.
** Accompagne de 14C
trouve d'autre 14C.
(3H/14C = 10.6). 11 n'a pas ete
Fig. 1 — Excretion urinaire cumulative de la radioactivite
(3H) apres administration per os de 3H/14C-E13G,
3H-E217G et 3H-E2.
aussi des Tableaux I et II que le(s) monoglucurona-
te(s) d'oestriol (E3) ne representai(en)t pas plus de
3-5% de la radioactivite enregistree dans Furine pen¬
dant les deux premiers jours. La contribution de E3
a augmente pendant cette periode et il est fort possi¬
ble qu'elle se serait accrue pendant les deux jours
suivants qui n'ont pas ete etudies en detail. Nous
avons pu exclure la possibilite que des quantites
significatives d'autres metabolites d'oestrogene soient
presentes pendant la periode de 0-48 heures.
Le Tableau III montre les metabolites urinaires
identifies apres administration buccale de E217G.
Le schema ressemble beaucoup a celui decrit ci-des-
TABLEAU I
Metabolites urinaires 3H (en pourcentage de 3H identifie)
apres administration per os de 3H/14C-E13G
(3H/14C = 5.8) au sujet LO.
sus pour l'Ei3G per os. II n'a pas ete trouve de
E217G dans l'urine et les Ej3G + E23G represen-
taient pour ainsi dire la totalite de la radioactivite
eliminee en 48 heures. Une tres faible quantite de
E3 conjugue a ete decelee; elle semblait s'accroitre
au cours de la periode de 48 a 72 heures (ne figure
pas dans le Tableau).
DISCUSSION
Fishman et coll12 ont signale qu'une fraction no¬
table d'une dose de E2 administree par voie buccale
est rapidement absorbee et eliminee dans l'urine
sous forme de conjugues glucuronates de E2 et Ei,
c'est-a-dire qu'il ne se produit plus guere de conver¬
sion ulterieure de la portion stero'fde- Toutefois, envi¬
ron 60% de la dose suivait un metabolisme similaire
a celui de l'E2 administre par injection intraveineuse
avec la production de quantites abondantes de meta¬
bolites 2-hydroxy et 16-hydroxy. II ressort clairement,
de la presente etude que, d'apres l'analyse des meta¬
bolites urinaires, tant l'Ei3G que l'E217G sont consi-
derablement sinon completement deconjugues dans
le cours du metabolisme a la suite de l'administration
buccale. Sans pouvoir ecarter la possibilite que l'es-
TABLEAU III
Metabolites urinaires marques au 3H
(en pourcentage de 3H identifie)
apres administration per os de 3H-E017G au sujet CL.
Heures apres





















Total 72.1 24.9 3.1
Position de conjugaison avec 1'acide glucuronique non
determinee.
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tomac puisse etre un site de deconjugaison dans nos
experiences, il semble improbable qu'une hydrolyse
importante puisse s'y produire, parce que le steroi'de
libre ainsi produit aurait vraisemblablement ete meta¬
bolise de la fa^on indiquee par Fishman et ses colla-
borateurs pour l'E2 libre. Or le contraire ressort
clairement de notre constatation, a savoir que l'admi-
nistration buccale de 3H/14C-E33G et 3H-E217G ne
produit guere autre chose que 3H-E33G et 3H-E23G
dans l'urine. En outre, le retard d'excretion des meta¬
bolites apres l'administration buccale des conjugues
(1-2% de la dose en trois heures) differe de l'excre-
tion constatee apres l'absorption de E2 libre, ou
7,5% de la dose ont ete elimines dans l'urine dans
les deux heures (Fig. 1). Quel que soit le site exact ou
intervient la deconjugaison (hydrolyse) des glucuro-
nates dans le systeme gastro-intestinal, il est tentant
de considerer que cette etape pourrait etre le facteur
limitant de reabsorption, puisque l'E2 (libre) adminis-
tre buccalement est rapidement absorbe12 et que les
3-glucuronates, une fois dans la circulation sanguine,
sont tres rapidement excretes dans l'urine2 (Fig. 2).
EXCRETION CUMULATIVE DE LA RADIOACTIVITE APRES
INJECTION INTRAVEINEUSE
Fig. 2 — Excretion urinaire cumulative de la radioactivite
(3H) apres injection intraveineuse de 3H/14C-E23G ou
E^G, 3H-E217G et 3H-E2.
Le manque relatif de metabolites steroi'daux autres
que Ei3G et E23G dans l'urine, a la suite de l'admi-
nistration buccale de Ei3G ou de E217G, donne
plutot a penser que les steroi'des ont penetre dans
le systeme porte sous forme conjuguee plutot que
sous la forme libre, autrement dit que le tractus gas¬
tro-intestinal est un site de deconjugaisons et de
reconjugaison.
II est interessant de s'interroger sur la fagon dont
il faut interpreter la courbe d'excretion de la radio¬
activite a la suite d'une injection intraveineuse de
3H-E217G (Fig. 2). Nous avons deja etabli que
l'excretion initiale rapide (0-3 heures) est due pres-
que entierement a 3H-E217G joint a une tres faible
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quantite de :!H-17/J-cestradiol-3-sulfate-17-glucuro-
nate (E23S17G).4 Le retard d'excretion, qui se pro¬
duit entre environ 3 et 6 heures, est similaire a celui
que l'on constate apres les 3 premieres heures a peu
pres qui suivent l'administration buccale de E217G
(Fig. 1). L'excretion de 3H au dela de 6 heures dans
l'experience avec injection intraveineuse est tres sem-











Fig. 3 — Fractionnement typique sur colonne Sephadex
DEAE de conjugues 3H dans les urines apres administra¬
tion orale de 3H/14C-E13G au sujet VA. Ce diagramme
concerne les conjugues urinaires entre 12 et 24 heures
apres administration du compose marque.
per os de E217G: presque toute la radioactivite
urinaire se retrouve sous forme de 3H-E33G et
3H-E23G4. Cela pourrait signifier qu'une partie de
l'E217G injecte est excretee dans la bile (peut-etre
sous forme de E23S17G) avec deconjugaison ulte-
rieure et reabsorption, et enfin excretion urinaire des
3-glucuronates des Ei et E2 reconjugues.
Resum4
De l'oestrone-6,7-3H-3-glucuronate-14C (marque
de fagon non specifique) a ete administre buccalement
a deux jeunes femmes normales. Pendant les 3 pre¬
mieres heures, 1-2% seulement de la dose a ete
excrete dans les urines, cette excretion contenant
a la fois 3H et 14C. Par la suite, 83% de la dose de
3H est apparu dans les urines en quatre jours, mais
il n'a plus ete retrouve de 14C. Au moins 90% du
3H des 48 heures representait de l'cestrone-3-glucuro-
nate et du 17/8-cestradiol-3-glucuronate et 3-5% cor-
respondait a un (ou des) glucuronate(s) d'oestriol. De
meme a-t-on note lors de l'administration de 17/3-
oestradiol-6,7-3H-17-glucuronate, un retard d'environ
3 heures dans l'excretion, et l'on retrouvait 85% de
la dose radioactive dans les urines en 3 jours. Le 3H
excrete en 48 heures etait presque entierement sous la
forme d'oestrone-3-glucuronate et de 17/j-oestradiol-
3-glucuronate. Ces donnees demontrent l'efficacite






20 30 40 50 60
VOLUMES COLLECTES (5ML)
ronates d'oestrogene et peut-etre aussi a les reconju-
guer avant l'excretion urinaire.
Summary
Estrone-6, 7-3H-3-glucosiduronate-14C (generally label¬
led) was administered orally to two normal young human
females. Over the first 3 hr. only 1-2% of the dose was
excreted in the urine and this contained both 3H and 14C.
Beyond this time, some 83% of the 3H dose appeared in
the urine over a period of 4 days, but no further 14C was
recovered. At least, 90% of the 3H in 48 hr. consisted of
estrone-3-glucosiduronate and 17/?-estradiol-3-glucosiduron-
ate while 3-5% corresponded to estriol glucosiduronate (s).
When 17/?-estradiol-6, 7-3H-17-glucosiduronate was similarly
administered, a lag in excretion of about 3 hrs. was again
seen, followed by recovery in the urine of 85% of the
radioactive dose within 3 days. The 3H excreted in 48 hrs.
was almost completely in the form of estrone-3-glucosi¬
duronate and 17/8-estradiol-3-glucosiduronate. These data
indicated the efficiency of the gastrointestinal tract in
deconjugating the estrogen glucosiduronates and perhaps
also in reconjugation prior to urinary excretion.
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etabolism of 17/3-Estradiol to 17/3-Estradiol-
-glucosiduronate and 17/3-Estradiol-17-glucosiduronate
y the Normal Human Female
R. HOBKIRK1 and MONA NILSEN
McGill University Medical Clinic, The Montreal General Hospital, Montreal, Quebec, Canada
ABSTRACT. 6,7-3H-17/3-estradiol (estradiol)
was administered intravenously into 2 normal
females and orally to 2 others. Urines collected
over various time intervals were analyzed for
3H-estradiol-3-glucosiduronate and 3H-estradiol-
17-glucosiduronate by Amberlite resin, DEAE-
Sephadex and Celite partition chromatography
followed by enzyme hydrolysis, derivative for¬
mation and reverse isotope dilution. In the first
2 hr after intravenous injection urinary estradiol-
17-glucosiduronate was more than 4 times greater
in amount than the 3-monoglucosiduronate. Of
the total estradiol-17-glucosiduronate excreted
in the first 24 hr after injection, at least 96% was
in the first 2 hr, whereas estradiol-3-glucosi-
duronate showed a gradual increase throughout
the 24-hr period. After ingestion of 3H-estradiol,
no firm evidence was obtained for the presence
of urinary estradiol-17-glucosiduronate, whereas
estradiol-3-glucosiduronate appeared to be ex¬
creted at a greater rate than following iv injec¬
tion. It is concluded that both monoglucosi-
duronates of estradiol are urinary metabolites
of intravenous estradiol but only the 3-gluco-
siduronate is a urinary metabolite of the ingested
hormone. (J Clin Endocr 32: 779,1971)
IITTLE appears to be known regarding-i the naturally occurring glucosiduro-
nate form(s) of 17/1-estradiol (hereafter re¬
ferred to as estradiol or E2)2 in the human
subject. Data obtained elsewhere suggest
the presence of estradiol-17-glucosiduronate
(E217G) in pregnancy urine (1, 2) and one
of these reports further suggests that the
17- and 3-monoglucosiduronates of E2 may
be present in approximately equal amounts
(2). More recently, the presence of labeled
E217G in urine following injection of 14C-
E2 to humans has been indicated on the
basis of chromatographic mobility (3).
The present communication deals with the
identification of both monoglucosiduro-
nates of E2 as urinary metabolites of ad-
Received December 14, 1970.
Supported by Grant MT 532 from the Medical
Research Council of Canada.
1 Research Associate of the Medical Research
Council of Canada.
2 The following trivial names and abbreviations
are used; estradiol-17-glucosiduronate (E2 17G)
= 3-hydroxyestra-l,3,5(10)-trien-17/3-yl-/3-d-gluco-






ministered 3H-E2 in the human female and
with the sequence in which they arise.
Materials and Methods
Labeled steroids and conjugates. 6,7-3H-E2 of
specific activity (SA) =39 Ci/mmole was pur¬
chased from New England Nuclear Corp.
(NENC), Boston, Mass., and was at least 98%
pure as judged by crystallization with carrier
following column partition chromatography
(CPC) on Celite (4).
4-14C-estradiol-3-glucosiduronate (E23G) was
biosynthesized as described elsewhere (5) by
incubating 14C-E2 (NENC, SA=52 mCi/
mmole) with unlabeled uridine diphosphate
glucuronic acid and a guinea pig liver homoge-
nate. The mixture of 14C-E23G and 14C-estrone-
3-glucosiduronate (E^G) so formed was re¬
duced with NaBH4 (5) and the resulting 14C-E2
3G was purified by DEAE-Sephadex and Celite
CPC (5). Hydrolysis followed by crystallization
with carrier E2 showed that some 98% of the
I4C-aglycone was in the form of the latter ste¬
roid. Hydrolysis was efficiently inhibited by sac-
charo-1,4-lactone.
4-14C-E217G of SA=45.2 mCi/mmole was
synthesized by NENC. Following chromatog¬
raphy on DEAE-Sephadex in a linear gradient
(0-0.4m) of NaCl (6), a portion was mixed with
purified 6,7-3H-E 217G (NENC, SA=1.0 Ci/
mmole) to yield a 3H/I4C ratio =7.5. This was
methylated (7) and hydrolyzed (7) to give an
ether-soluble fraction of isotope ratio =7.3.
Crystallization with unlabeled estradiol-3-
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methyl ether (E23MeE) resulted in crystals and
mother liquor of ratios 7.3 and 7.2, respectively.
Reagents, chemicals, etc. All organic solvents,
chemicals, Celite, etc., were of analytical grade
and were purified where necessary by published
procedures (4, 8). All unlabeled steroids were
purchased from Mann Research Laboratories,
Inc., New York, and were checked for purity
by melting point determination (microscope
hot stage) and thin-layer chromatography.
DEAE-Sephadex (A-25) was a product of
Pharmacia (Canada) Ltd., Montreal. Beef
liver /3-glucuronidase (Ketodase) was purchased
from Warner-Chilcott, Morris Plains, N. J.
Saccharo-l,4-lactone was pin-chased from Cal-
biochem, Los Angeles, Cal.
Administration of 3H-E2. This was injected, as
described elsewhere (4), in a single dose via an
arm vein into 2 normal female volunteers; sub¬
ject CR (received 25.6 gCi) and subject DE
(received 18 gCi). It was also administered or¬
ally in 10% (v/v) ethanol-H20 to 2 further
normal females; subject JN (received 25.5 gCi)
and subject JS (received 22.4 juCi). The 4 sub¬
jects were aged 21 to 25 yr and were at about
day 10 of the menstrual cycle. Urine was col¬
lected at 2 hr intervals up to 6 lir and again at
12 and 24 hr. In subject JN the 4 and 6 hr col¬
lections were inadvertently mixed, leading to a
2-6 hr collection. All urine was frozen until
analyzed.
Analysis of urinary conjugates. Suitable urine
volumes (corresponding to no less than 1 hr and
no greater than 6 hr collections) were processed
on Amberlite XAD-2 resin (9) followed by
DEAE-Sephadex chromatography (58 cm col¬
umn, 0-0.8m NaCl gradient, 10 ml fractions
collected; ref. 6). The "total" monoglucosidu-
ronate fraction so obtained (fractions 20-40
pooled) was chromatographed on Celite in iso-
octane:i-butanol: 1m NH4OH (2:5:5; ref. 10)
and then on a 0.9 X95 cm DEAE-Sephadex
column in a linear gradient (500 ml H 20 in mix¬
ing vessel, 500 ml 0.8m NaCl in donor vessel)
collecting 5 ml fractions. Purified 14C-E23G or
I4C-E217G or both were added at various points
of the procedure to act as internal standards
for purposes of checking recovery and as chro¬
matographic markers. Peaks containing E23G
were incubated with /3-glucuronidase (500 U/ml
for 20 hr at 38 C) with and without inhibitor
saccharolactone. The ether-soluble material re¬
leased was chromatographed on Celite in ben¬
zene: hexane: 70% methanol (55 :45 GOO; ref. 8)
and the E2-containing fraction crystallized with
carrier E2, before and after acetylation, to con
stant SA and, where appropriate, 3H/14C rati
Aliquots of chromatographic peaks containin
E217G were hydrolyzed and chromatographe
as above in order to identify the labele
aglycone. The greater part of each E217G
containing peak was methylated (7) and thei
hydrolyzed (7) and the resulting ether-solubk
radioactivity was crystallized with carriej
E23MeE to constant SA (and, where appro
priate, isotope ratio) prior to acetylation anc
recrystallization (7). Melting points of fina
derivatives were checked on a microscope hoi
stage. Peaks containing Ei glucosiduronatf
were hydrolyzed and then chromatographed tc
identify the aglycone estrone.
All radioactive counting was performed as
described elsewhere (4, 11) except that direct
counting of urine, and aqueous samples fron
DEAE-Sephadex columns, was carried out
after mixing directly with Aquasol (a xylene-
based scintillation fluid purchased from
NENC).
Results
General. The presence of saccharolactone
effectively inhibited the /3-glucuronidase
hydrolysis of separated conjugate frac¬
tions. In the absence of the inhibitor,
and when 14C-E23G and/or 14C-E217G had
been added as internal standards, release
of 14C in an ether-soluble form was at least
95% under the hydrolytic conditions em¬
ployed. Hydrolytic release of 3H varied
throughout the time period studied, pre¬
sumably due to the presence of metabolites
other than glucosiduronates of Ei and E2,
which metabolites were not hydrolyzed
completely by 500 U/ml of Ketodase for
20 hours. During each chromatographic
step, including Amberlite XAD-2 treat¬
ment to recover the conjugates from
aqueous solution following each DEAE-
Sephadex chromatography, no more than
5 to 10% of each 14C-standard was lost.
Intravenous ZH-E2. Within two hours after
injection, three well-defined peaks of 3H
were separable by DEAE-Sephadex chro¬
matography (Fig. 1 and 2). Peak I was at
least 90% Ei glucosiduronate, peak II cor¬
responded with standard 14C-E23G (Fig. 1,
subject CR), while peak III corresponded
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Fig. 1. Final DEAE-Sepha-
lex chromatography of uri¬
nary 3H-glucosiduronates (0-2
hr) after iv injection of 3H-E2
into subject CR. Pure 14C-E2










vith added 14C-E217G (Fig. 2, subject
DE). Table 1 provides further evidence for
;he presence of 3H-E23G (approx. 55%
)f total 3H in the peak) in peak II. Table
I shows similar evidence in favor of 3H-
3217G being virtually the sole 3H-constit-
rent of peak III. In these two experiments,
>ver zero to two hours, the ratio E217G:
323G =4:1 and 4.5:1, respectively.
FRACTION No. (5 ML)
At times between two and 24 hours
following injection, only two well-defined
3H-peaks could be seen after DEAE-
Sephadex chromatography (Fig. 3, sub¬
ject DE, 2-4 hr), these corresponding to
peaks I and II of Fig. 1 and 2. In all in¬
stances beyond two hours peak II was
shown to contain 3H-E23G, which, as a
percentage of the total peak, varied with
flg. 2. Final DEAE-Sepha-
lex chromatography of uri-
lary 3H-glueosiduronates (0-2
lr) after iv injection of 3H-E2
nto subject DE. Pure 14C-E2
7G was added prior to chro-
natography.
60 70 80 90
FRACTION No. (5 ML)
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Table 1. Identification of 3H-E2 as an aglycone released by enzyme hydrolysis of peak II (from a





Aliquot of E2 fraction following CPC; 91,300 2470 653 3.8
dpm 3H, 24,100 dpm 14C +36.9 mg carrier E2 (calculated)
Crystallization from methanol XLS I 2350 648 3.6
ML I 2650 680 3.9
XLS II 2230 662 3.4
ML II 2410 674 3.6
Acetylation; crystallization from methanol-H2Of XLS III 2350 628 3.7
ML III 2410 650 3.7
XLS IV 2410 670 3.6
ML IV 2380 658 3.6
Mean for crystals 2330 652 3.6
* 14C-E2 3G added prior to chromatography (see Fig. 1); after final DEAE-Sephadex column 3H/H(
for peak II =6.1; after enzyme hydrolysis-(-extraction, ratio =5.1; after CPC—>E2 fraction, ratio =3.8
t SA values calculated for free steroid (XLS = crystals, ML =mother liquor).
time and was considerably less in this re¬
spect than the 55% quoted for zero to two
hours. This percentage decrease was re¬
lated to the appearance of additional 3H-
metabolites, such as estriol glucosiduro-
nate, in peak II. Peak I contained Ei
glucosiduronate, again as a varying per¬
centage, over the period studied. The
chromatographic separation between peaks
I and II tended to become less distinct with
time (see Fig. 3), presumably due to the
increasing amounts of additional metab
olites. Attempts to verify whether smal
amounts of SH-E217G might be presen
beyond two hours led to the conclusioi
that of the total 3H-E217G in the urim
within 24 hours some 96% was in zero t<
two hours, no more than 3% was in two t<
four hours and <1% was in four to si:
hours.
Oral '■H-E'i. In both experiments th
Table 2. Identification of 3H-E23MeE as the derivative formed by methylation and hydrolysis of pea
III (from a DEAE-Sephadex chromatogram of the 0-2 hr urine,




Aliquot of hydrolyzate; 98,800 dpm 3H, 47,800 dpm 3900 1890 2.1
14C +25 .3 mg E23MeE carrier (calculated)
Crystallization from methanol XLS I 3730 1890 2.0
ML I 4150 1900 2.2
XLS II 3760 1930 2.0
ML II 4050 1960 2.1
Acetylation; crystallization from methanoI-H20j XLS III 3850 1890 2.0
ML III 4010 1920 2.1
XLS IV 3760 1930 2.0
ML IV 3850 1940 2.0
Mean for crystals 3780 1910 2.0
* 14C-E217G added prior to chromatography (see Fig. 2); after final DEAE-Sephadex column 3H/14'
for peak III =2.2; after methylation and extraction, ratio =2.2; after enzyme hydrolysis and extractioi
ratio =2.1.
t SA values calculated for free steroid (XLS = crystals, ML =mother liquor).
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fig. 3. Final DEAE-Sepha-
lex chromatography of uri-
lary 3H-glucosiduronates (2-4
lr) after iv injection of 3H-E2
nto subject DE. Pure I4C-E2
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iver the period zero to 24 hours was that
ihown in Fig. 4 (0-2 hr, subject JS). Two
H-peaks were found, these corresponding
:n position to peaks I and II described
ibove. Peak I contained Ei glucosiduronate
it each time period, while peak II was
shown to contain 3H-E2 3G. At any given
time, 3H-E23G, as a percentage of total
'H in peak II, was greater following in¬
gestion than after intravenous adminis¬
tration. Thus, after oral administration
ibout 85% of peak II in zero to two hours
was made up of E23G, this value decreas¬
ing in later urine samples. In neither oral
study was there any significant amount of
3H, associated with peak III, which could
be identified as 3H-E217G.
Cumulative excretion of E?. monogluco-
siduronates. Fig. 5 shows the cumulative
excretion of 3H-E23G after intravenous
and oral 3H-E2, and of 3H-E217G after
intravenous 3H-E2, over a zero to 24 hour
period. For the purposes of comparison
these values have been calculated relative
Fig. 4. Final DEAE-Sepha-
lex chromatography of uri-
aary 3H-glucosiduronates (0-2
ar) after oral administration
af 3H-E2 to subject JS. Pure
14C-E23G and "C-E217G were
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Fig. 5. Cumulative excretion of 3H-E2 monoglu-
cosiduronates: x—x = E2 3G from oral E2 (subject
JN); O—0=E2 17G from iv E2 (average of 2
exp); %—% =E2 3G from iv E2 (average of 2 exp).
to a dose of 40 X106 dpm 3H-E2 in each
experiment. The data represent the mathe¬
matical products of the various crystal¬
lized fractions and the corresponding
masses of carrier steroids added prior to
crystallization. No correction was made
for normal procedural losses during the
various chromatographic steps. It can be
seen that the early urinary production of
ET7G from circulating E2 was greatly in
excess of E23G but, whereas the latter
continued to be excreted up to (and pre¬
sumably beyond) 24 hours, the former
effectively ceased after two to four hours.
The rate of excretion of E23G after in¬
gestion of E2 appeared to be greater than
after intravenous injection of E2.
Discussion
It seems clear from this study that both
E217G and E23G are metabolites of intra¬
venously administered E2 in the normal
human female. The early occurrence of
these two conjugates in the urine rather
indicates a direct glucuronylation of E2,
favoring conjugation at C-17 over that at
C-3, perhaps in the liver. The time rela¬
tionship would certainly appear to exclude
an enterohepatic formation (12). This does
not, however, rule out the possibility thai
some such intermediate as E2-3-sulfat«
could act as substrate for a glucurony'
transfer to C-17, with subsequent decon-
jugation at C-3 to yield E217G. Also, the
excretion pattern of the two monogluco-
siduronates in question could conceivably
be related to a different rate of release o:
the two from their tissues of origin, al¬
though no good evidence is available or
this point. Regardless of these factors
the cessation of E217G excretion in th<
urine at about two hours is compatibh
with the view that this compound, onci
formed, is in part rapidly excreted as sucl
in the urine, and partly in the bile in th<
form of highly polar conjugates such as
E2-3-sulfate-17-glucosiduronate (E2 3S17G
ref. 13; Musey and Hobkirk, unpublishec
results). It is known that intravenously ad
ministered 6,7-3H-E23G-14C leads to £
rapid urinary excretion of radioactivity ir
the urine (70% of each isotope dose in 0-1
hr, about a further 10% of each in 3-6 hr
and a further 10% of 3H and no 14C ii
approx. 6-48 hr; ref. 11). In the presen
study it seems likely, therefore, that th<
early appearance of 3H-E23G in the urini
following intravenous 3H-E2 largely repre
sents that part of the labeled E2 which hat
been converted directly to that monocon
jugate, and/or that arising directly fron
Ei3G (11). The continuing excretion of sig
nificant amounts of E23G, however, (sei
Fig. 5) up to at least 24 hours, could mos
probably reflect excretion of E23S17G
(and perhaps other conjugates) in the bile
with subsequent deconjugation, and recon
jugation partly in the form of E-» 3G (rei
13; Musey and Hobkirk, unpublished re
suits). In support of this is the finding tha
oral 3H-E217G results in the urinary ex
cretion of little other than labeled Ej3C
3 Assuming that the metabolism of intravenou
E217G is similar to that of E217G formed fror
intravenous E2.
une 1971 MOJNOGLUCOS1DUKOJN
and E23G (14), and that intravenously
administered 3H-E217G is considerably
converted to urinary metabolites including
Ei3G, E23G and E23S17G (7). Thus,
urinary E23G may be from at least three
sources, namely: a) E2—>E23G, b) E2—>E2
17G—>E23S17G-^E23G, and c) a direct
conversion from Ei3G (11). This infor¬
mation further complicates the picture
when the "total urinary E2 glucosiduro-
nate" fraction is used as a "metabolite"
for calculation of secretion rate of estrogen.
The apparent absence of urinary E217G
beyond about four hours after intravenous
E2, and our failure to definitely identify it
following oral E2, suggests that this urinary
monoglucosiduronate is not of enteric or¬
igin in the human female.
It is interesting to note certain similar¬
ities between the metabolism of E2 mono-
glucosiduronates and those of estriol (E3;
ref. 15, 16). Thus, E33G is mainly, if not
entirely, of enteric origin, whereas E316G
appears to be formed by both liver and in¬
testine. Also, E33S16G is the principal
biliary metabolite of E3 and is converted
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The Role of an Enterohepatic System in the Metabolism
of 17/?-Estradiol-17-Glucosicluronate in the Human Female*
p. i. musey,1 r. n. green,2 and r. hobkirk3
University Medical Clinic, The Montreal General Hospital, Montreal, Quebec, and Department of Medicine,
Hotel Dieu Hospital, Kingston, Ontario, Canada
ABSTRACT. 17P-Estradiol-6,73H-17-glucosidu-
ronate (E,17G) was injected iv in a single dose
into 3 normal women and 3 women with biliary
drainage via T-tube. Urine and, where applicable,
bile was collected over various periods of time
and the conjugated metabolites were analyzed by
Amberlite resin, DEAE-Sephadex, Celite and thin-
layer chromatography, together with selective
enzymatic hydrolysis, derivative formation and
crystallization with unlabeled carriers. In the nor¬
mal women 62-70% of the dose appeared in the
urine in 24 hr with >80% in 72 hr. Some 95%
of the urinary 3H within 2-3 hr after injection
(17-48% dose) was E217G and the remainder
was 17P-estradiol-3-sulfate-17-glucosiduronate (E2
3S17G). Over about 2-6 hr a lag in 3H excretion
occurred, the latter 2 conjugates virtually dis¬
appeared and estrone-3-glucosiduronate (Ej3G)
plus estradiol-3-glucosiduronate (E23G) appeared
in the urine. Beyond 6 hr EX3G and E23G in¬
creased cumulatively and were by far the main
metabolites up to 72 hr. No E217G was excreted
at these later times but very small amounts of
other glucosiduronates, e.g. those of estriol (E3)
and 16-epiestriol (16-epiE3), were present. In the
T-tube patients E217G was the major labeled con¬
jugate in the urine within 3 hr, accompanied by
small amounts of E23S17G. Major amounts of
E23S17G appeared in the bile unaccompanied by
E217G. An unidentified conjugate, probably a sul-
foglucosiduronate, also appeared in variable
amounts in the bile. Beyond 3-6 hr the T-tube
patients excreted variable amounts of Ej3G and
E23G in the urine, these probably arising from
biliary E23S17G which had bypassed the collec¬
tion tube, and/or from precursors transported
into the intestine via the succus entericus. Ad¬
ministration of 3H-E23S17G directly into the du¬
odenum of a normal female was followed by
negligible urinary excretion of 3H up to 6 hr. After
that time the urinary metabolite pattern was sim¬
ilar to that seen after 6 hr following iv 3H-E217G
into normal women. Thus the metabolism of E217G
to urinary E]3G and E23G appears to occur in the
intestine from biliary E23S17G via deconjugation
and partial conversion of E2 to Ex before or after
reconjugation with endogenous glucuronyl groups
at C-3. About 7% of the dose was excreted in the
bile when labeled EX3G was injected iv into a
woman with biliary drainage via T-tube. (J Clin
Endocrinol Metab 35: 448, 1972)
Communications from this labora¬tory regarding the metabolism of iv ad¬
ministered labeled 17|3-estradiol-17-glucosi-
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duronate (e217g)4 by the human have
already been published (1,2). Although these
4 The following trivial names and abbreviations
for steroids and their conjugates have been used in
the text: 17P-estradiol-17-glucosiduronate (E217G)




= 17P-hydroxyestra-l ,3,5 (10)-trien-3-yl-P-D-gluco-
pyranosiduronate; 17P-estradiol-3-sulfate-17-gluco-







glucosiduronate (E316G) = 3,17P-dihydroxyestra-l,
3,5 (10) -trien-16a-yl-p-D-glucopyranosiduronate; 2-
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studies showed conclusively that E217G is
metabolized, mainly to urinary estrone-3-
glucosiduronate (EX3G) and 17(3-estradiol-
3-glucosiduronate (E23G), together with
small amounts of 17[3-estradiol-3-sulfate-17-
glucosiduronate (E23S17G), the sequence of
formation of the metabolites, and hence the
metabolic pathways involved, was not estab¬
lished. E217G was found in the labeled form
in the urine, probably representing un¬
changed injected material. Since only minor
amounts of urinary conjugates other than
those of 17(3-estradiol (E2) and estrone
(Ex) were identified in these experiments it
was concluded that metabolism did not pro¬
ceed via free E2 (at least not via liberation
of E2 into the main body pool) but rather,
perhaps through some conjugated interme¬
diate. In order to elucidate these matters in
the present work, 3H-E217G has been in¬
jected iv into normal female volunteers, into
female volunteers draining bile via T-tube,
and 3H-E23S17G has also been instilled into
the duodenum of one normal female volun¬
teer. In addition, in order to enquire further
into the excretion of monoglucosiduronates
in the bile, estrone-6,7-3H-3-glucosiduronate-
14C (3H-Ei3G-14C) was injected intrave¬
nously into one female volunteer draining
bile via a T-tube. Urinary and biliary metab¬
olites were studied at various time intervals.
An abstract of part of this work has ap¬
peared (3).
Materials and Methods
General. All chemicals and other reagents, in¬
cluding organic solvents, unlabeled steroids,
enzymes and chromatographic materials, were
methoxyestrone (2-MeOEx) = 2,3-dihydroxestra-l,
3,5(10)-trien-17-one-2-methyl ether; 16-epiestriol
(16-epiEg) = estra-1,3,5 (10)-trien-3,16(3,17P-triol;
ring Da-ketols = 3,16<x-dihydroxyestra-l,3,5(10)-
trien-17-one + 3,16|3-dihydroxyestra-l,3,5(10)-trien-
17-one + 3,17P-dihydroxyestra-l,3,5(10)-trien-16-
one; 2-methoxyestradiol-17|3 = estra-1,3,5(10)-trien-
2,3,17-triol-2-methyl ether; 17a-estradiol = estra-1,
3,5(10)-trien-3,17a-diol; dihydroequilin = estra-1,3,
5(10), 7(8)-tetraen-3,17P-diol; dihydroequilenin =
estra-1,3,5(10), 6,8(9)-pentaen-3,17P-diol.
obtained, purified when necessary, and used, a
described in previous publications (4-7).
Labeled steroid conjugates. 3H-E217G of SA =
2.2 [iCi/ug was purchased from New Englan
Nuclear Corp., Boston, Mass. (NENC) and wa
purified by published methods (1,4). E2-4-14C
17G (14C-E217G) was synthesized by NEN<
(7) while Ei-4-14C-3G (14C-EX3G), E2-4-14C-3<
(14C-E23G), Ej.-4-14C-3-sulfate (14C-EX3S) an
E2-4-14C-3-sulfate (14C-E23S) were prepared i
our laboratory (5). These latter 5 conjugate
were employed as internal standards at variou
points in the experimental procedures. 3H
E23S17G was prepared by incubating 3H-E217(
with a 105,000 X g supernatant from femal
guinea pig liver in the presence of ATP, MgSO
and KC1 (5). ®H-Ei3G-14C (glucuronic aci
generally labeled) was prepared as already de
scribed (8) by mixing appropriate quantities o
E!-6,7-3H-3G (3H-Ei3G)—prepared by incu
bating guinea pig liver homogenate with 3H-E
(NENC, SA = 10 uCi/ug) and unlabeled uri
dine diphosphate glucuronic acid (UDPGA)—
with E!-3G-14C prepared by a similar incuba
tion involving unlabeled Ex and UDPGA-14<
(NENC, SA r= 212 [iCi/ug). After purificatio:
(8) the 3H-Ei3G-14C had a 3H/14C ratio of 5.7
Administration of labeled conjugates; collectio,
of bile and urine. Prior to administration eac'
compound was filtered through Swinnex-13 fil
ters of pore size 22 p (Millipore Corp., Bedforc
Mass.).
3H-E217G was injected in a single dose int
an arm vein of each of three normal females a
about day 10 of the menstrual cycle, as de
scribed previously (6). Subject JJ, aged 34 yi
received 12.9 X 108 dpm; subject EN, 27 yi
received 54.9 X 10° dpm; subject TL, 25 yi
received 41.9 X 10® dpm of 3H. Urine collec
tions were made from JJ at 0-6, 6-12, 12-24
24-48 and 48-72 hr; from EN at similar time
except that 0-6 hr was divided into 0-3 am
3-6 hr; from TL at 0-2, 2-4, 4-6, 6-12, am
12-24 hr.
3H-E217G was injected as above into thre
females who had undergone cholecystectomy fo
gallstones about 7 days previously and who wer
draining bile via T-tube. At the time of injec
tion all liver function tests were in the norma
range. Bile was collected from each subject ove
0-3, 3-6 and 6-24 hr while urine was collectei
I
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over 0-3, 3-6, 6-12 and 12-24 hr. Each sub¬
ject, MT-31 yr, SA-36 yr and LM-31 yr, re¬
ceived 48 X 10° dpm of 3H.
3H-E23S17G (42.7 X 10° dpm) was instilled
in 10% (v/v) ethanol-HoO followed by H20
washings, into the second portion of the duode¬
num (confirmed by X-ray) of normal female JL
(25 yr). Urine was collected over 0-3, 3-6, 6-
12, 12-24, 24-48, 48-72, and 72-96 hr.
3H-E!3G-14C (12.6 X 10° dpm 3H, 2.21 X
10° dpm 14C) was injected iv, as above, in a
single dose, into an arm vein of female subject
MM (25 yr) who was draining bile via T-tube,
having undergone cholecystectomy for gallstones
7 days previously. All liver function tests were
normal. Bile and urine were collected over 0-3,
3-6, 6-12 and 12-24 hr.
All urine and bile samples were frozen (—15
C) until analyzed.
Analysis of urinary metabolites. The methodol¬
ogy has already been described in some detail
(2,4,7,8). Urine was chromatographed on Am-
berlite XAD-2 resin (9) and the conjugates
eluted were further chromatographed on DEAE-
Sephadex in linear concentration gradients of
NaCl (0-0.8m and 0-0.4m; ref. 4). Further
purification was achieved by Celite partition
chromatography (CPC) in iso-octane: t-buta-
nol: mNH4OH (2:5:5, refs. 5, 10) and/or n-
butanol:ethyl acetate: 0.2% NH4OH (3:1:4,
ref. 11). Radioactive peaks corresponding to
E43G and E23G were incubated with Ketodase
(^-glucuronidase) in the presence and absence
of inhibitor saccharo-l,4-lactone (7) and the
aglycones identified by a combination of Girard
separation and CPC (12) then finally by crys¬
tallization to constant SA with appropriate car¬
rier steroids before and after acetylation (6).
rn some instances Ei3G peaks were reduced
with NaBH4 (8) prior to enzyme hydrolysis and
the aglycone was identified as E2 by the above
methods. On occasion 3H-labeled E43G and
E23G fractions were rechromatographed in ad¬
mixture with 14C-E43G and 14C-E23G. Labeled
peaks corresponding to E217G were identified by
methylation, hydrolysis and crystallization with
:arrier 17|3-estradiol-3-methyl ether (E23MeE)
oefore and after acetylation (2,7). Aliquots of
radioactive peaks corresponding to E23S17G
were incubated separately with Mylase P (to re¬
move the 3-sulfate group; refs. 2,5) and (3-glu-
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curonidase (to remove the 17-glucuronyl group;
refs. 2,3) and the products, E217G and E23S
respectively, were chromatographed on DEAE-
Sephadex and/or processed by CPC in admixture
with 14C-E217G and 14C-E23S. Each was then
further identified by hydrolysis (Mylase P in¬
cubation of E23S; ^-glucuronidase incubation
of E217G before or after methylation; refs. 2,5)
followed by crystallization of the steroid moiety
as above. Conjugates of steroids other than E4
and E2, e.g. estriol (E3), 2-methoxyestrone (2-
MeOEi) and 16-epiestriol (16-epiE3), were
sought, through a combination of Girard separa¬
tion and CPC (6) and in some cases by crystal¬
lization.
Analysis of biliary metabolites. Total biliary ra¬
dioactivity was measured in 0.1 ml volumes of
bile in a dioxane-based liquid scintillation me¬
dium (6) or, later in the study, in a xylene-
based medium (Aquasol, NENC, ref. 7). Initial
attempts to recover biliary conjugates by pass¬
ing diluted bile (1:5 with H20) through XAD-2
resin were generally not satisfactory. Small vol¬
umes of bile (up to 15 ml) could, however, be
directly chromatographed on DEAE-Sephadex
in a linear concentration gradient (0-0.8m) of
NaCl (4,5). Although such columns ran very
slowly the eluted conjugates were well separated
from the main pigments and could subsequently
be rechromatographed on DEAE-Sephadex or
by CPC with some ease. Identification of biliary
conjugates was attempted in the general fashion
described for urinary conjugates (2,4-8).
All of the radioactive counting was performed
using a Nuclear Chicago liquid scintillation spec¬
trometer (Model 6725) and in a manner previ¬
ously described (6-8).
Results
Urinary metabolites of iv SH-E217G in nor¬
mal subjects. As shown in Table 1 a sizable
amount of 3H was excreted, apparently
within 2 or 3 hr followed by a lag period, up
to between 4 and 6 hr during which very
little isotope was excreted. After about 6 hr
the excretion recommenced and continued
up to at least 72 hr. In the three subjects
62-70% of the dose was excreted in 24 hr
while more than 80% was excreted in 72 hr
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Table 1. Urinary excretion of radioactivity (%








0-2 20 (0-3)* 43
2—4 28 (0-6)* 3.4
4-6 1.6 (3-6)* 1.5
6-12 20 20 10
12-24 22 20 10
24-48 10 15 **
48-72 7.5 5.6 **
Total 88 82 68 (24 hr)




EL3°i—,= —o - — — — — — -T-——C
E217G -~S
TIME (HOURS)
Fig. 1. Cumulative urinary excretion of total 3H
and sH-labeled metabolites after iv injection of 3H-
E217G into subject EN.
by the two subjects from whom urine was
collected for that length of time.
Within 2 hr (TL) and 3 hr (EN) about
95% of the urinary 3H was identified as
E217G, presumably unchanged injected ma¬
terial, the remainder being E23S17G. At
some point beyond 2 hr and within 6 hr the
latter two compounds declined and virtually
disappeared while Ej3G and E23G appeared
and exhibited a cumulative increase with
time. The 0-6 hr urine from JJ contained
mainly E217G and small amounts of E23S17G
but also the early portion of E^G and E23G.
In JJ and EN no E217G or E23S17G was
detected beyond 6 hr. In TL 1% of the dose
appeared in the urine as E217G in 6-12 and
12-24 hr, while E23S17G (no more than
0.3% of the dose) was found in each of these
time intervals. Fig. 1 shows the cumulative
excretion pattern of metabolites for subject
EN while Table 2 contains cumulative totals
for the identified E, and E2 conjugates in
the three subjects. The widely varying ex¬
cretion of 3H-E217G (17-48% dose) should
be noted as should the constant ratio E^G:
E23G of 2.3, 2.4 and 2.2 in JJ, EN and TL,
respectively. Beyond 12 hr following injec¬
tion additional 3H-glucosiduronates (e.g.
E3 and 16-epiE3) were detected in very
small amounts. In these experiments the
urinary 3H was almost completely identified
as conjugates of E! and E2. Losses during
purification were typical of normal method¬
ology and were reflected in small losses of
"C-E^G and 14C-E23G added as internal
standards.
3H in urine and bile after iv 3H-E217G in
subjects with T-tube drainage. A variable
percentage of the dose appeared in bile and
urine (Table 3). Total recoveries in MT,
SA and LM were 99, 86 and 87%, respec¬
tively. Biliary recovery was 28-65% and
urinary recovery was 21-59%.
Urinary metabolites of iv 3H-E217G in T-
tube subjects. Over 0-3 hr 78-95% of uri¬
nary 3H was identified as E217G and the
Table 2. Cumulative total urinary metabolites (%
dose) of iv injected 3H-E217G into normal women
Subjects
Metab¬ JJ* EN* XL**
olites (up to 72 hr) (up to 72 hr) (up to 24 hr)
Ej3G 42 45 11
E23G 18 19 5
E217G 24 17 48
E,3S17G 1.3 1 3
Total 85 82 67
* Very small amounts of additional glucosiduro-
nates were detected by CPC: e.g., 16-epiE3, E3;
2-MeOEi, particularly after 24 hr.
** E3 glucosiduronate (0.2% dose) was identified
by crystallization of the aglycone in 12-24 hr. 16-
EpiE3 glucosiduronate (0.1% dose) was detected bj
CPC in the same time period.
I
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Table 3. Excretion of 3H (% dose) in urine and
bile after iv injection of 3H-E217G into 3 females





(hr) Urine Bile Urine Bile Urine Bile
0-3 30 40 15 48 19 11







12-24 12 3 4
Total 50 49 21 65 59 28
* 6-24-hr collection.
remainder as E23S17G in the three subjects.
Between 3 and 6 hr the small amount of SH
(2% dose in urine) in MT and SA consisted
of Ex3G and E23G, together with minute
amounts of E,3S17G in MT, and residual
E,17G and E23S17G together with traces of
an unknown sulfoglucosiduronate conjugate
termed, for present purposes, E-SG (see be¬
low for bilary conjugates), in SA. The larger
fraction of the dose (18%) excreted in 3-6
hr by LM consisted mainly of Ej3G and
E23G with smaller amounts of E217G and
traces of E23S17G. Between 6 and 24 hr
after injection virtually all the urinary 3H
in MT was E%G and E23G, while very small
amounts of E3 and possibly ring Da-ketols
were detected at 12-24 hr in this subject
after P-glucuronidase hydrolysis. A similar
predominance of Ej3G and E23G occurred
over the same period in SA and LM. In both
the latter subjects E-SG was detected and
in MT small but definite amounts of E217G
and E23S17G persisted up to 12-24 hr. Fig.
2 shows the cumulative excretion pattern of
the urinary metabolites for subject MT.
Table 4 contains cumulative totals for the
metabolites at 24 hr in the three experi¬
ments. Ei3G and E23G together were highly
variable, accounting for 35, 18 and 2.4% of
the 3H-E217G dose in LM, MT and SA, re¬
spectively.
Biliary metabolites of iv 3H-E217G. Fig. 3
(subject MT) is qualitatively representative
TIME (HOURS)
Fig. 2. Cumulative excretion of labeled metabolites
of iv injected 3H-E217G in the urine and bile of
subject MT. RD-G = "ring Da-ketols" detected by
CPC after ^-glucuronidase hydrolysis.
of the DEAE-Sephadex patterns (0-0.8m
NaCl) obtained for 0-3 hr bile samples of
the three subjects. The 3-6 and 6-24 hr
samples also appeared to be substantially in
this form. In addition, the 6-24 hr sample
from MT contained a monoglucosiduronate
of an unidentified aglycone (1.5% of the
dose and termed here E-G), while the 0-3
hr sample from SA contained a monosulfate
(1.6% of the dose, termed here E-S). The
Table 4. Total cumulative excretion at 24 hr (%
dose) in urine and bile of 3H-metabolites after iv








Urine Bile Urine Bile
ex3g 14 — 2.2 — 28 —
e,3g 3.5 — 0.2 — 7 —
e217g 23 — 17 — 18 —
eo3s17g 7 40 1 29 1.7 14
e-sg — 7.4 0.5 34 0.7 7
e-g — 1.5 — — — —




Total 49 49 21 65 55 21
* Small amounts of 16-epi3 and 2-MeOE! were de¬
tected by CPC after P-glucuronidase hydrolysis.
** Detected by CPC after P-glucuronidase hydro¬
lysis.
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second labeled peak in Fig. 3 was identified
as E23S17G in all cases. The first labeled
peak (Fig. 3) behaved on hydrolysis as a
sulfoglucosiduronate conjugate but the "ste¬
roidal moiety" has thus far escaped identifi¬
cation. It is termed E-SG in this paper since
E is possibly the "steroid" present in E-G
and E-S, above. Biliary E-SG was 7, 34 and
7% of the dose in MT, SA and LM, respec¬
tively, whereas the corresponding values for
E23S17G were 40, 29 and 14%. Cumulative
patterns of biliary metabolites are shown for
MT in Fig. 2 and cumulative totals, at 24
hr, are shown for the three subjects in Table
4.
Attempts to identify E-SG. Incubation with
phenolsulfatase (Mylase P) yielded a 3H-
labeled compound (ether-insoluble) which
on DEAE-Sephadex (0-0.8m NaCl) ap¬
peared in fractions 24-32 whereas simulta¬
neously chromatographed 14C-E217G was
eluted in fractions 28-35. P-Glucuronidase
treatment of E-SG gave an ether-insoluble
product which was eluted in the above sys¬
tem in fractions 49-58, while "C-E^S and
14C-E23S appeared in fractions 57-62 and
63-70, respectively. Complete hydrolysis of
E-SG to a non-ketonic ether-extractable
form was achieved by sequential incubation
with the above two enzyme preparations.
CPC of this 3H- "steroid" in benzene: hex-
Fig. 3. DEAE-Sephadex (0-0.8m NaCl) chromato¬
graphic pattern of biliary metabolites (0-3 hr) of iv
injected 3H-E217G in subject MT.
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Table S. Urinary excretion of 3H after intraduo-
denal administration of SH-E23S17G to normal
female JL











in elution of the label in fractions 5-9.
3H-17a-estradiol5 was eluted in fractions 9-
12 and 14C-E, in 10-14. Thin-layer chroma¬
tography of "E" in ethyl acetate: cyclohex-
ane (1:1, ref. 13) suggested a similarity to
dihydroequilin or dihydroequilenin. How¬
ever, crystallization with the unlabeled
forms of these6 and with a number of other
carriers, including 2-methoxyestradiol-17P,
did not result in the achievement of radio¬
chemical homogeneity.
Urinary metabolites of intraduodenal 3H-
E23S17G. The 3H excretion pattern is shown
in Table 5. A very minute amount of label
appearing in 0-3 hr was tentatively identi¬
fied as E23S17G by enzymatic hydrolysis
and CPC. Beyond 6 hr the increased excre¬
tion was largely accounted for as labeled
E^G and E23G with smaller quantities of
E3, 16-epiE3 and 2-MeOE! which were re¬
leased by P-glucuronidase and crystallized
with carriers. Fig. 4 shows the cumulative
excretion pattern of the various metabolites.
Cumulative totals at 72 hr (% dose) were;
Ea3G = 44, E23G = 14.4, E3G = 2.4, 16-
epiE3G = 1.3, 2-MeOEjG =1.3 and "ring
Da-ketols G" = 3.1, total = 67%. The
5 Kindly donated by Dr. D. S. Layne, Dept. of
Biochemistry, Faculty of Medicine, University of
Ottawa, Ottawa, Ont., Canada.















riG. 4. Cumulative urinary excretion of labeled
netabolites of intraduodenally-instilled 3H-E23S17G
n subject JL. RD-G = "ring Da-ketols" detected
iy CPC after fi-glucuronidase hydrolysis. See text
or metabolite excreted over 0-3 hr.
'ring Da-ketols" were detected by CPC
inly.
Jrinary and biliary metabolites of iv "H-
3G-14C. The excretion pattern of the labels
s shown in Fig. 5. A small though measur-
ible amount of radioactivity appeared in the
)ile while major excretion was evident via
he urine. The metabolite patterns in bile
md urine, with isotope ratios, are shown in
rable 6 for the first 6 hr of this experiment,








'ig. 5. Cumulative excretion of 3H and 14C in
rine and bile of subject MM following iv injection
f 3H-E!3G-14C (3H/14C = S.7). Inscribed numbers
efer to 3H/14C ratios at the various times.
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Table 6. Labeled urinary and biliary metabolites
excreted within 6 hr of an iv injection of 3H-Ej3G-
14C (3H/14C = S.7) into normal female MM
Urine Bile
Metabolites 0-3 hr 3-6 hr 0-3 hr 3 -6 hr
Ej3G (% 3H dose) 59 4 4 2
Ej3G (3H/14C) 5.7 6.7 5.7 9.4
Eo3G (% 3H dose) 6 1.2 1.7 *
Eo3G (3H/14C) 5.7 9.3 5.7 oo
* Negligible radioactivity.
changed 3H/14C ratio (compared with that
injected) in both bile and urine within 3 hr
of injection should be noted.
Discussion
Since E217G is now known to be a me¬
tabolite of iv injected E2 (7) the present in¬
vestigation represents a study on a natu¬
rally-occurring compound. In the normal
subject the relative amounts of urinary
E217G, Ei3G and E23G formed from labeled
E217G are highly dependent upon the vari¬
able fraction of the latter excreted un¬
changed. A constant infusion of the pre¬
cursor, rather than a single injection, might
have resulted in a different overall quanti¬
tative pattern of metabolites (14,15) and
would have mirrored, in a more physiolog¬
ical fashion, the fate of conjugate continu¬
ously delivered to the tissues of metabolism.
The present study presents a more qualita¬
tive picture.
The lag in excretion of the label by the
normal subjects at about 2-6 hr following
intravenous E217G is obviously due to the
delivery of conjugate(s) via the bile to the
intestine, largely in the form of E23S17G.
This lag, and the subsequent production of
the main metabolites (Ej3G and E23G)
after about 6 hr is in agreement with the
present data for the metabolism of intra-
duodenally administered 3H-E23S17G and
also with earlier work (16) on orally admin¬
istered 3H-E217G and 3H-E13G-14C. In the
latter study the substrates underwent effi¬
cient deconjugation, then reconjugation with









endogenous glucuronyl groups, at the C-3
position only, of E2 and E^ Thus it would
appear that E23S17G undergoes a similar
fate, with partial conversion of released E2
to Ex prior to or after reconjugation with
glucuronic acid at C-3. It seems likely that
the reconjugation occurs mainly at the intes¬
tinal level since considerable absorption of
E2 (or Ej) in the free, or sulfate form would
presumably result in formation of major
amounts of more highly oxygenated metab¬
olites known to be formed from the free ste¬
roids (17). The small amounts of these more
polar metabolites (e.g. E3) found in the
urine following intravenous E217G or intra-
duodenal E23S17G in the present study
could presumably have arisen from precur¬
sors (Ei and/or E2) absorbed from the in¬
testine in the free or sulfate forms. Note
also that direct 16-hydroxylation of Ei3G
has been observed in the human fetoplacen¬
tal unit (18). The details of the conversion
E23S17G -» E23G + Ei3G without the pro¬
duction of major quantities of additional
conjugated phenolic steroids is not clear at
present but a possible intermediate, specu¬
lated upon elsewhere (2), namely, E2-3, 17-
diglucosiduronate, was not detected in this
study. It should be noted that a small degree
of intestinal absorption of unaltered E23S-
17G may possibly occur based on the pres¬
ence of a trace of it in the urine following its
administration into the duodenum.
The presence of very variable amounts of
labeled EX3G and E23G in the urine of the
T-tube subjects at and beyond 3-6 hr fol¬
lowing intravenous 3H-E217G could be due
to escape of bile resulting in delivery of
some E23S17G to the intestine.7 Alterna¬
7 Bile volumes were not sufficiently different be¬
tween the 3 subjects to indicate widely varying
diversion of bile into the duodenum. This could, of
course, relate to a variability of total biliary flow
between individuals. In MT and SA cholangiograms
were performed 20 hr prior to the above experiments
and in LM a similar procedure was carried out 3 hr
after completion of the experiment. Unimpeded flow
of bile was observed in all 3 cases, thus all were
tively, or in part, these metabolites coul
also arise from precursors transported int
the intestine via the succus entericus, i.t
the enteric circulation of Inoue et al. (19j
This latter possibility, however, would b
unlikely to account for the rather considei
able amounts of Ej3G and E23G observed i
certain of the subjects.
The metabolism of E217G bears a resen
blance to that of E3-16-glucosiduronat
(E316G) in the human and some compai
ison may be made here. The main biliar
metabolite of this conjugate, and of E3 itsel
is E3-3-sulfate-16-glucosiduronate (E33f
16G; refs. 11,15,20). Only small amounl
of the latter appear in the urine since it i
largely metabolized via deconjugation in tb
intestine followed by reconjugation as mont
glucosiduronates in the intestine and/c
liver (21). Both 16- and 3-monoglucosidi
ronates of E3 are formed in the intestine (11
15,22) and the 16- conjugate is also forme
in the human liver (11,23). The present r<
suits support the concept of intestinal foi
mation of EX3G and E23G from intravenor
E217G via biliary E23S17G. In additio
E23G is the sole urinary E2 glucosiduronal
formed from oral E2 (7) and it can also a\
parently be synthesized from free E2 at e;
tra-enteric sites (7) and from the same pri
cursor by human liver in vitro (24). Mori
over, urinary E217G is not an enteric mi
tabolite of E2(7) or of E217G or Et3G (16
in the human, but is formed, possibly intr;
hepatically, from intravenous E2 (7).
The apparent absence of E217G from tl
bile is of interest and it could be argued tha
due to efficient sulfurylation at C-3 little <
no unchanged monoglucosiduronate remaii
to be excreted by this route. However, tl
capable of passing bile into the duodenum at tl
above times. Therefore the results obtained in tl
study seem to be compatible with highly variat
diversion of bile, and the most likely scheme
metabolism for E217G would be that presented
Fig. 6. The possibility of an extra-enteric deconjug
tion must also remain as an additional, or alternate,
pathway.
1
56 MUSEY, GREEN AND HOBKIRK JCE&M • 1972Vol 3S • No 3
E217G(i.v.)
E23S17G 1 .
^|E2^E,|^EI3G+E23G17G(OWAL)—AE217G J~ I———I Ei3G
E-SG -*-» ? E23G
SMALL INTESTINE
ig. 6. Suggested scheme of metabolism for E217G
i the human female. Arrow thickness approximates
le quantitative importance of each step.
mount of unchanged E217G available for
rinary excretion might suggest this to be
rvalid. Again, it must be remembered that,
ad infusion rather than single injection
een carried out, the pattern of biliary me-
ibolites might have differed. Even so, a
mall but definite amount of intravenous
h3G (together with its metabolite, E,3G)
ppeared in the bile of the one subject shad¬
ed. A recent claim has been made8 that even
ae latter conjugate is excluded from the
ile.
As suggested in an earlier publication (7),
ae urinary excretion pattern of E2 and Ex
lonoglucosiduronates following intravenous
H-Eo appears to agree with the present re-
ults. Excretion of E,17G within 2 hr of E2
ljection is complete whereas Ej3G and
7>3G production continues up to at least
4 hr. The two latter compounds, in all prob-
bility, have their origin, at least partly, in
iliary E23S17G. A suggested scheme for
ae metabolism of E217G, based on the pres-
iit, and earlier studies from our laboratory
8,16), as well as upon those of others for
ae metabolism of E3 and its conjugates (11,
5,19,21), is shown in Fig. 6. It assumes a
major role for liver and intestine in the pro¬
cess but confers upon the kidney only an
excretory function.9
The occurrence of the unidentified con¬
jugate E-SG in the bile complicates the
above picture. Its routes of formation and
excretion are not known. Based on the
almost complete identification of urinary
radioactivity as known metabolites, par¬
ticularly in the normal subjects, it does not
seem likely that important amounts of it,
or its metabolites are excreted in the urine.
Excretion in the feces would appear pos¬
sible although no firm data are available.
Although E-SG may be on occasion a major
biliary metabolite of intravenous E217G it
may not be so with respect to secreted E2
since E217G (as judged by urinary studies)
is not a major metabolite of the secreted
hormone when compared with the amounts
of 2- and 16-hydroxy steroids formed from
the latter.
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ABSTRACT. 17/3-Estradiol-6,7-3H-3-glucoside-
l4C (uniformly labeled) was prepared and in¬
jected intravenously into 2 normal young women.
Within about 2 hr 20% of the dose was excreted in
the urine of each subject in the form of estrogen
glucoside with a substantially unchanged 3H/I4C
ratio. Approximately 11 % of the latterwas identi¬
fied as estrone-3-glucoside, the remainder being
the compound injected. 3H-labeled estrogen
glucosiduronates and, to a smaller extent, 3H-
estrogen sulfates, were also excreted during the
first 2 hr and these metabolites continued to ap¬
pear in the urine, unaccompanied by 14C, uptc
and including the fourth day after injection. Re¬
covery of 3H in the urine (including that associatec
with the urinary glucosides) was 60 and 81% ir
the 2 subjects. The steroid pattern identified ir
the urinary 3H-glueosiduronate fraction indi
cated that the major part of the injected 1.7/3-
estradiol-3-glucoside had been hydrolyzed, anc
that the 17/3-estradiol released was metabolized
in a manner similar to that of intravenously in¬
jected 17/3-estradiol. (J Clin Endocr 32:476,1971:
STEROID conjugation with glucose hasnot thus far been reported in th u¬
man. An estrogen glucoside has, however,
been isolated from rabbit urine (1), while
others have been made by rabbit tissue in
vitro (2). An investigation of the metab¬
olism of 17a-estradiol-3-glucoside:i has also
been reported for this species (3). In view
of the fact that the metabolism of 17/3-
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3 The following trivial names for steroids and
their conjugates are employed in the text: 17a-
estradiol-3-glucoside = 17a-hydroxyestra-l,3,5 (10)-
trien-3-yl-/3-d-glucopyranoside; 17 /3-estradiol-3-glu-
coside = 17/3-hydroxyestra-l,3,5(10)-trien-3-yl-/3-d-







/3-D-glucopyranosiduronate; 2-methoxyestrone = 2-
methoxy-3-hydroxyestra-l,3,5(10)-trien-17-one; 16-
epiestriol = estra-l,3,5(10)-triene-3,16/3,17/3-triol; ring
da-ketols =3,16a-dihydroxyestra-l,3,5(10)-trien-17-
one -+-3,17/3-dihydroxyestra-1,3,5 (10) -trien-16-one
+3,16/3-dihydroxyestra-l,3,5(10)-trien-17-one.
estradiol-3-glucosiduronate has been in¬
vestigated in some detail in the human (4), i1
was considered worthwhile to study the
metabolism of 17/3-estradiol-3-glucoside un¬
der similar conditions. The study reported
here concerns the urinary metabolites oi
intravenously administered 17/3-estradiol-




was prepared essentially as described elsewhere
(4). Estrone-3-glucosiduronate-14C was synthe¬
sized by incubating 0.13 pinole of unlabeled
estrone and 50 pCi of uridine diphosphate glu¬
curonic acid-14C (uniformly labeled) of specific
activity (SA) 0.173 Ci/mmole (New England
Nuclear Corp., Boston, Mass.) with a guinea
pig liver homogenate at pH 7.4. A 14C-labeled
peak corresponding to estrone-3-glucosiduro-
nate was recovered following DEAE-Sephadex
chromatography in 0-0.8m NaCl (4,5) and this
was mixed with suitably purified estrone-6,7-
3H-3-glucosiduronate (New England Nucleai
Corp., SA =1 Ci/mmole) to yield a 3H/14C ratic
of about 6. The mixed material was further
purified by DEAE-Sephadex chromatography
(0-0.4m NaCl) (5) and by Celite partition chro¬
matography in isooctane :t-butanol :m NH |OH
(2 :5 :5, ref. 4, 7) prior to reduction with NaBH,
(4). Thel7/3-estradiol-6,7-3H-3-glucosiduronate-
14C thus obtained (3H/14C =5.9) was rechroma-
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tographed on DEAE-Sephadex and Celite as
above. Hydrolysis with /3-glucuronidase con¬
firmed the presence of 3H-17|3-estradiol, which
was identified by crystallization with carrier
steroid followed by derivative formation and
recrystallization.
17f}-Estradiol-6,7-3H-3-glucoside-uC. This com¬
pound was prepared by NaBH4 reduction of the
methylester of the 17/3-estradiol-6,7-3H-3-gluco-
siduronate-14C described above. The procedure
followed was exactly as described by Collins
et al. (2) for the preparation of 17a-estradiol-
6,7-3H-3-glucoside-14C, except that the amounts
of the various reagents employed were reduced
to one tenth of those used by these authors. The
ratio of 3H to 14C in the 17/3-estradiol-6,7-3H-
3-glucoside-14C after purification was 5.88.
Reagents, etc. All organic solvents and materials
for chromatography were obtained, and puri¬
fied where necessary, as described elsewhere (8).
Ketodase (beef liver /^-glucuronidase) was pur¬
chased from Warner-Chilcott, Morris Plains,
N. J., and was used for hydrolysis in concentra¬
tions of 250-500 U/ml at pH 5 and 38 C for
times of 20-96 hr. Saccharo-l,4-lactone was
purchased from Calbiochem. Ltd., Los Angeles,
Cal. Unlabeled steroids were purchased from
Mann Research Laboratories, Inc., New York,
N. Y. Almond emulsin /3-glucosidase and
glucono-l,5-lactone were obtained from Sigma
Chemical Company, St. Louis, Mo.
Injection of 17fl-estradiol-6,7-3H-3-glucoside-uC.
Prior to injection the labeled material was
filtered through Swinnex-13 filters of pore size
22 p (Millipore Corp., Bedford, Mass.). Injec¬
tion (10.6 pCi 3H, 1.8 pCi 14C) was performed in
10 ml of 10% (v/v) ethanol-saline (8) into an
arm vein of each of 2 normal 21-yr-old females,
MYL and BER, at about day 10 of the cycle.
Urine was collected at intervals up to 96 hr (see
Results) and frozen until required for analysis.
Analysis of urinary metabolites. Urines from
subject MYL over 0-6, 6-24 and 24 48 hr were
processed on Amberlite XAD-2 resin (9) fol¬
lowed by DEAE-Sephadex chromatography
(0-0.8m NaCl, ref. 6). An eluted peak of radio¬
activity corresponding to a glucoside conjugate
was rechromatographed on Sephadex G25 in
H20 (10) and then on DEAE-Sephadex in H/3
(6). An aliquot of the labeledmaterial recovered
was subjected to thin layer chromatography on
silica gel H (Merck) in chloroform-ethanol 4:1
and in chloroform-isopropanol-formic acid,
5:3:1. A further aliquot was hydrolyzed with
/3-glucosidase for 20 hr at 37 C in 0.1m sodium
citrate buffer at pH 4.3 (11). This hydrolysis
was carried out with and without the presence
of glucono-l,5-lactone. The benzene extractable
radioactive material obtained by hydrolysis
was chromatographed on thin layer plates in
benzene-ethyl acetate 7:3.
Peaks from the initial DEAE-Sephadex
columns (0-0.8m NaCl), behaving like gluco-
siduronates, were incubated with Ketodase
with and without the addition of saccharolac-
tone. The steroids released were subjected to
investigation by Celite partition chromatogra¬
phy following Girard separation (8).
Glucoside-like peaks from subject BER over
0-2 and 2-4 hr were isolated by DEAE-
Sephadex chromatography and analyzed as
above, as were glucosiduronate-like peaks from
the same time intervals. Urine over 4-48 hr was
pooled, incubated with Ketodase, and the ste¬
roids released identified as above. All radio¬
active counting was performed as described
elsewhere (8).
Results
Table 1 shows the urinary excretion of
radioactivity by each subject. In MYL no
14C could be detected beyond 0 6 hr. In
BER very little 14C was seen beyond 0-2
hr. The recovery of 3H was considerably
greater in BER (81%) than in MYL (60%).
The 0-6 hr urine from MYL yielded,
on XAD-2 resin chromatography, 7.18 X
106 dpm 3H and 0.786 XlO6 dpm 14C (8H/
14C =9.1). At least 90% of this radioactivity
was accounted for following DEAE-Seph¬
adex chromatography (0-0.8m NaCl, col¬
lecting 10 ml fractions) which yielded two
main broad peaks: peak 1, fractions 5-20
containing 3.94 XlO6 dpm 3H and 0.65 XlO6
dpm 14C (3H/14C =6.1), and peak 2, frac¬
tions 25-40 containing 2.22 X 106 dpm 3H
and no 14C. Some further 3H was associated
with the sulfate conjugate fraction but this
was not processed. Peak 1 was eluted from
Sephadex G25, yielding 3.74 XlO6 dpm 3H
and 0.595 XlO6 dpm 14C (3H/l4C =6.2) in a
single peak, and then from DEAE-Sephadex
in H>0 to give 3.4X10° dpm 3H and
0.573 XlO6 dpm 14C (3H/14C =5.9) also in a
single peak. These steps removed consider¬
able amounts of urinary pigments from the
fraction. Analysis of this fraction by thin
layer chromatography indicated that the
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Table 1. Excretion of 3H and 14C in the urine (% dose) following injection of 17/3-estradiol-
6,7-3H-3-glucoside-14C into MYL and BER
MYL BER
Time 3H HC Time 3H 14C
(hr) (% dose) (hr) (% dose)
0-2** 25.8 20.2
0-6* 33 19 2-4 5.7 <0.05
4-6 4.2 t
6-12 12.5 *
6-24 10.6 t 12-24 13.6 t
24-48 12.3 t 24-48 12.5 t
48-72 2.2 t 48-72 5.4 t
72-96 1.4 t 72-96 1.7 t
Total 60 19 Total 81 20
* Urinary 3H/14C ratio = 10.3.
** Urinary 3H/14C ratio =7.2.
t No 14C detected.
radioactivity was still in the form of gluco-
side. This was confirmed by almost com¬
plete hydrolysis of the material by almond
emulsin and 90% inhibition of this hy¬
drolysis by gluconolactone. The benzene
extractablematerial obtained on hydrolysis
contained 3H but no 14C. Thin layer
chromatography indicated that 11% of
thismaterial was estrone, and the remainder
was 17/3-estradiol.
Peak 2 from the original DEAE-Sepha-
dex column (0-0.8m NaCl) yielded 90%
of the 3H in an ether-soluble form after a
72 hour incubation with Ketodase. The
hydrolysis was inhibited 95% by 7 X 10_4m
saccharolactone. Analysis of the fraction
released by ^-glucuronidase showed that
77% of the 3H consisted of estrone and
17/3-estradiol, while the remainder was
composed of estriol and related triols, 2-
methoxyestrone and material with the
chromatographic mobility of the phenolic
steroid ring D a-ketols.
DEAE-Sephadex chromatography (0-
0.8m, followed by 0-0.4m NaCl) of the 6-24
and 24-48 hr urines gave evidence of par¬
tially separated peaks of 3H behaving like
phenolic steroid glucosiduronates. No glu-
coside-like material was detected beyond
0-6 hr. Smaller amounts of 3H were de¬
tected in the steroid sulfate fraction. The
glucosiduronate fraction over 6-24 hr was
81% hydrolyzed by Ketodase (95% in¬
hibited by saccharolactone) and that over
24-48 hr was hydrolyzed only 62% by the
/3-glucuronidase preparation. These later
glucosiduronate fractions showed increas¬
ing amounts of triols and other metabolites
as compared with estrone and 17/3-estradiol.
Table 2 shows the pattern of steroids in the
glucosiduronate fraction between 0 and 48
hours for subject MYL.
The 0-2 hr urine from BER, when chro-
matographed on XAD-2 resin, gave 5.39
X106 dpm 3H and 0.696 XlO6 dpm 14C
(3H/14C =7.7). DEAE-Sephadex chroma¬
tography (0-0.8m NaCl, 10 ml fractions)
resulted in a number of peaks. Peak 1,
fractions 4-9, contained 4.22 XlO6 dpm 3H
and 0.675 XlO6 dpm 14C (3H/14C =6.2);
peak 24, fractions 15-20, contained 0.158
XlO6 dpm 3H and 0.026 XlO6 dpm 14C
(3H/14C =6.1); peaks 3-5, partially sep¬
arated over fractions 22-31, contained
0.936 XlO6 dpm 3H and no 14C. These var¬
ious peaks, together with a very small
amount of 3H in the steroid sulfate region
(fractions 45-60), represented complete re¬
covery of the radioactivity applied to the
column.
Peak 1, corresponding to glucoside,
4 The chromatographic peaks obtained for BER
were much sharper than those for MYL, perhaps
due to the smaller urine aliquots used in the former.
This may have led to the apparent failure to detect
peak 2 in MYL.
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Table 2. Pattern of 3H-metabolites (% total
identified) in the urinary glucosiduronate
fractions over 0 to 48 hours in
MYL and BER





Ring Da-Ketols* 25 28
2-Methoxyestrone 10 2
* Probably contains some 2-OH metabolites.
showed, on further analysis, very similar
results to those obtained with the corre¬
sponding material from MYL. The mate¬
rial behaved chromatographically as glu-
coside, was hydrolyzed by almond emulsin,
and this hydrolysis was inhibited by glu-
conolactone. Between 10 and 15% of the
aglycone released by hydrolysis was estrone,
and the remainder was 17/3-estradiol.
Peak 2 was intermediate in polarity be¬
tween a monoglucoside and a monogluco-
siduronate. Chromatography and enzyme
hydrolytic experiments indicated that this
material was neither a sulfate nor a glu¬
cosiduronate, and suggested that it was a
diglycoside containing two non-acidic sug¬
ars. Because of the small amount of ma¬
terial, further characterization was not
possible.
Peaks 3-5, pooled, yielded >90% hy¬
drolysis with Ketodase (>90% inhibition
with saccharolactone), and subsequent
chromatography showed that 80% of the
3H released was in the form of estrone and
17/3-estradiol. Small amounts of the other
various estrogen metabolites were also de¬
tected.
The 2-4 hr urine from BER yielded a
pattern of radioactivity on DEAE-Sepha-
dex chromatography (0-0.8m NaCl) as
shown in Fig. 1. A small residue corre¬
sponding to glucoside was followed by
major amounts of 3H in the glucosiduronate
region, followed in turn by smaller amounts
in the sulfate region. The glucosiduronate
peak was combined with suitable aliquots
of urine collected between 4 and 48 hours
FRACTION NO. (I0MI EACH)
Fig. 1. DEAE-Sephadex chromatography of
metabolites in 2-4 hr, subject BER. Peak 1 = gluco¬
side, peak 2 = glucosiduronate, peak 3= sulfate.
3H= A A, 14C= •
and incubated with Ketodase, resulting in
77% hydrolysis. The 3H released was com¬
bined with that from the hydrolyzed glu¬
cosiduronate fraction from 0-2 hr and the
whole was analyzed to yield the steroid
pattern over the period 0-48 hr (Table 2).
In subjects MYL and BER, respectively,
46 and 41% of the 3H in the urinary non-
glucoside fractions (uncorrected for pro¬
cedural losses) were found in the form of
the various estrogen metabolites by the
methods used.
Discussion
Some 75% of intravenously administered
17/3-estradiol-3-glucosiduronate is excreted
rapidly without deconjugation in the urine
of the human female (4). A portion of this,
however, undergoes direct dehydrogenation
to estrone-3-glucosiduronate. A further 10
to 15% of the dose is excreted almost ex¬
clusively in the form of the 3-glucosidu-
ronates of estrone and 17/3-estradiol but
representing material which has been de-
conjugated and reconjugated during its
stay in the body (4).
In contrast to the metabolism of 17/3-
estradiol-3-glucosiduronate, it is apparent
from the present study that 17/3-estradiol-
3-glucoside, following intravenous injec¬
tion, is subjected to considerable decon¬
jugation (hydrolysis) in that only 20% can
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be recovered in the urine as the glucoside.
Some 11% of this apparently undergoes
direct dehydrogenation to estrone-3-glu-
coside as judged following hydrolysis by
almond emulsin. The remainder of the dose
appears to be subjected to hydrolysis, the
released 17/3-estradiol then being metabo¬
lized in a similar manner to intravenously
injected 17/3-estradiol. Evidence for this in¬
cludes the increasing amounts of metabo¬
lites other than estrone and 17/3-estradiol
with time; the decreasing ability of /3-glu-
curonidase to hydrolyze the excreted con¬
jugates with time; the relatively small
amount of urinary radioactivity identified
as compared with the case of metabolites
of injected estrogen glucosiduronates (4,
12, 13); and the final over-all pattern of
urinary metabolites in the form of gluco¬
siduronates which resemble those excreted
following administration of 17/3-estradiol
(8).
In the rabbit, steroid glucosidase activ¬
ity with a high specificity for the phenolic
3-glucoside has been found (14) and this
activity is distinct from /3-glucuronidase.
It seems likely that a similar glucosidase
or glucosidases may exist in the human,
and the different pattern of metabolism of
17/3-estradiol-3-glucosiduronate and 17/3-
estradiol-3-glucoside suggests that the glu¬
cosidase must act on the steroid conjugate
either in a different organ or at a different
subcellular site than does the glucuroni¬
dase.
It is of interest to note that intravenously
administered 17/3-estradiol-17-glucosidu-
ronate in the human is deconjugated to the
extent of about 65% as judged by urinary
metabolites (Musey & Hobkirk, unpub¬
lished observations). However, unlike th(
case of 17/3-estradiol-3-glucoside, there i
no widespread metabolism of released 17/3
estradiol as judged by the very small amount
of urinary metabolites other than the con
jugates of estrone and 17/3-estradiol follow
ing injection of the 17-glucosiduronate
(12,13).
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ABSTRACT. 17P-Estradiol-6,7-3H-17-glucoside
(E2-17-glucoside) was injected iv into two normal
young women. Within 72 hr, 61 and 64% of the
3H dose was excreted in the urine in the two
experiments. Within 2 hr of injection 0.7 and
1.9% of the dose was excreted as the unchanged
glucoside together with 2.5 and 4.4% in the form
of a double conjugate, identified with some cer¬
tainty as E2-3-glucosiduronate-17-glucoside. Be¬
tween 2 and 4 hr after injection in one subject,
and between 2 and 6 hr in the other, a lag in
excretion of the label occurred, the small amount
of 3H found at these times being in all probability
the above double conjugate. No unchanged mono-
glucoside was detected beyond 2 hr after injection
and no double conjugate was detected with cer¬
tainty beyond 6 hr. After 4 hr in one subject, and
6 hr in the other, the excretion of label increased
markedly. Over the period 6-48 hr in each experi¬
ment only monoglucosiduronates were excreted
and of these, 74% and 91% were composed of
the 3-glucosiduronates of E2 and of estrone (E,)
in the two studies. Smaller amounts of estriol,
2-methoxyestrone, 16-epiestriol and ring D a-
ketol glucosiduronates were also present. It is
suggested that E2-3-glucosiduronate-17-glucoside,
once formed, might be excreted in the bile with
subsequent hydrolysis, and reconjugation largely
in the form of the 3-glucosiduronates of E2 and
Ex. (/ Clin Endocr 34: 690, 1972)
RECENT work in our laboratory has ledto the elucidation of the metabolism of
iv administered E2-3-glucosiduronate3 (1)
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and E2-17-glucosiduronate (2-4) in the hu¬
man female. Further studies have involved
the metabolism of E2-3-glucoside in the hu¬
man (5). This was done because glucosides
of phenolic steroids have now been identified
in both the rabbit (6,7) and the human (8)
and it was of interest to compare the hand¬
ling of the 3-glucoside in the human with
that of the 3-glucosiduronate. Since there
are now known to be considerable differences
in the metabolism of these three conjugates
of E2 (3-glucosiduronate, 17-glucosiduron-
ate, 3-glucoside) by the human (1-5), it
was considered worthwhile to compare the
picture obtained for the metabolism of iv
injected E2-6,7-3H-17-glucoside. The study
reported here concerns such an investigation.
Materials and Methods
E-2-17-$-D-glucoside. This compound was syn¬
thesized by a Koenigs-Knorr reaction as previ¬
ously described for the preparation of 17a-
estradiol-17-glucoside (6). The product had the
2-methoxyestrone = 2-methoxy-3-hydroxyestra-l,3,
5(10)-trien-17-one;







following properties: mp 175-185; [a]^5 = 0°;
(C = 0.1, methanol), 2800-3500 (OH),
1500 cm"1 (aromatic); nuclear magnetic reson¬
ance (DMSO) 6.97 (H-l, 1 proton, d, Ji.2 —
8HZ), 6.48 (H-2, 4, 2 protons, m, spacing 12HZ),
4.91-4.15 (five sugar protons 1', 2', 3', 4', 5').
Analysis: Calc. for C24 H34 07-j^ H20 (443.54)
C = 65.00, H = 7.96%. Found C = 65.17, H
= 7.98%.
E2-6,7-3H-17-glucoside. This compound, of spe¬
cific activity (sa) =30 Ci/mmole, was prepared
by reduction of the methyl ester of E2-6,7-3H-
17-glucosiduronate (New England Nuclear Corp.,
Boston, Mass.) with NaBH4. The method used
was that of Collins et al. (7) except that the
free phenolic group of the estrogen was blocked
by acetylation prior to methylation by diazo-
methane in anhydrous benzene. Acetate groups
were removed (6) and the product was purified
by thin layer chromatography (TLC) on Silica
Gel H in chloroform-ethanol (4:1). Constant sa
was obtained after one crystallization with pure
En-17-glucoside.
Eo-d-^CS-glucosiduronate. This was prepared
by reducing biosynthesized Ei-4-14C-3-glucosi-
duronate with NaBH4 (9). All steps, including
purification, have been published (1,5,9).
E2-4-14C-17-glucosiduronate. This conjugate was
chemically synthesized by New England Nuclear
Corp.
Reagents, etc. All organic solvents, materials for
chromatography, enzymes, inhibitors and steroids
were obtained, purified where necessary, and used
as described elsewhere (9-11).
Injection of E2-6,7-3H-17-glucoside. The labelled
material was first passed through Swinnex-13
filters of pore size 22 p (Millipore Corp., Bed¬
ford, Mass.). Injection was performed in 10 ml
of 10% (v/v) ethanol-saline (10) into an arm
vein of each of 2 normal females at about day
10 of the cycle. Subject MCG (30 yr) received
25.5 X 106 dpm 3H and subject PET (21 yr)
received 19 X 10° dpm. Urine was collected in
each case at 2, 4, 6, 24, 48 and 72 hr after
injection and was frozen (—15 C) until re¬
quired for analysis.
Analysis of urinary metabolites. Aliquots of urine
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(up to 6 hr) were processed on Amberlite XAD-2
resin (12) and then chromatographed on DEAE-
Sephadex (A-25) in a linear gradient (0-0.8m)
of NaCl (13). Peaks corresponding to E2-17-
glucoside were rechromatographed on A-25 in
H20 (13) and aliquots were extracted with ethyl
acetate, then incubated with emulsin. Free E2
was extracted with benzene.
Peaks from the salt gradient, behaving like
E2-3-glucosiduronate-17-glucoside, were incu¬
bated with Ketodase (^-glucuronidase), with and
without saccharolactone, and the 17-glucoside
formed was extracted with ethyl acetate after an
initial benzene extraction. The presumptive
monoglucoside was then chromatographed on
A-25 in H20 and aliquots were incubated with
emulsin prior to benzene extraction. Further
aliquots were methylated with dimethyl sulfate
in borate buffer (14) prior to acid hydrolysis and
identification of the E2-3-methyl ether formed
(3). Attempts were also made to remove the 17-
glucoside moiety from the presumptive double
conjugate by incubation with emulsin -j- sac¬
charolactone (11), Mylase P (11) and a purified
rabbit liver |3-glucosidase preparation (15). The
product was chromatographed on A-25 (0-0.4m
NaCl) along with pure E2-4-14C-3-glucosidu-
ronate.
Peaks from the original 0-0.8m NaCl gradient,
behaving like monoglucosiduronates, were sub¬
jected to Celite column partition chromatography
(CPC) in iso-octane:t-butanol:M NH4OH
(2:5:5) followed by the same solvents in the
ratio of 2:10:10 (16). The eluted 3H was mixed
with pure E2-4-14C-3-glucosiduronate and E2-4-
14C-17-glucosiduronate and rechromatographed
on A-25 in a 0-0.4M NaCl gradient (13). The
separated peaks were incubated with Ketodase,
with and without saccharolactone, and the ben¬
zene-, or ether-soluble 3H released was submitted
to a Girard separation followed by CPC of the
labelled aglycones (10).
All hydrolyzed steroids and their derivatives
were crystallized to constant SA with appropriate
unlabelled carriers (10). E2-17-glucoside was
crystallized in the conjugated form.
All radioactive counting was performed as
previously described (10).
Results
Table 1 shows the excretion of 3H in the
urine of the two subjects. After excretion
of about 5% of the dose in 2 hr, there was
1
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Fig. 1. DEAE-Sephadex (0-0.8m) chromatographic
pattern of 0-2 hr urine after iv injection of E2-6,
7-3H-17-glucoside into subject MCG. Peak A =
E2-17-glucoside; peak B = E2-3-glucosiduronate-
17-glucoside.
a lag phase (ca. 2-4 hr in MCG and 2-6 hr
in PET) followed by an increased excretion
of 3H up to 48 or 72 hr.
In general the two experiments gave simi¬
lar results. The 3H in 0-2 hr yielded the
chromatographic pattern shown in Fig. 1
(subject MCG). Peak A was identified as
E2-l 7-glucoside. Rechromatography of this
on A-2S in H20 gave a single peak between
fractions 9 and 13 (5 ml fractions collected).
(Pure E2-3-glucoside appears between frac¬
tions 4 and 6). The presumptive 17-glucoside
was extractable by ethyl acetate but not by
benzene, and on TLC in chloroform-ethanol
(4:1) had an Rf identical to authentic E2-17-
glucoside. It was 100% hydrolyzed (inhib¬
ited by gluconolactone) by emulsin to a
Table 1. Excretion of 3H (% dose) in the
urine following injection of E2-6,7-3H-17-
glucoside into MCG and PET









Vol 34 • No 4
benzene-soluble form identified as E2 by
TLC in benzene:ethyl acetate (7:3).
Ketodase incubation of Peak B rendered
3-6% of the 3H extractable by benzene and
89-94% by ethyl acetate. In the presence of
saccharolactone no 3H was extracted by
benzene and no more than 2% by ethyl
acetate. The ethyl acetate-soluble 3H from
the uninhibited hydrolysis was eluted from
A-2S by HoO in a position similar to E2-17-
glucoside. An aliquot was 95% hydrolyzed
by emulsin to E2 (identified by crystalliza¬
tion). Another aliquot was crystallized with
pure E2-l 7-glucoside whereupon constant sa
was obtained. A further aliquot, following
methylation and hydrolysis, yielded E2-3-
methyl ether (identified by crystallization).
None of the enzyme preparations used re¬
moved more than 2% of the glucose from
C-17 of the intact double conjugate. After
each attempted hydrolysis the 3H-labelled
product was eluted from A-25 in 0-0 ,4m
NaCl over fractions (5 ml each) 64-74
whereas simultaneously chromatographed
E2-4-14C-3-glucosiduronate appeared over
fractions 73-81. On CPC in the 2:5:5 system
the 3H was eluted between holdback volumes
(HBV's) 12-15 while the 14C appeared at
8-10. In 0-2 hr 1.9% of the dose was
excreted as unchanged glucoside in PET and
the corresponding value for MCG was 0.7%.
At the same time about 4.4% and 2.5% of
the dose appeared as the double conjugate
in the respective subjects.
In 2-4 hr for MCG and 2-6 hr for PET
the 3H excreted behaved like the double
conjugate on A-25. In neither experiment
was any E2-l 7-glucoside detected at this
time.
Over 4-48 hr for MCG and 6-48 hr for
PET the A-25 pattern (0-0.8m NaCl gradi¬
ent) exhibited 3H solely in the region typical
of phenolic steroid monoglucosiduronate(s).
After CPC in the 2:5:5 system (ca. 96%
of the 3H eluted with this solvent; some 4%
with the 2:10:10 system and methanol strip¬
ping), followed by A-25 chromatography in
0-0.4m NaCl with added E2-4-14C-3-gluco-
f
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Fig. 2. DEAE-Sephadex (0-0.4m) chromatographic
pattern of 6-48 hr urine after iv injection of E2-6,7-
3H-17-glucoside into subject PET. Peak C = mainly
3H-labelled Ei-3-gIucosiduronate; peak D = mainly
3H-labelled E2-3-glucosiduronate (plus standard 14C-
E2-3-glucosiduronate); peak E = standard 14C-E2-
17-glucosiduronate.
siduronate and E2-14C-17-glucosiduronate,
only two 3H-labelled peaks were seen (Fig. 2
subject PET). Peak C was of a similar
mobility to Ei-3-glucosiduronate while peak
D was in the position of E2-3-glucosiduron-
ate. No 3H coincided with standard E2-4-14C-
17-glucosiduronate (peak E). Peak C was
hydrolyzed 97-100% and peak D 89-94%
by Ketodase (both inhibited 97% by sac-
:harolactone). Of the 3H released from peaks
C and D by Ketodase in the 2 experiments,
53-88% was recovered after Girard separa¬
tion and CPC. Peak C was 83-91% Ex and
peak D was 52-72% E2. Table 2 shows the
composition of the 8H in the combined
monoglucosiduronate fractions in 6-48 hr
after crystallization to constant sa. Based
upon sequential hydrolysis and extraction
the maximum amount of double conjugate
excreted in 6-48 hr was 3-4% of that in
D-2 hr; i.e., ca. 0.1% of the dose.
Discussion
The metabolism of iv administered E2-17-
^lucoside in the human female is clearly
different from that of E2-3-glucoside. Thus
20% of the latter is rapidly excreted un¬
changed in the urine and the remainder
appears to undergo cleavage to E2 which is
metabolized similarly to iv injected E2 (5).
This is in accord with the finding that E2-3-
glucoside is an excellent in vitro substrate
for rabbit liver glucosidase whereas E2-17-
glucoside is a poor one (15).
The metabolism of E2-17-glucoside is
similar in some respects to that of E2-17-
glucosiduronate although differing in others.
Thus <2% of the former is excreted un¬
changed in the urine whereas 20-40% of the
latter appears unchanged (4). The lag in 3H
excretion at about 2-6 hr after 3H-E2-17-
glucoside injection is similar to that seen
for 3H-E2-17-glucosiduronate (4). In the
latter case this is due to biliary excretion
of a sulfurylated form (E2-3-sulfate-17-
glucosiduronate) of the injected conjugate,
together with another double conjugate (4;
Musey and Hobkirk, in preparation), fol¬
lowed by slow intestinal reabsorption. In
the case of injected E2-17-glucoside the dou¬
ble conjugate formed is almost certainly E2-
3-glucosiduronate-17-glucoside which could
conceivably be excreted via the bile with
subsequent hydrolysis and reconjugation,
before, during, or after reabsorption, with
the formation of the 3-glucosiduronates of
E2 and E2 as major metabolites. These latter
2 conjugates are the main urinary metabo¬
lites of biliary E2-3-sulfate-l 7-glucosiduron¬
ate (4; Musey and Hobkirk, in preparation).
The formation of small amounts of glucosi-
duronates of more highly oxygenated pheno¬
lic steroids suggests that some part of the
original E2-17-glucoside, or the double con¬
jugate formed from it, might have been
Table 2. Pattern of 3H-metabolites (%
of total identified) in the urinary
glucosiduronate fractions over
6-48 hr in MCG and PET
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hydrolyzed to E2 which was then released
into the main body pool.
It is interesting to note that the glucose
residue at C-17 of the double conjugate
found in this study was not removed by
enzymes in the presence of the 3-glucosidur-
onate grouping, in spite of the facile removal
of the latter group by Ketodase.
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Williamson, D. G., Layne, D. S., Nilsen, M., and Hobkirk, R. Metabolism of intravenously
administered 17a-[6,7-3H]estradiol-17-glucoside in normal women. Can. J. Biochem. 50, 958-962(1972).
17a-[6,7-3H]estradiol-17-glucoside was injected intravenously into two normal young women. Within
72 h, 60 and 46% of the 3H dose was excreted in the urine in the two experiments. In the first 6 h, 4 and
1.4% of the dose was excreted as the unchanged glucoside, together with 14 and 5% in the form of a double
conjugate, identified as 17a-estradiol-3-glucuronide-17-glucoside. Over the periods 6-24 h and 24-48 h
none of the injected glucoside and only minor amounts of the double conjugate were present in the urine.
The main excretory product after 6h was 17 a-estradiol-17-glucuronide. This latter result contrasts with
that obtained in previous experiments in which 17/J-estradiol-6,7-3H-17-glucoside was injected, and in
which the main monoconjugates excreted were the 3-glucuronides of 17/1-estradiol and estrone.
Williamson, D. G., Layne, D. S., Nilsen, M., et Hobkirk, R. Metabolism of intravenously administered
17a-[6,7-3H]estradiol-17-glucoside in normal women. Can. J. Biochem. 50, 958-962 (1972).
Le 17a-[6,7-3H]oestradiol-17-glucoside est injecte par voie intraveineuse a deux jeunes femmes normales.
Apres 72 h, respectivement 60 et 46% de 1' 3H injecte est excrete dans Purine. Durant les 6 premieres heures,
4 et 1.4% de la substance injectee est excretee sans que le glucoside soit change et 14 et 5% sous forme d'un
double conjugue, le 17a-oestradiol-3-glucuronide-17-glucoside. Durant les periodes allant de 6 a 24 h et de
24 a 48 h apres l'injection, rien du glucoside injecte et seulement de petites quantites du double conjugue
sont presents dans Purine. Le principal produit d'excretion apres 6 h est le 17a-oestradiol-17-glucuronide.
Ce dernier resultat contraste avec celui obtenu dans des experiences anterieures ou le 17/?-oestradiol-6,7-
3H-17-glucoside a ete injecte et ou les principaux monoconjugues excretes etaient les 3-glucuronides du
17/i-oestradiol et de l'oestrone. [Traduit par le journal]
Introduction
In a recent study (1) we examined the me¬
tabolism of intravenously administered 17/?-
estradiol-17-glucoside3 in the human female,
and compared the results with those previously
'Supported by Grants MT 3287 and MT 532 from the
Medical Research Council of Canada.
2Research Associate of the Medical Research Council
of Canada. Present address: Department of Pathological
Chemistry, University of Western Ontario, London,
Ontario.
3The following trivial names for steroids and their




3-glucoside, 17/S-hydroxyestra-l ,3,5( 10)-trien-3-yl-/?-d-glu-
copyranoside: 17a-estradiol-3-glucuronide, 17a-hydroxy-
estra-1,3,5(10)-trien-3-yl-/J-D-glucopyranosiduronic acid:







(2), 17/?-estradiol-3-glucuronide (3), or 17/?-
estradiol-3-glucoside (4) were administered to
similar subjects. Williamson and Layne (5) have
shown that human liver and kidney tissue in
vitro can form the 17-glucoside of 17a-estradiol,
but not of 17/?-estradiol, and it therefore became
of interest to investigate the metabolism of
17oc-estradiol-17-glucoside in the human.
Materials and Methods
Reagents and General Methods
All organic solvents and materials for chromatography
were obtained, and purified where necessary, as described
elsewhere (6, 7). Amberlite XAD-2 resin was purchased
from Rohm and Haas, Philadelphia, Pa., and was washed
extensively with methanol and water prior to use. Ketodase
(beef liver /3-glucuronidase) was purchased from Warner-
Lambert, Morris Plains, N.J., and was used for incubation
in concentrations of 125-500 U/ml in 0.1 M acetate buffer,
pH 5, for 24 h at 38 °C. Saccharo-1,4-lactone (used as
//-glucuronidase inhibitor at a concentration of 1 mg/ml)
was purchased from Calbiochem, Los Angeles, Calif.
Almond emulsin /J-glucosidase (used for hydrolysis at a
concentration of 0.2 mg/ml of 0.1 M acetate buffer, pH 5,
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for 24 h at 38 °C) and glucono-l,5-lactone (inhibitor of
glucosidase, used at a concentration of lOmg/ml as
described previously (8) were obtained from Sigma Chemical
Co. Unlabelled steroids were purchased from Mann
Research Laboratories, Inc., New York. N.Y.
All radioactive counting was performed, as previously
described, on Nuclear Chicago liquid-scintillation spectrom¬
eters (6).
Preparation of I7a-[6,7-3H]estradiol-I7-glucoside
This material was prepared by the incubation of 17a-
[6,7-3H]estradiol with human kidney homogenate in the
presence of UDP-glucose as described by Williamson and
Layne (5). The material was extracted from the incubations
with ethyl acetate and purified by thin-layer chromatography
in chloroform methanol (4:1). The specific activity was
21.7 Ci/mmol.
Injection of I7tx-[6,7-3H]estradiol-17-glueoside
The labelled material was first passed through Swinnex-13
filters of pore size 22 p (Millipore Corp., Bedford. Mass.).
No radioactivity was lost during this procedure. Injection
was performed in 10 ml of 10% (v/v) ethanol-saline (6)
into an arm vein of each of two normal females at about
day 10 of the cycle. Subject AT (25 years) received
24.7 x 106 d.p.m. 3H and subject KH (25 years) received
25.6 x 106 d.p.m. Urine was collected in each case at 6, 24,
48, and 72 h after injection and was frozen at — 15 °C until
required for analysis.
Analysis of Urinary Metabolites
Aliquots of urine were processed on Amberlite XAD-2
resin (9). An aliquot of 30 000 d.p.m. of 17a-[4-14C]-
estradiol-3-glucuronide prepared as described by Collins
et al. (10) was added to each extract, and the extracts were
then chromatographed on DEAE-Sephadex (A25) in a
linear gradient (0-0.8 M) of NaCl (11). Material in peaks
corresponding to 17a-estradiol-17-glucoside was submitted
to ethyl acetate extraction followed by incubation with
emulsin. Free 17a-estradiol was extracted with benzene.
The material in peaks from the salt gradient, with the
chromatographic characteristics expected of 17a-estradiol-
3-glucuronide-17-glucoside, was submitted to incubation
with Ketodase, with and without saccharolactone, and the
I7-glucoside so formed was extracted with ethyl acetate
after an initial benzene extraction. Attempts were made to
remove the 17-glucoside moiety from the presumptive
double conjugate by incubation with emulsin and saccharo¬
lactone, Mylase P. and a purified rabbit liver /(-glucosidase
preparation (12).
The material in peaks from the 0-0.8 M NaCl gradient,
with the chromatographic characteristics of monoglucuron¬
ides, was incubated with Ketodase, with and without
saccharolactone, and the benzene-soluble tritiated material
released was identified as 17a-estradiol by thin-layer
chromatography (t.l.c.), and in some instances by recrystal-
lization to constant specific activity with the authentic
steroid.
Results
Table 1 shows the excretion of 3H in the urine
of the two subjects. In each case excretion was
relatively rapid in the 0-6 h period and declined
Table 1. Excretion of 3H










steadily thereafter (Table 1). The urinary re¬
covery was 60% of the dose in subject AT and
46% in subject KH. The excretion was not
necessarily complete at 72 h, when the collec¬
tions were stopped in these experiments.
The pattern of metabolites obtained in the
urine from the two experiments was practically
identical. The 3H in the 0-6 h collections
yielded the chromatographic pattern shown in
Fig. 1 (subject AT), together with the 14C pattern
derived from the added sample of 17a-[4-14C]-
estradiol-3-glucuronide. Peak A was identified
as 17a-estradiol-17-glucoside by chromato¬
graphic comparison with the authentic material
(13). Emulsin caused 100% hydrolysis of the
radioactive material to a benzene-extractable
form, and this hydrolysis was inhibited by
gluconolactone. The aglycone extracted into
benzene after incubation with emulsin was
identified as 17a-estradiol by t.l.c. in benzene-
ethyl acetate (7:3). Peak A accounted for 4.0%
of the dose in subject AT and 1.4% in subject
KH.
The tritiated material in peak B comprised
14.0 and 5.1% of the dose in AT and KH,
respectively, and was shown to be 17a-estradiol-
3-glucuronide-17-glucoside. The identification
of this compound was carried out as described
by Hobkirk et al. (1) for the identification, in
similar experiments, of 17jS-estradiol-3-glucuro-
nide-17-glucoside. Incubation of the material
with Ketodase yielded 17a-estradiol-17-gluco¬
side which was identified by recrystallization to
constant specific activity with authentic material
(13). The glucoside was in turn hydrolyzed by
emulsin to yield an aglycone which was identical
on t.l.c. with 17a-estradiol. The successive
hydrolyses were inhibited by saccharolactone
and by gluconolactone, respectively. None of
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Fig. 1. DEAE-Sephadex chromatographic pattern of 0-6 h urine after intravenous injection of 17a-[6,7-3H]estradiol-
17-glucoside into subject AT. For identity of materials in peaks see text. (O) 3H, (•) 14C.
the enzyme preparations used was effective in
removing the 17-glucoside from the double
conjugate without prior removal of the 3-
glucuronide.
Peak D (Fig. 1) consisted of a compound
which was separated from 17a-[4-14C]estradioI-
3-glucuronide (peak C) but which migrated like
a monoglucuronide on t.l.c. in chloroform-iso-
propanol-formic acid (5:3:1). The 3H was
extracted with benzene after Ketodase hydrol¬
ysis, and this hydrolysis was completely in¬
hibited by saccharolactone. The aglycone con¬
sisted entirely of 17a-[6,7-3H]estradiol as
determined by t.l.c. and by recrystallization
with nonlabelled material. Peak D contained
6.3% of the dose in subject AT and 3.4% in
subject KH.
Continued elution of the Sephadex column
beyond fraction 80 resulted in the recovery of a
very small amount of tritium which probably
represented double conjugates, such as a sulfo-
glucuronide, of 17a-estradiol.
Fig. 2 shows the chromatographic pattern of
3H obtained when the metabolites in the 6-24 h
urine collection (subject AT) were chromato-
graphed on DEAE-Sephadex. Peak A (Fig. 1)
was no longer evident, and peak B was ex¬
tremely small. Peak D (17a-estradiol-17-glucuro-
nide) now constituted the quantitatively major
metabolite, amounting to 7.5% and 6.4% of the
dose in subjects AT and KH, respectively. A
small amount of a new tritium peak, C, had
appeared. This material, which represented less
than 2.0% of the dose, was coincident on the
column with 17a-[4-14C]estradiol-3-glucuro-
nide, and also behaved as a monoglucuronide
on t.l.c. The aglycone crystallized to constant
specific activity with authentic 17a-estradiol.
The Sephadex chromatography pattern ob¬
tained with the 24-48 h urine samples was
essentially similar to that in the 6-24 h collec¬
tion (Fig. 2). The main metabolite was again
peak D, with a small amount of peak C.
Discussion
The identification of the excreted conjugates,
while not absolute, is reasonably firm. The
material in peak A was identified as the com¬
pound injected, namely 17a-estradiol-17-gluco-
side, by chromatography and also by its
hydrolysis with emulsin to yield an aglycone
chromatographically identical with 17a-estra-
diol. The inhibition of this hydrolysis by
gluconolactone is strong evidence for a /?-d-
glucoside, and the possibility that this might be
the 3-glucoside of 17a-estradiol seems remote.
These two glucosides of 17a-estradiol can, in
fact, be separated on the t.l.c. system employed.
In the case of the double conjugate in peak B
(Figs. 1 and 2) the 17-monoconjugate moiety
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Fig. 2. DEAE-Sephadex chromatographic pattern of 6-24 h urine after intravenous injection of 17a-[6,7-3H]estradiol-







was firmly identified as 17a-estradiol-17-gluco-
side by crystallization to constant specific
activity with the authentic compound. The
removal of a conjugating group from the 3
position by Ketodase, and the inhibition of this
hydrolysis by saccharolactone, is acceptable
evidence that the 3 position of the steroid is
conjugated with glucuronic acid.
The results indicate that 17a-estradiol-17-
glucoside is partly converted to the 3-glucuro-
nide and excreted as 17a-estradiol-3-glucuro-
nide-17-glucoside (peak B, Fig. 1). A similar
double conjugate with glucuronic acid at the 3
position is excreted in the early urinary collec¬
tions after the injection of 17/5-estradiol-17-
glucoside (1). However, in the present work, in
vivo removal of glucose from the 17 position
led to the excretion of 17a-estradiol mainly as
a monoglucuronide (peak D, Figs. 1 and 2),
which appears to be 17a-estradiol-17-glucuro-
nide on the basis of the following evidence. The
material was separated on DEAE-Sephadex
from authentic 17a-[4-14C]estradiol-3-glucuro-
nide (Figs. 1 and 2). Ketodase completely
hydrolyzed the compound to yield 17a-estradiol,
and this hydrolysis was inhibited by saccharo-
1,4-lactone.
Several small peaks of radioactivity, which
were not identified, can be seen in the chromato¬
graphic pattern shown in Fig. 2. It must be
borne in mind that while these represent only
small fractions of the injected dose, their relative
quantitative significance is appreciable, and
might well increase in the urine excreted after
72 h, which was not collected in this study.
The present results differ from those obtained
after the injection of 17j?-estradiol-17-glucoside,
in that the monoglucuronide excreted in that
case was 17/2-estradiol-3-glucuronide (1). It
appears likely that, in the human, the 17a-
hydroxyl group is much more readily conju¬
gated with glucuronic acid than is the 17/2
group. Sa'at and Slaunwhite (14) have demon¬
strated the in vitro formation of the 3-glucuro-
nides of estrone and of 17/2-estradiol by human
liver homogenates. However, in unpublished
work, we have been able to show the transfer,
by human liver and kidney homogenates, of
glucuronic acid from UDP-glucuronic acid to
17a-estradiol under conditions in which no
formation of glucuronides of either estrone or
17/2-estradiol was detected. It is possible that
the 3-glucuronide of 17/2-estradiol found by
Hobkirk et al. (1), as well as the very minor
amounts of 17a-estradiol-3-glucuronide which
probably constitute peak C in the later urine
collections in the present work, may be formed
in the intestine following biliary excretion of
liver metabolites. The 3-glucuronide could arise
either by removal of glucose from the 3-
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glucuronide-17-glucoside double conjugate, by
complete deconjugation of the double conjugate
followed by reconjugation with glucuronic acid
at C-3, or by conjugation of free steroid formed
by removal of glucose from the injected
steroid-17-glucoside.
Williams and Layne (15) have reported that
17oe-estradiol injected into human subjects is
excreted largely unchanged, except for conjuga¬
tion. A minor amount of metabolism in ring A
takes place to form 2-methoxy-17a-estradiol,
but the extensive ring D metabolism which
converts estrone or 17/?-estradiol to a variety
of metabolites is absent. This is confirmed by
the results of the present experiments, in that
17a-estradiol was the only steroid identified as
an aglycone of the urinary conjugates investi¬
gated. It may well be that ready conjugation of
the 17a-hydroxyl group by, for example, the
liver, protects 17a-estradiol from further me¬
tabolism in ring D, and from dehydrogenase
action which might convert it to estrone and
17/?-estradiol. It would be of interest to know
the site of this 17-conjugation, as to whether it
occurs in the intestine from a biliary precursor
or whether at an extra-enteric location. 17/?-
Estradiol-17-glucuronide is not, in contrast to
the 3-glucuronide, an enteric metabolite of
17/?-estradiol (16).
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